Advance

HOSONO Makoto

    Department of Medicine　Professor
Last Updated :2024/04/20

Researcher Information

Degree

  • MD, PhD（Kyoto University）

URL

J-Global ID

Profile

  • Makoto Hosono, MD, PhD,  is Professor of Department of Radiology, Kindai University Faculty of Medicine, Osaka, Japan, and serves as a member of ICRP C3 since 2017 and a member of Radiation Council, Nuclear Regulatory Agency, Government, Japan since 2022. After graduating from Kyoto University School of Medicine, Japan, he has been contributing to the fields including nuclear oncology, tumor targeting, and radiation protection as well as neurology and cardiology. In Japanese Society of Nuclear Medicine (JSNM), he serves as the Chair of PET Committee since 2011 and as an active member of Radionuclide Therapy Committee. He also served as the Chief of Working Group for establishment of the first ever National Diagnostic Reference Levels in 2015 (Japan DRLs 2015) for diagnostic radiology and nuclear medicine in the framework of Japan Network for Research and Information on Medical Exposure (J-RIME). Since 2017, he is the Chair of J-RIME and involved in revision of DRLs, which was published as Japan DRLs 2020. He has been the principal Investigator of a Research Group on Radiation Protection in Medicine of Ministry of Health in Japan since 2007. He was responsible for the clinical trials of Ra-223 dichloride in Japan as one of principal investigators since 2011. He contributed to the approval of Lu-177 DOTATATE in Japan by establishing safety standards and release criteria. He has participated in numerous educational activities for PET and SPECT oncology imaging and radionuclide therapy at national and international events.

Research Interests

  • Radiology   Radiological Protection   Nuclear Oncology   Targeted Molecular Therapy   Molecular Imaging   tumor targeting   

Research Areas

  • Life sciences / Radiology

Academic & Professional Experience

  • 2005/10 - Today  Kindai University Faculty of MedicineDepartment of RadiologyProfessor
  • 2003/04 - 2005/09  Kindai University Faculty of MedicineDepartment of RadiologyAssociate Professor
  • 1995/10 - 2003/04  Saitama Medical UniversityDepartment of RadiologyLecturer
  • 1994/10 - 1995/09  French Government Research FellowshipINSERM U211, Nantes UniversityResearch Fellow
  • 1993/10 - 1994/09  Humboldt Foundation Research FellowshipBonn University Department of Nuclear MedicineHumboldt Foundation Research Fellow
  • 1993/04 - 1993/09  Kyoto University HospitalDepartment of Radiology and Nuclear MedicineFellow
  • 1986/04 - 1989/03  Kitano Hospital (Osaka)Department of RadiologyFellow
  • 1985/04 - 1986/03  Kyoto University HospitalDepartment of Radiology and Nuclear MedicineResident

Education

  • 1989/04 - 1993/03  Kyoto University Graduate School of Medicine  Internal Medicine System  Radiology and Nuclear Medicine
  • 1979/04 - 1985/03  Kyoto University Faculty of Medicine  医学部

Association Memberships

  • Société française de Médecine Nucléaire et Biophysique   European Association of Nuclear Medicine   Radiological Society of North America   Society of Nuclear Medicine   日本癌学会   断層映像研究会   日本画像医学会   日本核医学会   日本医学放射線学会   

Published Papers

  • Nishida T; Hayashi S; Takenaka M; Hosono M
    Journal of Gastroenterology in press 2024/05 [Refereed]
  • Watabe T; Namba M; Yanagida S; Nakamura Y; Yamada T; Tatsuno S; Ri A; Yoshida S; Uyama K; Kinuya S; Tomiyama N; Hosono M
    Ann Nucl Med in press 2024/03 [Refereed]
  • Watanabe H; Yamamoto K; Sakamoto H; Imao M; Sejimo Y; Kato H; Takenaka M; Akahane K; Kanda R; Torisu K; Mikami Y; Hosono M
    JART 71 (2) 138 - 147 2024/02 [Refereed]
    ダウンロード
  • Differentiating Brown Tumor from Bone Metastasis in Parathyroid Cancer using 18F-FDG PET and 99mTc-MIBI SPECT
    Tsukamoto S; Kawabata K; Kawamura H; Takata K; Hosono M
    Clin Nucl Med in press 2024/02 [Refereed]
  • Hosono M
    Suizo 38 (6) 375 - 380 2023/12 [Refereed][Invited]
  • Tokura J; Yoshio T; Hayashi S; Yamamoto M; Asai S; Yakushijin T; Ikezawa K; Nagaike K; Takagi T; Fujisawa T; Yamada T; Tsumura H; Maetani I; Hori Y; hara H; Matsunaga K; Kuwai T; Ito Y; Hasatani K; Komeda Y; Kurita A; Yamaguchi S; Maruyama H; Iwashita T; Takenaka M; Hosono M; Nishida T
    JGH Open 12993 1 - 6 2023/12 [Refereed]
  • Doi H; Ri A; Inada M; Tatsuno S; Uehara T; Matsuura T; Ishikawa K; Nakamatsu K; Hosono M; Nishimura Y
    Int J Clin Oncol 28 (12) 1607 - 1605 2023/12 [Refereed][Invited]
     
    BACKGROUND: This study aimed to reveal the long-term outcomes and late toxicities (> 5 years) after definitive intensity-modulated radiation therapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). METHODS: Data from 43 patients (median age, 55 years; range, 17-72 years) with NPC who underwent definitive IMRT between 2001 and 2018 were analyzed. All patients were alive and disease-free 5 years after IMRT. A total dose of 70 (range, 66-70) Gy was delivered in 35 (33-35) fractions with concurrent cisplatin chemotherapy. RESULTS: The median follow-up duration was 119 (range, 61.5-242.1) months. Three patients developed locoregional failure at 79, 92, and 149 months after IMRT, respectively. Of these, 2 patients died of disease progression at 136 and 153 months after IMRT. One patient died of aspiration pneumonia 141 months after IMRT, despite salvage of the recurrent tumor by re-irradiation. In addition, one patient died of aspiration pneumonia 62 months after the IMRT. Thus, the 10-year overall survival, progression-free survival, and locoregional control rates were 98%, 92%, and 94%, respectively. Grade ≥ 2 and ≥ 3 late toxicities were observed in 28 (65%) and 9 (21%) patients, respectively. Nine second primary cancers, including five tongue cancers and two external auditory canal carcinomas, were observed in seven (16%) patients. CONCLUSION: Late recurrences, severe late toxicities, and second primary cancers were observed > 5 years after IMRT. A long-term follow-up of > 5 years is needed in patients with NPC.
  • Kawabata K; Hosono M; Kanagaki M; Tsukamoto S; Ando S; Ito S
    Clin Nucl Med 48 (12) 1015 - 1020 2023/12 [Refereed]
  • Okuhata K; Monzen H; Nakamura Y; Takai G; Nagano K; Nakamura K; Kubo K; Hosono M
    Ann Nucl Med 37 (11) 629 - 634 2023/11 [Refereed]
     
    OBJECTIVE: The purpose of this study is to determine the dose reduction of different shielding materials at various distances from a 177Lu photon radiation source. METHODS: Two protective aprons with lead equivalent thicknesses of 0.25 mm and 0.35 mm and tungsten-containing rubber (TCR) were used as shielding materials. A vial containing 177Lu was sealed in a lead container so that a narrow beam went out through a 3 mm-diameter hole. The dose rate was measured at distances of 0, 10, 50, 100, and 200 cm from the source using a NaI scintillation survey meter to obtain the rate of dose reduction. TCR was tested with thicknesses ranging from 0.3 to 1.0 mm at 0.1 mm intervals and from 1.0 to 4.0 mm at 0.5 mm intervals. RESULTS: At distances of 0, 10, 50, 100, and 200 cm, the dose reduction for the lead equivalent thickness of 0.25 mm were 32.7%, 54.5%, 93.1%, 97.9%, and 99.6%, respectively; and for the lead equivalent thickness of 0.35 mm were 53.4%, 70.6%, 95.6%, 98.9%, and 99.6%, respectively. Without any shielding, the dose rate decreased by 34.4% at 10 cm and by 88.8% at 50 cm from the radiation source. The dose reduction for the TCR thickness of 3.5 mm was 89.8% at 0 cm and 93.3% at 10 cm. The TCR thickness of 0.4 mm provided a dose reduction comparable to or greater than that of the 0.25 mm lead equivalent, whereas the TCR thickness of 1.0 mm or greater provided a dose reduction comparable to that of the 0.35 mm lead equivalent. CONCLUSIONS: Achieving a reduction of 95% or more requires the 0.25 mm lead equivalent for a distance of 100 cm, the 0.35 mm lead equivalent for 50 cm, the TCR thickness of 0.3 mm for 100 cm, or the TCR thickness of 0.9 mm for 50 cm. Without wearing a protective apron, a reduction of approximately 95% is observed at distances greater than 100 cm. These findings would be useful for medical staff engaging in related activities.
  • Umehana M; Hosono M; Hijikata Y; Takahashi M; Kanagaki M
    Clin Nucl Med 48 e529 - e531 2023/10 [Refereed]
  • 【肝胆膵癌に対する放射線治療:2023 Update】放射線被曝 胆膵領域における放射線被曝の現状
    竹中 完; 細野 眞; 工藤 正俊
    肝胆膵 (株)アークメディア 87 (1) 91 - 99 0389-4991 2023/07
  • Peptide receptor radionuclide therapy (PRRT) for pancreatic NEN
    Hosono M; Ri A; Tatsuno S; Hukuda H; Ishida N; Uehara T; Inada M; Matsuura K; Doi K; Nakamatsu K; Monzen H; Matsuo Y
    Kan Tan Sui (Liver, Bile,Pancreas) (株)アークメディア 87 (1) 79 - 84 0389-4991 2023/07 [Invited]
  • Kitajima K; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Sasaki R; Narita M; Yamakado K
    Cancers MDPI AG 15 (10) 2784 - 2784 2023/05 [Refereed]
     
    To evaluate the usefulness of change in the automated bone scan index (aBSI) value derived from bone scintigraphy findings as an imaging biomarker for the assessment of treatment response and survival prediction in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Ra-223. This study was a retrospective investigation of a Japanese cohort of 205 mCRPC patients who received Ra-223 in 14 hospitals between July 2016 and August 2020 and for whom bone scintigraphy before and after radium-223 treatment was available. Correlations of aBSI change, with changes in the serum markers alkaline phosphatase (ALP) and prostate-specific antigen (PSA) were evaluated. Additionally, the association of those changes with overall survival (OS) was assessed using the Cox proportional-hazards model and Kaplan–Meier curve results. Of the 205 patients enrolled, 165 (80.5%) completed six cycles of Ra-223. Following treatment, ALP decline (%ALP < 0%) was noted in 72.2% (148/205), aBSI decline (%aBSI < 0%) in 52.7% (108/205), and PSA decline (%PSA < 0%) in 27.8% (57/205). Furthermore, a reduction in both aBSI and ALP was seen in 87 (42.4%), a reduction in only ALP was seen in 61 (29.8%), a reduction in only aBSI was seen in 21 (10.2%), and in both aBSI and ALP increasing/stable (≥0%) was seen in 36 (17.6%) patients. Multiparametric analysis showed changes in PSA [hazard ratio (HR) 4.30, 95% confidence interval (CI) 2.32–8.77, p < 0.0001], aBSI (HR 2.22, 95%CI 1.43–3.59, p = 0.0003), and ALP (HR 2.06, 95%CI 1.35–3.14, p = 0.0008) as significant prognostic factors for OS. For mCRPC patients treated with Ra-223, aBSI change is useful as an imaging biomarker for treatment response assessment and survival prediction.
  • Ikezawa K; Hayashi S; Takenaka M; Yakushijin T; Nagaike K; Takada R; Yamai T; Matsumoto K; Yamamoto M; Omoto S; Minaga K; Ishii S; Shimizu T; Nagai K; Hosono M; Nishida T
    Scientific Reports 13 (1) 7824 - 7824 2023/05 [Refereed]
     
    This study aimed to examine occupational radiation exposure to the lens of the eyes during endoscopic retrograde cholangiopancreatography (ERCP). In this multicenter, prospective, observational cohort study, we collected data regarding occupational radiation exposure to the lens of the eyes during ERCP. We measured radiation exposure of patients and examined its correlation with occupational exposure. In dosimetrically-measured ERCPs (n = 631), the median air kerma at the patient entrance reference point, air kerma-area product, and fluoroscopy time were 49.6 mGy, 13.5 Gycm2, and 10.9 min, respectively. The median estimated annual radiation dose to the lens of the eyes was 3.7, 2.2, and 2.4 mSv for operators, assistants, and nurses, respectively. Glass badge over lead aprons and eye dosimeter results were similar in operators but differed in assistants and nurses. A strong correlation was shown between eye dosimeter measurements and patients' radiation exposure. The shielding rates of the lead glasses were 44.6%, 66.3%, and 51.7% for operators, assistants, and nurses, respectively. This study revealed the actual occupational exposure dose for the lens of the eyes during ERCP and the efficacy of lead glass. Values of radiation exposure to patients can help estimate exposure to the lens of the eyes of medical staff.
    ダウンロード
  • Wada Y; Monzen H; Ishida N; Ri A; Tatsuno S; Uehara T; Inada M; Doi H; Nakamatsu K; Hosono M; Nishimura Y
    Medical Dosimetry 48 (3) 193 - 196 2023/05 [Refereed]
  • 転移性去勢抵抗性前立腺癌に対するRadium-223治療における予後予測因子の検討(Prognostic factors of patients with metastatic CRPC treated by radium-223)
    西本 光寿; 藤田 和利; 藤本 西蔵; 桑原 賢; 菊池 尭; 安富 正悟; 齋藤 允孝; 森 康範; 南 高文; 野澤 昌弘; 吉村 一宏; 細野 眞; 植村 天受
    日本泌尿器科学会総会 (一社)日本泌尿器科学会総会事務局 110回 OP60 - 04 2023/04
  • Yusuke Sakai; Hajime Monzen; Yoshiki Takei; Hiroyuki Kosaka; Kenji Nakamura; Yuya Yanagi; Kazuki Wakabayashi; Makoto Hosono; Yasumasa Nishimura
    48 (2) 189 - 194 2023/04 [Refereed]
  • 林 史郎; 竹中 完; 木暮 宏史; 薬師神 崇行; 池澤 賢治; 山口 真二郎; 藤澤 聡郎; 田丸 弓弦; 前谷 容; 丸山 紘嗣; 淺井 哲; 高木 忠之; 長生 幸司; 堀 寧; 住吉 徹哉; 津村 英隆; 中井 陽介; 細野 眞; 西田 勉
    日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A333 - A333 0446-6586 2023/03
  • Nagaike K; Hayashi S; Yakushijin T; Yamamoto M; Sumiyoshi T; Yamaguchi S; Tamaru Y; Yamada T; Tsumura H; Nakai Y; Doyama H; Maetani I; Takagi T; Asai S; Matsubara K; Takenaka M; Hosono M; Nishida T
    British Journal of Radiology 96 (1146) 20230086  2023/03 [Refereed]
  • Hayashi S; Takenaka M; Kogure H; Yakushijin T; Nakai Y; Ikezawa K; Yamaguhci S; Fujisawa T; Tamaru Y; Maetani I; Maruyama H; Asai S; Takagi T; Nagaike K; Hori Y; Sumiyoshi T; Tsumura H; Doyama H; Yoshio T; Hara K; Abe S; Oda I; Kato M; Nebiki H; Mikami T; Miyazaki M; Matsunaga K; Hosono M; Nishida T; Egawa S; Nishihara A; Ohnita K; Minami R; Tada N; Kobayashi K; Kato M
    DEN Open 3 (1) e227  2023/03 [Refereed]
     
    OBJECTIVES: We surveyed and reported low protective equipment usage and insufficient knowledge among endoscopy-fluoroscopy departments in Japan in 2020. Two years later, we conducted a follow-up survey of doctors, nurses, and technologists in Japan. METHODS: We conducted a questionnaire survey on radiation protection from May to June 2022. The participants were medical staff, including doctors, nurses, and radiological and endoscopy technicians in endoscopy-fluoroscopy departments. The questionnaire included 17 multiple-choice questions divided into three parts: background, equipment, and knowledge. RESULTS: We surveyed 464 subjects from 34 institutions. There were 267 doctors (58%), 153 nurses (33%), and 44 technologists (9%). The rate of wearing a lead apron was 98% in this study. The rates of wearing a thyroid collar, lead glasses, and radiation dosimeter were 27%, 35%, and 74%, respectively. The trend of the protective equipment rate was similar to that of our previous study; however, radiation dosimetry among doctors was still low at 58%. The percentage of subjects who knew the radiation exposure (REX) dose of each procedure was low at 18%. Seventy-six percent of the subjects attended lectures on radiation protection, and 73% knew about the three principles of radiation protection; however, the concept of diagnostic reference levels was not well known (18%). Approximately 60% of the subjects knew about the exposure dose increasing cancer mortality (63%) and the 5-year lens REX limit (56%). CONCLUSIONS: There was some improvement in radiation protection equipment or education, but relatively little compared to the 2020 survey of endoscopy departments.
    ダウンロード
  • The proposals on peptide receptor radionuclide therapy: from the past to the future
    Hosono M
    Tan to Sui (Japan) 44 (1) 95 - 101 2023/01 [Invited]
  • Inada M; Nishimura Y; Hanaoka K; Nakamatsu K; Doi H; Uehara T; Komanishi N; Ishii K; Kaida H; Hosono M
    Radiotherapy and Oncology 180 109491  2023/01 [Refereed]
    ダウンロード
  • Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S, Kono Y, Tamaki Y, Seko-Nitta A, Ishiwata Y, Ito K, Toriihara A, Watanabe S, Hosono M, Miyake H, Yamamoto S, Narita M, Daimon T, Yamakado K
    Eur J Nucl Med Mol Imaging Springer Science and Business Media LLC 50 (5) 1487 - 1498 1619-7070 2022/12 [Refereed]
  • Movements in Japan to enhance the framework of nuclear medicine therapy
    Higashi T; Hosono M; Kato K
    Rad Fan 20 (12) 85 - 88 2022/12 [Invited]
  • Mikoto Tamura; Yoshihiro Ueda; Jun-Ichi Fukunaga; Tatsuya Kamima; Yumiko Shimizu; Yuta Muraki; Kazuki Kubo; Kiyoshi Nakamatsu; Makoto Hosono; Hajime Monzen
    Anticancer Research 42 (11) 5305 - 5314 2022/11 [Refereed]
     
    BACKGROUND/AIM: This study evaluated the impact of knowledge-based plan (KBP) model improvement on plan complexity and delivery accuracy in volumetric modulated arc therapy (VMAT) for prostate cancer at multiple institutions. MATERIALS AND METHODS: Five institutions created the first KBP model before April 2017 and subsequently devised a new model (second model) based on feedback from the first KBP and the efforts of planners after April 2019. The dose-volume histogram (DVH) parameters were validated for two prostate cancer cases between the first and second KBPs. Plan complexity metrics, of the modulation complexity score for VMAT (MCSv), closed leaf score (CLS), small aperture score (SAS), and leaf travel (LT), were compared. The delivery accuracy metrics of γ pass rate and point dose discrepancy (plan vs. measurement) at isocenter were also compared. RESULTS: There were no significant differences in DVH parameters between the KBPs. Conversely, V50% of the rectum and bladder was reduced in 6/10 and 8/10 patients, respectively, and these variations were also converged from the first KBP to the second KBP. The mean±1SDs of MCSv, CLS, SAS20mm, and LT (first KBP vs. second KBP) were 0.27±0.033 vs. 0.26±0.044, 0.062±0.032 vs. 0.14±0.091, 0.59±0.048 vs. 0.70±0.14, and 411.91±32.08 mm vs. 548.33±127.50 mm, respectively. The delivery accuracy did not differ, whereas MCSv was moderately correlated with the point dose discrepancy. CONCLUSION: Multi-leaf collimator motion could be more complex with KBP model improvement, which had the potential to deteriorate the delivery accuracy.
  • Inagaki T; Doi H; Inada M; Ishida N; Ri A; Tatsuno S; Wada Y; Uehara T; Nakamatsu K; Hosono M; Nishimura Y
    Strahlentherapie und Onkologie 199 (5) 465 - 476 2022/11 [Refereed]
  • Report on a survey of individual dosimeter and protective devices for radiation workers in medical institutions
    Watanabe H; Yamamoto K; Sakamoto H; Imao M; Sejimo Y; Kato H; Takenaka M; Akahane Keiichi; Mikami Y; Hosono M
    JART 69 (11) 1289 - 1299 2022/11 [Refereed]
    ダウンロード
  • Oguma Y; Hosono M; Okajima K; Inoue E; Nakamatsu K; Doi H; Matsuura T; Inada M; Uehara T; Wada Y; Ri A; Yamamoto Y; Yoshimura Y; Uemura H; Nishimura Y
    Radiation 2 (3) 273 - 284 2022/09 [Refereed]
    ダウンロード
  • Trends of radiotheranostics research
    Hosono M
    Jpn J Cancer Chemother 49 (8) 809 - 812 2022/08 [Invited]
  • Ukon N; Higashi T; Hosono M; Kinuya S; Yamada T; Yanagida S; Namba M; Nakamura Y
    Ann Nucl Med Springer Science and Business Media LLC 36 (8) 695 - 709 0914-7187 2022/07 [Refereed]
     
    Abstract In this manuscript, we present the guideline for use of meta-[211At] astatobenzylguanidine ([211At] MABG), a newly introduced alpha emitting radiopharmaceutical to the up-coming World’s first clinical trial for targeted alpha therapy (TAT) at Fukushima Medical University in Japan, focusing on radiation safety issues in Japan. This guideline was prepared based on a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on Oct. 5th, 2021. The study showed that patients receiving [211At] MABG do not need to be admitted to a radiotherapy room and that TAT using [211At] MABG is possible on an outpatient basis. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers or patient’s family members. In this guideline, the following contents are also included: precautions for patients and their families, safety management associated with the use of [211At] MABG, education and training, and disposal of medical radioactive contaminants. TAT using [211At] MABG in Japan should be carried out according to this guideline. Although this guideline is based on the medical environment and laws and regulations in Japan, the issues for radiation protection and evaluation methodology presented in this guideline are useful and internationally acceptable as well.
    ダウンロード
  • Current status and issues of radium chloride-223 (223Ra) therapy for bone metastases
    Hosono M
    Japanese Journal of Clinical Urology 49 (8) 568 - 571 2022/07 [Invited]
  • Watanabe H; Yamamoto K; Sakamoto H; Imao M; Sejimo Y; Kato H; Takenaka M; Akahane Keiichi; Mikami Y; Hosono M
    JART 69 (7) 716 - 723 2022/07 [Refereed]
    ダウンロード
  • Takano S; Ogawa M; Kobayashi N; Ichikawa Y; Hosono M; Hata M
    Radioisotopes 71 135 - 140 2022/06 [Refereed]
    ダウンロード
  • Hosono M
    KAN･TAN･SUI 84 (6) 825 - 830 2022/06 [Invited]
  • Takenaka M; Hosono M; Hayashi S; Nishida T; Kudo M
    Digestive Endoscopy 34 890 - 900 2022/06 [Refereed]
     
    Fluoroscopy-guided endoscopic procedures (FGEPs) are rapidly gaining popularity in the field of gastroenterology. Radiation is a well-known health hazard. Gastroenterologists who perform FGEPs are required to protect themselves, patients, as well as nurses and radiologists engaged in examinations from radiation exposure. To achieve this, all gastroenterologists must first understand and adhere to the International Commission on Radiological Protection Publication. In particular, it is necessary to understand the three principles of radiation protection (Justification, Optimization, and Dose Limits), the As Low As Reasonably Achievable principle, and the Diagnostic Reference Levels (DRLs) according to them. This review will mainly explain the three principles of radiation exposure protection, DRLs, and occupational radiological protection in interventional procedures while introducing related findings. Gastroenterologists must gain knowledge of radiation exposure protection and keep it updated.
    ダウンロード
  • Hachisuka A; Higashi T; Hosono M; Ono M; Uehara T; Nishimura S; Murakami M; Watanabe R; Nemoto T; Takai N; Saijo T; Hatano T; Maya Y; Takemori H; Komoto S; Saji H
    Regulatory Science of Medical Products 12 (2) 161 - 177 2022/05 [Refereed]
  • ERCP時の術者被ばく線量、および防護メガネによる水晶体被ばく低減効果の検討 REX-GI試験からの検討
    池澤 賢治; 林 史郎; 竹中 完; 藥師神 崇行; 長生 幸司; 高田 良司; 山井 琢陽; 松本 健吾; 山本 政司; 鎌田 研; 三長 孝輔; 石井 修二; 清水 健史; 長井 健悟; 細野 眞; 西田 勉; REX-GI試験グループ
    Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 64 (Suppl.1) 807 - 807 0387-1207 2022/04
  • ERCP時の術者被ばく線量、および防護メガネによる水晶体被ばく低減効果の検討 REX-GI試験からの検討
    池澤 賢治; 林 史郎; 竹中 完; 藥師神 崇行; 長生 幸司; 高田 良司; 山井 琢陽; 松本 健吾; 山本 政司; 鎌田 研; 三長 孝輔; 石井 修二; 清水 健史; 長井 健悟; 細野 眞; 西田 勉; REX-GI試験グループ
    Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 64 (Suppl.1) 807 - 807 0387-1207 2022/04
  • Watanabe H, Konno M, Fujita Y, Kurihara S, Todokoro K, Hagiwara M, Yamamoto K, Sakamoto H, Takenaka M, Hosono M
    Japanese Journal of Radiological Technology 78 (4) 364 - 371 2022/04 [Refereed]
    ダウンロード
  • Watanabe H; Yamamoto K; Sakamoto H; Imao M; Sejimo Y; Kato H; Takenaka M; Akahane Keiichi; Mikami Y; Hosono M
    JART 69 (4) 49 - 56 2022/04 [Refereed]
    ダウンロード
  • Kudo A; Ukihide T; Yoshimura R; Tsuchiya J; Yokoyama K; Takano S; Kobayashi N; Utsunomiya D; Hata M; Ichikawa Y; Hosono M; Tanabe M; Kinuya S
    J Hepatobiliary Pancreat Sci 29 (4) 487 - 499 2022/04 [Refereed]
     
    BACKGROUND: The present prospective phase 1/2 study aimed to elucidate the efficacy and safety of 177 Lu-DOTATATE (four cycles of 7.4 GBq) in Japanese patients with unresectable, progressive neuroendocrine tumors (NETs). METHODS: From April 2018 to October 2020, 15 patients with advanced NETs (five midgut, eight pancreatic, and two lung NETs) were enrolled. Objective response rate (ORR), progression-free survival (PFS), and adverse events (AEs) were evaluated. Pharmacokinetics and dosimetry were also evaluated in three midgut patients. RESULTS: The mean absorbed doses of 177 Lu-DOTATATE to the kidneys (20.7 Gy/29.6 GBq) and the bone marrow (0.631 Gy/29.6 GBq) were within the radiation tolerance doses. The ORR of the whole population was 53% (90% CI, 30%-76%). ORRs of the midgut and non-midgut NETs were 60% (90% CI, 19%-92%) and 50% (90% CI, 22%-78%), respectively. There was no difference in the maximum reduction rate of the sum of the target lesion diameters between patients with midgut and non-midgut NET. The median PFS was not reached; the PFS rate at 52 weeks was 80% (90% CI, 56.1%-91.7%). AEs of Grade 3 or higher were lymphopenia (47%) and leukopenia (7%). CONCLUSION: 177 Lu-DOTATATE demonstrated remarkable tumor shrinkage and tolerability in Japanese patients with advanced NETs.
  • Takenaka M; Rehani M; Hosono M; Yamazaki T; Omoto S; Minaga K; Kamata K; Yamao K; Hayashi S; Nishida T; Kudo M
    J Clin Med 11 (6) 1705  2022/03 [Refereed]
     
    Fluoroscopy forms an essential part of endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) and hepaticogastrostomy with antegrade stenting (EUS-HGAS). To date, no study has assessed and compared radiation exposure between EUS-HGS and EUS-HGAS. This study aimed to compare the radiation exposure parameters between EUS-HGS and EUS-HGAS. This retrospective single-center cohort study included consecutive patients who underwent EUS-HGS or EUS-HGAS from October 2017 to March 2019. The air kerma (AK: mGy), kerma-area product (KAP: Gycm2), fluoroscopy time (FT: min), and procedure time (PT: min) were assessed and compared between the two procedures. Altogether, 45 and 24 patients underwent EUS-HGS and EUS-HGAS, respectively. The median AK, KAP, FT, and PT were higher in the EUS-HGAS group than in the EUS-HGS group. A comparison revealed no difference in the technical success rate, complications rate, adverse event occurrence rate, and re-intervention rate between both procedures. This is the first report in which radiation exposure was used as a comparative parameter between EUS-HGS and EUS-HGAS. This study revealed that radiation exposure is significantly higher in EUS-HGAS than in EUS-HGS. Increased awareness on radiation exposure is warranted among gastroenterologists so that they choose the procedure with lower radiation exposure in cases where both procedures are indicated.
    ダウンロード
  • Hayashi S; Takenaka M; Hosono M; Kogure H; Hasatani K; Suda T; Maruyama H; Matsunaga K; Ihara H; Yoshio T; Nagaike K; Yamada T; Yakushijin T; Takagi T; Tsumura H; Kurita A; Asai S; Ito Y; Kuwai T; Hori Y; Maetani I; Ikezawa K; washita T; Matsumoto K; Fujisawa T; Nishida T
    Lancet Reg Health West Pac 20 (100376) 1 - 8 2022/03 [Refereed]
     
    BACKGROUND: Diagnostic reference levels (DRLs) are required to optimize medical exposure. However, data on DRLs for interventional fluoroscopic procedures are lacking, especially in gastroenterology. This study aimed to prospectively collect currently used radiation doses and help establish national DRLs for fluoroscopy-guided gastrointestinal procedures in Japan. METHODS: This multicentre, prospective, observational study collected actual radiation dose data from endoscopic retrograde cholangiopancreatography (ERCP), interventional endoscopic ultrasound (EUS), balloon-assisted enteroscopy (BAE), enteral metallic stent placement, and enteral tube placement from May 2019 to December 2020. The study outcomes were fluoroscopy time (FT: min), air kerma at the patient entrance reference point (Ka,r: mGy), air kerma area product (PKA: Gycm2), and radiation dose rate (RDR: mGy/min). Additionally, the basic settings of fluoroscopy equipment and the factors related to each procedure were investigated. This study was registered in the UMIN Clinical Trial Registry (UMIN 000036525). FINDINGS: Overall, 12959 fluoroscopy-guided gastrointestinal procedures were included from 23 hospitals in Japan. For 11162 ERCPs, the median/third quartile values of Ka,r (mGy), PKA (Gycm2), and FT (min) were 69/145 mGy, 16/32 Gycm2, and 11/20 min, respectively. Similarly, these values were 106/219 mGy, 23/41 Gycm2 and 17/27 min for 374 interventional EUSs; 53/104 mGy, 16/32 Gycm2 and 10/15 min for 523 metallic stents; 56/104 mGy, 28/47 Gycm2, and 12/18 min for 599 tube placements; and 35/81 mGy, 16/43 Gycm2 and 7/15 min for 301 BAEs, respectively. For the overall radiation dose rate, the median/third quartile values of RDR were 5.9/9.4 (mGy/min). The RDR values at each institution varied widely. INTERPRETATION: This study reports the current radiation doses of fluoroscopy-guided gastrointestinal procedures expressed as DRL quantities. This will serve as a valuable reference for national DRL values. FUNDING: This work was supported by a clinical research grant from the Japanese Society of Gastroenterology.
    ダウンロード
  • Takenaka M; Hosono M; Rehani MM; Chiba Y; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Minaga K; Kamata K; Yamao K; Hayashi S; Nishida T; Kudo M
    Digestive endoscopy 34 (3) 579 - 586 2022/03 [Refereed]
     
    OBJECTIVES: The transpapillary drainage by endoscopic retrograde cholangiopancreatography (ERCP-D) cannot be performed without fluoroscopy, and there are many situations in which fluoroscopy is required even in endoscopic ultrasound-guided drainage (EUS-D). Previous studies have compared the efficacy, but not the radiation exposure of EUS-D and ERCP-D. While radiation exposure in ERCP-D has been previously evaluated, there is a paucity of information regarding radiation doses in EUS-D. This study aimed to assess radiation exposure in EUS-D compared with that in ERCP-D. METHODS: This retrospective single-center cohort study included consecutive patients who underwent EUS-D and ERCP-D between October 2017 and March 2019. The air kerma (AK, mGy), kerma-area product (KAP, Gycm2 ), fluoroscopy time (FT, min), and procedure time (PT, min) were assessed. The invasive probability weighting method was used to qualify the comparisons. RESULTS: We enrolled 372 and 105 patients who underwent ERCP-D and EUS-D, respectively. The mean AK, KAP, and FT in the EUS-D group were higher by 53%, 28%, and 27%, respectively, than those in the ERCP-D group, whereas PT was shorter by approximately 11% (AK, 135.0 vs. 88.4; KAP, 28.1 vs. 21.9; FT, 20.4 vs. 16.0; PT, 38.7 vs. 43.5). The sub-analysis limited to biliary drainage cases showed the same trend (AK, 128.3 vs. 90.9; KAP, 27.0 vs. 22.2; FT, 16.4 vs. 16.1; PT, 32.5 vs. 44.4). CONCLUSIONS: This is the first study to assess radiation exposure in EUS-D compared with that in ERCP-D. Radiation exposure was significantly higher in EUS-D than in ERCP-D, despite the shorter procedure time.
    ダウンロード
  • Inagaki T; Doi H; Ishida N; Ri A; Tatsuno S; Wada Y; Uehara T; Inada M; Nakamatsu K; Hosono M; Nishimura Y
    Cancers 14 (4) 933  2022/02 [Refereed]
     
    Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage lung cancer. The purpose of this study was to investigate the optimal dose distribution and prognostic factors for local control (LC) after SBRT for lung cancer. A total of 104 lung tumors from 100 patients who underwent SBRT using various treatment regimens were analyzed. Dose distributions were corrected to the biologically effective dose (BED). Clinical and dosimetric factors were tested for association with LC after SBRT. The median follow-up time was 23.8 months (range, 3.4-109.8 months) after SBRT. The 1- and 3-year LC rates were 95.7% and 87.7%, respectively. In univariate and multivariate analyses, pathologically confirmed squamous cell carcinoma (SQ), T2 tumor stage, and a Dmax < 125 Gy (BED10) were associated with worse LC. The LC rate was significantly lower in SQ than in non-SQ among tumors that received a Dmax < 125 Gy (BED10) (p = 0.016). However, there were no significant differences in LC rate between SQ and non-SQ among tumors receiving a Dmax ≥ 125 Gy (BED10) (p = 0.198). To conclude, SQ, T2 stage, and a Dmax < 125 Gy (BED10) were associated with poorer LC. LC may be improved by a higher Dmax of the planning target volume.
    ダウンロード
  • FDG-Avid Tracheal Mass and Cartilage Involvements in ANCA-Negative Granulomatosis With Polyangiitis
    Tanaka H; Hosono M; Kawabata K; Kageyama G; Yamashita M
    Clin Nucl Med 47 (1) 83 - 85 2022/01 [Refereed]
  • Hosono M; Uemura H; Kakehi Y; Masumori N; Takahashi S; Okayama Y; Sunaya T; Horio T; Kinuya S
    Kaku-igaku Japanese Society of Nuclear Medicine 58 (1) 91 - 101 2021/10 [Refereed]
    ダウンロード
  • Takenaka M; Hosono M; Hayashi S; Nishida T; Kudo M
    British Journal of Radiology 94 (1126) 20210399 - 20210399 2021/10 [Refereed][Invited]
     
    Although many interventions involving radiation exposure have been replaced to endoscopic procedure in the gastrointestinal and hepatobiliary fields, there remains no alternative for enteroscopy and endoscopic retrograde cholangiopancreatography (ERCP), which requires the use of radiation. In this review, we discuss the radiation doses and protective measures of endoscopic procedures, especially for ERCP. For the patient radiation dose, the average dose area product for diagnostic ERCP was 14-26 Gy.cm², while it increased to as high as 67-89 Gy.cm² for therapeutic ERCP. The corresponding entrance skin doses for diagnostic and therapeutic ERCP were 90 and 250 mGy, respectively. The mean effective doses were 3- 6 mSv for diagnostic ERCP and 12-20 mSv for therapeutic ERCP. For the occupational radiation dose, the typical doses were 94 μGy and 75 μGy for the eye and neck, respectively. However, with an over-couch-type X-ray unit, the eye and neck doses reached as high as 550 and 450 μGy, with maximal doses of up to 2.8 and 2.4 mGy/procedure, respectively.A protective lead shield was effective for an over couch X-ray tube unit. It lowered scattered radiation by up to 89.1% in a phantom study. In actual measurements, the radiation exposure of the endoscopist closest to the unit was reduced to approximately 12%. In conclusion, there is a clear need for raising awareness among medical personnel involved endoscopic procedures to minimise radiation risks to both the patients and staff.
    ダウンロード
  • Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y
    Ann Nucl Med 35 (9) 1332 - 1341 2021/09 [Refereed]
     
    PURPOSE: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression. We have, for the first time, reported the results of the tolerability, safety, pharmacokinetics, dosimetry, and efficacy of this treatment for Japanese patients with NET. METHODS: Patients with unresectable, somatostatin receptor scintigraphy (SRS)-positive NETs were enrolled in this phase I clinical trial. They were treated with 29.6 GBq of 177Lu-DOTATATE (four doses of 7.4 GBq) combined with amino acid solution infusion plus octreotide long-acting release (LAR) 30 mg. The primary objective of this study was to evaluate the tolerability, safety, pharmacokinetics, and dosimetry of a single administration of this treatment in patients with SRS-positive NETs. RESULTS: Six Japanese patients (three men and three women; mean age 61.5 years; range 50-70 years) with SRS-positive unresectable NETs were recruited. 177Lu-DOTATATE was eliminated from the blood in a two-phase manner. Cumulative urinary excretion of radioactivity was 60.1% (range 49.0%-69.8%) within the initial 6 h. The cumulative renal absorbed dose for 29.6 GBq of 177Lu-DOTATATE was 16.8 Gy (range 12.0-21.2 Gy), and the biological effective dose was 17.0 Gy (range 12.2-21.5 Gy). Administration of 177Lu-DOTATATE was well tolerated, with no dose-limiting toxicities. Grade 3 lymphopenia occurred in two (33.3%) cases, but there were no other severe toxicities. Four patients achieved partial response (objective response rate, 66.7%), one patient had stable disease, and one patient had progressive disease. CONCLUSION: PRRT with 177Lu-DOTATATE was well-tolerated and showed good outcomes in Japanese patients with unresectable NETs. Peptide receptor radionuclide therapy, 177Lu-DOTA0-Tyr3-octreotate .
    ダウンロード
  • Serum lactate dehydrogenase is a predictive biomarker in oropharyngeal cancer patients undergoing radiotherapy; a retrospective study on predictive factors
    Uehara T, Doi H, Ishikawa K, Inada M, Tatsuno S, Wada Y, Oguma Y, Kawakami H, Nakamatsu K, Hosono M, Nishimura Y
    Head & Neck 43 3132 - 3141 2021/09 [Refereed]
    ダウンロード
  • G-CSF administration at 1 hour before F-18 FDG-PET does not increase bone marrow FDG accumulation
    Kawabata K; Hosono M; Tanaka H; Hyuga M; Kanagaki M
    Clin Nucl Med 46 (9) 770 - 771 2021/09 [Refereed]
  • Inverted papilloma originating from the lacrimal sac and the nasolacrimal duct with marked FDG accumulation
    Ito S; Hosono M; Kawabata K; Kawamura H; Ishikawa M; Kanagaki M
    Radiology Case Reports 16 (11) 3577 - 3580 2021/08 [Refereed]
    ダウンロード
  • Yamanishi H; Ito T; Hosono M
    Ann ICRP SAGE Publications 50 (1_S) 95 - 101 0146-6453 2021/07 [Refereed]
     
    This paper does not necessarily reflect the views of the International Commission on Radiological Protection.Kawamata Town in Date District, Fukushima Prefecture is located more than 30 km north-west of Fukushima Daiichi nuclear power plant, but on 22 April 2011, part of the Yamakiya District of Kawamata Town was designated as a planned evacuation area. The exposure of children was a concern in Kawamata Town. Based on the proposal of Kindai University, Kawamata Town Board of Education took the initiative to measure individual radiation doses with an integrated dosimeter (glass badge) for all kindergarten children, nursery school children, elementary school students, and junior high school students in the town. These measurements were continued for nearly 3 years from June 2011 until the end of March 2014. The total number of measurements was approximately 16,800 across 11-cycle measurement, with 3 months' accumulation taken as one-cycle measurement. Kindai University provided financial support for the glass badge measurement service, and cooperated in the analysis of measured values and the development of advice based on the results. The main body implementing the measurements was Kawamata Town Board of Education, and the data obtained belong to Kawamata Town. When measurements were starting to be taken, schools got involved in the collection and distribution of dosimeters after explanations were provided to principals and school nurses who were in charge of risk communication. Thanks to the efforts of the schools, the recovery rate exceeded 90%, increasing the reliability of the measurements. It was clear who needed the information - the children and their parents. Kawamata Town Board of Education summarised the cumulative dose results for each measurement and notified parents via personal reports. These were sent to parents with advice on measurement results prepared by Kindai University, and care was taken to ensure that people could understand the measured results. Further briefing sessions were held as appropriate. At the briefing sessions, at the request of Kawamata Town Board of Education, the faculty members of Kindai University explained the measurement results from a professional point of view, and a professor from the Faculty of Medicine provided individual health consultations. Kawamata Town took the lead in using specialists to gain peace of mind, and this was key to the project's success. The situation was managed by taking measurements by dosimetry, and asking experts to interpret the data and provide advice to help reassure the residents. Keywords: Experts; Exposure of children; Glass badges; Nuclear accident; Support for reconstruction.
    ダウンロード
  • Takenaka M; Hosono M; Hayashi S; Nishida T; Kudo M
    British J Radiology 94 (1126) 2021/07 [Refereed][Invited]
  • Hosono M; Takenaka M; Monzen H; Tamura M; Kudo M; Nishimura Y
    British Journal of Radiology 94 (20210388) 2021/06 [Refereed][Invited]
    ダウンロード
  • Watabe T; Hosono M; Kinuya S; Yamada T; Yanagida S; Namba M; Nakamura Y
    Ann Nucl Med 35 (7) 753 - 766 2021/06 [Refereed]
    ダウンロード
  • Hayashi S; Takenaka M; Kogure H; Yakushijin T; Maruyama H; Hori Y; Yoshio T; Ikezawa K; Takagi T; Asai S; Matsunaga K; Matsumoto K; Tsumura H; Yamaguchi S; Sumiyoshi T; Nagaike K; Tamaru Y; Hara K; Fujisawa T; Oda I; Ohnita K; Kato M; Nebiki H; Mikami T; Nishihara A; Egawa S; Minami R; Hosono M; Nishida T
    DEN open 1 (e5) 1 - 7 2021/05 [Refereed]
     
    OBJECTIVES: We surveyed and reported low protective equipment usage and insufficient knowledge among endoscopy-fluoroscopy departments in Japan in 2020. Two years later, we conducted a follow-up survey of doctors, nurses, and technologists in Japan. METHODS: We conducted a questionnaire survey on radiation protection from May to June 2022. The participants were medical staff, including doctors, nurses, and radiological and endoscopy technicians in endoscopy-fluoroscopy departments. The questionnaire included 17 multiple-choice questions divided into three parts: background, equipment, and knowledge. RESULTS: We surveyed 464 subjects from 34 institutions. There were 267 doctors (58%), 153 nurses (33%), and 44 technologists (9%). The rate of wearing a lead apron was 98% in this study. The rates of wearing a thyroid collar, lead glasses, and radiation dosimeter were 27%, 35%, and 74%, respectively. The trend of the protective equipment rate was similar to that of our previous study; however, radiation dosimetry among doctors was still low at 58%. The percentage of subjects who knew the radiation exposure (REX) dose of each procedure was low at 18%. Seventy-six percent of the subjects attended lectures on radiation protection, and 73% knew about the three principles of radiation protection; however, the concept of diagnostic reference levels was not well known (18%). Approximately 60% of the subjects knew about the exposure dose increasing cancer mortality (63%) and the 5-year lens REX limit (56%). CONCLUSIONS: There was some improvement in radiation protection equipment or education, but relatively little compared to the 2020 survey of endoscopy departments.
    ダウンロード
  • Shiro Hayashi; Mamoru Takenaka; Hirofumi Kogure; Takayuki Yakushijin; Hirotsugu Maruyama; Yasuki Hori; Toshiyuki Yoshio; Kenji Ikezawa; Tadayuki Takagi; Satoshi Asai; Kazuhiro Matsunaga; Kengo Matsumoto; Hidetaka Tsumura; Shinjiro Yamaguchi; Tetsuya Sumiyoshi; Koji Nagaike; Yuzuru Tamaru; Kazuo Hara; Toshio Fujisawa; Ichiro Oda; Ken Ohnita; Motohiko Kato; Hiroko Nebiki; Tatsuya Mikami; Akihiro Nishihara; Satoshi Egawa; Ryuki Minami; Makoto Hosono; Tsutomu Nishida
    DEN open 1 (1) e5  2021/04 
    BACKGROUND AND AIMS: It is essential for endoscopists, technologists, and nurses to understand radiation protection. However, protective equipment usage is still low, and there is little awareness of radiation protection in practice. METHODS: We conducted a questionnaire survey on radiation protection from January to February 2020. The participants were medical staff, including medical doctors, nurses, and radiological and endoscopy technician in endoscopy-fluoroscopy departments. The questionnaire included 14 multiple-choice questions divided among three parts: background, equipment, and knowledge. RESULTS: We surveyed a total of 282 subjects from 26 institutions. There were 168 medical doctors (60%), 90 nurses (32%), and 24 technologists (9%). Although almost all staff members (99%) always wore a lead apron, only a few wore a thyroid collar (32%) and lead glasses (21%). The rate of wearing a radiation dosimeter was insufficient (69%), especially among doctors (52%). A few subjects knew the radiation exposure dose of each procedure (15%), and slightly over half had attended lectures on radiation protection (64%) and knew about the three principles of radiation protection (59%). Protection adherence did not differ by years of experience, knowledge of fluoroscopy, awareness of radiation exposure doses, or attendance at basic lectures on radiation protection. However, medical doctors who were aware of the radiation exposure dose of each procedure were significantly more likely to wear dosimeters than those who were not (p = 0.0008). CONCLUSION: Medical staff in endoscopy departments in Japan do not have enough radiation protection equipment or education.
  • Uemura H; Masumori N; Takahashi S; Hosono M; Kinuya S; Sunaya T; Horio T; Okayama Y; Kakehi Y
    International journal of clinical oncology 26 (4) 753 - 763 2021/04 [Refereed]
     
    BACKGROUND: Based on results from Japanese post-marketing surveillance, exploratory analyses were performed to investigate real-world outcomes of radium-223 for metastatic CRPC (mCRPC) according to patient characteristics. METHODS: This non-interventional, prospective study enrolled mCRPC patients selected for radium-223 treatment in clinical practice. Six-month safety and effectiveness were evaluated in subgroups who had/had not received prior chemotherapy (prior-chemo/no prior-chemo groups), and a subgroup who had not received concomitant androgen-receptor axis-targeted agents (ARATs). RESULTS: In the overall population (n = 296), the prior-chemo group (n = 126) tended to have more bone metastases, more analgesic use, and higher prostate-specific antigen values than the no prior-chemo group (n = 170). Incidences of treatment-emergent adverse events (TEAEs), drug-related TEAEs, and ≥ grade 3 drug-related hematological TEAEs were 47% vs. 53%, 25% vs. 29%, and 4% vs. 7% in the no prior-chemo and prior-chemo groups, respectively. Incidences of TEAEs (61%), drug-related TEAEs (36%), and ≥ grade 3 drug-related hematological events (12%) were numerically higher in 33 patients who had received two lines of prior chemotherapy. Multivariate analysis showed that two lines of prior chemotherapy, and hemoglobin, platelet, and lactate dehydrogenase values were baseline factors significantly related to ≥ grade 2 platelet count decreased. Safety and effectiveness in patients without concomitant ARATs (n = 201) were similar to those in the overall population. CONCLUSION: In a real-life setting, radium-223 was well tolerated irrespective of prior chemotherapy, but relatively higher incidences of TEAEs and hematotoxicities were suggested in patients with two lines of prior chemotherapy, possibly reflecting more advanced disease. Radium-223 safety and effectiveness in patients without concomitant ARATs were favorable.
    ダウンロード
  • Kanda R; Akahane M; Koba Y; Chang W; Akahane K; Okuda Y; Hosono M
    Japanese journal of radiology 39 (4) 307 - 314 2021/04 [Refereed]
    ダウンロード
  • Satoh Y; Kawamoto M; Kubota K; Murakami K; Hosono M; Senda M; Sasaki M; Momose T; Ito K; Okamura T; Oda K; Kuge Y; Sakurai M; Tateishi U; Fujibayashi Y; Magata Y; Yoshida T; Waki A; Kato K; Hashimoto T; Uchiyama M; Kinuya S; Higashi T; Magata Y; Machitori A; Maruno H; Minamimoto R; Yoshinaga K
    Annals of Nuclear Medicine 35 (3) 406 - 414 2021/03 [Refereed]
     
    Breast positron emission tomography (PET) has had insurance coverage when performed with conventional whole-body PET in Japan since 2013. Together with whole-body PET, accurate examination of breast cancer and diagnosis of metastatic disease are possible, and are expected to contribute significantly to its treatment planning. To facilitate a safer, smoother, and more appropriate examination, the Japanese Society of Nuclear Medicine published the first edition of practice guidelines for high-resolution breast PET in 2013. Subsequently, new types of breast PET have been developed and their clinical usefulness clarified. Therefore, the guidelines for breast PET were revised in 2019. This article updates readers as to what is new in the second edition. This edition supports two different types of breast PET depending on the placement of the detector: the opposite-type (positron emission mammography; PEM) and the ring-shaped type (dedicated breast PET; dbPET), providing an overview of these scanners and appropriate imaging methods, their clinical applications, and future prospects. The name "dedicated breast PET" from the first edition is widely used to refer to ring-shaped type breast PET. In this edition, "breast PET" has been defined as a term that refers to both opposite- and ring-shaped devices. Up-to-date breast PET practice guidelines would help provide useful information for evidence-based breast imaging.
    ダウンロード
  • Tanaka H; Hosono M; Kanagaki M; Shimizu M; Matsubara N; Kawabata K; Miyamoto T; Itoi K
    Asia Oceania journal of nuclear medicine & biology aojnmb 9 (1) 71 - 75 2021 [Refereed]
     
    A 73-year-old man with lung cancer underwent bone scintigraphy for disease staging. Diffuse myocardial technetium hydroxymethylene diphosphonate (99mTc-HMDP) uptake was incidentally found. A diagnosis of amyloid transthyretin (ATTR) cardiac amyloidosis was suspected, although the patient had no symptoms at this time. Single-photon emission computed tomography (SPECT) showed particularly strong uptake in the ventricular septum. Cardiac magnetic resonance imaging (CMR) showed widespread subendocardial and partly transmural enhancement of the left ventricular myocardium on delayed postcontrast T1-weighted images. These findings were consistent with ATTR cardiac amyloidosis. 18F-FDG uptake in the left ventricle wall was observed on PET/CT. He was finally diagnosed with ATTR by endomyocardial biopsy. There are two major subtypes of cardiac amyloidosis: ATTR amyloidosis and amyloid light-chain (AL) amyloidosis. Endomyocardial biopsy is the gold standard for diagnosis. Recently, however, several reports have shown that bone scintigraphy using a 99mTc-labelled bone-seeking agent can detect ATTR cardiac amyloidosis and differentiate it from AL amyloidosis. Bone scintigraphy may play an important role in the detection and differentiation of ATTR cardiac amyloidosis.
  • Hayashi S; Nishida T; Osugi N; Yamaoka S; Sugimoto A; Mukai K; Nakamatsu D; Matsumoto K; Yamamoto M; Fukui K; Takenaka M; Hosono M; Inada M
    The American Journal of Gastroenterology 116 (1) 100 - 105 2021/01 [Refereed]
     
    INTRODUCTION: The global needs for a reduction in radiation exposure (RE) are increasing. Endoscopic retrograde cholangiopancreatography (ERCP) is a significant fluoroscopic procedure in the gastrointestinal field. However, the actual RE in ERCP and its annual trend are still unclear. Therefore, we examined the yearly trend of RE in ERCP. METHODS: This retrospective, single-center cohort study included consecutive cases of ERCP from September 2012 to June 2019. We measured the air kerma (AK, mGy), dose area product (DAP, Gycm2), and fluoroscopy time (FT, min). We also evaluated the annual trend of the RE before and after the fluoroscopy device update. RESULTS: In total, 2,174 patients receiving ERCP were enrolled. Among these, the mean age was 74.3 years, and 913 patients were women (42.0%). The median/third quartile values of AK (mGy), DAP (Gycm2), and FT (min) were 109/234 mGy, 13.3/25.8 Gycm2, and 18.2/27.7 minutes. The annual AK, DAP, and FT from 2012 to 2019 were 138, 207, 173, 177, 106, 71.0, 45.0, and 33.3 mGy; 23, 21.4, 19, 18.3, 11.9, 9.0, 6.8, and 6.4 Gycm2; and 12.5, 12.1, 9.7, 9.8, 8.2, 10.8, 9.4, and 10.3 minutes, respectively. The corresponding values before and after the update in July 2016 were 177 and 52 mGy (P < 0.0001), 19.2 and 7.6 Gycm2 (P < 0.0001), and 10.2, and 9.9 minutes (P = 0.05), respectively. DISCUSSION: The RE from ERCP tended to decrease every year, especially after fluoroscopy device updates.
    ダウンロード
  • Hayashi S; Nishida T; Kuriki S; Chang LS; Aochi K; Meren E; Sakamoto T; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Matsumoto K; Nakamatsu D; Yamamoto M; Fukui K; Takenaka M; Hosono M; Inada M
    Endoscopy international open Georg Thieme Verlag KG 8 (12) E1872-E1877 - E1877 2364-3722 2020/12 [Refereed]
     
    Background and study aims  Fluoroscopy-guided gastrointestinal procedures (FGPs) are increasingly common. However, the radiation exposure (RE) to patients undergoing FGPs is still unclear. We examined the actual RE of FGPs. Patients and methods  This retrospective, single-center cohort study included consecutive FGPs, including endoscopic retrograde cholangiopancreatography (ERCP), interventional endoscopic ultrasound (EUS), enteral stenting, balloon-assisted enteroscopy, tube placement, endoscopic injection sclerotherapy (EIS), esophageal balloon dilatation and repositioning for sigmoid volvulus, from September 2012 to June 2019. We measured the air kerma (AK, mGy), dose area product (DAP, Gycm 2 ), and fluoroscopy time (FT, min) for each procedure. Results  In total, 3831 patients were enrolled. Overall, 2778 ERCPs were performed. The median AK, DAP, and FT were as follows: ERCP: 109 mGy, 13.3 Gycm 2 and 10.0 min; self-expandable enteral stenting (SEMS): 62 mGy, 12.4 Gycm 2 and 10.4 min; tube placement: 40 mGy, 13.8 Gycm 2 and 11.1 min; balloon-assisted enteroscopy: 43 mGy, 22.4 Gycm 2 and 18.2 min; EUS cyst drainage (EUS-CD): 96 mGy, 18.3 Gycm 2 and 10.4 min; EIS: 36 mGy, 8.1 Gycm 2 and 4.4 min; esophageal balloon dilatation: 9 mGy, 2.2 Gycm 2 and 1.8 min; and repositioning for sigmoid volvulus: 7 mGy, 4.7 Gycm 2 and 1.6 min. Conclusion  This large series reporting actual RE doses of various FGPs could serve as a reference for future prospective studies.
    ダウンロード
  • Abe K; Hosono M; Igarashi T; Iimori T; Ishiguro M; Ito T; Nagahata T; Tsushima H; Watanabe H
    Annals of Nuclear Medicine 34 (11) 799 - 806 2020/11 [Refereed]
     
    The diagnostic reference levels (DRLs) are one of several effective tools for optimizing nuclear medicine examinations and reducing patient exposure. With the advances in imaging technology and alterations of examination protocols, the DRLs must be reviewed periodically. The first DRLs in Japan were established in 2015, and since 5 years have passed, it is time to review and revise the DRLs. We conducted a survey to investigate the administered activities of radiopharmaceuticals and the radiation doses of computed tomography (CT) in hybrid CT accompanied by single photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. We distributed a Web-based survey to 915 nuclear medicine facilities throughout Japan and survey responses were provided by 256 nuclear medicine facilities (response rate 28%). We asked for the facility's median actual administered activity and median radiation dose of hybrid CT when SPECT/CT or PET/CT was performed for patients with standard habitus in the standard protocol of the facility for each nuclear medicine examination. We determined the new DRLs based on the 75th percentile referring to the 2015 DRLs, drug package inserts, and updated guidelines. The 2020 DRLs are almost the same as the 2015 DRLs, but for the relatively long-lived radionuclides, the DRLs are set low due to the changes in the Japanese delivery system. There are no items set higher than the previous values. Although the DRLs determined this time are roughly equivalent to the DRLs used in the US, overall they tend to be higher than the European DRLs. The DRLs of the radiation dose of CT in hybrid CT vary widely depending on each imaging site and the purpose of the examination.
    ダウンロード
  • Role of J-RIME from view-point of revision of Japan DRLs2020
    Hosono M; Kanda R; Chang W; Koba Y; Akahane K; Okuda Y
    Innervision 35 (10) 4 - 4 2020/10 [Invited]
  • Outline of revision of nuclear medicine DRLs and points of utilization
    Hosono M; Abe K; Iimori T; Igarashi T; Ishiguro M; Ito T; Tsushima H; Nagahata T; Watanabe H
    Innervision 35 (10) 22 - 24 2020/10 [Invited]
  • Matsumori N; Kakei Y; Hosono M; Kinuya M; Takahashi S; Okayama Y; Sunaya T; Horio T; Uemura H
    Shinryo to Shinyaku （Med Cons New-Remed） 57 (7) 705 - 717 2020/07 [Refereed]
    ダウンロード
  • Safety and effectiveness of radium-223 in Japansese patients with CRPC and bone metastases in real world-settings: the results of post-marketing surveillance (PMS)
    Takahashi S, Uemura H, Matsumori N, Kinuya S, Hosono M, Okayama Y, Sunaya T, Horio T, Kakehi Y
    Jpn J Urol Surg 33 (4) 435 - 449 2020/04 [Refereed]
  • Matsubara N; Kimura G; Uemura H; Uemura H; Nakamura M; Nagamori S; Mizokami A; Kikukawa H; Hosono M; Kinuya S; Krissel H; Siegel J; Kakehi Y
    International journal of clinical oncology 25 (4) 720 - 731 2020/04 [Refereed]
     
    BACKGROUND: ERA 223 compared concurrent abiraterone acetate/prednisolone (AAP) plus radium-223 with AAP plus placebo in men with chemotherapy-naïve asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. We report data from a subgroup of Japanese patients in ERA 223. METHODS: Patients were randomized to radium-223 (55 kBq/kg) or placebo once every 4 weeks (max. 6 cycles), and also received oral abiraterone acetate 1000 mg once daily plus prednisone/prednisolone 5 mg twice daily during and after radium-223/placebo treatment, until a symptomatic skeletal event (SSE). The primary endpoint was SSE-free survival (SSE-FS); overall survival (OS) was a secondary endpoint. RESULTS: Of 806 patients randomized in ERA 223, 114 patients (57 per arm) were enrolled in Japan. SSE-FS was not improved significantly in the radium-223 arm [25.5 months, 95% CI 20.6-not estimated (NE)] compared with the placebo arm (28.7 months, 95% CI 19.7-NE) (HR = 0.907, 95% CI 0.501-1.642). OS and other secondary endpoints were not improved significantly in the radium-223 arm. The incidence of fracture was 23% and 11% in the radium-223 and placebo arms, respectively. The incidence of death was 32% and 36%, respectively. CONCLUSIONS: In the Japanese ERA 223 subgroup, concurrent treatment with AAP and radium-223 did not significantly improve SSE-FS and increased the incidence of fracture, similar to outcomes achieved in the overall population, while an increased incidence of death was not evident. The combination of radium-223 with AAP is not recommended in Japanese patients with asymptomatic or mildly symptomatic mCRPC and bone metastases. CLINICAL TRIAL REGISTRATION: Clinical trial registration no: NCT02043678.
    ダウンロード
  • Nishida T; Hayashi S; Takenaka M; Hosono M; Kogure H; Hasatani K; Yamaguchi S; Maruyama H; Doyama H; Ihara H; Yoshio T; Nagaike K; Yamada T; Yakushijin T; Takagi T; Tsumura H; Kurita A; Asai S; Ito Y; Kuwai T; Hori Y; Maetani I; Ikezawa K; Iwashita T; Matsumoto K; Inada M
    BMJ open 10 (2) e033604 - 8 2020/02 [Refereed]
     
    INTRODUCTION: Recently, the use of various endoscopic procedures under X-ray fluoroscopic guidance, such as endoscopic retrograde cholangiopancreatography (ERCP), interventional endoscopic ultrasonography (EUS), enteral endoscopy and stenting, has been rapidly increasing because of the minimally invasive nature of these procedures compared with that of surgical intervention. With the spread of CT and fluoroscopic interventions, including endoscopic procedures under X-ray guidance, high levels of radiation exposure (RE) from medical imaging have led to major concerns throughout society. However, information about RE related to these image-guided procedures in gastrointestinal endoscopy is scarce, and the RE reference levels have not been established. The aim of this study is to prospectively collect the actual RE dose and to help establish diagnostic reference levels (DRLs) in the field of gastroenterology in Japan. METHODS AND ANALYSIS: This is a multicentre, prospective observational study that is being conducted to collect the actual RE from treatments and diagnostic procedures, including ERCP, interventional EUS, balloon-assisted enteroscopy, enteral metallic stent placement and enteral tube placement. We will measure the total fluoroscopy time (min), the total dose-area product (Gycm2) and air-kerma (mGy) of those procedures. Because we are collecting the actual RE data and identifying the influential factors through a prospective, nationwide design, this study will provide guidance regarding the DRLs of ERCP, interventional EUS, balloon-assisted enteroscopy, enteral metallic stent placement and enteral tube placement. ETHICS AND DISSEMINATION: Approval was obtained from the Institutional Review Board of Toyonaka Municipal Hospital (25 April 2019). The need for informed consent will be waived via the opt-out method of each hospital website. TRIAL REGISTRATION NUMBER: The UMIN Clinical Trials Registry, UMIN000036525.
    ダウンロード
  • Shunji Takahashi; Yoshiyuki Kakehi; Naoya Masumori; Makoto Hosono; Seigo Kinuya; Yutaka Okayama; Toshiyuki Sunaya; Masafumi Okumura; Hirotsugu Uemura
    JOURNAL OF CLINICAL ONCOLOGY AMER SOC CLINICAL ONCOLOGY 38 (6) 0732-183X 2020/02 [Refereed]
  • 真性腸石のCT所見
    浜川 岳文; 松木 充; 鈴木 絢子; 沼本 勲男; 小田 晃義; 門場 智也; 細野 眞; 石井 一成
    Japanese Journal of Radiology (公社)日本医学放射線学会 38 (Suppl.) 42 - 42 1867-1071 2020/02
  • 横行結腸に生じたバンドによる絞扼性イレウスの1例 横行結腸軸捻転との比較
    沼本 勲男; 松木 充; 土居 秀平; 鈴木 絢子; 小田 晃義; 門場 智也; 藤谷 哲也; 松久保 祐子; 山田 穣; 兵頭 朋子; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 柏木 伸夫; 鶴崎 正勝; 細野 眞; 石井 一成
    Japanese Journal of Radiology (公社)日本医学放射線学会 38 (Suppl.) 42 - 42 1867-1071 2020/02
  • 梗塞性耳下腺腫瘍のMRI所見
    柏木 伸夫; 石井 一成; 小塚 健倫; 任 誠雲; 松木 充; 細野 眞
    Japanese Journal of Radiology (公社)日本医学放射線学会 38 (Suppl.) 45 - 45 1867-1071 2020/02
  • HOSONO Makoto
    Journal of Kyoto Prefectural University of Medicine 129 (2) 153 - 157 2020/02 [Refereed][Invited]
    ダウンロード
  • Makoto Hosono; Kengo Ito
    Isotope News Japan Radioisotope Association (767) 16 - 19 2020/02 [Invited]
    ダウンロード
  • Hiroshi Mori; Anri Inaki; Daiki Kayano; Hiroshi Wakabayashi; Makoto Hosono; Tatsuya Higashi; Noboru Oriuchi; Koichiro Abe; Mayuki Uchiyama; Seigo Kinuya
    Kaku igaku. The Japanese journal of nuclear medicine Japanese Society of Nuclear Medicine 57 (1) 39 - 46 2020 [Refereed]
     
    Targeted radionuclide therapy with high-dose radioisotopes should be performed in isolation rooms. Patients can be released only after radioactivity remaining in their bodies becomes less than the limits determined by the release criteria in order to secure public protection. Patients are asked to stay in isolation rooms for a few days. Physicians often face difficulties to carry out therapy in patients with limited activities of daily living and those undergoing hemodialysis, and have to avoid therapy in such cases. The Japanese Society of Nuclear Medicine conducted a nationwide survey in order to find out the actual situation. The survey results should reflect future improvement of therapeutic environment in collaborating with related societies and administrative bodies.
    ダウンロード
  • Mamoru Takenaka; Makoto Hosono; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi Kudo
    Journal of Japanese Society of Gastroenterology (一財)日本消化器病学会 116 (12) 1053 - 1055 0446-6586 2019/12 [Refereed]
    ダウンロード
  • HATAZAWA Jun; HOSONO Makoto
    Japanese Journal of Clinical Radiology 64 (13) 1495 - 1495 2019/12 [Invited]
  • Hosono M; Ikebuchi H; Kinuya S; Yanagida S; Nakamura Y; Yamada T; Sakaguchi K; Sugano H; Kojima K; Hatazawa J
    Annals of nuclear medicine 33 (11) 787 - 805 2019/11 [Refereed]
     
    We present the guideline for use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine. Treatment using yttrium-90-labeled anti-P-cadherin antibody injection in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown here are considered internationally useful as well. Only the original Japanese version is the formal document.
    ダウンロード
  • NAGATSU K; UKON N; YAMADA T; HOSONO M
    Japanese Journal of Radiation Safety Management (一社)日本放射線安全管理学会 18 (2) 36 - 40 1347-1503 2019/11 [Refereed]
  • 放射線治療の基礎知識
    細野 眞
    西日本泌尿器科 西日本泌尿器科学会 81 (増刊) np2 - np2 0029-0726 2019/10 [Refereed]
  • Hosono M
    International journal of radiation biology 95 (10) 1427 - 1430 2019/10 [Refereed][Invited]
     
    Purpose: Radionuclide therapy (RNT) involves the selective delivery of radiation, emitted from radionuclides to tumors or target organs. The techniques of RNT are increasingly being used for the treatment of various tumors. The purpose of this article is to report on the current state of RNT, to clarify the issues of radiation protection associated with RNT, and to show future prospects. Results and conclusions: Medical exposure of patients has unique features; application of dose limits is not undertaken, and justification and optimization do apply but in a different way from in other exposures. The expanding use of RNT has raised concern regarding potential carcinogenic and leukemogenic effects and research on second primary cancer after RNT have been developing. RNT combined with imaging and dosimetry and featuring a theranostic approach is undergoing a significant expansion, and such dosimetry-based treatment planning leads to individualization, or personalization, which is likely to improve the effectiveness and safety of patient management in RNT.
    ダウンロード
  • Yonekura Y; Mattsson S; Flux G; Bolch WE; Dauer LT; Fisher DR; Lassmann M; Palm S; Hosono M; Doruff M; Divgi C; Zanzonico P
    Ann ICRP SAGE Publications 48 (1) 5 - 95 0146-6453 2019/10 [Refereed][Invited]
    ダウンロード
  • 新たな治療手法に対応する医療放射線防護に関する研究 2016-2018年度厚生労働科学研究の概要
    細野 眞; 高橋 健夫; 山口 一郎; 赤羽 正章; 池渕 秀治; 柳田 幸子; 中村 吉秀
    Thermal Medicine (一社)日本ハイパーサーミア学会 35 (Suppl.) 112 - 112 1882-2576 2019/09
  • DRLsの現状と改訂に向けた取り組み
    細野 眞
    日本医学放射線学会秋季臨床大会抄録集 (公社)日本医学放射線学会 55回 S457 - S457 0048-0428 2019/09 [Refereed]
  • FDG-PETにおいて悪性リンパ腫の再発と脂肪壊死の鑑別が困難であった一例
    山中 彩; 川端 和奈; 細野 眞; 金柿 光憲; 尾谷 知亮; 松原 菜穂子; 岡 祥次郎; 田中 寛彬; 汪 洋; 田中 宏明; 山中 健也; 右京 直哉; 渡邊 光正; 木村 弘之
    日本医学放射線学会秋季臨床大会抄録集 (公社)日本医学放射線学会 55回 S505 - S505 0048-0428 2019/09 [Refereed]
  • Tomoaki Otani; Makoto Hosono; Mitsunori Kanagaki; Yasuyuki Onishi; Naoko Matsubara; Kazuna Kawabata; Hiroyuki Kimura
    AJR. American journal of roentgenology 213 (2) W50-W56 - W56 2019/08 [Refereed]
     
    OBJECTIVE. The purpose of this study was to characterize the Bayesian penalized likelihood (BPL) reconstruction algorithm in comparison with an ordered subset expectation maximization (OSEM) reconstruction algorithm and to determine its optimal penalization factor (expressed as a beta value) for clinical use. MATERIALS AND METHODS. FDG PET/CT scans of 46 patients with lung cancer were reconstructed using OSEM and BPL with beta values of 200, 300, 400, 500, and 1000. The liver signal-to-noise ratio, mean standardized uptake value (SUVmean) of the liver, and maximum standardized uptake value (SUVmax) and SUVmean of the cancers were measured. Tumors were categorized into three size groups, and the percentage difference in the tumor SUVmax between OSEM and BPL with a beta value of 200 as well as the percentage difference in the SUVmax between BPL with a beta value of 200 and BPL with a beta value of 1000 were calculated. Image quality was assessed by visual scoring. RESULTS. BPL showed a significantly higher liver signal-to-noise ratio than OSEM, except for BPL with a beta value of 200. The liver SUVmean showed no statistical difference among all algorithms. The SUVmax and SUVmean of tumors decreased as the beta value increased. BPL with a beta value of 200 produced a significantly higher tumor SUVmax than did OSEM (p < 0.01), and BPL with a beta value of 400, 500, or 1000 produced a significantly lower tumor SUVmax than did OSEM (p < 0.01). Visual analysis showed the highest and lowest scores for BPL with beta values of 500 and 200, respectively. In the small size group, the percentage difference in the SUVmax between OSEM and BPL with a beta value of 200 and the percentage difference in the SUVmax between BPL with a beta value of 200 and BPL with a beta value of 1000 were significantly larger than that in the other size groups (p < 0.01). CONCLUSION. The BPL algorithm improves image quality without compromising image quantification. A beta value of 500 appeared to be optimal in this study. Smaller tumors were more influenced by BPL.
    ダウンロード
  • Ooe K; Watabe T; Kamiya T; Yoshimura T; Hosono M; Shinohara A; Hatazawa J
    EJNMMI physics 6 (1) 13 - 13 2019/07 [Refereed]
     
    BACKGROUND: The α-emitting radionuclide radium-223 (223Ra) is widely used for the treatment of bone metastasis in patients with castration-resistant prostate cancer. However, 223Ra decays into radon-219 (219Rn) which is a noble-gas isotope, and 219Rn may escape from patients treated with 223Ra via their respiration. In this study, we quantified the amount of 219Rn contained in the breath of patients treated with 223Ra to estimate its effect on the internal exposure dose of caregivers. METHODS: A total of 12 breath samples were collected using a breath collection bag from a total of six patients treated with 223RaCl2. Approximately 300 mL of exhaled breath was collected in a breath bag at 1 min and at 5 min after the start of 223RaCl2 administration. The contents of each bag were measured using an HPGe detector, and the amount of 219Rn was quantified based on the detection of the γ peak of 211Bi, which is a descendant nuclide of 219Rn, persisting in the breath bag. The effective dose to caregivers arising from the inhalation of 219Rn was estimated by referring to the scenario for the calculation of release criteria established for 131I therapy in Japan. RESULTS: A small peak for the 351-keV γ ray of 211Bi originating from the exhalation of 219Rn was observed. Using the observed γ peak of 211Bi, the average amounts of 219Rn per unit breath volume at 1 min and 5 min after the start of 223RaCl2 administration were calculated as 90 ± 56 Bq/mL and 28 ± 9 Bq/mL, respectively. The effective dose of 219Rn to caregivers was estimated to be 3.5 μSv per injection. CONCLUSIONS: The amount of 219Rn in the exhaled breath of patients treated with 223RaCl2 was quantitatively calculated using breath collection bags. The internal radiation exposure of caregivers from 219Rn in the exhaled breath of patients treated with 223RaCl2 is relatively small.
    ダウンロード
  • 放射線治療の基礎知識
    細野 眞
    日本泌尿器科学会雑誌 (一社)日本泌尿器科学会 110 (3) np1 - np1 0021-5287 2019/07 [Refereed]
  • Takenaka M; Hayashi S; Nishida T; Hosono M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Minaga K; Kamata K; Yamao K; Kudo M
    GASTROINTESTINAL ENDOSCOPY 89 (6) AB444 - AB445 0016-5107 2019/06 [Refereed]
  • Fukumoto G; Hosono M; Kanagaki M; Ichinose M; Nishisaka K
    Japanese Archive of Cases Conference of Clinical Nuclear Medicine 1 23 - 27 2019/06 [Refereed]
  • Hosono M
    Nuclear medicine and molecular imaging 53 (3) 167 - 171 2019/06 [Refereed][Invited]
     
    Radionuclide therapy (RNT) stands on the delivery of radiation to tumors or non-tumor target organs using radiopharmaceuticals that are designed to have specific affinity to targets. RNT is recently called molecular radiotherapy (MRT) by some advocators in order to emphasize its characteristics as radiotherapy and the relevance of dosimetry-guided optimization of treatment. Moreover, RNT requires relevant radiation protection standards because it employs unsealed radionuclides and gives therapeutic radiation doses in humans. On the basis of these radiation protection standards, the development and use of radiopharmaceuticals for combined application through diagnostics and therapeutics lead to theranostic approaches that will enhance the efficacy and safety of treatment by implementing dosimetry-based individualization.
    ダウンロード
  • Fukumoto G; Hosono M; Kanagaki M; Otani T; Ikegaki S
    Japanese Archive of Cases Conference of Clinical Nuclear Medicine 1 17 - 22 2019/05 [Refereed]
  • Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    International journal of clinical oncology 24 (5) 557 - 566 2019/05 [Refereed]
     
    BACKGROUND: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC. METHODS: Patients with symptomatic mCRPC, ≥ 2 bone metastases and no known visceral metastases received up to 6 injections of radium-223 (55 kBq/kg), one every 4 weeks. Adverse events (AEs) considered to be related to radium-223 were reported until 3 years after the first injection. Pre-specified conditions, such as acute myelogenous leukemia, myelodysplastic syndrome, aplastic anemia, primary bone cancer, or other primary malignancies, were reported regardless of causality. RESULTS: Of the 49 patients enrolled in the study, 44 (89.8%) entered the survival follow-up period and 33 (67.3%) died. Throughout the entire study, there were no reports of second primary malignancy or other pre-specified conditions. Eight patients (16.3%) experienced post-treatment drug-related AEs, which were all hematological (anemia and decreased lymphocyte, platelet, and white blood cell counts). No serious post-treatment drug-related AEs were reported. Updated median OS was 19.3 months (95% CI: 14.2, 28.5). CONCLUSIONS: In Japanese patients with symptomatic mCRPC and bone metastases, radium-223 had a favorable long-term safety profile with no second primary malignancies reported. Taken together with median OS, which was comparable to that in the pivotal phase III ALSYMPCA study, these results support continued benefit from radium-223 in Japanese patients with mCRPC.
    ダウンロード
  • 骨転移を有する去勢抵抗性前立腺癌患者を対象とした塩化ラジウム-223の使用成績調査中間解析結果 日本および海外実臨床下における患者背景の特徴
    植村 天受; 舛森 直哉; 高橋 俊二; 細野 眞; 絹谷 清剛; 平野 和史; 筧 善行
    日本泌尿器科学会総会 (一社)日本泌尿器科学会総会事務局 107回 OP - 497 2019/04 [Refereed]
  • 化学療法未治療の無症候性/軽度症候性の骨転移を有するCRPCにおける塩化ラジウム-223とアビラテロン及びプレドニゾロンの併用試験(ERA223試験) 日本人部分集団解析
    木村 剛; 松原 伸晃; 上村 博司; 植村 天受; 中村 元信; 永森 聡; 溝上 敦; 菊川 浩明; 細野 眞; 絹谷 清剛; Krissel Heiko; Shen Junwu; 筧 善行; ERA223 Investigators in Japan
    日本泌尿器科学会総会 (一社)日本泌尿器科学会総会事務局 107回 OP - 498 2019/04 [Refereed]
  • HOSONO Makoto
    Innervision 34 (3) 32 - 33 2019/03 [Invited]
    ダウンロード
  • Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
    Annals of nuclear medicine 33 (3) 211 - 221 2019/03 [Refereed]
     
    Radium-223 dichloride (Ra-223) is the first targeted alpha therapy approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastasis. Ra-223 improved overall survival in the international Phase III ALSYMPCA (ALpharadin in SYMPtomatic Prostate Cancer) study. Ra-223 was also demonstrated to be efficacious and safe in Japanese patients in Phase I and Phase II clinical trials. Ra-223 was approved in Japan for the treatment of patients with CRPC with bone metastasis in 2016. The conduct of clinical studies with radionuclides in Japan involves mandatory compliance with local and international regulations pertaining to radiation protection. Without an existing Japanese framework for the handling of α-emitters in clinical practice, we encountered many challenges to initiate the clinical studies. Therefore, we started on a project to determine best practice on the use of Ra-223 in clinical studies. For this project, we evaluated all applicable laws and regulations on the use of radionuclides in medicine, then examined whether and how the α-emitter Ra-223 could meet these legal and regulatory requirements. This included how to approach the matter of discharging patients administered Ra-223 from hospital and radiation protection for caregivers, general public and medical care professionals. Subsequently, we published Manual on the proper use of radium-223 dichloride injection in clinical trials that summarized the essential requirements necessary to allow the safe use of Ra-223 in clinical trials in Japan. As the result, we succeeded in demonstrating that clinical trials of an α-emitter, Ra-223, could be implemented safely in Japan. Our experience in Japan highlights the importance of a multidisciplinary team-based approach and continued professional training in a clinical setting. This article summarizes the rationale behind the development of this manual. We hope that by sharing our experience and information, we can help other countries considering the introduction of radionuclides for clinical use, and support the future development of radionuclide therapies in a safe and effective manner.
    ダウンロード
  • 肺癌手術にて病理診断されたMultiple minute pulmonary meningothelial-like nodulesの1例
    和田 祐太郎; 松木 充; 土居 秀平; 鈴木 絢子; 沼本 勲男; 小田 晃義; 山田 穣; 兵頭 朋子; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 細川 知紗; 小塚 健倫; 柏木 伸夫; 鶴崎 正勝; 今岡 いずみ; 細野 眞; 石井 一成; 村上 卓道; 榎木 英介
    Japanese Journal of Radiology (公社)日本医学放射線学会 37 (Suppl.) 40 - 40 1867-1071 2019/02
  • 竹中完; 細野眞; 細野眞; 中井敦史; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 林史郎; 西田勉; 工藤正俊
    日本消化器病学会雑誌(Web) 116 (12) 1349-7693 2019
  • 甲斐田 勇人; 山田 穣; 松久保 祐子; 花岡 宏平; 任 誠雲; 柳生 行伸; 細野 眞; 石井 一成
    核医学 (一社)日本核医学会 56 (1) 153 - 153 0022-7854 2019 [Refereed]
  • Hayashi S; Takenaka M; Hosono M; Nishida T
    World journal of clinical cases 6 (16) 1087 - 1093 2307-8960 2018/12 [Refereed][Invited]
     
    Endoscopic retrograde cholangiopancreatography (ERCP) is one of the most frequently used image-guided procedures in gastrointestinal endoscopy. Post-ERCP pancreatitis is an important concern, and prophylaxis, cannulation and other related technical procedures have been well documented by endoscopists. In addition, medical radiation exposure is of great concern in the general population because of its rapidly increasing frequency and its potential carcinogenic effects. International organizations and radiological societies have established diagnostic reference levels, which guide proper radiation use and serve as global standards for all procedures that use ionizing radiation. However, data on gastrointestinal fluoroscopic procedures are still lacking because the demand for these procedures has recently increased. In this review, we present the current status of quality indicators for ERCP and the methods for measuring radiation exposure in the clinical setting as the next quality indicator for ERCP. To reduce radiation exposure, knowledge of its adverse effects and the procedures for proper measurement and protection are essential. Additionally, further studies on the factors that affect radiation exposure, exposure management and diagnostic reference levels are necessary. Then, we can discuss how to manage medical radiation use in these complex fluoroscopic procedures. This knowledge will help us to protect not only patients but also endoscopists and medical staff in the fluoroscopy unit.
  • 細野 眞; 千田 道雄; 佐々木 雅之; 百瀬 敏光; 伊藤 健吾; 岡村 光英; 織田 圭一; 川本 雅美; 久下 裕司; 櫻井 実; 立石 宇貴秀; 藤林 康久; 間賀田 泰寛; 村上 康二; 吉田 毅; 脇 厚生; 加藤 克彦; 橋本 禎介; 内山 眞幸; 絹谷 清剛; 東 達也; 待鳥 詔洋; 丸野 廣大; 南本 亮吾; 吉永 恵一郎; 日本核医学会, PET核医学委員会, 健保委員会
    核医学 (一社)日本核医学会 55 (1) 1 - 22 0022-7854 2018/12
  • 骨転移を有する去勢抵抗性前立腺癌患者を対象とした塩化ラジウム-223の使用成績調査(中間解析結果)
    絹谷 清剛; 筧 善行; 舛森 直哉; 高橋 俊二; 細野 眞; 平野 和史; 松葉 康浩; 砂谷 敏行; 植村 天受
    核医学 (一社)日本核医学会 55 (Suppl.) S189 - S189 0022-7854 2018/11 [Refereed]
  • FDG PET/CTによる食道癌術前化学療法の予後解析
    甲斐田 勇人; 白石 治; 岩間 密; 加藤 寛章; 木村 豊; 花岡 宏平; 山田 穣; 北島 一宏; 細野 眞; 安田 卓司; 石井 一成
    核医学 (一社)日本核医学会 55 (Suppl.) S200 - S200 0022-7854 2018/11 [Refereed]
  • 短寿命α核種等のRI利用における合理的な放射線安全管理のあり方に関する研究
    細野 眞; 織内 昇; 右近 直之; 永津 弘太郎; 伊藤 哲夫; 山西 弘城; 松田 外志朗; 山田 崇裕; 蜂須賀 暁子; 中村 吉秀
    核医学 (一社)日本核医学会 55 (Suppl.) S215 - S215 0022-7854 2018/11 [Refereed]
  • 乳癌骨転移に対しビスホスホネート製剤の長期投与中に発症した非定型大腿骨骨折の骨シンチグラフィ所見
    田中 寛彬; 細野 眞; 松原 菜穂子; 金柿 光憲; 川端 和奈; 木村 弘之; 猪坂 直義; 岡田 有紀; 太治 智愛; 諏訪 裕文
    核医学 (一社)日本核医学会 55 (Suppl.) S227 - S227 0022-7854 2018/11 [Refereed]
  • 放射性同位元素内用療法の現状と発展 国内の核医学治療の現状と将来
    細野 眞
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 56回 PD18 - 1 2018/10 [Refereed]
  • HOSONO Makoto
    Radiation Effects Association 10 (97) 21 - 22 2018/10 [Invited]
  • Yukie Yoshii; Mitsuyoshi Yoshimoto; Tatsuya Higashi; Makoto Hosono
    Kakuigaku 55 (1) 77 - 87 2018/07 [Refereed]
  • Watanabe Shota; Sakaguchi Kenta; Hosono Makoto; Ishii Kazunari; Murakami Takamichi; Ichikawa Katsuhiro
    Japanese Journal of Radiological Technology 公益社団法人 日本放射線技術学会 74 (4) 375 - 381 0369-4305 2018/04 [Refereed]
     

    The purpose of this study was to evaluate the effect of a hybrid-type iterative reconstruction method on Z-score mapping of hyperacute stroke in unenhanced computed tomography (CT) images. We used a hybrid-type iterative reconstruction [adaptive statistical iterative reconstruction (ASiR)] implemented in a CT system (Optima CT660 Pro advance, GE Healthcare). With 15 normal brain cases, we reconstructed CT images with a filtered back projection (FBP) and ASiR with a blending factor of 100% (ASiR100%). Two standardized normal brain data were created from normal databases of FBP images (FBP-NDB) and ASiR100% images (ASiR-NDB), and standard deviation (SD) values in basal ganglia were measured. The Z-score mapping was performed for 12 hyperacute stroke cases by using FBP-NDB and ASiR-NDB, and compared Z-score value on hyperacute stroke area and normal area between FBP-NDB and ASiR-NDB. By using ASiR-NDB, the SD value of standardized brain was decreased by 16%. The Z-score value of ASiR-NDB on hyperacute stroke area was significantly higher than FBP-NDB (p<0.05). Therefore, the use of images reconstructed with ASiR100% for Z-score mapping had potential to improve the accuracy of Z-score mapping.

  • HOSONO Makoto; CHATAL Jean-François
    Resistance to Targeted Anti-Cancer Therapeutics 1 - 158 2018/04 [Refereed][Invited]
  • Hosono M; Ikebuchi H; Nakamura Y; Nakamura N; Yamada T; Yanagida S; Kitaoka A; Kojima K; Sugano H; Kinuya S; Inoue T; Hatazawa J
    Annals of Nuclear Medicine Springer Tokyo 32 (3) 217 - 235 1864-6433 2018/04 [Refereed][Invited]
     
    Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.
  • Murakami T; Hosono M; Shibata T
    Asian Cardiovascular and Thoracic Annals SAGE Publications Inc. 26 (3) 250 - 251 1816-5370 2018/03 [Refereed]
  • Tachibana I; Nishimura Y; Hanaoka K; Inada M; Fukuda K; Tatebe H; Ishikawa K; Nakamatsu K; Kanamori S; Hosono M
    Anticancer research 38 (3) 1775 - 1781 0250-7005 2018/03 [Refereed]
     
    BACKGROUND/AIM: 18F-misonidazole positron emission tomography (FMISO PET)/computed tomography (CT) obtained before and during radiotherapy (RT) was analyzed as to whether it could predict clinical outcome. PATIENTS AND METHODS: Twenty-two patients were included. FMISO PET/ CT was performed twice before RT and at a dose of approximately 20 Gy/10 fractions. FMISO maximum standardized uptake values (SUVmax), the tumor-to-muscle ratios (T/M), and hypoxic volume (HV) in gross target volumes were measured. RESULTS: Of the 22 tumors, 18 had hypoxic areas (SUVmax ≥1.60) before RT. SUVmax, T/M, and HV on the first PET/CT were significantly correlated with initial tumor response, although the values during RT were not related to the response. The overall survival and loco-regional control rates of patients below cut-off values were significantly better than those above the cut-off values. CONCLUSION: Tumor hypoxia detected by FMISO PET/CT before RT may predict clinical outcome.
  • 福井秀行; 松木充; 任誠雲; 甲斐田勇人; 柳生行伸; 小塚健倫; 細川知紗; 熊野正士; 柏木伸夫; 鶴崎正勝; 今岡いずみ; 細野眞; 石井一成; 村上卓道
    Japanese Journal of Radiology (公社)日本医学放射線学会 36 (Supplement) 34 - 34 1867-1071 2018/02
  • 沼本勲男; 松木充; 福井秀行; 若林雄一; 日高正二郎; 渡口真史; 藤谷哲也; 山川美帆; 兵頭朋子; 山田穣; 任誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 細川知紗; 小塚健倫; 鶴崎正勝; 今岡いずみ; 細野眞; 石井一成; 村上卓道
    Japanese Journal of Radiology (公社)日本医学放射線学会 36 (Suppl.) 27 - 27 1867-1071 2018/02 [Refereed]
  • Nobuaki Matsubara; Satsohi Nagamori; Yoshiaki Wakumoto; Hirotsugu Uemura; Go Kimura; Akira Yokomizo; Hiroaki Kikukawa; Atsushi Mizokami; Takeo Kosaka; Naoya Masumori; Yoshihide Kawasaki; Junji Yonese; Yasutomo Nasu; Satoshi Fukasawa; Takayuki Sugiyama; Seigo Kinuya; Makoto Hosono; Iku Yamaguchi; Hirokazu Tsutsui; Hiroji Uemura
    International journal of clinical oncology 23 (1) 173 - 180 1341-9625 2018/02 [Refereed]
     
    BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles. The primary endpoint was the percent change in total alkaline phosphatase (ALP) from baseline at 12 weeks. Secondary endpoints included the percent ALP change from baseline to end of treatment (EOT), ALP response rates, percent change in prostate-specific antigen (PSA) from baseline to 12 weeks and EOT, PSA response rates, overall survival (OS), and time to symptomatic skeletal events (SSEs). Adverse events were monitored throughout the study period. RESULTS: Of the 49 Japanese patients (median age 74 years), 28 completed all infusions. Mean percent change in total ALP and PSA from baseline to 12 weeks was -19.3 and +97.4%, respectively. One-year OS and SSE-free rate at the end of active follow-up were 78 and 89%, respectively. The ALP response rate was 31%, while the PSA response rate was 6%. Grade 3/4 treatment-emergent adverse events observed in ≥10% of patients included decreased lymphocyte count (14%), anemia (14%), anorexia (10%), and bone pain (10%). CONCLUSIONS: Radium-223 is effective and well tolerated in Japanese patients with CRPC and bone metastases. Results were comparable with the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01929655.
  • 細野眞; 細野眞
    泌尿器外科 30 (10) 1521‐1526  0914-6180 2017/10
  • HOSONO Makoto
    hinyoki-geka 30 (10) 1521 - 1526 2017/10 [Invited]
  • Hiroji Uemura; Hirotsugu Uemura; Nobuaki Matsubara; Seigo Kinuya; Makoto Hosono; Yoko Yajima; Toshihiko Doi
    International journal of clinical oncology 22 (5) 954 - 963 1341-9625 2017/10 [Refereed]
     
    BACKGROUND: Radiation therapy with radium-223 dichloride improves overall survival, reduces symptomatic skeletal events in Caucasian patients with castration-resistant prostate cancer (CRPC) and bone metastases, and is well tolerated. We report here the results of the first efficacy and safety study of radium-223 dichloride in a Japanese population. METHODS: In this open-label, uncontrolled, non-randomized, phase I trial, radium-223 dichloride was given to Japanese patients with CRPC and ≥2 bone metastases in 4-week cycles. The patients were divided into three cohorts, with cohort 1 and the expansion cohort receiving injections of radium-223 dichloride [55 kBq/kg body weight (BW)] every 4 weeks (Q4W) for up to six injections, and cohort 2 receiving an initial single radium-223 dichloride injection of 110 kBq/kg BW followed by up to five injections of 55 kBq/kg BW Q4W. Safety was determined via adverse event (AE) reporting, and biochemical bone markers were assessed for treatment efficacy. RESULTS: In total 19 patients received at least one dose of radium-223 dichloride and 18 patients experienced at least one treatment-emergent AE (TEAE) of which the most common were anemia, thrombocytopenia, and lymphocytopenia. Serious AEs were reported in three patients but none were drug-related. In the patients of cohort 1 + expansion cohort (55 kBq/kg BW Q4W treatment; n = 16), prostate-specific antigen levels remained stable or slightly increased while the bone alkaline phosphatase (ALP) level significantly decreased. The response rates of bone ALP (≥30 and ≥50% reductions) were 81.8 and 36.4% at week 12, and 81.3 and 50.0% at the end of treatment. CONCLUSIONS: Radium-223 dichloride was well tolerated in these Japanese patients and, at a dose of 55 kBq/kg BW, efficacy on biomarkers was as expected. The outcomes in Japanese patients were consistent with those reported in other non-Japanese populations. TRIAL REGISTRATION: ClinicalTrials.gov record NCT01565746.
  • HOSONO Makoto
    Pharma Medica 35 (9) 96 - 101 0289-5803 2017/09 [Invited]
  • Volumetric parameterを用いた食道癌切除患者の予後因子の検討
    甲斐田 勇人; 石井 一成; 細川 知紗; 柳生 行伸; 任 誠雲; 兵頭 朋子; 山田 穣; 細野 眞; 安田 卓司; 村上 卓道
    核医学 (一社)日本核医学会 54 (Suppl.) S193 - S193 0022-7854 2017/09
  • 呼吸同期FDG PET/CTによる放射線治療計画について
    花岡 宏平; 奥村 雅彦; 西村 泰昌; 門前 一; 渡邊 翔太; 柴田 侑亮; 細野 眞; 石井 一成; 村上 卓道
    核医学 (一社)日本核医学会 54 (Suppl.) S167 - S167 0022-7854 2017/09 [Refereed]
  • 細野眞
    日本医学放射線学会秋季臨床大会抄録集 (公社)日本医学放射線学会 53回 S435 - S436 0048-0428 2017/08 [Refereed]
  • 大西康之; 細野眞; 金柿光憲; 福本元気; 尾谷知亮; 松原菜穂子; 木村弘之
    核医学症例検討会症例集 38 (2) 41  0910-2213 2017/08
  • 藤井康司; 白髭賢也; 竹中達明; 細野眞
    核医学症例検討会症例集 38 (2) 31‐32  0910-2213 2017/08
  • Hiroshi Watanabe; Kimiya Noto; Tomokazu Shohji; Yasuyoshi Ogawa; Toshioh Fujibuchi; Ichiro Yamaguchi; Hitoshi Hiraki; Tetsuo Kida; Kazutoshi Sasanuma; Yasushi Katsunuma; Takurou Nakano; Genki Horitsugi; Makoto Hosono
    Radiological Physics and Technology Springer Tokyo 10 (2) 213 - 226 1865-0341 2017/06 [Refereed]
     
    The goal of this study is to develop a more appropriate shielding calculation method for computed tomography (CT) in comparison with the Japanese conventional (JC) method and the National Council on Radiation Protection and Measurements (NCRP)-dose length product (DLP) method. Scattered dose distributions were measured in a CT room with 18 scanners (16 scanners in the case of the JC method) for one week during routine clinical use. The radiation doses were calculated for the same period using the JC and NCRP-DLP methods. The mean (NCRP-DLP-calculated dose)/(measured dose) ratios in each direction ranged from 1.7 ± 0.6 to 55 ± 24 (mean ± standard deviation). The NCRP-DLP method underestimated the dose at 3.4% in fewer shielding directions without the gantry and a subject, and the minimum (NCRP-DLP-calculated dose)/(measured dose) ratio was 0.6. The reduction factors were 0.036 ± 0.014 and 0.24 ± 0.061 for the gantry and couch directions, respectively. The (JC-calculated dose)/(measured dose) ratios ranged from 11 ± 8.7 to 404 ± 340. The air kerma scatter factor κ is expected to be twice as high as that calculated with the NCRP-DLP method and the reduction factors are expected to be 0.1 and 0.4 for the gantry and couch directions, respectively. We, therefore, propose a more appropriate method, the Japanese-DLP method, which resolves the issues of possible underestimation of the scattered radiation and overestimation of the reduction factors in the gantry and couch directions.
  • HOSONO Makoto
    臨床放射線 62 619 - 612 2017/05 [Refereed]
  • 赤座 英之; 酒井 英樹; 米田 俊之; 細野 眞; 和久本 芳彰
    泌尿器外科 医学図書出版(株) 30 (4) 409 - 416 0914-6180 2017/04
  • Tomofumi Misaka; Makoto Hosono; Takashi Kudo; Takamichi Ito; Tsutomu Syomura; Masanobu Uemura; Kaoru Okajima
    ANNALS OF NUCLEAR MEDICINE SPRINGER 31 (3) 235 - 244 0914-7187 2017/04 [Refereed]
     
    Objective The association between left ventricular (LV) dyssynchrony parameters, given by phase analysis of gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), and acquisition orbits is unclear. The aim of this study was to assess the dependence of LV dyssynchrony parameters on acquisition orbits. Methods Ninety-nine patients who underwent Tl-201-gated SPECT MPI were categorized into minor hypoperfusion or major hypoperfusion groups. Forty-four patients who underwent Tc-99m-tetrofosmin-gated SPECT MPI were categorized into minor hypoperfusion or major hypoperfusion groups. The major hypoperfusion group with Tl-201 was divided into inferior or non-inferior wall hypoperfusion subgroups, and anteroseptal or non-anteroseptal wall hypoperfusion subgroups. Gated SPECT MPI data over a 360A degrees acquisition orbit (360A degrees images) and a 180A degrees acquisition orbit (180A degrees images) were reconstructed, and histogram bandwidth (HBW) and phase standard deviation (PSD) were compared. Results Between 360A degrees and 180A degrees images with Tl-201, there were significant differences in HBW and PSD both globally (HBW 34.8 +/- 16.6 vs. 29.1 +/- 10.2; PSD 8.8 +/- 4.9 vs. 7.0 +/- 2.3, p < 0.05 for both) and in the inferior wall (HBW 29.5 +/- 15.5 vs. 23.3 +/- 9.0; PSD 7.6 +/- 4.6 vs. 5.6 +/- 2.4, p < 0.001 for both) in the major hypoperfusion group, and also in the inferior wall in all subgroups of the major hypoperfusion group. In contrast, no segment had any significant differences in HBW or PSD between 360A degrees and 180A degrees images with Tc-99m. Conclusion Differences in acquisition orbit had a significant influence on HBW and PSD with Tl-201-gated SPECT MPI in the inferior wall in patients with major hypoperfusion myocardium.
  • 細野眞
    日本放射線技術学会総会学術大会予稿集 73rd 112  1884-7846 2017/03
  • 藤井康司; 白髭賢也; 竹中達明; 細野眞
    日本放射線技術学会総会学術大会予稿集 73rd 302  1884-7846 2017/03
  • 上顎洞術後変化としての眼窩下管拡大
    福井 秀行; 柏木 伸夫; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 細川 知紗; 熊野 正士; 鶴崎 正勝; 松木 充; 今岡 いずみ; 石井 一成; 細野 眞; 村上 卓道
    Japanese Journal of Radiology (公社)日本医学放射線学会 35 (Suppl.) 54 - 54 1867-1071 2017/02
  • 甲斐田 勇人; 石井 一成; 細川 知紗; 仁 誠雲; 細野 眞; 村上 卓道; 花岡 宏平; 乾 浩己
    核医学 (一社)日本核医学会 54 (1) 668 - 669 0022-7854 2017/02 [Refereed]
  • 横川正樹; 中松清志; 稲田正浩; 福田浩平; 建部仁志; 石川一樹; 立花和泉; 門前一; 金森修一; 西村恭昌; 細野眞
    Japanese Journal of Radiology (公社)日本医学放射線学会 35 (Suppl.) 51 - 51 1867-1071 2017/02
  • アイソトープ治療の現状と展望 アルファ核種の利用
    細野 眞
    Japanese Journal of Radiology (公社)日本医学放射線学会 35 (Suppl.) 45 - 45 1867-1071 2017/02
  • Tomohiro Matsuura; Yasumasa Nishimura; Kiyoshi Nakamatsu; Shuichi Kanamori; Kazuki Ishikawa; Izumi Tachibana; Makoto Hosono; Toru Shibata
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 22 (1) 52 - 58 1341-9625 2017/02 [Refereed]
     
    Background Clinical results of computed tomography (CT) simulations and [F-18]-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/CT simulations were compared retrospectively. Materials and methods Between 2006 and 2011, [F-18]FDG PET/CT simulation was performed on 68 consecutive patients with pharyngeal cancers (PET/CT group). As an historical control, conventional CT simulation was performed on 56 consecutive patients with pharyngeal cancer between 2000 and 2006 (CT group). In the PET/CT group, the primary sites were nasopharynx (NPC), oropharynx (OPC), and hypopharynx (HPC) in 35, 20, and 13 patients, respectively; in the CT group, the primary sites were NPC, OPC, and HPC in 21, 17, and 18 patients, respectively. All but five patients in the PET/CT group were treated with intensity modulated radiation therapy (IMRT). Results In the PET/CT group, TNM and clinical stages changed in 11 (16 %) and eight (12 %) patients, respectively. Although the 5-year overall survival (OS) rates for the PET/CT and the CT groups were 80 and 64 %,respectively (p = 0.0420), this result may be attributable to the background difference between the two groups. Similarly, the 5-year locoregional control rates of the two groups were 82 and 70 %, respectively (p = 0.0501). Notably, marginal recurrences around the planning target volume (PTV) were only noted in four CT group patients. Conclusion PET/CT simulation was useful for delineating an accurate clinical target volume (CTV) of pharyngeal cancer, and its clinical results were satisfactory.
  • Kenta Sakaguchi; Makoto Hosono; Tomomi Imamura; Naomi Takahara; Misa Hayashi; Yuko Yakushiji; Kazunari Ishii; Tatsuro Uto; Takamichi Murakami
    EJNMMI physics 3 (1) 28 - 28 2197-7364 2016/12 [Refereed]
     
    BACKGROUND: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is now a routine procedure for the management of cancer patients. Intravenous administration of FDG is sometimes halted due to troubles. In such cases, estimations of the FDG dosage injected prior to halting administration may be helpful. We have established a method of estimating the activity of FDG to patients on the basis of the dose equivalent rate on the surface of the right temporal region of the head. The correlation of actual administered dosage with independent variables, such as the dose equivalent rate on the right temporal region of the head, age, sex, and body weight, was analyzed using multiple regression analysis to obtain linear, quadratic, and cubic regression equations. RESULTS: When entering independent variables, the cubic regression equation could be used to estimate an administered dosage with an accuracy of ±10 % for 62 % of all patients and ±20 % for 90 % of all patients. CONCLUSIONS: We conclude that this method is useful for estimating the administered dosage from the dose equivalent rate on the temporal region of the head.
  • 細野眞
    Innervision 31 (12) 2‐4  0913-8919 2016/11
  • 【医療被ばくの正当化と最適化に向けてPart II】 診断参考レベル(DRL)に対する活動と課題 核医学検査の診断参考レベル(DRL)に対する活動と課題
    細野 眞
    INNERVISION (株)インナービジョン 31 (12) 12 - 14 0913-8919 2016/11 
    医療放射線に関連した学会・団体が、医療被ばく研究情報ネットワーク(Japan Network for Research and Information on Medical Exposure:J-RIME)の枠組みにて協働して診断参考レベルの設定に取り組み、2015年6月7日に「診断参考レベル2015(Japan DRLs 2015)」(以下、DRLs2015)を公表した。これに含まれる6つのモダリティの1つに核医学検査がある。核医学検査の診断参考レベルは、全国のすべての核医学診療施設を対象にして調査を実施し、その集計結果に基づいて「実投与量」として設定したものである。また、小児の核医学検査における放射性薬剤の適正投与量の設定も重要な課題であった。これについては、診断参考レベルとは別の概念に基づいて検討され、「小児核医学検査適正施行のコンセンサスガイドライン」に示された。したがって、現在、成人の適正投与量についてはDRLs2015、小児の適正投与量については「小児核医学検査適正施行のコンセンサスガイドライン」に規定されている仕組みとなっており、この2つの適正投与量とその内容を十分に理解して核医学検査を実施することが要である。これらの適正投与量が公表(2013〜2015年)された後、関連した学会・団体は学術集会、機関誌、Webサイトなどを通じてその普及に努めている。(著者抄録)
  • 細野眞
    Innervision (株)インナービジョン 31 (12) 26 - 27 0913-8919 2016/11
  • 認知症患者における線条体アミロイド沈着の検討
    細川 知紗; 石井 一成; Sauerbeck Julia; Sheiwein Franziska; 甲斐田 勇人; 兵頭 朋子; 山田 穣; 細野 眞; 花岡 宏平; 村上 卓道
    核医学 (一社)日本核医学会 53 (Suppl.) S276 - S276 0022-7854 2016/10 [Refereed]
  • 健康長寿社会をめざして 核医学の挑戦 Theranostics イメージングと治療の融合
    細野 眞
    核医学 (一社)日本核医学会 53 (Suppl.) S58 - S58 0022-7854 2016/10 [Refereed]
  • 認知症を持つ患者さんと核医学診療
    細野 眞
    核医学 (一社)日本核医学会 53 (Suppl.) S202 - S202 0022-7854 2016/10 [Refereed]
  • 東 達也; 池渕 秀治; 内山 眞幸; 織内 昇; 絹谷 清剛; 細野 眞
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 54回 S18 - 2 2016/10
  • 細野眞
    核医学技術 36 386  0289-100X 2016/09
  • 逐次近似応用再構成法が超急性期脳梗塞CT画像におけるZスコアマッピングに与える影響
    渡邊 翔太; 坂口 健太; 細野 眞; 石井 一成; 村上 卓道; 市川 勝弘
    日本放射線技術学会雑誌 (公社)日本放射線技術学会 72 (9) 813 - 813 0369-4305 2016/09
  • 渡邊翔太; 坂口健太; 黒川敏昭; 小西達郎; 吉田修平; 又野嘉枝子; 細野眞
    核医学症例検討会症例集 37 (1) 3‐4  0910-2213 2016/08
  • Hiroshi Watanabe; Kazunari Ishii; Makoto Hosono; Etsuko Imabayashi; Koichiro Abe; Masayuki Inubushi; Kazuko Ohno; Yasuhiro Magata; Kinya Ono; Kei Kikuchi; Kei Wagatsuma; Tadashi Takase; Kyoko Saito; Yasuyuki Takahashi
    ANNALS OF NUCLEAR MEDICINE SPRINGER 30 (6) 435 - 444 0914-7187 2016/07 [Refereed]
     
    The optimization of medical exposure is one of the major issues regarding radiation protection in the world, and The International Committee of Radiological Protection and the International Atomic Energy Agency recommend establishing diagnostic reference levels (DRLs) as tools for dose optimization. Therefore, the development of DRLs based on the latest survey has been required for nuclear medicine-related societies and organizations. This prompted us to conduct a nationwide survey on the actual administered radioactivity to adults for the purpose of developing DRLs in nuclear medicine. A nationwide survey was conducted from November 25, 2014 to January 16, 2015. The questionnaire was sent to all of the 1249 nuclear medicine facilities in Japan, and the responses were collected on a website using an answered form. Responses were obtained from 516 facilities, for a response rate of 41 %. 75th percentile of Tc-99m-MDP and Tc-99m-HMDP: bone scintigraphy, Tc-99m-HM-PAO, Tc-99m-ECD and I-123-IMP: cerebral blood flow scintigraphy, Tc-99m-Tetrofosmin, Tc-99m-MIBI and Tl-201-Cl; myocardial perfusion scintigraphy and F-18-FDG: oncology PET (in-house-produced or delivery) in representative diagnostic nuclear medicine scans were 932, 937, 763, 775, 200, 831, 818, 180, 235 and 252, respectively. More than 90 % of the facilities were within the range of 50 % from the median of these survey results in representative diagnostic nuclear medicine facilities in Japan. Responses of the administered radioactivities recommended by the package insert, texts and guidelines such as 740 MBq (Tc-99m-MDP and Tc-99m-HMDP: bone scintigraphy), 740 MBq (Tc-99m-ECD and Tc-99m-HM-PAO: cerebral blood flow scintigraphy) and 740 MBq (Tc-99m-Tetrofosmin and Tc-99m-MIBI: myocardial perfusion scintigraphy), etc. were numerous. The administered activity of many radiopharmaceuticals of bone scintigraphy (Tc-99m-MDP and Tc-99m-HMDP), cerebral blood flow scintigraphy (Tc-99m-HM-PAO) and myocardial perfusion scintigraphy (Tc-99m-Tetrofosmin and Tc-99m-MIBI), etc. were within the range of the EU DRLs and almost none of the administered radioactivity in Japan exceeded the upper limit of SNMMI standard administered radioactivity. This survey indicated that the administered radioactivity in diagnostic nuclear medicine in Japan had been in the convergence zone and nuclear medicine facilities in Japan show a strong tendency to adhere to the texts and guidelines. Furthermore, the administered radioactivities in Japan were within the range of variation of the EU and the SNMMI administered radioactivities.
  • 細野眞
    近畿大学医学雑誌 近畿大学医学会 41 (1-2) 3‐7 - 7 0385-8367 2016/06
  • Hosono M; Shibata T
    Nihon rinsho. Japanese journal of clinical medicine 74 Suppl 4 Pt 1 482 - 6 0047-1852 2016/06 [Refereed]
  • Hanaoka Kohei; Hosono Makoto; Tatebe Hitoshi; Ishikawa Kazuki; Monzen Hajime; Ishii Kazunari; Nishimura Yasumasa
    JOURNAL OF NUCLEAR MEDICINE 57 0161-5505 2016/05 [Refereed]
  • Hosono Makoto; Tachibana Izumi; Nishimura Yasumasa; Hanaoka Kohei; Sakaguchi Kenta; Ishikawa Kazuki; Nakamatsu Kiyoshi; Kanamori Shuichi
    JOURNAL OF NUCLEAR MEDICINE 57 0161-5505 2016/05 [Refereed]
  • 細野眞
    FB News (473) 1 - 3 1349-6395 2016/05
  • 稲田正浩; 西村恭昌; 石川一樹; 花岡宏平; 坂口健太; 細野眞
    臨床放射線 金原出版 61 (5) 657 - 666 0009-9252 2016/05
  • 細野眞
    日本診療放射線技師会誌 63 (4) 403‐405  2187-2538 2016/04
  • 東 達也; 池渕 秀治; 内山 眞幸; 織内 昇; 絹谷 清剛; 細野 眞
    核医学 (一社)日本核医学会 53 (1) 27 - 43 0022-7854 2016/02 
    我が国では急激な甲状腺癌の増加やRI内用療法施設の実稼働ベッド数の減少などから、RI内用療法施設への入院待ち待機時間が延長し地域格差が広がっており、その現状はがん対策推進基本計画がめざす「医療の均てん化」とはほど遠い状況にある。2015年国会においてRI内用療法に関連する質問主意書が提出され、これに対しRI内用療法は重点的に取り組むべき課題であるとの政府答弁がなされており、今後の研究・診療の推進等が期待されている。本稿では医療経済的考察も含めて我が国におけるRI内用療法の現状と問題点をとりまとめ、甲状腺癌の将来的な疾病状況を予測の上、これに対応可能なRI内用療法環境を提示し、欧米諸国の現状との比較も交えて、我が国のRI内用療法のあるべき将来像を見据えた提言を行う。(著者抄録)
  • 上顎洞術後変化としての眼窩下管拡大
    福井 秀行; 柏木 伸夫; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 細川 知紗; 熊野 正士; 鶴崎 正勝; 松木 充; 今岡 いずみ; 細野 眞; 石井 一成; 村上 卓道
    Japanese Journal of Diagnostic Imaging 日本画像医学会 34 (1) 116 - 116 2187-266X 2016/02
  • 当院における胃粘膜下腫瘍に対する18F-FDG PET検査
    沼本 勲男; 松木 充; 福井 秀行; 若林 雄一; 渡口 真史; 千葉 輝明; 山田 穣; 柏木 伸夫; 細川 知紗; 小塚 健倫; 細野 眞; 石井 一成; 村上 卓道
    Japanese Journal of Radiology (公社)日本医学放射線学会 34 (Suppl.) 56 - 56 1867-1071 2016/02
  • 細川 知紗; 石井 一成; Sauerbeck Julia; Scheiwein Franziska; 甲斐田 勇人; 山田 穣; 兵頭 朋子; 細野 眞; 花岡 宏平; 村上 卓道
    核医学 (一社)日本核医学会 53 (1) 561 - 561 0022-7854 2016/02
  • 花岡 宏平; 細野 眞
    核医学 (一社)日本核医学会 53 (1) 536 - 536 0022-7854 2016/02 [Refereed]
  • 細野 眞
    核医学 (一社)日本核医学会 53 (1) 538 - 538 0022-7854 2016/02 [Refereed]
  • 細野 眞; 池渕 秀治; 中村 吉秀; 中村 伸貴; 山田 崇裕; 柳田 幸子; 北岡 麻美; 小島 清孝; 菅野 宏泰
    核医学 (一社)日本核医学会 53 (1) 558 - 558 0022-7854 2016/02 [Refereed]
  • 坂口健太; 赤羽正章; 薬師寺優子; 高原尚美; 花岡宏平; 細野眞
    医療における放射線防護と関連法令整備に関する研究 平成27年度 総括・分担研究報告書 162‐166  2016
  • 細野眞; 池渕秀治; 上田いづみ; 北岡麻美; 坂口健太; 中村伸貴; 中村吉秀; 花岡宏平; 柳田幸子; 山田崇裕
    医療における放射線防護と関連法令整備に関する研究 平成27年度 総括・分担研究報告書 9‐30  2016
  • Ishii K; Hosokawa C; Hyodo T; Sakaguchi K; Usami K; Shimamoto K; Hosono M; Yamazoe Y; Murakami T
    Nuclear Medicine In Clinic 49 (6) 89 - 90 2016 [Refereed]
  • Higashi T; Ikebuchi S; Uchiyama M; Oriuchi N; Kinuya S; Hosono M
    Kaku igaku. The Japanese journal of nuclear medicine 53 (1) 27 - 43 0022-7854 2016 [Refereed]
  • Chisa Hosokawa; Kazunari Ishii; Yuichi Kimura; Tomoko Hyodo; Makoto Hosono; Kenta Sakaguchi; Kimio Usami; Kenji Shimamoto; Yuzuru Yamazoe; Takamichi Murakami
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 56 (12) 1910 - 1915 0161-5505 2015/12 [Refereed]
     
    The goal of this study was to clarify whether binding potential (BP) images using C-11-Pittsburgh compound B (C-11-PiB) and dynamic PET can reliably detect cortical amyloid deposits for patients whose C-11-PiB PET static images are ambiguous and whether visual ratings are affected by white matter retention. Methods: Static and BP images were constructed for 85 consecutive patients with cognitive impairment after C-11-PiB dynamic PET. Cortical uptake was visually assessed as positive, negative, or equivocal for both types of images. Quantitatively, the standardized uptake value ratio (SUVR) from the static image, the nondisplaceable BP from the dynamic image for mean gray matter uptake, and the ratio of gray matter uptake to white matter retention were compared among C-11-PiB-positive, C-11-PiB-equivocal, and C-11-PiB-negative groups. Results: Forty-three scans were visually assessed as C-11-PiB-positive in both the static and the BP images. Ten scans were C-11-PiB-equivocal in the static images. In 8 of them, the BP images were C-11-PiB-positive, whereas the other 2 were C-11-PiB-equivocal. Thirty-two scans were assessed as C-11-PiB-negative in the static images. In the BP images, 4 were C-11-PiB-positive and 2 were C-11-PiB-equivocal. The mean gray matter uptake of C-11-PiB in SUVR and nondisplaceable BP, respectively, showed statistically significant differences among the C-11-PiB-positive, C-11-PiB-equivocal, and C-11-PiB-negative groups. The ratio of gray matter uptake to white matter retention was lower in the BP images than static images from the C-11-PiB-negative and C-11-PiB-equivocal groups, whereas it was higher in the C-11-PiB-positive group. Conclusion: C-11-PiB PET BP images can clarify visual interpretation of clinical static C-11-PiB-equivocal images by reducing the interference of nonspecific white matter retention. We conclude that C-11-PiB-equivocal PET findings on static images reflect cortical amyloid deposits, which can be verified using BP images. Furthermore, quantitative assessments, such as SUVR and nondisplaceable BP, are of no use for correctly rating equivocal visual findings.
  • I. Tachibana; M. Hosono; M. Inada; K. Fukuda; H. Tatebe; K. Ishikawa; M. Yokokawa; K. Nakamatsu; S. Kanamori; Y. Nishimura
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ELSEVIER SCIENCE INC 93 (3) S105 - S105 0360-3016 2015/11 [Refereed]
  • M. Hosono; I. Tachibana; Y. NIshimura; K. Hanaoka; S. Kanamori; K. Nakamatsu; K. Ishikawa; K. Sakaguchi
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 42 S712 - S712 1619-7070 2015/10
  • K. Hanaoka; M. Hosono; M. Inada; K. Sakaguchi; K. Shimomura; M. Tamura; K. Matsumoto; H. Monzen; Y. Nishimura
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 42 S408 - S408 1619-7070 2015/10
  • PiB陰性例の18F-FDG PETによる脳代謝分布の検討
    細川 知紗; 石井 一成; 若林 雄一; 兵頭 朋子; 花田 一志; 甲斐田 勇人; 細野 眞; 木村 裕一; 村上 卓道
    核医学 (一社)日本核医学会 52 (3) 262 - 262 0022-7854 2015/09
  • 超急性期脳梗塞症例に対する頭部単純CT画像を用いたコンピューター支援診断システムの開発
    渡邊 翔太; 坂口 健太; 細野 眞; 石井 一成; 村上 卓道
    日本放射線技術学会雑誌 (公社)日本放射線技術学会 71 (9) 896 - 896 0369-4305 2015/09
  • Makoto Hosono; Izumi Tachibana; Yasumasa Nishumura; Kohei Hanaoka; Shuichi Kanamori; Kiyoshi Nakamatsu; Kazuki Ishikawa
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 56 (3) 0161-5505 2015/05 [Refereed]
  • Makoto Hosono; Naomi Takahara; Yuuko Yakushiji; Kenta Sakaguchi; Kazunari Ishii
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 56 (3) 0161-5505 2015/05 [Refereed]
  • Kohei Hanaoka; Makoto Hosono; Yoichi Tatsumi; Kazunari Ishii; Sung-Woon Im; Norio Tsuchiya; Kenta Sakaguchi; Itaru Matsumura
    EJNMMI RESEARCH SPRINGER HEIDELBERG 5 10  2191-219X 2015/03 [Refereed]
     
    Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of In-111-ibritumomab tiuxetan (Zevalin (R)) and tumor accumulation of F-18-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin's lymphoma patients receiving Y-90-ibritumomab tiuxetan (Zevalin (R)) therapy. Methods: Sixteen patients with histologically confirmed non-Hodgkin's B-cell lymphoma who underwent Y-90-ibritumomab tiuxetan therapy along with In-111-ibritumomab tiuxetan single-photon emission computerized tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of In-111-ibritumomab tiuxetan were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and In-111-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images. Results: A positive correlation was observed between the FDG SUVmax and accumulation of In-111-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in In-111-ibritumomab tiuxetan SUVmax was observed between the two groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices between responders and non-responders, while In-111-ibritumomab tiuxetan demonstrated skewness of 0.58 +/- 0.16 and 0.73 +/- 0.24 (p < 0.05), kurtosis of 2.39 +/- 0.32 and 2.78 +/- 0.53 (p < 0.02), and AUC-CSH of 0.37 +/- 0.04 and 0.34 +/- 0.05 (p < 0.05) for responders and non-responders. Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in Y-90-ibritumomab tiuxetan therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of In-111-ibritumomab tiuxetan was correlated with the tumor response.
  • Chisa Hosokawa; Kazunari Ishii; Tomoko Hyodo; Kenta Sakaguchi; Kimio Usami; Kenji Shimamoto; Yuzuru Yamazoe; Makoto Hosono; Kazushi Hanada; Masami Ueda; Kazuma Saigo; Takamichi Murakami
    ANNALS OF NUCLEAR MEDICINE SPRINGER 29 (2) 164 - 169 0914-7187 2015/02 [Refereed]
     
    We have encountered occasional equivocal findings when assessing cerebral cortical amyloid retention with C-11-Pittsburgh compound B (PiB) PET. We investigated the diagnostic significance of equivocal PiB PET findings. This retrospective study included 101 consecutive patients complaining of cognitive disorders (30 Alzheimer's disease, 25 mild cognitive impairment, 8 Lewy body disease, 7 frontotemporal lobar degeneration, 31 others) who underwent both C-11-PiB PET and F-18-fluorodeoxy-d-glucose (FDG) PET. We visually classified PiB-positive, PiB-equivocal or PiB-negative ratings according to cortical uptake. For quantitative assessments of PiB PET, standard uptake values referred to cerebellar cortex (SUVR) were calculated in regional template volume of interests (frontal, temporoparietal, precuneus/posterior cingulate cortex, cerebral white matter and cerebellar cortex). The results of visual assessment were compared with the regional and mean cortical SUVRs and cortical-to-white matter ratio of PiB uptake, as well as clinical and FDG PET findings. Among the 101 scans, 41 were PiB negative, 11 were PiB equivocal, and 49 were rated PiB positive in the visual assessments. The mean cortical SUVR and cortical-to-white matter ratio were 0.97 +/- A 0.07 and 0.57 +/- A 0.21 in PiB-negative, 1.51 +/- A 0.17 and 0.75 +/- A 0.06 in PiB equivocal and 2.10 +/- A 0.33 and 0.97 +/- A 0.11 in PiB-positive group, respectively. Nine of 11 subjects with PiB-equivocal findings had cognitive impairments and FDG distribution compatible with Alzheimer's disease or dementia with Lewy bodies. We considered equivocal visual findings on PiB PET equivalent to PiB-positive with slight cortical uptake. In addition, slight cortical amyloid deposits were considered to cause cerebral metabolic abnormality and cognitive impairment. Although mean cortical SUVR was more sensitive than visual assessment because of low cortical-to-white matter contrast due to non-specific accumulation in white matter, it is important not to overlook small amounts of cortical uptake of PiB in visual inspection for exact diagnosis.
  • 細野眞; 宇佐美公男; 坂口健太; 花岡宏平; 上田いづみ; 池渕秀治; 中村吉秀; 中村伸貴; 山田崇裕; 柳田幸子; 北岡麻美
    医療における放射線防護と関連法令整備に関する研究 平成26年度 総括・分担研究報告書 1‐3,5‐38  2015
  • Genichiro Wakabayashi; Akihiro Nohtomi; Eriko Yahiro; Toshioh Fujibuchi; Junichi Fukunaga; Yoshiyuki Umezu; Yasuhiko Nakamura; Katsumasa Nakamura; Makoto Hosono; Tetsuo Itoh
    Radiological Physics and Technology Springer-Verlag Tokyo 8 (1) 125 - 134 1865-0341 2015 [Refereed]
     
    The applicability of the activation of an NaI scintillator for neutron monitoring at a clinical linac was investigated experimentally. Thermal neutron fluence rates are derived by measurement of the I-128 activity generated in an NaI scintillator irradiated by neutrons β-rays from I-128 are detected efficiently by the NaI scintillator. In order to verify the validity of this method for neutron measurement, we irradiated an NaI scintillator at a research reactor, and the neutron fluence rate was estimated. The method was then applied to neutron measurement at a 10-MV linac (Varian Clinac 21EX), and the neutron fluence rate was estimated at the isocenter and at 30 cm from the isocenter. When the scintillator was irradiated directly by high-energy X-rays, the production of I-126 was observed due to photo-nuclear reactions, in addition to the generation of I-128 and Na-24. From the results obtained by these measurements, it was found that the neutron measurement by activation of an NaI scintillator has a great advantage in estimates of a low neutron fluence rate by use of a quick measurement following a short-time irradiation. Also, the future application of this method to quasi real-time monitoring of neutrons during patient treatments at a radiotherapy facility is discussed, as well as the method of evaluation of the neutron dose.
  • Kazunari Ishii; Chisa Hosokawa; Tomoko Hyodo; Kenta Sakaguchi; Kimio Usami; Kenji Shimamoto; Makoto Hosono; Yuzuru Yamazoe; Takamichi Murakami
    ANNALS OF NUCLEAR MEDICINE SPRINGER 29 (1) 78 - 83 0914-7187 2015/01 [Refereed]
     
    There is evidence that some cases of patients with dementia with Lewy bodies (DLB) can demonstrate Alzheimer disease (AD) like reduced glucose metabolism without amyloid deposition. The aim of this study was to clarify whether regional hypometabolism is related to amyloid deposits in the DLB brain and measure the degree of regional hypometabolism. Ten consecutive subjects with DLB and 10 AD patients who underwent both Pittsburgh compound B (PiB)-PET and F-18-fluoro-2-deoxyglucose (FDG)-PET were included in this study. Regional standardized uptake value ratio (SUVR)s normalised to cerebellar cortices were calculated in the FDG- and PiB-PET images. All AD patients and five DLB patients showed amyloid deposits (PiB positive). In the DLB group the parietotemporal and occipital metabolism were significantly lower than those in the AD group but there was no difference between the posterior cingulate hypometabolism between DLB and AD groups. There were no differences in regional glucose metabolism between PiB positive and negative DLB patients. In the DLB brain, it is suggested that decreased regional glucose metabolism is unrelated to amyloid deposits, although the hypometabolic area overlaps with the AD hypometabolic area and the degree of parietotemporal and occipital hypometabolism in DLB brain is much larger than that in AD brain.
  • Nishimura Y; Hosono M; Usami K
    Eizo-Joho medical 産業開発機構 46 (13) 1164 - 1168 1346-1354 2014/12 [Invited]
  • 若林 雄一; 石井 一成; 河内 崇; 細川 知紗; 山川 美帆; 兵頭 朋子; 任 誠雲; 鶴崎 正勝; 足利 竜一郎; 松木 充; 細野 眞; 北村 登; 村上 卓道
    核医学 (一社)日本核医学会 51 (4) 438 - 439 0022-7854 2014/11
  • M. Hosono; S. Hohara; H. Yamanishi; M. Inagaki; G. Wakabayashi; T. Matsuda; K. Sakaguchi; K. Hanaoka; T. Itoh
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 41 S329 - S329 1619-7070 2014/10
  • M. Hosono; K. Hanaoka; K. Ishii; K. Sakaguchi; M. Yamada; Y. Komeya; N. Tsuchiya; S. Im; Y. Tatsumi; I. Matsumura
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 41 S174 - S174 1619-7070 2014/10
  • M. Hosono; I. Tachibana; Y. Nishimura; K. Hanaoka; S. Kanamori; K. Nakamatsu; K. Ishikawa
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 41 S248 - S248 1619-7070 2014/10
  • 軽症アルツハイマー病の18F-FDG PETと11C-PiB PET検査の経時的画像変化の検討
    細川 知紗; 石井 一成; 兵頭 朋子; 坂口 健太; 宇佐美 公男; 若林 雄一; 鶴崎 正勝; 松木 充; 細野 眞; 村上 卓道
    核医学 (一社)日本核医学会 51 (3) 284 - 284 0022-7854 2014/09
  • M. Hosono; I. Tachibana; Y. Nishimura; K. Hanaoka; S. Kanamori; K. Nakamatsu; T. Shibata; K. Ishikawa; M. Tamura
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ELSEVIER SCIENCE INC 90 S792 - S792 0360-3016 2014/09
  • Makoto Hosono; Tsuneo Saga; Kengo Ito; Shinichiro Kumita; Masayuki Sasaki; Michio Senda; Jun Hatazawa; Hiroshi Watanabe; Hiroshi Ito; Shinichi Kanaya; Yuichi Kimura; Hideo Saji; Seishi Jinnouchi; Hiroyoshi Fukukita; Koji Murakami; Seigo Kinuya; Junichi Yamazaki; Mayuki Uchiyama; Koichi Uno; Katsuhiko Kato; Tsuyoshi Kawano; Kazuo Kubota; Takashi Togawa; Norinari Honda; Hirotaka Maruno; Mana Yoshimura; Masami Kawamoto; Yukihiko Ozawa
    ANNALS OF NUCLEAR MEDICINE SPRINGER 28 (6) 597 - 602 0914-7187 2014/07 [Refereed]
  • Chisa Hosokawa; Kazunari Ishii; Yuichi Kimura; Kenta Sakaguchi; Makoto Hosono; Takamichi Murakami
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 55 0161-5505 2014/05
  • Makoto Hosono; Sin-ya Hohara; Hirokuni Yamanishi; Masayo Inagaki; Genichiro Wakabayashi; Kenta Sakaguchi; Kohei Hanaoka; Tetsuo Itoh
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 55 0161-5505 2014/05
  • Makoto Hosono; Kohei Hanaoka; Kazunari Ishii; Kenta Sakaguchi; Sung-Woon Im; Norio Tsuchiya; Yoshihiro Komeya; Yoichi Tatsumi; Itaru Matsumura
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 55 0161-5505 2014/05 [Refereed]
  • Chisa Hosokawa; Kazunari Ishii; Yuichi Kimura; Kenta Sakaguchi; Makoto Hosono; Takamichi Murakami
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 55 0161-5505 2014/05 [Refereed]
  • 多発結節影を呈した肺アミロイドーシスの1例
    日高 正二朗; 小塚 健倫; 柳生 行伸; 柏木 伸夫; 今岡 いずみ; 松木 充; 足利 竜一朗; 細野 眞; 石井 一成; 村上 卓道
    Japanese Journal of Radiology (公社)日本医学放射線学会 32 (Suppl.) 39 - 39 1867-1071 2014/02
  • 腫瘤形成した慢性唾液腺炎のFDG-PET/CT所見
    細川 知紗; 柏木 伸夫; 松久保 祐子; 山田 穣; 任 誠雲; 兵頭 朋子; 高橋 洋人; 柳生 行伸; 岡田 真広; 小塚 健倫; 今岡 いずみ; 鶴崎 正勝; 松木 充; 足利 竜一郎; 細野 眞; 石井 一成; 村上 卓道; 筑後 雅章
    Japanese Journal of Radiology (公社)日本医学放射線学会 32 (Suppl.) 45 - 45 1867-1071 2014/02
  • 芳原新也; 稲垣昌代; 細野眞; 山西弘城; 伊藤哲夫
    日本原子力学会秋の大会予稿集(CD-ROM) 2014 2014
  • 細野眞; 池渕秀治; 中村吉秀; 中村伸貴; 山田崇裕; 柳田幸子; 北岡麻美; 宇佐美公男; 坂口健太; 花岡宏平; 上田いづみ
    医療放射線防護に関する研究 平成25年度 総括・分担研究報告書 HOSONO,25-76  2014
  • 細野眞; 山口一郎; 小高喜久雄; 佐藤幸光; 奥山康男; 平出博一; 遠山尚紀
    医療放射線防護に関する研究 平成25年度 総括・分担研究報告書 YAMAGUCHI,15-30  2014
  • 細野眞; 山口一郎; 小川泰良; 笹沼和智; 庄司友和; 中野拓郎; 能登公也; 平出博一; 藤淵俊王; 渡邉浩
    医療放射線防護に関する研究 平成25年度 総括・分担研究報告書 YAMAGUCHI,1-13  2014
  • A newly designed radioimmunoconjugate releasing a hippurate-like radiometal chelate for enhanced target/non-target radioactivity
    Arano Y; Matsushima H; Tagawa M; Inoue T; Koizumi M; Hosono M; Sakahara H; Endo K; Konishi J; Yokoyama A
    Nucl Med Biol 21 63 - 69 2014 [Refereed]
  • 細川 知紗; 石井 一成; 木村 裕一; 兵頭 朋子; 坂口 健太; 宇佐美 公男; 細野 眞; 村上 卓道
    核医学 (一社)日本核医学会 50 (4) 327 - 327 0022-7854 2013/11
  • Izumi Tachibana; Yasumasa Nishimura; Toru Shibata; Shuichi Kanamori; Kiyoshi Nakamatsu; Ryuta Koike; Tatsuyuki Nishikawa; Kazuki Ishikawa; Masaya Tamura; Makoto Hosono
    Journal of Radiation Research 6 54 (6) 1078 - 1084 0449-3060 2013/11 [Refereed]
     
    To visualize intratumoral hypoxic areas and their reoxygenation before and during fractionated radiation therapy (RT), 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISOPET/CT) were performed. A total of 10 patients, consisting of four with head and neck cancers, four with gastrointestinal cancers, one with lung cancer, and one with uterine cancer, were included. F-MISO PET/CT was performed twice, before RT and during fractionated RT of approximately 20 Gy/10 fractions, for eight of the 10 patients. F-MISO maximum standardized uptake values (SUVmax) of normal muscles and tumors were measured. The tumor-to-muscle (T/M) ratios of F-MISO SUVmax were also calculated. Mean SUVmax ± standard deviation (SD) of normal muscles was 1.25 ± 0.17, and SUVmax above the mean + 2 SD (=1.60 SUV) was regarded as a hypoxic area. Nine of the 10 tumors had an F-MISO SUVmax of =1.60. All eight tumors examined twice showed a decrease in the SUVmax, T/M ratio, or percentage of hypoxic volume (F-MISO =1.60) at approximately 20 Gy, indicating reoxygenation. In conclusion, accumulation of F-MISO of =1.60 SUV was regarded as an intratumoral hypoxic area in our F-MISO PET/CT system. Most human tumors (90%) in this small series had hypoxic areas before RT, although hypoxic volume was minimal (0.0-0.3%) for four of the 10 tumors. In addition, reoxygenation was observed in most tumors at two weeks of fractionated RT. © The Author 2013. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Therapeutic Radiology and Oncology.
  • M. Hosono; K. Hanaoka; K. Ishii; S. Im; K. Sakaguchi; Y. Yagyu; Y. Matsukubo; Y. Ohno; H. Ikegami
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 40 S231 - S232 1619-7070 2013/10
  • HOHARA Sin-ya; HOSONO Makoto; INAGAKI Masayo; IM Sung-Woon; MORIMOTO Hideo; HANAOKA Kohei; SAKAGUCHI Kenta; YAMANISHI Hirokuni; ITOH Tetsuo
    RADIOISOTOPES 公益社団法人 日本アイソトープ協会 62 (9) 659 - 665 0033-8303 2013/09 
    In recent years, attention has been focused on radionuclide therapy with &alpha; emission nuclides. Research and clinical tests of pharmaceuticals including <sup>223</sup>Ra, which has short half-life and a number of &alpha; & &beta; decays with its decay family, started in Japan in this year. Despite the fact that research on pharmaceuticals including <sup>223</sup>Ra is continuing, methods and knowledge of <sup>223</sup>Ra radiation controls have not been researched.<br>Contamination controls of radioactive pharmaceuticals in clinical sites are very important because of radiation protection, and research on <sup>223</sup>Ra-contamination controls should be performed as soon as possible before any medical application becomes licensed.<br>In this work, we performed demonstration experiments of <sup>223</sup>Ra-contamination with commonly-used survey meters. The results of experiments show that a Geiger-Muller type survey meter(TGS-133:Hitachi Aloka Medical) is effective to find <sup>223</sup>Ra-contamination, but an NaI(Tl) scintillation type survey meter(TCS-161:Hitachi Aloka Medical) should be used carefully due to the measurement limit in a <sup>223</sup>Ra-contamination survey.
  • 細野 眞; 佐賀 恒夫; 伊藤 健吾; 汲田 伸一郎; 佐々木 雅之; 千田 道雄; 畑澤 順; 渡邉 浩; 伊藤 浩; 金谷 信一; 木村 裕一; 佐治 英郎; 陣之内 正史; 福喜多 博義; 村上 康二; 絹谷 清剛; 山崎 純一; 内山 眞幸; 宇野 公一; 加藤 克彦; 川野 剛; 窪田 和雄; 戸川 貴史; 本田 憲業; 丸野 廣大; 吉村 真奈; 川本 雅美; 小澤 幸彦; 日本核医学会PET核医学委員会, 日本核医学会健保委員会
    核医学 (一社)日本核医学会 50 (3) 1 - 9 0022-7854 2013/09
  • 細川 知紗; 石井 一成; 木村 裕一; 兵頭 朋子; 細野 眞; 坂口 健太; 宇佐美 公男; 村上 卓道
    核医学 (一社)日本核医学会 50 (3) S182 - S182 0022-7854 2013/09
  • 細野 眞
    Isotope news (711) 2 - 7 0285-5518 2013/07
  • 御前 隆; 石津 浩一; 石守 崇好; 工藤 崇; 中本 裕士; 東 達也; 細野 眞
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 50 (1) 34 - 35 0022-7854 2013/02
  • 医療放射線防護に関する厚生労働省班研究の概要
    細野 眞; 山口 一郎; 高橋 健夫; 赤羽 正章; 成田 雄一郎; 池渕 秀治; 中村 吉秀; 柳田 幸子; 中村 伸貴; 山田 崇裕
    日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 72回 S162 - S162 0048-0428 2013/02
  • 松久保 祐子; 村上 卓道; 柏木 伸夫; 佐藤 隆夫; 足利 竜一朗; 細野 眞; 森 一功; 土井 勝美
    臨床放射線 金原出版 58 (3) 459 - 462 0009-9252 2013
  • Kenta Sakaguchi; Makoto Hosono; Masakazu Otsuka; Kohei Hanaoka; Kimio Usami; Tatsuro Uto; Kazunari Ishii
    ANNALS OF NUCLEAR MEDICINE SPRINGER 27 (1) 65 - 73 0914-7187 2013/01 [Refereed]
     
    The purpose of this study was to develop and evaluate a new method for respiratory gated pulmonary perfusion SPECT (RGPS) based on dynamic acquisition without using an external tracking device (ETD) or list-mode data acquisition. In the phantom study, our method used a dynamic sequence technique, which was specified by sequences of 50-ms acquisition during 30 s per view of SPECT instead of using an ETD. For this purpose, we created a computer program that identified respiratory phases by calculating the center of activity (COA) in each dynamic frame image. We compared RGPS using the dynamic sequence acquisition (RGPS-DS) and RGPS using ETD (RGPS-ETD) in phantom studies employing a cylinder phantom filled with technetium-99m solution attached to an instrument providing a simple harmonic motion. In the patient study, RGPS-DS was applied to data collected from 3 patients during a routine study of Tc-MAA pulmonary perfusion SPECT. In the phantom study, the calculation of COA indicated a good agreement between RGPS-DS and RGPS-ETD. With an oscillatory phantom movement amplitude of 30 mm, the amplitudes determined by RGPS-DS and RGPS-ETD (28.36 and 27.58 mm, respectively) were identical on considering a pixel size of 4.66 mm for reconstructed SPECT images. In the patient study, applicability of our method to patient data was demonstrated. We have showed the feasibility of our method to obtain RGPS without ETD, and conclude that RGPS-DS may be an innovative and efficient technique in respiratory gated pulmonary perfusion SPECT. Further studies with a larger number of patients should demonstrate the accuracy of our method.
  • 細野眞; 宇佐美公男; 花岡宏平; 上田いづみ; 池渕秀治; 中村吉秀; 中村伸貴; 山田崇裕; 柳田幸子; 北岡麻美
    医療放射線防護に関する研究 平成24年度 総括・分担研究報告書 38 - 63 2013
  • 米矢吉宏; 細野眞; 山田穣; 松木充; 花岡宏平; 坂口健太; 任誠雲; 柳生行伸; 石井一成; 辰巳陽一; 松村到; 土屋典生
    核医学 (一社)日本核医学会 49 (4) 439 - 439 0022-7854 2012/11
  • 細野 眞; 佐賀 恒夫; 伊藤 健吾; 汲田 伸一郎; 佐々木 雅之; 千田 道雄; 畑澤 順; 渡邉 浩; 伊藤 浩; 金谷 信一; 木村 裕一; 佐治 英郎; 陣之内 正史; 福喜多 博義; 村上 康二; 絹谷 清剛; 山崎 純一; 内山 眞幸; 宇野 公一; 加藤 克彦; 川野 剛; 日下部 きよ子; 窪田 和雄; 戸川 貴史; 本田 憲業; 丸野 廣大; 吉村 真奈; 宍戸 文男; 井上 登美夫; 福田 寛; 中村 佳代子
    Jpn J Nucl Med (Kaku Igaku) (一社)日本核医学会 49 (4) 391 - 401 0022-7854 2012/11
  • 御前 隆; 石津 浩一; 石守 崇好; 工藤 崇; 中本 裕士; 東 達也; 細野 眞
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 49 (4) 357 - 389 0022-7854 2012/11
  • 石井一成; 兵頭朋子; 坂口健太; 花岡宏平; 宇佐美公男; 島元健次; 山添譲; 山田穣; 松木充; 細野眞; 村上卓道
    核医学 (一社)日本核医学会 49 (4) 435 - 435 0022-7854 2012/11
  • 脳血管性認知症のcilostazol投与前後における脳血流変化の検討
    花田 一志; 細野 眞; 辻井 農亜; 船津 浩二; 明石 浩幸; 原田 毅; 三川 和歌子; 池田 真優子; 白川 治; 村上 卓道
    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 日本臨床精神神経薬理学会・日本神経精神薬理学会 22回・42回 146 - 146 2012/10 [Refereed]
  • M. Hosono; K. Hanaoka; K. Ishii; K. Sakaguchi; S. Im; N. Tsuchiya; Y. Komeya; Y. Yagyu; Y. Tatsumi; I. Matsumura
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 39 S372 - S372 1619-7070 2012/10
  • Recognition of complete response by long-term observation after treatment with 90Y-Ibritumomab tiuxetan for relapsed follicular lymphoma
    辰巳 陽一; 賴 晋也; 嶋田 高広; 山口 晃史; 森田 泰慶; 川西 一信; 宮武 淳一; 芦田 隆司; 前田 裕弘; 細野 眞; 松村 到
    Acta Med Kinki Univ 近畿大学 36 (2) 87 - 89 2012/09
  • Recognition of complete response by long-term observation after treatment with 90Y-Ibritumomab tiuxetan for relapsed follicular lymphoma
    Tatsumi Y; Rai S; Shimada T; Yamaguchi K; Morita Y; Kawanishi K; Miyatake J; Ashida T; Hosono M; Matsumura I
    Acta Med Kinki Univ 36 (2) 87 - 89 2012/09 [Refereed]
  • Takahide Kakigi; Makoto Hosono; Taro Shimono; Taizo Hiraoka; Kazumasa Nishimura
    EUROPEAN JOURNAL OF RADIOLOGY ELSEVIER IRELAND LTD 81 (9) 2348 - 2352 0720-048X 2012/09 [Refereed]
     
    Purpose: To prospectively evaluate the feasibility of using the "iliac wing sign (IWS)" as an indicator of bone and/or soft-tissue injury of the pelvis and hips on magnetic resonance (MR) imaging. IWS means edema of the iliacus muscle attachment entering the iliac wing that is visualized as a linear high signal intensity on fat-suppressed T2-weighted MR images. Methods: Consecutive 106 patients who complained of hip pain were enrolled in this study. We evaluated the correlation between IWS and bone and/or soft-tissue injury of the pelvis and hips using Fisher's exact test. Further, performance parameters of sensitivity, specificity, accuracy, the positive predictive value (PPV), and negative predictive value (NPV) of IWS were calculated. Results: Thirty-eight of the 106 (36%) patients had bone and/or soft-tissue injury. Twenty-seven of these 38 (71%) patients with injury showed a positive IWS, while only 11 of 68 (16%) patients without injury showed a positive IWS (p < .0001). IWS, thus, yielded a sensitivity of 71%, specificity of 84%, accuracy of 79%, positive predictive value (PPV) of 71%, and negative predictive value (NPV) of 84%. Conclusion: In cases with a positive IWS, the careful interpretation of MR images is needed because injury presence is highly likely, as suggested by the relatively high sensitivity and PPV. IWS absence may mean a low probability of injury because of the high specificity and NPV. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
  • 細野眞
    核医学 49 (3) 164  0022-7854 2012/08
  • 兵頭朋子; 石井一成; 坂口健太; 花岡宏平; 宇佐美公男; 島元健次; 山添譲; 山田穣; 松木充; 細野眞; 村上卓道
    核医学 (一社)日本核医学会 49 (3) 294 - S274 0022-7854 2012/08
  • 細野眞; 花岡宏平; 米矢吉宏; 土屋典生; 坂口健太; 高田裕史; 森元英夫; 宇佐美公男; 石井一成
    核医学症例検討会症例集 33 (1) 15-16  0910-2213 2012/08
  • Kazunari Ishii; Kohei Hanaoka; Masahiro Okada; Seishi Kumano; Yoshihiro Komeya; Norio Tsuchiya; Makoto Hosono; Takamichi Murakami
    ANNALS OF NUCLEAR MEDICINE SPRINGER 26 (3) 241 - 247 0914-7187 2012/04 [Refereed]
     
    The aim of this study was to elucidate the regional differences between brain perfusion single photon emission computed tomography (SPECT) images reconstructed with a uniform attenuation correction using Chang's method (AC-Chang) and a non-uniform attenuation correction with CT using SPECT/CT (AC-CT). SPECT images of a phantom with and without head holder were obtained, and reconstructed images of AC-Chang and AC-CT were compared. Twenty-eight consecutive patients with brain disease examined by SPECT/CT brain perfusion imaging were selected, and images were reconstructed with AC-Chang and AC-CT. The AC-Chang and AC-CT reconstructed images were then compared by voxel-based analysis using three-dimensional stereotactic surface projections. Counts in the frontal area of the AC-Chang phantom image with head holder were higher than those in the posterior area. Counts in the frontal area of the AC-Chang clinical images were significantly higher than those in the AC-CT images, while the counts in the margin of the frontal lobe and posterior margin of the parietal, occipital cortices and cerebellum of the AC-Chang images were significantly lower. Relative frontal perfusion was 5.0% higher and relative cerebellar perfusion was 4.6% lower in the AC-Chang images relative to the AC-CT images, on average. We demonstrated the frontal dominant hyper-perfusion and parieto-occipital and cerebellar hypo-perfusion in brain SPECT images reconstructed with AC-Chang compared to those reconstructed with AC-CT. We suggest that to obtain an accurate attenuation-corrected brain perfusion SPECT image, attenuation correction by Chang's method is inadequate.
  • 細野眞; 岡野友宏; 山口一郎; 高橋健夫; 赤羽正章; 雫石一也; 池渕秀治; 柳田幸子; 米矢吉宏; 土屋典生
    日本医学放射線学会総会抄録集 (公社)日本医学放射線学会 71st S150 - S150 0048-0428 2012/02
  • 花岡宏平; 大塚正和; 吉田修平; 井上亮; 石井一成; 村上卓道; 細野眞
    日本放射線技術学会総会学術大会予稿集 (公社)日本放射線技術学会 68th 185-186 - 186 1884-7846 2012/02
  • 細野眞; 花岡宏平; 米矢吉宏; 土屋典生; 宇佐美公男; 高田裕史; 坂口健太; 森元英夫; IM Sung‐Woon; 石井一成; 辰巳陽一; 下野太郎
    核医学症例検討会症例集 32 (2) 41-42  0910-2213 2012/02
  • 細野眞; 山口一郎; 藤田真紀; 清堂峰明
    医療放射線の安全確保と有効利用に関する研究 平成22-23年度 総合研究報告書 YAMAGUCHI,1-19  2012
  • 細野眞; 山口一郎; 藤田真紀; 清堂峰明
    医療放射線の安全確保と有効利用に関する研究 平成23年度 総括・分担研究報告書 YAMAGUCHI,1-9  2012
  • Tatsumi Yoichi; Rai Shinya; Shimada Takahiro; Yamaguchi Terufumi; Morita Yasuhiro; Kawanishi Kazunobu; Miyatake Junichi; shida Takashi; Maeda Yasuhiro; Hosono Makoto; Matsumura Itaru
    Acta Medica Kinki University The Kinki University Medical Association 36 (2) 87 - 89 0386-6092 2011/12 
    [Abstract] Monoclonal antibodies have markedly changed the treatment possibilities for patients with indolent B-cell lymphoma. ^<90>Y-Ibritumomab tiuxetan (Zevalin) is the first radioimmunotherapy (RIT) agent approved for the treatment of relapsed and refractory indolent lymphoma patients. In most cases, the maximum clinical response were observed two to three months after RIT. Treatment with ^<90>Y-ibritumomab tiuxetan may have potential late effects in some cases of relapsed follicular lymphomas, and we must be careful to start the next treatment after RIT.
  • HOSONO Makoto
    保健物理 : hoken buturi 日本保健物理学会 46 (4) 288 - 291 0367-6110 2011/12
  • 兵頭朋子; 石井一成; 細野眞; 阪本祐一; 米矢吉宏; 柳生行伸; 土屋典生; 熊野正士; 足利竜一朗; 中村一郎; 植村天受; 村上卓道
    核医学 (一社)日本核医学会 48 (4) 471 - 471 0022-7854 2011/11
  • K. Hanaoka; M. Hosono; Y. Yamazoe; Y. Tatsumi; Y. Komeya; N. Tsuchiya; K. Ishii; K. Usami; T. Murakami; T. Uto
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SPRINGER 38 S426 - S426 1619-7070 2011/10
  • 細野眞
    核医学 48 (3) 245  0022-7854 2011/09
  • 大久保充; 小泉潔; 徳植公一; 西村恭昌; 細野眞
    核医学 48 (3) 238  0022-7854 2011/09
  • 米矢 吉宏; 細野 眞; 土屋 典生; 熊野 正士; 山田 譲; 任 誠雲; 柳生 行伸; 石井 一成; 足利 竜一朗; 西村 恭昌; 村上 卓道
    核医学 (一社)日本核医学会 48 (3) S272 - S272 0022-7854 2011/09
  • Kohei Hanaoka; Makoto Hosono; Kimio Usami; Yoichi Tatsumi; Yuzuru Yamazoe; Yoshihiro Komeya; Norio Tsuchiya; Kazunari Ishii; Mitsugu Sumita
    NUCLEAR MEDICINE COMMUNICATIONS LIPPINCOTT WILLIAMS & WILKINS 32 (8) 678 - 683 0143-3636 2011/08 [Refereed]
     
    Purpose To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin's lymphoma. Methods A total of 127 patients with confirmed non-Hodgkin's lymphoma who underwent FDG PET within 60 days from the last administration of G-CSF were retrospectively reviewed. Thirty age-matched and sex-matched healthy controls were also included to evaluate physiological FDG uptake. PET/CT examinations were retrospectively reviewed, and maximum standardized uptake value (SUV(max)) was measured by placing volumetric regions of interest over each thoracic and lumbar vertebra on PET images referring to CT images. Bone marrow SUV was defined as the mean SUV(max) of the vertebra. The correlation between the interval after G-CSF and the bone marrow SUV was plotted and analyzed with polynomial approximation. Results In controls, physiological bone marrow SUV of the spine was determined. In patients with lymphoma, bone marrow SUV decreased over time and reached a plateau at about 14 days after G-CSF administration, and this was higher by 5% than the plateau at 10 days. SUV declined to the 'physiological range', that is, mean+ 1 standard deviation of patients, at about 7 days. Conclusion For a PET/CT study, an interval of 10 days after G-CSF administration is recommended to minimize the influence of G-CSF on the bone marrow when evaluating treatment response in patients with non-Hodgkin's lymphoma. Nucl Med Commun 32:678-683 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
  • Usami K; Sakaguchi K; Ootsuka M; Nagamoto K; Inoue R; Fukuda K; Kano Y; Yoshida K; Hosono M
    Nihon Hoshasen Gijutsu Gakkai zasshi 7 67 (7) 785 - 792 0369-4305 2011/07 [Refereed]
     
    Radiography is used in medical practices based on the principles of justification and optimization. Patients’ exposure doses should be kept as low as still allows for image quality that does not disturb the diagnostic processes. To optimize diagnostic radiological procedures, the international commission on radiological protection (ICRP) advocated the establishment of diagnosis reference levels (DRLs) in the new basic recommendation (Publication 103) in 2007 by stating that “The DRL should be expressed as a readily measurable patient-dose-related quantity for the specified procedure.” In th...
  • 宇佐美 公男; 坂口 健太; 大塚 正和; 永元 啓介; 井上 亮; 福田 光道; 狩野 好延; 吉田 浩一; 細野 眞
    日本放射線技術学会雑誌 (公社)日本放射線技術学会 67 (7) 785 - 792 0369-4305 2011/07 
    放射線安全を背景とした動向を踏まえ、患者被曝線量に関連する算出可能な量として単純X線撮影系での被写体入射位置における空中線量を簡易的に測定する方法(簡易測定法)を提唱した。測定手順をできる限り簡素化し、X線の被写体入射位置で空中線量を測定する方法を採用した。しかし、測定に際しては撮影条件の選択、散乱体の排除、照射野の設定、測定器の配置など測定結果に影響する因子は残るため、手順説明書やチェックシートなどの活用により、手順の標準化を行い、正確に空中線量を測定することが必要と考えられた。また、測定にはガラスバッジの支持台や撮影室の壁などからの散乱線の影響が及ばない配置が望まれるが、撮影室の状況から理想的な配置が困難な場合も想定される。
  • 井上 登美夫; 渡邉 直行; 絹谷 清剛; 細野 眞; 油野 民雄; 並木 宣雄; 藤村 洋子; 梅田 泉; 荒野 泰
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 48 (1) 49 - 51 0022-7854 2011/02
  • 御前 隆; 石津 浩一; 石守 崇好; 工藤 崇; 中本 裕士; 東 達也; 細野 眞
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 48 (1) 47 - 48 0022-7854 2011/02
  • 減弱を考慮した副腎皮質アドステロール摂取率の簡易的な算出方法
    大塚 正和; 花岡 宏平; 宇佐美 公男; 澄田 貢; 石井 一成; 村上 卓道; 細野 眞
    日本放射線技術学会総会学術大会予稿集 (公社)日本放射線技術学会 67回 320 - 320 1884-7846 2011/02
  • 坂口 健太; 高田 裕史; 宇佐美 公男; 米矢 吉宏; 土屋 典生; 熊野 正士; 細野 眞; 花岡 宏平; 大塚 正和; 井上 亮; 新谷 祐子; 吉田 修平; 森元 英夫; 宇都 辰郎; 澄田 貢; 柿木 崇秀; 柳生 行伸; 石井 一成; 足利 竜一郎; 村上 卓道
    核医学 (一社)日本核医学会 48 (1) 63 - 64 0022-7854 2011/02
  • 収集時間の減少が123I-IMP脳血流SPECT/CT検査に与える影響について
    花岡 宏平; 坂口 健太; 大塚 正和; 澄田 貢; 石井 一成; 村上 卓道; 細野 眞
    日本放射線技術学会総会学術大会予稿集 (公社)日本放射線技術学会 67回 251 - 251 1884-7846 2011/02
  • I. Tachibana; Y. Nishimura; T. Shibata; S. Kanamori; K. Nakamatsu; M. Tamura; R. Koike; T. Nishikawa; K. Ishikawa; M. Hosono
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ELSEVIER SCIENCE INC 81 (2) S731 - S732 0360-3016 2011
  • 細野眞; 山口一郎; 小高喜久雄; 矢野和秀
    医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書 68 - 90 2011
  • 細野眞; 山口一郎; 金谷信一; 小高喜久雄; 渡邉浩; 池渕秀治; 中村伸貴; 柳田幸子
    医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書 107 - 114 2011
  • 細野眞; 山口一郎; 小高喜久雄; 渡邉浩; 堀越亜希子; 池渕秀治; 柳田幸子
    医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書 91 - 106 2011
  • HOSONO Makoto
    Jpn. J. Health Phys. Japan Health Physics Society 46 (4) 288 - 291 0367-6110 2011
  • Kohei Hanaoka; Makoto Hosono; Taro Shimono; Kimio Usami; Yoshihiro Komeya; Norio Tsuchiya; Yuzuru Yamazoe; Kazunari Ishii; Youichi Tatsumi; Mitsugu Sumita
    ANNALS OF NUCLEAR MEDICINE SPRINGER 24 (10) 707 - 711 0914-7187 2010/12 [Refereed]
     
    Faint brain [(18)F]fluoro-2-deoxyglucose (FDG) uptake has sporadically been reported in patients with FDG-avid large or diffusely extended tumors. The purpose of this study was to investigate whether there is a correlation between massive tumor uptake and decreased brain uptake on FDG positron emission tomography/computed tomography (PET/CT). Sixty-five patients with histologically confirmed non-Hodgkin's lymphoma who underwent FDG-PET/CT were enrolled. Thirty control subjects were also included to evaluate normal brain FDG uptake. PET/CT examinations were retrospectively reviewed. The volumetric regions of interest were placed over lesions by referring to CT and PET/CT fusion images to measure mean standardized uptake value (SUVavg). The products of SUVavg and tumor volume were calculated as total glycolytic volume (TGV). The maximum SUV (SUVmax) and SUVavg were measured in the cerebrum and cerebellum. The values of TGV and brain FDG uptake were plotted and analyzed with a linear regression method. In the lymphoma patients, there were statistically significant negative correlations between TGV and brain SUVs. Demonstrating a significant negative correlation between TGV and brain uptake validated the phenomenon of decreased brain FDG uptake. Diversion of FDG from the brain to the lymphoma tissue may occur during the FDG accumulation process. Recognition of this phenomenon prevents unnecessary further neurological examinations in such cases.
  • 熊野 正士; 岡田 真広; 柳生 行伸; 今岡 いずみ; 石井 一成; 足利 竜一朗; 細野 眞; 村上 卓道
    肝胆膵画像 (株)医学書院 12 (5) 585 - 591 1882-5087 2010/09 
    転移性肝癌の診断において,既に原発巣がわかっている場合には,存在診断が重要であり,もし転移があれば,治療方針を決定するためにサイズ,個数を正確に評価しなければならない.転移性肝癌の検出には,造影CTで検索することが多いが,SPIO造影MRIを組み合わせることで診断能が向上する.また,近年ではGd-EOB-DTPAが発売され,より小さな病変が指摘できるようになった.FDG PET-CTは良性病変との鑑別や治療後効果判定に役立つ.胆嚢転移は非常に稀であるが,膵転移は比較的目にすることが多い.膵転移は腎細胞癌からの転移が多いが,術後10年以上の経過で見つかることも少なくなく,注意が必要である.(著者抄録)
  • RI標識モノクローナル抗体療法におけるIn-Zevalin、FDGの腫瘍集積と奏効の関係について
    花岡 宏平; 細野 眞; 米矢 吉宏; 土屋 典生; 山添 譲; 宇佐美 公男; 澄田 貢; 石井 一成; 村上 卓道
    核医学 (一社)日本核医学会 47 (3) 432 - 432 0022-7854 2010/09
  • Masahiro Okada; Norihide Sato; Kazunari Ishii; Kaname Matsumura; Makoto Hosono; Takamichi Murakami
    RADIOGRAPHICS RADIOLOGICAL SOC NORTH AMERICA 30 (4) 939 - 960 0271-5333 2010/07 [Refereed]
     
    Malignant lymphoma is the most common form of hematologic cancer, yet because of advanced methods of assessment, the traditional histology-based classification of lymphoma is insufficient for understanding lymphoma imaging. Still, radiologists should be familiar with the imaging findings in lymphoma. Integrated positron emission tomography (PET) computed tomography (CT) allows improved diagnostic accuracy, and uptake of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) can help predict response during treatment. The sensitivity and specificity of FDG PET are superior to those of gallium 67 scintigraphy in all but indolent lymphoma. Both magnetic resonance (MR) imaging and CT allow excellent assessment of bone texture, but FDG PET is superior in demonstrating bone marrow metabolic activity. Thus, FDG PET is important in both the primary diagnosis and the evaluation of therapy in lymphoma. It may be difficult to determine whether residual abnormalities seen after the completion of chemotherapy radiation therapy represent residual tumor or fibrotic tissue, but PET/CT may allow more accurate diagnosis than MR imaging or CT, thereby helping identify patients who require more intensive treatment. Some diagnostic pitfalls are encountered at FDG PET. However, anatomic CT helps localize and define disease and avoid these potential pitfalls. (c) RSNA, 2010 . radiographics.rsna.org
  • Mitsuru Okubo; Yasumasa Nishimura; Kiyoshi Nakamatsu; Masahiko Okumura; Toru Shibata; Shuichi Kanamori; Kouhei Hanaoka; Makoto Hosono
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ELSEVIER SCIENCE INC 77 (2) 350 - 356 0360-3016 2010/06 [Refereed]
     
    Purpose: Clinical applicability of a multiple-threshold method for [F-18]fluoro-2-deoxyglucose (FDG) activity in radiation treatment planning was evaluated. Methods and Materials: A total of 32 patients who underwent positron emission and computed tomography (PET/CT) simulation were included; 18 patients had lung cancer, and 14 patients had pharyngeal cancer. For tumors of cm <= 2 to 5 cm, and >5 cm, thresholds were defined as 2.5 standardized uptake value (SUV), 35%, and 20% of the maximum FDG activity, respectively. The cervical and mediastinal lymph nodes with the shortest axial diameter of >= 10 mm were considered to be metastatic on CT (LNCT). The retropharyngeal lymph nodes with the shortest axial diameter >= 5 of mm on CT and MRI were also defined as metastatic. Lymph nodes showing maximum FDG activity greater than the adopted thresholds for radiation therapy planning were designated LNPET-RTP, and lymph nodes with a maximum FDG activity of >= 2.5 SUV were regarded as malignant and were designated LNPET-2.5 SUV. Results: The sizes of gross tumor volumes on PET (GTVPET) with the adopted thresholds in the axial plane were visually well fitted to those of GTV on CT (GTVCT). However, the volumes of GTVPET were larger than those of GTVCT, with significant differences (p < 0.0001) for lung cancer, due to respiratory motion. For lung cancer, the numbers of LNCT, LNPET-RTP, and LNPET-2.5 SUV were 29, 28, and 34, respectively. For pharyngeal cancer, the numbers of LNCT, LNPET-RTP, and LNPET-2.5 SUV were 14, 9, and 15, respectively. Conclusions: Our multiple thresholds were applicable for delineating the primary target on PET/CT simulation. However, these thresholds were inaccurate for depicting malignant lymph nodes. (C) 2010 Elsevier Inc.
  • 宍戸 文男; 千田 道雄; 伊藤 健吾; 井上 登美夫; 汲田 伸一郎; 佐々木 雅之; 畑澤 順; 伊藤 浩; 金谷 信一; 佐治 英郎; 陣之内 正史; 細野 眞; 福喜多 博義; 福田 寛; 丸野 廣大; 本田 憲業; 山崎 純一; 内山 眞幸; 宇野 公一; 加藤 克彦; 窪田 和雄; 戸川 貴史; 中村 佳代子; 吉村 真奈
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine (一社)日本核医学会 47 (2) 153 - 162 0022-7854 2010/05
  • 細野 眞
    放射線防護分科会会誌 公益社団法人日本放射線技術学会 (30) 13 - 14 1345-3246 2010/04
  • 細野眞; 宇佐美公男; 岡野友宏; 米矢吉宏; 土屋典生; 赤羽正章; 成田浩人; 大場久照; 山口一郎; 並木宣雄
    日本医学放射線学会総会抄録集 69th S146  0048-0428 2010/02
  • Akihiro Kuriu; Taro Shimono; Masatomo Kuwabara; Ryuichiro Ashikaga; Makoto Hosono; Takamichi Murakami
    JAPANESE JOURNAL OF RADIOLOGY SPRINGER 28 (2) 166 - 168 1867-108X 2010/02 [Refereed]
     
    We report a case of fourth ventricular mixed germ cell tumor (GCT) in a 20-year-old man. Neuroradiological investigations revealed a fourth ventricular hemorrhagic tumor with adipose tissue. We suspected mixed GCT because adipose tissue was seen preoperatively, but mixed GCT occurring after childhood in this location has not previously been reported. We describe herein the imaging findings for mixed GCT and discuss the differential diagnoses of fourth ventricular tumors with adipose tissue.
  • SPECT/CTによる脳血流SPECTの減弱補正効果
    栗生 明博; 石井 一成; 米谷 吉宏; 柳生 行伸; 熊野 正士; 足利 竜一朗; 細野 眞; 村上 卓道
    日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 69回 S183 - S184 0048-0428 2010/02
  • 三次元差分処理を用いた副甲状腺SPECT/CT画像について
    花岡 宏平; 坂口 健太; 宇佐美 公男; 森元 英夫; 澄田 貢; 石井 一成; 細野 眞
    日本放射線技術学会総会学術大会予稿集 (公社)日本放射線技術学会 66回 226 - 227 1884-7846 2010/02
  • 呼吸同期装置を用いない呼吸同期SPECT収集の検討
    坂口 健太; 花岡 宏平; 森元 英夫; 宇佐美 公男; 澄田 貢; 石井 一成; 細野 眞
    日本放射線技術学会総会学術大会予稿集 (公社)日本放射線技術学会 66回 280 - 280 1884-7846 2010/02
  • Radiation treatment planning using positron emission and computed tomography (PET/CT) for lung and pharyngeal cancers: A multiple thresholds method for FDG activity.
    大久保 充; 西村 恭昌; 中松 清志; 奥村 雅彦; 柴田 徹; 金森 修一; 花岡 宏平; 細野 眞
    Int J Radiat Oncol Biol Phys 77 350 - 356 2010 
    肺癌と咽頭癌に対するPET/CTを用いた治療計画法で、多段階閾値設定法を提案し、その臨床的意義と問題点をあきらかにした。
  • 細野眞; 日下部きよ子; 伊藤公一; 渋谷洋; 絹谷清剛; 伊藤充; 横山邦彦; 東達也; 戸川貴史; 小泉潔; 吉村真奈; 内山眞幸; 岡本高宏; 金谷信一; 金谷和子; 米山達也; 池渕秀治; 柳田幸子; 柴田敬悟; 瀬川浩史; 山本篤
    医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書 2010
  • 細野眞; 大場久照; 笈田将皇; 藤淵俊王; 西部茂美; 早川登志雄
    医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書 KADAI6,31-122  2010
  • 細野眞; 大場久照; 三田創吾; 浅沼治; 山口一郎; 小高喜久雄; 池渕秀治; 中村伸貴
    医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書 KADAI6,1-29  2010
  • 細野眞; 山口一郎; 金谷信一; 小高喜久雄; 櫻井公一; 池渕秀治; 中村吉秀; 中村伸貴; 柳田幸子
    医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書 KADAI4,1-17  2010
  • 井上登美夫; 細野眞; 雫石一也; 山口一郎; 池渕秀治; 中村伸貴; 柳田幸子
    医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書 KADAI1,77-84  2010
  • 細野眞; 山口一郎; 金谷信一; 西澤真理子; 小高喜久雄; 諸澄邦彦; 櫻井公一; 池渕秀治; 中村吉秀; 中村伸貴; 柳田幸子
    医療放射線の安全確保に関する研究 平成19-21年度 総括・分担研究報告書 23 - 38 2010
  • 細野眞; 山口一郎; 小高喜久雄; 藤淵俊王
    医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書 KADAI4,31-96  2010
  • Hosono M; Tatsumi Y; Kanamaru A; Yamazoe Y
    Blood Frontier 19 (12) 1905 - 1911 1344-6940 2009/12 [Refereed][Invited]
    ダウンロード
  • HOSONO M
    Jpn. J. Radiol. Technol. 金原出版 54 (13) 1772 - 1778 0009-9252 2009/12
  • 花岡 宏平; 宇佐美 公男; 高田 裕史; 坂口 健太; 米矢 吉宏; 山添 譲; 土屋 典生; 澄田 貢; 細野 眞
    核医学技術 (NPO)日本核医学技術学会 29 (予稿集) 414 - 415 0289-100X 2009/08
  • 花岡 宏平; 坂口 健太; 井上 亮; 宇佐美 公男; 森元 英夫; 高田 裕史; 澄田 貢; 細野 眞
    核医学技術 (NPO)日本核医学技術学会 29 (予稿集) 463 - 463 0289-100X 2009/08
  • Mieko Kawai; T. Tada; M. Hosono; Y. Takada; K. Ishii; T. Nagahata; T. Sahara; Y. Inoue
    British Journal of Radiology 82 (978) 447 - 451 0007-1285 2009/06 [Refereed]
     
    The quality of the portal verification radiographs produced using the enhanced-contrast localisation (EC-L) Fast cassette-EC-L film (F-EC) combination and the EC-L Oncology cassette-EC-L film (O-EC) combination was investigated fundamentally and clinically. A computerised radiography (CR) system was used for comparison. In the clinic, portal verification radiographs produced for 22 patients with breast cancer were evaluated. The characteristic curves showed that the relative speed was 0.92 for the O-EC combination when the speed of the F-EC combination was defined to be 1, and that the average gradients were 4.76 and 4.35 for the F-EC combination and the O-EC combination, respectively. The smallest visible volumes of Burger's phantom were 50.3 mm3, 60.8 mm3 and 199.5 mm3 for the F-EC combination, the O-EC combination and the CR system, respectively, at an energy of 9 MeV, and 68.4 mm3, 74.2 mm3 and 195 mm3, respectively, at an energy of 12 MeV. In the clinic, both combinations at an energy of 6 MeV and the O-EC combination at 9 MeV showed very poor quality owing to underdensity. However the F-EC combination at an energy of 12 MeV and the O-EC combination at an energy of 15 MeV demonstrated a higher quality. When bremsstrahlung dose passing through the body is sufficient, the quality of portal verification radiography using EC-L film is appropriate for clinical use. © 2009 The British Institute of Radiology.
  • Masahiro Okada; Taro Shimono; Yoshihiro Komeya; Rina Ando; Yuki Kagawa; Takashi Katsube; Masatomo Kuwabara; Yukinobu Yagyu; Seishi Kumano; Izumi Imaoka; Norio Tsuchiya; Ryuichiro Ashikaga; Makoto Hosono; Takamichi Murakami
    ANNALS OF NUCLEAR MEDICINE SPRINGER 23 (4) 349 - 354 0914-7187 2009/06 [Refereed]
     
    To investigate whether integrated fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can differentiate benign from adrenal malignant lesions on the basis of maximum standardized uptake value (SUV(max)), tumor/liver (T/L) SUV(max) ratio, and CT attenuation value (Hounsfield Units; HU) of unenhanced CT obtained from FDG-PET/CT data. We studied 30 patients with 35 adrenal lesions (16 adrenal benign lesions, size 16 +/- A 5 mm, in 15 patients; and 19 adrenal malignant lesions, 24 +/- A 12 mm, in 15 patients) who had confirmed primary malignancies (lung cancer in 23 patients, lymphoma in 2, esophageal cancer in 2, hypopharyngeal cancer in 1, prostate cancer in 1, and 1 patient in whom lesions were detected at cancer screening). All patients underwent PET/CT at 1 h post FDG injection. Diagnosis of adrenal malignant lesions was based on interval growth or reduction after chemotherapy. An adrenal mass that remained unchanged for over 1 year was the standard used to diagnose adrenal benign lesions. Values of FDG uptake and CT attenuation were measured by placing volumetric regions of interest over PET/CT images. Adrenal uptake of SUV(max) a parts per thousand yen 2.5 was considered to indicate a malignant lesion; SUV(max) < 2.5 was considered to indicate a benign lesion. In further analysis, 1.8 was employed as the threshold for the T/L SUV(max) ratio. Unenhanced CT obtained from PET/CT data was considered positive for adrenal malignant lesions based on a CT attenuation value a parts per thousand yen 10 HU; lesions with a value < 10 HU were considered adrenal benign lesions. Mann-Whitney's U test was used for statistical analyses. SUV(max) in adrenal malignant lesions (7.4 +/- A 3.5) was higher than that in adrenal benign lesions (2.1 +/- A 0.5, p < 0.05). The CT attenuation value of adrenal malignant lesions (27.6 +/- A 11.9 HU) was higher than that of adrenal benign lesions (10.1 +/- A 12.3 HU, p < 0.05). In differentiating between adrenal benign and malignant lesions, a CT threshold of 10 HU corresponded to a sensitivity of 57%, specificity of 94%, accuracy of 74%, positive predictive value of 92% and negative predictive value of 65%. An SUV(max) cut-off value of 2.5 corresponded to a sensitivity of 89%, specificity of 94%, accuracy of 91%, positive predictive value of 94% and negative predictive value of 88%. The T/L SUV(max) ratio was 1.0 +/- A 0.2 for adrenal benign lesions and 4.5 +/- A 3.0 for adrenal malignant lesions. And T/L SUV(max) ratio cut-off value of 1.8 corresponded to a sensitivity of 85%, specificity of 100%, accuracy of 91%, positive predictive value of 100% and negative predictive value of 83%. FDG-PET/CT with additional SUV(max) analysis improves the diagnostic accuracy of adrenal lesions in cancer patients.
  • Hanada Kazushi; Hosono Makoto; Hitomi Yoshie; Tsuchiya Norio; Komeya Yoshihiro; Tsujii Noa; Kitahata Daisuke; Takahashi Eriko; Murakami Takumi; Shirakawa Osamu
    JOURNAL OF NUCLEAR MEDICINE 50 0161-5505 2009/05 [Refereed]
  • Taro Shimono; Makoto Hosono; Ryuichiro Ashikaga; Seishi Kumano; Izumi Imaoka; Yukinobu Yagyu; Masahiro Okada; Masatomo Kuwabara; Takamichi Murakami
    NEURORADIOLOGY SPRINGER 51 (3) 145 - 150 0028-3940 2009/03 [Refereed]
     
    We have occasionally seen ring-shaped lateral ventricular nodules < 1 cm in diameter during routine brain magnetic resonance imaging (MRI). We investigated retrospectively clinical and MRI findings of the nodules. Review of radiological records was performed for 39,607 patients who underwent brain MRI between January 2001 and April 2008. Nodules were assessed for number, location, shape, and signal intensity, which was determined based on the range of signal intensity from gray to white matter on T1- and T2-weighted imaging. Fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging (DWI), contrast enhancement characteristics, and serial MRI changes of nodules were assessed when available. Nine of 39,607 patients (0.023%) showed the nodules. No symptoms associated with the nodules. Among the nine patients, 11 nodules were identified (one nodule in seven patients (77.8%) and two nodules in two patients (22.2%)). Location was limited to the roof of the body for six nodules (54.5%) and the frontal horn for five patients (45.5%). All nodules (100%) were round and isointense on T1- and T2-weighted imaging. On FLAIR imaging of eight nodules, six (75%) were hyperintense, and two (25%) were isointense. On DWI of seven nodules, all nodules (100%) were isointense. None of seven nodules (0%) examined using postcontrast MRI showed enhancement. None of eight nodules (0%) examined using serial MRI (range, 4-60 months) showed changes in morphology over time. These nodules were incidentally encountered and shared similar MRI features. Although pathological confirmation was lacking in our cases, these nodules may be of nonaggressive nature.
  • 大久保充; 中松清志; 柴田徹; 金森修一; 西川龍之; 小池竜太; 立花和泉; 奥村雅彦; 西村恭昌; 細野眞
    日本医学放射線学会総会抄録集 68th S226  0048-0428 2009/02
  • Recovery Coefficient(RC)-SUV部分容積効果補正による肺癌リンパ節転移の評価
    米矢 吉宏; 細野 眞; 花岡 宏平; 宇佐美 公男; 高田 裕史; 坂口 健太; 岡田 真広; 土屋 典生; 香川 祐毅; 村上 卓道
    日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 68回 S318 - S318 0048-0428 2009/02
  • T. Katsube; T. Shimono; R. Ashikaga; M. Hosono; H. Kitagaki; T. Murakami
    AMERICAN JOURNAL OF NEURORADIOLOGY AMER SOC NEURORADIOLOGY 30 (2) 386 - 388 0195-6108 2009/02 
    Neuroacanthocytosis is a rare hereditary disorder characterized by involuntary choreiform movements and erythrocytic acanthocytosis in the peripheral blood. Clinical manifestations of this disorder resemble those of Huntington disease (HID). Neuroimaging features of neuroacanthocytosis are atrophy and signal intensity change of the striata on MR imaging, as in HID. We report herein the cases of 2 siblings with neuroacanthocytosis showing cerebellar atrophy as well as atrophy and signal intensity changes of striata.
  • Ohba H; Fujibuchi T; Mita S; Horikoshi A; Iwanaga T; Ikebuchi H; Hosono M
    Nihon Hoshasen Gijutsu Gakkai zasshi 1 65 (1) 57 - 63 0369-4305 2009/01 [Refereed]
     
    The purpose of this study was to verify the shielding evaluation method for medical X-ray imaging facilities in Report No. 147 of the National Council on Radiation Protection and Measurements (NCRP). We investigated the concept of radiation protection and the major revised point in Report No. 147. The goal of radiation protection in Report No. 147 was compared with that in Japan. Using the data of the Imaging Performance Assessment of CT scanners (ImPACT) 2006 and the latest pre-installation manuals of several manufactures for different computed tomography (CT) scanner models, we verified t...
  • 細野眞; 大場久照; 笈田将皇; 藤淵俊王; 西部茂美; 早川登志雄
    医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書 199 - 257 2009
  • 細野眞; 山口一郎; 金谷信一; 西澤真理子; 小高喜久雄; 諸澄邦彦; 櫻井公一; 池渕秀治; 中村吉秀; 中村伸貴
    医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書 124 - 168 2009
  • 細野眞; 山口一郎; 金谷信一; 小高喜久雄; 諸澄邦彦; 櫻井公一; 池渕秀治; 中村吉秀; 中村伸貴
    医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書 169 - 178 2009
  • 細野眞; 山口一郎; 金谷信一; 小高喜久雄; 諸澄邦彦; 櫻井公一; 池渕秀治; 中村吉秀; 中村伸貴
    医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書 179 - 188 2009
  • Masahiro Okada; Takamichi Murakami; Seishi Kumano; Masatomo Kuwabara; Taro Shimono; Makoto Hosono; Hitoshi Shiozaki
    ANNALS OF NUCLEAR MEDICINE SPRINGER 23 (1) 73 - 80 0914-7187 2009/01 [Refereed]
     
    To assess whether integrated fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can improve the diagnostic accuracy of metastatic regional lymph nodes (LNs) in esophageal cancer compared with contrast enhanced CT (CECT). We examined 180 consecutive patients with esophageal cancer by integrated PET/CT between April 2006 and March 2007. Eighteen patients (M:F 14:4) underwent radical esophagectomy after evaluations by PET/CT and CECT of 5-7-mm-thick slices 70-80 s after injection. Regional LNs of esophageal cancer were retrospectively reviewed on CECT images by two blinded evaluators on the basis of the following cutoff sizes: 7 mm for all regional LNs (Protocol A), 10 mm for paratracheal LNs (Protocol B), and 7 mm for others. In addition, the maximum standardized uptake value (SUVmax) on PET/CT was evaluated for positive uptake by LNs. Of 210 LNs excised at surgery, 25 were positive and 185 were negative for metastasis at pathology. The PET/CT images identified 15 true-positive and 184 truenegative LNs, whereas CECT identified 15 true positives and 176 true negatives in Protocol A, and 14 true positives and 180 true negative in Protocol B. The sensitivity, specificity, accuracy, positive, and negative predictive values of PET/CT were respectively 60.0%, 99.5%, 94.8%, 93.8%, and 94.8%, whereas those of CECT were 60.0%, 95.1%, 91.0%, 62.5%, and 94.6% (Protocol A) and 56.0%, 97.3%, 92.4%, 73.7%, and 94.2% (Protocol B). A comparison of the two CECT protocols revealed fewer false-positive LNs in Protocol B, but slightly lower sensitivity in Protocol B than in Protocol A. Substantial numbers of false-positive LNs were determined by CECT in the paratracheal regions (6 of 9, 66.7%) and CECT revealed central necrosis in 4 of 15 (26.7%) true-positive LNs > 1.8 cm. The mean SUVmax on PET/CT was 2.9 (range 1.7-5.5) in true-positive LNs. The smallest LN metastasis detectable by PET/CT was 6 mm. Integrated PET/CT improves the PPV of regional LNs when compared with CECT.
  • 花岡 宏平; 永元 啓介; 西垣外 尚弘; 森元 英夫; 宇佐美 公男; 澄田 貢; 細野 眞
    核医学技術 (NPO)日本核医学技術学会 28 (3) 253 - 253 0289-100X 2008/09
  • 永元 啓介; 花岡 宏平; 西垣外 尚弘; 森元 英夫; 宇佐美 公男; 澄田 貢; 細野 眞
    核医学技術 (NPO)日本核医学技術学会 28 (3) 253 - 253 0289-100X 2008/09
  • 米矢 吉宏; 細野 眞; 花岡 宏平; 宇佐美 公男; 高田 裕史; 坂口 健太; 岡田 真広; 土屋 典生; 香川 祐毅; 任 誠雲; 村上 卓道
    核医学 (一社)日本核医学会 45 (3) S205 - S205 0022-7854 2008/09
  • OOKP(歯根部利用人工角膜)手術後のCT像
    桑原 雅知; 下野 太郎; 勝部 敬; 藤谷 哲也; 松久保 祐子; 足利 竜一朗; 細野 眞; 村上 卓道; 福田 昌彦; 濱田 傑
    日本医学放射線学会秋季臨床大会抄録集 (公社)日本医学放射線学会 44回 S500 - S500 0048-0428 2008/09
  • 細野 眞
    近畿大学医学雑誌 近畿大学医学部 33 (3) 193 - 198 0385-8367 2008/09
  • Mitsuru Okubo; Yasumasa Nishimura; Kiyoshi Nakamatsu; Masahiko Okumura; Toru Shibata; Shuichi Kanamori; Kouhei Hanaoka; Makoto Hosono
    ANNALS OF NUCLEAR MEDICINE SPRINGER 22 (7) 579 - 586 0914-7187 2008/08 [Refereed]
     
    Objective To determine an appropriate threshold value for delineation of the target in positron emission tomography (PET) and to investigate whether PET can delineate an internal target volume (ITV), a series of phantom studies were performed. Methods An ellipse phantom (background) was filled with 1028 Bq/ml of [(18)F] fluoro-2-deoxyglucose ((18)FDG), and six spheres of 10 mm, 13 mm, 17 mm, 22 mm, 28 mm, and 37 mm in diameter inside it were filled with (18)FDG activity to achieve source-to-background (S/B) ratios of 10, 15, and 20. In static phantom experiments, an appropriate threshold value was determined so that the size of PET delineation fits to an actual sphere. In moving phantom experiments with total translations of 10 mm, 20 mm, and 30 mm and a period of oscillation of 4s, the maximum size of PET delineation with the appropriate threshold value was measured in both the axial and sagittal planes. Results In the static phantom experiments, the measured maximum (18)FDG activities of spheres of less than 22 mm were lower than 80% of the injected (18)FDG activity, and those for the larger spheres ranged from 90% to 110%. Appropriate threshold values determined for the spheres of 22 mm or more ranged from 30% to 40% of the maximum (18)FDG activity, independent of the S/B ratio. Therefore, we adopted an appropriate threshold value as 35% of the measured maximum (18)FDG activity. In moving phantom experiments, the maximum (18)FDG activity of spheres decreased significantly, dependent on the movement distance. Although the sizes of PET delineation with 35% threshold value tended to be slightly smaller (< 3 mm) than the actual spheres in the axial plane, the longest sizes in the sagittal plane were larger than the actual spheres. Conclusions When a threshold value of 35% of the measured maximum (18)FDG activity was adopted, the sizes of PET delineation were almost the same for static and moving phantom spheres of 22 mm or more in the axial plane. In addition, PET images have the potential to provide an individualized ITV.
  • Masatomo Kuwabara; Taro Shimono; Mami Toyomasu; Mitsuaki Shioyama; Yoshiyuki Mitsui; Eiji Yoshinaga; Akira Kawada; Makoto Hosono; Takamichi Murakami; Susumu Kusunoki
    RADIATION MEDICINE SPRINGER 26 (7) 438 - 441 1862-5274 2008/08 [Refereed]
     
    Relapsing polychondritis is a rare autoimmune disease characterized by recurrent inflammation of cartilage in multiple sites of the body, including the auricles. Central nervous system involvement appears rare. We encountered a case of relapsing polychondritis with encephalitis that could be diagnosed by the unique appearance of the auricle with signal hyperintensity on diffusion-weighted magnetic resonance imaging.
  • Teruaki Yoh; Makoto Hosono; Yoshihiro Komeya; Sung-Woon Im; Ryuichiro Ashikaga; Taro Shimono; Norio Tsuchiya; Masahiro Okada; Kazushi Hanada; Yukinobu Yagyu; Yasumasa Nishimura; Takamichi Murakami
    ANNALS OF NUCLEAR MEDICINE SPRINGER 22 (6) 513 - 519 0914-7187 2008/07 [Refereed]
     
    Objective The objective of our study was to evaluate diagnostic ability and features of quantitative indices of three modalities: uptake rate on norcholesterol scintigraphy, computed tomography (CT) attenuation value, and fat suppression on chemical-shift magnetic resonance imaging (MRI) for characterizing adrenal adenomas. Methods Image findings of norcholesterol scintigraphy, CT, and MRI were reviewed for 78 patients with functioning (n = 48) or nonfunctioning (n = 30) adrenal masses. The norcholesterol uptake rate, attenuation value on unenhanced CT, and suppression on in-phase to opposed-phase MRI were measured for adrenal masses. Results The norcholesterol uptake rate, CT attenuation value, and MR suppression index showed the sensitivity of 60%, 82%, and 100%, respectively, for functioning adenomas of < 2.0 cm, and 96%, 79%, and 67%, respectively, for those of >= 2.0 cm. A statistically significant correlation was observed between size and norcholesterol uptake, and between CT attenuation value and MR suppression index. Regarding norcholesterol uptake, the adenoma-to-contralateral gland ratio was significantly higher in cortisol releasing than in aldosterone-releasing adenomas. Conclusions The norcholesterol uptake rate was reliable for characterization of adenomas among adrenal masses of >= 2.0 cm. CT attenuation value and MR suppression index were well correlated with each other, and were useful regardless of mass size.
  • 香川 祐毅; 細野 眞; 米矢 吉宏; 岡田 真広; 土屋 典生; 花岡 宏平; 宇佐美 公男; 高田 裕史; 坂口 健太; 葉 輝明; 任 誠雲; 柳生 行伸; 足利 竜一朗; 村上 卓道
    映像情報Medical 産業開発機構(株) 40 (6) 618 - 619 1346-1354 2008/06 
    ファントム実験で得られた回復係数(RCs)を用い、部分容積効果の影響を受けやすいリンパ節のStandardized uptake values(SUV)補正を行うことで、肺癌および食道癌での縦隔リンパ節転移の診断能が向上するか検討した。肺癌においても食道癌においても、リンパ節転移の診断には、ROC解析でsizeよりもSUVmaxとcSUVmaxでの評価の方が大きなAzを示し、高い診断能を有した。SUVmaxとcSUVmaxの比較では、補正によりAzがやや低下し、小病変の低いSUVmaxが過大に補正されて診断能を損なった可能性があった。食道癌の転移陽性リンパ節は肺癌の転移陽性リンパ節に比してsizeが小さく、SUVmaxが低い傾向があり、腫瘍ごとにリンパ節転移のsize、SUVmaxについて指標を設定する必要が考えられた。
  • Masahiro Okada; Takamichi Murakami; Seishi Kumano; Izumi Imaoka; Taro Shimono; Ryuichiro Ashikaga; Makoto Hosono
    AMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 190 (6) W323 - W326 0361-803X 2008/06 [Refereed]
     
    OBJECTIVE. The purpose of our study was to evaluate whether simultaneous injection into cubital veins bilaterally at one half of the standard injection rate achieves similar hepatic and aortic enhancement on MDCT as the conventional injection rate into a single cubital vein. MATERIALS AND METHODS. Thirty-two patients underwent multiphase MDCT because they were suspected of having a hepatic tumor. Patients were assigned to one of the following two groups: group A, 100 mL of 370 mg I/mL of contrast medium injected into a unilateral cubital vein (one-route) via a 20-gauge cannula at a rate of 4 mL/s; or group B, 50 mL of contrast medium injected into the cubital veins bilaterally (two-route) via 24-gauge cannulas at 2 mL/s. Peak contrast enhancement of the liver and abdominal aorta for groups A and B was measured using regions of interest and compared; arrival time of the contrast media was also compared using a bolus-tracking system. Analysis was performed using Wilcoxon's signed rank test. RESULTS. Peak aortic enhancement of groups A and B was 367 +/- 67 H and 361 +/- 113 H (p = 0.61, not significant), respectively, and peak hepatic enhancement of groups A and B was 56 +/- 11 H and 56 +/- 16 H (p = 0.88, not significant), respectively. Mean arrival time to the aorta of group B (19.4 +/- 3.4 seconds) was significantly later compared with that of group A (15.5 +/- 3.5 seconds) (p = 0.005). CONCLUSION. The slower two-route injection produced the same aortic and hepatic enhancement as the faster one-route method with faster injection, but the arrival time of the contrast medium was later using the two-route method.
  • 頭部FDG-PETにおける3D収集の有用性
    永元 啓介; 花岡 宏平; 西垣内 尚弘; 宇佐美 公男; 坂口 健太; 高田 裕史; 細野 眞
    日本放射線技術学会近畿部会雑誌 (公社)日本放射線技術学会-近畿支部 14 (1) 118 - 118 2008/05
  • 大久保充; 中松清志; 柴田徹; 金森修一; 小池竜太; 廣井啓二; 奥村雅彦; 西村恭昌; 花岡宏平; 宇佐美公男; 細野眞
    Radiat Med 26 46  0288-2043 2008/04
  • 大久保充; 中松清志; 柴田徹; 金森修一; 小池竜太; 廣井啓二; 西村恭昌; 奥村雅彦; 細野眞
    Radiat Med 26 52  0288-2043 2008/04
  • 武輪 光彦; 谷口 貢; 岩永 善高; 石瀬 卓郎; 小林 直也; 平野 豊; 宮崎 俊一; 筑後 孝章; 足利 竜一朗; 村上 卓道; 細野 眞
    Circulation journal : official journal of the Japanese Circulation Society 社団法人日本循環器学会 72 (0) 993 - 993 1346-9843 2008/04
  • 大久保 充; 中松 清志; 柴田 徹; 金森 修一; 小池 竜太; 廣井 啓ニ; 西川 龍之; 奥村 雅彦; 西村 恭昌; 花岡 宏平; 細野 眞
    肺癌 日本肺癌学会 48 (2) 147 - 147 0386-9628 2008/04
  • 大動脈解離後に発症した下腸間膜動脈領域の虚血性腸炎
    任 誠雲; 下野 太郎; 柳生 行伸; 清水 利栄; 葉 輝明; 坪山 尚寛; 桑原 雅知; 小塚 健倫; 今岡 いずみ; 足利 竜一朗; 村上 卓道; 米矢 吉宏; 土屋 典生; 岡田 真広; 細野 眞; 井上 剛裕; 梅原 泰; 土手 健作
    Radiation Medicine (公社)日本医学放射線学会 26 (Suppl.I) 47 - 47 0288-2043 2008/04
  • 卵巣腫瘤との鑑別が困難であった限局性腹膜偽粘液腫の1例
    清水 利栄; 今岡 いずみ; 下野 太郎; 桑原 雅知; 小塚 健倫; 葉 輝明; 任 誠雲; 坪山 尚寛; 柳生 行伸; 熊野 正士; 足利 竜一朗; 村上 卓道; 米矢 吉宏; 土屋 典生; 岡田 真広; 細野 眞
    Radiation Medicine (公社)日本医学放射線学会 26 (Suppl.I) 50 - 50 0288-2043 2008/04
  • Taro Shimono; Takahiro Tsuboyama; Masatomo Kuwabara; Sung-woon Im; Yukinobu Yagyu; Izumi Imaoka; Ryuichiro Ashikaga; Makoto Hosono; Takamichi Murakami
    RADIATION MEDICINE SPRINGER 26 (3) 151 - 155 1862-5274 2008/04 [Refereed]
     
    Purpose. Motion artifact is problematic in the diagnosis of Creutzfeldt-Jakob disease (CJD) because of dementia. The purpose was to compare the occurrence of this artifact between a diffusion-weighted (DW) magnetic resonance ( MR) imaging sequence and conventional sequences. Materials and methods. Ten MR examinations comprising T2- weighted, T1- weighted, DW, and fl uidattenuated inversion recovery imaging in seven CJD patients were retrospectively evaluated. The occurrence of motion artifacts on each sequence were assessed, and the examination was classifi ed into four groups as follows: group A, motion artifact not revealed on DW imaging but revealed on one or more other sequences; group B, revealed on DW imaging and one or more other sequences; group C, not revealed on any sequences; and group D, revealed on DW imaging but not on any other sequences. Results. The 10 MR examinations were classifi ed as eight group A ( 80%), one B ( 10%), one C ( 10%), and zero D ( 0%). Conclusion. Motion artifacts are likely to occur in any conventional imaging sequences in CJD, but the fastimaging ability of DW imaging can reduce this artifact. The combination of an absence of motion artifact on DW imaging and the presence on conventional sequences may be one of the frequent fi ndings of CJD.
  • 細野 眞
    月刊新医療 エム・イ-振興協会 35 (3) 56 - 59 0910-7991 2008/03
  • 大久保充; 中松清志; 柴田徹; 金森修一; 小池竜太; 廣井啓二; 西川龍之; 奥村雅彦; 西村恭昌; 花岡宏平; 細野眞
    核医学 45 (1) 54 - 55 0022-7854 2008/02
  • 大久保充; 中松清志; 柴田徹; 金森修一; 西川龍之; 小池竜太; 廣井啓二; 奥村雅彦; 西村恭昌; 細野眞
    日本医学放射線学会総会抄録集 67th S258  0048-0428 2008/02
  • 原発性肺癌のリンパ節転移の評価におけるrecovery coefficient(RC) SUV補正の有用性
    米矢 吉宏; 細野 眞; 花岡 宏平; 宇佐見 公男; 高田 裕史; 坂口 健太; 岡田 真広; 土屋 典生; 香川 祐毅; 村上 卓道
    日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 67回 S376 - S376 0048-0428 2008/02
  • KATO Katsuhiko; HOSONO Makoto; ITO Kengo; OKADA Masahiro; KOMEYA Yoshihiro; IM Sung-WOON; TSUCHIDA Norio; TORIZUKA Kanji
    RADIOISOTOPES Japan Radioisotope Association 57 (1) 13 - 23 0033-8303 2008/01 
    The usefulness of [<SUP>18</SUP>F] FDG-PET for the diagnosis of bone and soft tissue tumors was evaluated using 75 cases(20 kinds of diseases)which were collected from7institutions in Japan by sending out questionnaires. The data of the study patients, who had osteosarcoma, Ewing′s sarcoma(including primitive neuroectodermal tumor), liposarcoma, leiomyosarcoma, Hemangiosarcoma, synovial sarcoma, rhabdomyosarcoma, giant cell tumor, schwannoma, malignant fibrous histiocystoma, chondrosarcoma, alveolar soft part sarcoma, epithelioid sarcoma, endometrial stromal sarcoma, hibernoma, fibrosarcoma, multiple osteochondroma, sacral chordoma, Langerhans cell histiocytosis, and neurofibromatosis, respectively, were analyzed. From the analytical results it was concluded that the usefulness of [<SUP>18</SUP>F] FDG-PET is high for the diagnosis of these tumors.
  • 頭部FDG-PETにおける3D収集の有用性
    永元 啓介; 西垣外 尚弘; 花岡 宏平; 坂口 健太; 高田 裕史; 宇佐美 公男; 細野 眞
    日本放射線技術学会近畿部会雑誌 (公社)日本放射線技術学会-近畿支部 13 (3) 66 - 66 2008/01
  • 細野眞; 大場久照; 藤淵俊王; 三田創吾; 中村吉秀; 岩永哲雄; 堀越亜希子
    医療放射線の安全確保に関する研究 平成19年度 総括・分担研究報告書 486 - 549 2008
  • 細野眞; 山口一郎; 金谷信一; 西澤真理子; 中沢敦; 迫義知; 池渕秀治; 中村伸貴
    医療放射線の安全確保に関する研究 平成19年度 総括・分担研究報告書 406 - 448 2008
  • 加藤 克彦; 細野 眞; 伊藤 健吾
    Radioisotopes 日本アイソトープ協会 57 (1) 15 - 25 0033-8303 2008/01
  • RI内用療法の最新動向-新しい核医学治療-
    細野 眞
    新医療 35 (3) 56 - 59 2008
  • 骨軟部腫瘍の診断における[18F]FDG-PET検査の臨床的有用性
    加藤克彦; 細野 眞; 伊藤健吾; 岡田真広; 米矢吉宏; 任 誠雲; 土屋典生; 鳥塚莞爾
    RADIOISOTOPES 57 13 - 23 2008
  • Report of 3rd Steering Panel Meeting on the International Action Plan for the Radiological Protection of Patients
    IAEA Report 2008
  • 細野 眞
    核医学 44 (3) S119  0022-7854 2007/10
  • 腎血管性高血圧患者に対して腎動脈塞栓術が著効した1例
    任 誠雲; 柳生 行伸; 桑原 雅知; 坪山 尚寛; 下野 太郎; 清水 利栄; 小塚 健倫; 今岡 いずみ; 熊野 正士; 葉 輝明; 細野 眞; 土屋 典生; 岡田 真広; 米矢 吉宏; 村上 卓道; 竹村 司
    IVR: Interventional Radiology (一社)日本インターベンショナルラジオロジー学会 22 (4) 495 - 495 1340-4520 2007/10
  • recovery coefficient(RC)に基づくSUV補正を用いた肺癌リンパ節転移の評価
    米矢 吉宏; 細野 眞; 花岡 宏平; 宇佐見 公男; 高田 裕史; 坂口 健太; 任 誠雲; 土屋 典生; 岡田 真広; 葉 輝明; 村上 卓道
    核医学 (一社)日本核医学会 44 (3) 287 - 287 0022-7854 2007/10
  • 花岡 宏平; 宇佐美 公男; 高田 裕史; 坂口 健太; 澄田 貢; 米矢 吉宏; 細野 眞
    日本放射線技術學會雜誌 公益社団法人日本放射線技術学会 63 (9) 1018 - 1018 0369-4305 2007/09
  • 香川 祐毅; 柳生 行伸; 村上 卓道; 下野 太郎; 桑原 雅知; 任 誠雲; 坪山 尚寛; 荒木 哲朗; 松久保 祐子; 安藤 理奈; 葉 輝明; 熊野 正士; 今岡 いずみ; 足利 竜一郎; 米矢 吉宏; 土屋 典生; 岡田 真広; 細野 眞
    近畿大学医学雑誌 近畿大学 32 (3) 14A - 14A 0385-8367 2007/09
  • Kumano S; Okada M; Imaoka I; Shimono T; Hosono M; Murakami T
    Gan to kagaku ryoho. Cancer & chemotherapy 9 34 1357 - 1360 0385-0684 2007/09 [Refereed]
  • 土屋典生; 下野太郎; 足利竜一朗; 岡田真広; 柳生行伸; 米矢吉宏; 任誠雲; 葉輝明; 細野眞; 大久保充; 廣井啓二; 小池竜太; 中松清志; 金森修一; 柴田徹; 西村泰昌
    Radiat Med 25 79  0288-2043 2007/04
  • 肝門部胆管癌術後に生じた門脈狭窄に対して門脈ステント留置を行った1例
    児玉 彩; 柳生 行伸; 桑原 雅知; 任 誠雲; 米矢 吉宏; 土屋 典生; 岡田 真広; 坪山 尚寛; 葉 輝明; 清水 利栄; 小塚 健倫; 今岡 いずみ; 下野 太郎; 足利 竜一朗; 細野 眞; 村上 卓道
    IVR: Interventional Radiology (一社)日本インターベンショナルラジオロジー学会 22 (2) 266 - 266 1340-4520 2007/04
  • 大久保充; 中松清志; 金森修一; 小池竜太; 廣井啓二; 柴田徹; 西村恭昌; 奥村雅彦; 花岡宏平; 細野眞
    日本医学放射線学会学術集会抄録集 66th S332  0048-0428 2007/02
  • クロイツフェルト・ヤコブ病(CJD)のMRI診断において詳細な読影をする前に可能性を想起できるか?
    下野 太郎; 坪山 尚寛; 桑原 雅知; 任 誠雲; 柳生 行伸; 今岡 いずみ; 小塚 健倫; 足利 竜一朗; 細野 眞; 村上 卓道
    日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 66回 S306 - S307 0048-0428 2007/02
  • 田中 基幹; 斎藤 允孝; 清水 信貴; 森 康範; 南 高文; 林 泰司; 辻 秀憲; 松本 成史; 野澤 昌弘; 石井 徳味; 植村 天受; 細野 眞
    日本泌尿器科学会雑誌 (一社)日本泌尿器科学会 98 (2) 360 - 360 0021-5287 2007/02
  • Y. Nishimura; M. Okubo; K. Nakamatsu; M. Okumura; T. Shibata; S. Kanamori; R. Koike; K. Hiroi; T. Nishikawa; M. Hosono
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ELSEVIER SCIENCE INC 69 (3) S694 - S695 0360-3016 2007
  • 足利 竜一朗; 栁生 行伸; 桑原 雅知; 坪山 尚寛; 任 誠雲; 下野 太郎; 小塚 健倫; 熊野 正士; 今岡 いずみ; 村上 卓道; 米矢 吉宏; 岡田 真広; 土屋 典生; 細野 眞; 山田 浩司; 黒川 敏昭; 霜村 康平; GEメディカルシステム
    INNERVISION インナービジョン 22 (5) 106 - 109 0913-8919 2007 
    64列MDCTの臨床画像を供覧し、その実際について述べた。
  • 細野 眞
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 43 (3) S130  0022-7854 2006/10
  • 大久保充; 中松清志; 柴田徹; 金森修一; 小池竜太; 廣井啓二; 西村恭昌; 奥村雅彦; 細野眞
    日本放射線腫よう学会誌 18 (Supplement 1) 147  1040-9564 2006/10
  • 宇佐美 公男; 高田 裕史; 坂口 健太; 細野 眞; 花岡 宏平; 尾崎 彩希; 澄田 貢
    日本放射線技術學會雜誌 公益社団法人日本放射線技術学会 62 (9) 1312 - 1313 0369-4305 2006/09
  • 花岡 宏平; 尾崎 彩希; 澄田 貢; 宇佐美 公男; 高田 裕史; 坂口 健太; 細野 眞
    日本放射線技術學會雜誌 公益社団法人日本放射線技術学会 62 (9) 1313 - 1314 0369-4305 2006/09
  • 泌尿器科領域におけるFDG-PETの有用性
    田中 基幹; 清水 信貴; 森 康範; 南 高文; 林 泰司; 辻 秀憲; 松本 成史; 能勢 和宏; 野澤 昌弘; 石井 徳味; 細野 眞; 植村 天受
    日本癌治療学会誌 (一社)日本癌治療学会 41 (2) 481 - 481 0021-4671 2006/09
  • 岡田 真広; 細野 眞; 米矢 吉宏; 土屋 典生; 坂口 健太; 花岡 宏平; 尾崎 彩希; 高田 裕史; 宇佐美 公男; 小塚 健倫; 村上 卓道
    INNERVISION (株)インナービジョン 21 (8) 55 - 59 0913-8919 2006/07
  • K Hanada; M Hosono; T Kudo; Y Hitomi; Y Yagyu; E Kirime; Y Komeya; N Tsujii; K Hitomi; Y Nishimura
    NUCLEAR MEDICINE COMMUNICATIONS LIPPINCOTT WILLIAMS & WILKINS 27 (6) 535 - 541 0143-3636 2006/06 [Refereed]
     
    Background Alzheimer's disease and major depression are representative diseases that present forgetfulness and a depressive mood. It is often difficult to make a differential diagnosis between the two in the initial phase. Aim To evaluate the differential diagnosis method using regional cerebral blood flow patterns with a three-dimensional stereotactic surface projection technique. Methods Twenty early-elderly patients with mild and moderate forgetfulness were studied. Among them, 10 were diagnosed as having major depression (the MD group) and the other 10 as having Alzheimer's disease (the AD group). All patients underwent cerebral perfusion single photon emission computed tomography (SPECT) with [I-123] iodoamphetamine. A z-score was calculated for each pixel of the cerebral surface. Twenty-one circular regions of interest (ROIs) were placed on the z-score map. The significance of the statistical difference in ROI values between the two groups was determined by using the two-sided Mann-Whitney U-test. Results The z-scores for the lateral parietal, lateral temporal, bilateral precuneus and bilateral posterior cingulate gyrus were significantly reduced in the AD group compared with those in the MD group. The z-scores for the lateral frontal, left thalamus and bilateral medial frontal regions were significantly lower in the MD group than in the AD group. Conclusion Our study demonstrated a difference in regional cerebral blood flow patterns between the early elderly with Alzheimer's disease and those with major depression. All patients were classified into the appropriate categories using discriminant analysis and z-scores of frontal and parietal regions. Brain perfusion SPECT was a useful tool for the differential diagnosis between Alzheimer's disease and major depression.
  • Justification and optimization procedures for medical exposure
    Hosono M
    World J of Nucl Med 5 324 - 326 2006
  • 細野真; 米矢吉宏; 油野民雄; 日下部きよ子; 草間経二; 山口一郎; 小林一三; 渡辺浩; 並木宣雄; 藤村洋子; 堀越亜希子
    核医学 (一社)日本核医学会 42 (3) 293 - 293 0022-7854 2005/09
  • NISHIMURA Keiichiro; TAKAHASHI Takeo; OSADA Hisato; MURATA Osamu; HONDO Mikito; HOSONO Makoto; HONDA Norinari
    The Journal of JASTRO 日本放射線腫瘍学会 17 (2) 97 - 101 1040-9564 2005/06
  • H Nakada; H Ishida; D Hashimoto; T Mori; M Hosono
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES SPRINGER 19 (4) 563 - 568 0930-2794 2005/04 
    Background: The effect of different pneumoperitoneal pressures on tumor cell distribution was investigated. Methods: Donryu rats were allocated to receive carbon dioxide pneumoperitoneum at 5, 10, or 15 mmHg for 60 min or to serve as a control. During the procedure, each rat was inoculated with radiolabeled ascites hepatoma cells via the portal vein (experiment 1) or femoral vein (experiment 2). In both experiments, the rats were killed 30, 60, 90, or 120 min after tumor cell inoculation, and the liver and lungs were extirpated for radioactivity count (n = 5 or 6 for each time point in each group). Results: In experiment 1, the percentage of injected dose (% ID) for the liver was greater than for the other three groups 120 min after tumor cell inoculation. There were no significant differences in the %IDs of the lungs at any time point among the groups. In experiment 2, there were no significant differences in the %IDs of the liver and lungs at any time point among the groups. Conclusions: These results Suggest that an elevated insufflation pressure facilitates the location of intraportally injected tumor cells in the liver, and that pulmonary location of the tumor cells may not depend on insufflation pressures in this animal model.
  • Aggressive multiple lung metastases from intracranial atypical meningioma
    Takahashi T; 細野 眞; Honda N Oku; S; Kashimada; A Osada H Murata; O Hondo M Nishimura; K Ohno H
    Jpn J Tomogrraphy 32 (1) 24 - 27 2005/01
  • K Ishii; M Hosono; Y Wada; S Kondo; Y Takada; T Tada; T Okamura; M Maeda; Y Watanabe; Y Inoue
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ELSEVIER SCIENCE INC 63 (2) S483 - S484 0360-3016 2005
  • NISHIMURA Keiichiro; TAKAHASHI Takeo; OSADA Hisato; MURATA Osamu; HONDO Mikito; HOSONO Makoto; HONDA Norinari
    The Journal of JASTRO 一般社団法人 日本放射線腫瘍学会 17 (2) 97 - 101 1040-9564 2005 
    Locally advanced non-small cell lung cancer is often inoperable. It is difficult to choose the optimal therapy for locally advanced lung carcinoma with malignant airway obstruction. We applied Neodymiumyttrium-aluminum garnet (Nd-YAG) laser therapy combined with external beam radiotherapy. Seven patients were treated with Nd-YAG laser and 60 Gy and more of conventional radiotherapy. All patients had malignant airway obstructions and severe dyspnea at the beginning of Nd-YAG laser therapy. These patients received good to excellent palliation and were able to have normal daily lifes after the treatments. The Nd-YAG laser combined with external radiotherapy may be one of the most useful treatment for locally advanced lung cancer with malignant airway stenosis to improve quality of life.
  • 花田 一志; 切目 栄司; 大賀 征夫; 田村 善史; 人見 一彦; 細野 眞; 足利 竜一朗; 柳生 行伸; 西村 恭昌
    近畿大学医学雑誌 近畿大学 29 (2) 53A  0385-8367 2004/10
  • AK Mishra; P Panwar; M Hosono; K Chuttani; P Mishra; RK Sharma; JF Chatal
    JOURNAL OF DRUG TARGETING TAYLOR & FRANCIS LTD 12 (9-10) 559 - 567 1061-186X 2004/10 [Refereed]
     
    Objective : The purpose of this study was to obtain the convenient, synthetically useful bifunctional chelating agent, 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8,11-tetraazacyclotridecane, and to apply it to stable 99m Tc-labelling of monoclonal antibodies (mAbs). Methods : The chelate was synthesised by reaction of nitrobenzyl malonate and triethylenetetramine followed by alkylation by reacting with bromoacetic acid at pH 10. The amino group was converted to isothiocyanato derivative by reacting with thiophosgene at pH 2.0. Conjugation with mAbs [(anti-carcinoembryonic antigen (CEA) and anti-epidermal growth factor receptor (EGFr)] was performed at pH 8.4 using trisodium phosphate solution by incubating at 37degreesC for 1 h and subjected to purification on size exclusion chromatography. Results : When radioimmunoconjugates were labelled with Tc-99m, the specific activity of immunoconjugates was 20-30 mCi/mg of protein and their immunoreactivity exceeded 80%. The stability in serum indicated that the metal remained bound to antibodies. Biodistribution studies in athymic mice grafted with U-87 human glioblastoma multiforme and MDA-MB-468 human breast carcinoma tumours revealed significant localisation of Tc-99m-labelled antibodies in tumours and reduced accumulation in normal organs. Conclusion : This bifunctional chelating agent is promising for immunoscintigraphy because of good tumour-to-normal organ contrast.
  • 細野 眞
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 41 (3) 270 - 270 0022-7854 2004/09
  • T Takahashi; K Machida; N Honda; M Hosono; S Oku; H Osada; O Murata; K Nishimura; H Ohno
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 18 (2) 157 - 160 0914-7187 2004/04 [Refereed]
     
    We report a case of esophageal carcinoma that showed extraosseous accumulation of Tc-99m-MDP in lymph node metastases to the cervical and paracardial lymph nodes. There are few cases showing abnormal extraosseous accumulation of Tc-99m-MDP in esophageal cancer lesion. The patient was a 53-year-old man with advanced esophageal cancer. Bone scintigraphy demonstrated extraosseous accumulations in left supraclavicular and paracardial lymph node metastases. The histopathological diagnosis was small cell carcinoma of the esophagus, which is a rare disease with aggressive behavior and poor prognosis. Our patient underwent 2 courses of systemic chemotherapy (CDDP + VP16), but died of rapidly growing systemic metastases 5 months after the initial treatment.
  • 小泉 満; 遠藤 啓吾; 成田 雄一郎; 細野 眞; 小坂 昇; 小須田 茂; 横山 邦彦; 木下 富士美; 日下部 きよ子; 森 豊
    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine 41 (1) 48 - 50 0022-7854 2004/02
  • Alzheimer型痴呆の診断における3D-SRTの有用性
    花田 一志; 細野 眞; 柳生 行伸; 中松 清志; 小池 竜太; 米矢 吉宏; 西村 恭昌; 切目 栄司; 辻井 農亜; 人見 一彦
    日本医学放射線学会雑誌 (公社)日本医学放射線学会 64 (2) S141 - S141 0048-0428 2004/02 [Refereed]
  • Koizumi M; Endo K; Yokoyama K; Narita Y; Kinoshita F; Hosono M; Kusakabe K; Kosaka N; Mori Y; Kosuda S
    Kaku igaku. The Japanese journal of nuclear medicine 1 41 48 - 50 0022-7854 2004/02 [Refereed]
  • Takeo Takahashi; Kikuo Machida; Norinari Honda; Makoto Hosono; Shinya Oku; Hisato Osada; Osamu Murata; Keiichiro Nishimura; Hitoshi Ohno
    Annals of Nuclear Medicine Springer Tokyo 18 (2) 157 - 160 0914-7187 2004 
    We report a case of esophageal carcinoma that showed extraosseous accumulation of 99mTc-MDP in lymph node metastases to the cervical and paracardial lymph nodes. There are few cases showing abnormal extraosseous accumulation of 99mTc-MDP in esophageal cancer lesion. The patient was a 53-year-old man with advanced esophageal cancer. Bone scintigraphy demonstrated extraosseous accumulations in left supraclavicular and paracardial lymph node metastases. The histopathological diagnosis was small cell carcinoma of the esophagus, which is a rare disease with aggressive behavior and poor prognosis. Our patient underwent 2 courses of systemic chemotherapy (CDDP + VP16), but died of rapidly growing systemic metastases 5 months after the initial treatment.
  • N Honda; K Machida; T Matsumoto; H Matsuda; E Imabayashi; J Hashimoto; M Hosono; Y Inoue; K Koizumi; S Kosuda; T Momose; Y Mori
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 17 (8) 641 - 648 0914-7187 2003/12 [Refereed]
     
    Objectives: Alzheimer's disease (AD) is diagnosed by either inspection of the brain perfusion SPECT, or three-dimensional stereotactic surface display (3D-SSP). The purpose was to compare diagnostic performances of these methods. Methods: Sixteen nuclear medicine physicians independently interpreted Tc-99m-ECD SPECT in one session and SPECT with 3D-SSP in another session without clinical information for 50 studies of AD patients and 40 studies of healthy volunteers. Probabilities of AD were reported according to a subjective scale from 0% (normal) to 100% (definite AD). Receiver operating characteristics curves were generated to calculate areas under the ROC curves (Az's) for the inspection as well as for an automated diagnosis based on a mean Z value in the bilateral posterior cingulate gyri in a 3D-SSP template. Results: Mean Az for visual interpretation of SPECT alone (0.679 +/- 0.058) was significantly smaller than that for visual interpretation of both SPECT and 3D-SSP (0.778 +/- 0.060). Az for the automated diagnosis (0.883 +/- 0.037) was. significantly greater than that for both modes of visual interpretation. Conclusions: 3D-SSP enhanced performance of the nuclear medicine physicians inspecting SPECT. Performance of the automated diagnosis exceeded that of the physicians inspecting SPECT with and without 3D-SSP.
  • 花田 一志; 細野 眞; 中松 清志; 小池 竜太; 米矢 吉宏; 杉本 美和; 東 睦広; 辻井 農亜
    核医学 (一社)日本核医学会 40 (4) 503 - 504 0022-7854 2003/11 [Refereed]
  • 放射性核種の免除レベルとクリアランスレベルの算出に関する考察
    細野 眞; 西村 恭昌; 粟井 和夫; 井上 正昭; 下野 太郎; 金森 修一; 柳生 行伸; 中松 清志; 花田 一志; 小池 竜太; 米矢 吉宏
    核医学 (一社)日本核医学会 40 (4) 507 - 508 0022-7854 2003/11
  • Optimal Injection Protocol In Hepatic Dynamic CT Using MDCT
    粟井 和夫; 栁生 行伸; 綿井 良輔; 下野 太郎; 井上 正昭; 細野 眞; 西村 恭昌
    画像診断 秀潤社 23 (9) 1017 - 1025 2003/09 
    肝のDynamic MDCTでは造影剤投与後適切な撮像時間帯でスキャンすることが不可欠である。このためには体内での造影剤の動態、および造影剤投与時の種々の因子について理解しておくことが必要である。これらの点について解説した。
  • H Ishida; H Nakada; Takeuchi, I; M Yokoyama; T Okita; D Hashimoto; M Hosono; T Mori
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES SPRINGER-VERLAG 17 (8) 1278 - 1282 0930-2794 2003/08 
    Background: Few studies have examined tumor cell distribution following laparoscopic surgery for colorectal cancer. We examined the effect of carbon dioxide pneumoperitoneum on the distribution of intrasplenically injected colon cancer cells in mice. Methods: Mice were intrasplenically injected with 2 x 10(4) colon 26 cells labeled with (11I) In-oxine and were randomized to undergo pneumoperitoneum at 10 mmHg for 30 min or to receive no treatment other than anesthesia. Radioactivity of the liver, lungs, and spleen was measured 30, 60, 90, or 150 min following tumor inoculation. Results: The dynamic changes in the hepatic radioactivity were not similar between groups. However, the values were not significantly different at any time point. The radioactivity of lungs was extremely low in both groups throughout the experimental period. Conclusions: Pneumoperitoneum does not appear to cause the accumulation of intraportally spreading tumor cells in the liver, but it may affect the dynamic changes of tumor cells. Also, tumor cell localization in the lungs is negligible in both pneumopentoneum and control groups.
  • M Hosono; K Machida; N Honda; T Takahashi; N Ohtawa
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT WILLIAMS & WILKINS 28 (5) 398 - 399 0363-9762 2003/05
  • K Machida; Y Inoue; N Honda; M Hosono; T Takahashi; A Kashimada
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT WILLIAMS & WILKINS 28 (5) 405 - 407 0363-9762 2003/05
  • N Honda; K Machida; M Hosono; A Kashimada; T Takahashi; H Osada; W Watanabe; O Murata; T Okada
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 44 (5) 376P - 376P 0161-5505 2003/05
  • M Hosono; K Machida; N Honda; T Takahashi; N Ohtawa
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT WILLIAMS & WILKINS 28 (5) 398 - 399 0363-9762 2003/05 [Refereed]
  • K Machida; Y Inoue; N Honda; M Hosono; T Takahashi; A Kashimada
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT WILLIAMS & WILKINS 28 (5) 405 - 407 0363-9762 2003/05 [Refereed]
  • Takeo Takahashi; Kikuo Machida; Norinari Honda; Makoto Hosono; Akio Kashimada; Osamu Murata; Hisato Osada; Keiichiro Nishimura
    Radiation Medicine - Medical Imaging and Radiation Oncology 3 21 (3) 135 - 137 0288-2043 2003/05 [Refereed]
     
    A case of embryonal rhabdomyosarcoma (RMS) arising from an axillary space is described. RMS is one of the most common soft-tissue neoplasms in children, but adult embryonal RMS is rare. The patient was a 55-year-old man with a tumor of the left axillary area. RMS arising from an axillary area is also uncommon. The histological diagnosis was embryonal RMS. He received irradiation combined with chemotherapy (VAC: VCR, act-D, CPA) for the primary and metastatic lesions, obtained complete remission, and has remained disease-free for over four years as of this report.
  • Adult embryonal rhabdomyosarcoma in axilla
    Takahashi T; 細野 眞; Machida K Honda; Kashimada A Murata; O; Osada H; Nishimura K
    Radiation Medicine 21 (3) 135 - 137 2003/03
  • 小泉 満; 遠藤 啓吾; 横山 邦彦; 成田 雄一郎; 木下 富士美; 細野 眞; 日下部 きよ子; 中沢 圭治; 小坂 昇; 森 豊; 小須田 茂
    核医学 40 (1) 81 - 82 0022-7854 2003/02
  • 町田 喜久雄; 大島 統男; 小泉 潔; 小須田 茂; 橋本 順; 細野 眞; 本田 憲業; 松田 博史; 松本 徹; 百瀬 敏光; 森 豊
    核医学 40 (1) 54 - 56 0022-7854 2003/02
  • Effective radiotherapy and an abscopal effect for bone metastases of an unknown origin
    Takahashi T; 細野 眞; Machida K Honda; Kashimada A Murata; O; Osada H; Watanabe W Nishimura; K Ohno H
    Jpn J Tomogrraphy 30 96 - 99 2003/02
  • M Hosono; K Machida; Y Inoue; N Honda; T Takahashi; A Kashimada; N Ohtawa; H Ohno; T Yamano
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 17 (1) 69 - 72 0914-7187 2003/02 [Refereed]
     
    A 46-year-old woman with multiple myeloma presented with neurological symptoms in the right upper extremity. After MR imaging of the cervical spine failed to show the cause of her symptoms, Ga-67 scintigraphy demonstrated increased uptake in multiple areas including the right supraclavicular region and bilateral lower extremities. Histology of the specimen obtained from the left thigh proved soft-tissue involvement of myeloma, and extensive extramedullary involvement was diagnosed. Radiotherapy to the right supraclavicular mass relieved her symptoms. Although Ga-67 scintigraphy is generally considered of limited value in multiple myeloma, this modality contributed to the development of an appropriate strategy in this patient with extensive extramedullary involvement.
  • M Hosono; K Machida; N Honda; T Takahashi; A Kashimada; O Murata; H Osada; N Ohtawa; S Itoyama
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT WILLIAMS & WILKINS 28 (1) 25 - 28 0363-9762 2003/01 
    The authors examined three patients with pure primary mediastinal seminomas, all of whom had marked Ga-67 uptake on scintigraphy. The unusual presentation of sclerotic bone metastases with remarkable extraosseous soft tissue involvement was observed in one patient. Another had a seminoma associated with a multiloculated thymic cyst, which is a rare lesion.
  • Makoto Hosono; Kikuo Machida; Yusuke Inoue; Norinari Honda; Takeo Takahashi; Akio Kashimada; Nobuyuki Ohtawa; Hitoshi Ohno; Takafumi Yamano
    Annals of Nuclear Medicine Japanese Society of Nuclear Medicine 17 (1) 69 - 72 0914-7187 2003 
    A 46-year-old woman with multiple myeloma presented with neurological symptoms in the right upper extremity. After MR imaging of the cervical spine failed to show the cause of her symptoms, Ga-67 scintigraphy demonstrated increased uptake in multiple areas including the right supraclavicular region and bilateral lower extremities. Histology of the specimen obtained from the left thigh proved soft-tissue involvement of myeloma, and extensive extramedullary involvement was diagnosed. Radiotherapy to the right supraclavicular mass relieved her symptoms. Although Ga-67 scintigraphy is generally considered of limited value in multiple myeloma, this modality contributed to the development of an appropriate strategy in this patient with extensive extramedullary involvement.
  • M Hosono; K Machida; N Honda; T Takahashi; A Kashimada; O Murata; H Osada; N Ohtawa; S Itoyama
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT WILLIAMS & WILKINS 28 (1) 25 - 28 0363-9762 2003/01 [Refereed]
     
    The authors examined three patients with pure primary mediastinal seminomas, all of whom had marked Ga-67 uptake on scintigraphy. The unusual presentation of sclerotic bone metastases with remarkable extraosseous soft tissue involvement was observed in one patient. Another had a seminoma associated with a multiloculated thymic cyst, which is a rare lesion.
  • TAKAHASHI Takeo; MACHIDA Kikuo; HONDA Norinari; HOSONO Makoto; MURATA Osamu; OSADA Hisato; OMICHI Masahide
    The Journal of JASTRO Japanese Society for Therapeutic Radiology and Oncology 14 (4) 233 - 238 1040-9564 2002/12 
    Introduction: Evaluation of QOL in cancer patients is an important theme. However, we do not have an established method to assess QOL in cancer patients during radiotherapy in Japan. We evaluated both the changes of QOL and the factors affecting QOL in radiotherapy patients.
    Materials and Methods: Three hundred and fifty-five cancer patients, who filled in a questionnaire at the beginning, middle, and end of radiotherapy between 1998 and 2001, were studied. Weused"The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD)" devisedby Kurihara et al, the Ministry of Health and Welfare. The QOL Questionnaire had five categories: physical activity, physical condition, mental state, social interaction, and face scale. The total score, sum of the score of five categories, were established synthetically (maximum score is 110).
    Results: The mean of total QOL scores were 75.8, 77.6, and 78.2 at the beginning, middle, and end of radiotherapy respectively. Patients with symptoms related to cancer had apparent improvement of QOL score. Patients receiving chemotherapy had a decreased QOL score at the end of radiotherapy. The score of physical condition was reduced improvement.
    Conclusions: It was suggested that radiotherapy could be performed without losing QOL of cancer patients, including older patients. However, patients receiving chemotherapy and those with head and neck cancer may lose their QOL, therfore, we should treat such patients carefully.
  • M Hosono; K Machida; N Honda; T Takahashi; A Kashimada; H Osada; O Murata; N Ohtawa; K Nishimura
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 16 (8) 577 - 581 0914-7187 2002/12 
    Objective: Frequent association between liver cirrhosis and hypoxemia. has been well documented. It is mostly attributable to intrapulmonary shunt due to dilation of pulmonary vasculature. We performed quantitative lung perfusion scintigraphy to detect an intrapulmonary shunt in cirrhosis patients. Methods: Prior to injection, Tc-99m MAA was applied to thin layer chromatography for quality control. Three cirrhosis patients who had hypoxemia were examined as well as 11 control subjects. After i.v. injection of Tc-99m MAA, whole body anterior and posterior images were taken at 5 min in patients with cirrhosis and at 8 time points up to 60 min in control subjects. Regions of interest were placed at the bilateral lungs and the whole body, and pulmonary accumulation was calculated. Results: All the control subjects demonstrated more than 90% of radioactivity in the lungs until 20 min. In contrast, all the patients showed values less than 80% at 5 min. In the cirrhosis patients with hypoxemia, the presence of intrapulmonary shunt was confirmed on quantitative lung perfusion scan. In control subjects, pulmonary accumulation of Tc-99m MAA dropped as a function of time and became less than 90% after 30 min. Conclusion: The timing of measurements is essential in evaluating intrapulmonary shunt.
  • M Hosono; K Machida; N Honda; T Takahashi; A Kashimada; H Osada; O Murata; N Ohtawa; K Nishimura
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 16 (8) 577 - 581 0914-7187 2002/12 [Refereed]
     
    Objective: Frequent association between liver cirrhosis and hypoxemia. has been well documented. It is mostly attributable to intrapulmonary shunt due to dilation of pulmonary vasculature. We performed quantitative lung perfusion scintigraphy to detect an intrapulmonary shunt in cirrhosis patients. Methods: Prior to injection, Tc-99m MAA was applied to thin layer chromatography for quality control. Three cirrhosis patients who had hypoxemia were examined as well as 11 control subjects. After i.v. injection of Tc-99m MAA, whole body anterior and posterior images were taken at 5 min in patients with cirrhosis and at 8 time points up to 60 min in control subjects. Regions of interest were placed at the bilateral lungs and the whole body, and pulmonary accumulation was calculated. Results: All the control subjects demonstrated more than 90% of radioactivity in the lungs until 20 min. In contrast, all the patients showed values less than 80% at 5 min. In the cirrhosis patients with hypoxemia, the presence of intrapulmonary shunt was confirmed on quantitative lung perfusion scan. In control subjects, pulmonary accumulation of Tc-99m MAA dropped as a function of time and became less than 90% after 30 min. Conclusion: The timing of measurements is essential in evaluating intrapulmonary shunt.
  • 町田 喜久雄; 大島 統男; 小泉 潔; 小須田 茂; 橋本 順; 細野 眞; 本田 憲業; 松田 博史; 松本 徹; 百瀬 敏光; 森 豊
    核医学 39 (4) 556 - 557 0022-7854 2002/11
  • Norinari Honda; Kikuo Machida; Makoto Hosono; Tohru Matsumoto; Hiroshi Matsuda; Motoo Oshima; Kiyoshi Koizumi; Shigeru Kosuda; Toshimitsu Momose; Yutaka Mori; Jun Hashimoto; Yuji Shimizu
    Radiation Medicine - Medical Imaging and Radiation Oncology 6 20 (6) 281 - 289 0288-2043 2002/11 [Refereed]
     
    Brain perfusion SPECT (BP-SPECT) has characteristic patterns of abnormality, enabling the differential diagnosis of dementia. The purpose of this study was to measure interobserver variations in the diagnosis of dementia using BP-SPECT. BP-SPECT images of 57 cases, 19 of Alzheimer's disease (AD), eight of multi-infarct dementia (MID), three of Pick's disease, five of other dementias, and 22 normal controls, were interpreted by ten nuclear medicine physicians with varying levels of experience. Brain MR images of the cases were then interpreted apart from SPECT. The physicians independently rated all of the diagnoses listed beforehand according to a five-point scale, with clinical information provided. Receiver-operating characteristic (ROC) curves and the area under the ROC curve (Az) were calculated. Az varied from 0.48 to 0.87. Mean Az's were significantly larger (p< 0.05) in the diagnosis by SPECT than in that by MRI (0.715 and 0.629 for dementia vs. normal, 0.670 and 0.560 for AD or MID vs. normal, 0. 610 and 0.416 for AD vs. normal, and 0.672 and 0.412 for AD vs. MID, respectively). Considerable interobserver variation was present in BP-SPECT interpretation. BP-SPECT may be more effective for the evaluation of dementia than MRI when the same nuclear medicine physicians interpret both images.
  • N Honda; K Machida; Y Inoue; M Hosono; T Takahashi; A Kashimada; H Osada; O Murata; M Ohmichi; W Watanabe; T Okada; S Itoyama
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 16 (4) 289 - 292 0914-7187 2002/06 [Refereed]
     
    Mucosa-associated lymphoid tissue (MALT) lymphoma has been established as a distinct entity among non-Hodgkin's lymphomas, and the most common primary site is the stomach. We describe scintigraphic findings in a patient with MALT lymphoma. of the thyroid. A 71-year-old woman with Hashimoto's thyroiditis suffered from rapid cervical swelling, and ultrasonography and CT revealed a thyroid nodule. The nodule showed accumulation of Tc-99m pertechnetate comparable to the surrounding thyroid tissue, mimicking a benign nodule. Both Ga-67 and Tl-201 imaging visualized the lesion as an increased uptake area. After radiotherapy, abnormally increased uptake disappeared on 67Ga images, which predicted a favorable outcome. MALT lymphoma of the thyroid may be visualized as a warm nodule on Tc-99m pertechnetate scintigraphy.
  • Interobserver variation in diagnosis of dementia by brain perfusion SPECT
    Honda N; 細野 眞; Machida K; Matsumoto T; Matsuda; H Oshima M; Koizumi K Kosuda; S Momose; T; Mori Y; Hashimoto; Shimizu Y
    Radiation Medicine 20 281 - 289 2002/05
  • JA Thie; K Machida; N Honda; M Hosono; S Dei; M Takahashi
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 43 (5) 145P - 145P 0161-5505 2002/05
  • 本田 憲業; 町田 喜久雄; 細野 眞
    月刊新医療 エム・イー振興協会 ; 1975- 29 (5) 112 - 115 0910-7991 2002/05
  • Measurement of decreased cerebellar blood flow of Machado-Joseph Disease by brain perfusion SPECT
    Machida K; 細野 眞; Honda N; Takahashi T; Kashimada A Shimizu; Y; Osada H; Watanabe; Ohmichi M Ohtawa; N; Kinoshita M
    Jpn J Tomography 28 94 - 98 2002/03
  • H Ishida; D Hashimoto; H Nakada; Takeuchi, I; T Hoshino; N Murata; Y Idezuki; M Hosono
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES SPRINGER-VERLAG 16 (2) 331 - 335 0930-2794 2002/02 
    Background: The effect of different insufflation pressures and durations of CO2 pneumoperitoneum on the growth of liver metastasis was investigated in a mouse model. The possible mechanisms involved in the pressure-related enhancement of liver metastasis were also examined. Methods: Mice inoculated intraportally with colon 26 cells underwent CO, pneumoperitoneum at different pressures (5, 10, or 15 mmHg) for 30 or 60 min, or received no treatment other than tumor cell inoculation (control). The subsequent growth of liver mestastases was examined. Mice injected intraportally with In-111-oxine-labeled colon 26 cells underwent pneumoperitoneum at three different pressures or served as controls. The radioacitivity of the liver was determined to evaluate tumor accumulation in the liver. Mice received pneumoperitoneum at three different pressures or received trocar placement alone. Changes in plasma interleukin-6 levels were determined. Results: The growth of liver metastases on day 14 was influenced by increased insufflation pressures (p<0.05) rather than the prolonged duration of pneumoperitoneum without significant interaction. The 15-mmHg pneumoperitoneum group showed a higher (p<0.05) accumulation of radioactivity in the liver compared with the 5-mmHg pneumoperitoneum group and controls. Pneumoperitoneum groups with 5 and 10 mmHg showed higher (p<0.05) peak levels of IL-6 compared with controls. Conclusions: An elevated insufflation pressure plays an important role in the enhancement of liver metastases, and this pressure-related adverse effect may be partly relevant to facilitating accumulation of tumor cells in the liver.
  • M Hosono; K Machida; T Matsui; N Honda; T Takahashi; S Dei; A Kashimada; Y Shimizu; H Osada; M Ohmichi; T Asano
    NUCLEAR MEDICINE COMMUNICATIONS LIPPINCOTT WILLIAMS & WILKINS 23 (1) 5 - 11 0143-3636 2002/01 
    The purpose of this prospective study was to detect symptomatic cerebral vasospasm in aneurysmal subarachnoid haemorrhage (SAH) by a non-invasive mean cerebral blood flow (mCBF) quantification using Tc-99m-ethyl cysteinate dimer. Measurement of mCBF without blood sampling and single photon emission tomography (SPECT) were performed at 1 and 7 days after surgery in 35 consecutive SAH patients, of whom 16 were examined at day 30 as well. A decrease in mCBF of more than 10% on day 7 versus day 1 was considered to indicate vasospasm. On visual interpretation of SPECT, a perfusion decrease which appeared newly on day 7 was considered to indicate vasospasm. In total, nine of 35 patients had cerebral vasospasm confirmed by computed tomography (CT) and/or angiography. The mCBF measurement showed a 77.8% (7/9) sensitivity, a 88.5% (23/26) specificity, a 70.0% (7/10) positive predictive value, and a 92.0% (23/25) negative predictive value. SPECT yielded a 33.3% (3/9) sensitivity, a 73.1% (19/26) specificity, a 30.0% (3/10) positive predictive value, and a 76.0% (19/25) negative predictive value. On SPECT, decreased perfusion was observed in most of the patients at clipping sites, which might represent post-operative transient abnormal perfusion and should not be read as vasospasm. In conclusion, thus mCBF measurement is more accurate than visual interpretation of SPECT for detecting vasospasm. ((C) 2002 Lippincott Williams & Wilkins).
  • Machida K; Hosono M; Honda N; Takahashi T; Kashimada A; Shimizu Y Osada; H Ohmichi M Watanabe; Okada T; Usui N Ohtawa; N Hondo; M Nishimura; K; Itoyama S
    Jpn J Tomography 29 29 - 32 2002/01
  • TAKAHASHI Takeo; MACHIDA Kikuo; HONDA Norinari; HOSONO Makoto; MURATA Osamu; OSADA Hisato; OMICHI Masahide
    J Jpn Soc Ther Radiol Oncol Japanese Society for Therapeutic Radiology and Oncology 14 (4) 233 - 238 1040-9564 2002 
    Introduction: Evaluation of QOL in cancer patients is an important theme. However, we do not have an established method to assess QOL in cancer patients during radiotherapy in Japan. We evaluated both the changes of QOL and the factors affecting QOL in radiotherapy patients.<BR>Materials and Methods: Three hundred and fifty-five cancer patients, who filled in a questionnaire at the beginning, middle, and end of radiotherapy between 1998 and 2001, were studied. Weused"The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD)" devisedby Kurihara et al, the Ministry of Health and Welfare. The QOL Questionnaire had five categories: physical activity, physical condition, mental state, social interaction, and face scale. The total score, sum of the score of five categories, were established synthetically (maximum score is 110).<BR>Results: The mean of total QOL scores were 75.8, 77.6, and 78.2 at the beginning, middle, and end of radiotherapy respectively. Patients with symptoms related to cancer had apparent improvement of QOL score. Patients receiving chemotherapy had a decreased QOL score at the end of radiotherapy. The score of physical condition was reduced improvement.<BR>Conclusions: It was suggested that radiotherapy could be performed without losing QOL of cancer patients, including older patients. However, patients receiving chemotherapy and those with head and neck cancer may lose their QOL, therfore, we should treat such patients carefully.
  • M Hosono; K Machida; N Honda; T Takahashi; A Kashimada; H Osada
    RADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 221 480 - 480 0033-8419 2001/11
  • M Hosono; K Machida; T Matsui; N Honda; T Takahashi; T Asano
    RADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 221 237 - 237 0033-8419 2001/11
  • K Nishimura; K Machida; N Honda; M Hosono; A Kashimada; T Takahashi
    RADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 221 129 - 129 0033-8419 2001/11
  • N Honda; K Machida; T Matsumoto; H Matsuda; M Hosono; M Oshima
    RADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 221 238 - 238 0033-8419 2001/11
  • K Machida; N Honda; M Hosono; Y Shimizu; S Kosuda; H Matsuda; M Ohshima; T Momose; K Koizumi; T Matsumoto; J Hashimoto
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE SPRINGER-VERLAG 28 (8) 1019 - 1019 0340-6997 2001/08
  • M Hosono; K Machida; T Matsui; N Honda; T Takahashi; A Kashimada; H Osada; Y Shimizu; M Ohmichi; S Dei; T Asano
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE SPRINGER-VERLAG 28 (8) 1222 - 1222 0340-6997 2001/08
  • 遠藤 啓吾; 小泉 満; 菊地 透; 横山 邦彦; 木村 良子; 成田 雄一郎; 中沢 圭治; 木下 富士美; 小坂 昇; 細野 眞; 森 豊; 日下部 きよ子
    核医学 38 (4) 374 - 375 0022-7854 2001/07
  • Makoto Hosono; Kikuo Machida; Toru Matsui; Norinari Honda; Takeo Takahashi; Akio Kashimada; Hisato Osada; Takao Asano; Shinji Itoyama
    Computerized Medical Imaging and Graphics 25 (4) 361 - 365 0895-6111 2001/07 
    In this report, we examine the case of a 6-year-old girl with a mixed oligodendroglioma demonstrating uncommon neuroradiological images. CT and MR showed an intratemporal mass with multilocular cystic formation and intratumoral massive calcification, suggestive either of astrocytoma, dysembryoplastic neuroepithelial tumor, or ganglioglioma as a presumptive differential diagnosis. The tumor was almost completely removed. Post-operative histological examination revealed a mixed oligodendroglioma with a small component of astrocytoma. The combination of radiotherapy and chemical treatment was supplemented. Copyright © 2001 Elsevier Science Ltd.
  • N Honda; K Machida; H Osada; M Hosono; T Takahashi; A Kashimada; Y Shimizu; W Watanabe; M O'Michi; S Dei; Y Usui; M Hondo; T Okada; K Nishimura; N Otawa; A Tanaka; M Takahashi
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 42 (5) 346P - 346P 0161-5505 2001/05
  • M Hosono; K Machida; T Matsui; N Honda; T Takahashi; K Kashimada; Y Shimizu; H Osada; S Dei; M Ohmichi; N Ootawa; T Okada; K Nishimura; T Asano
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 42 (5) 232P - 232P 0161-5505 2001/05
  • H Osada; K Machida; N Honda; M Hosono; T Takahashi; A Kashimada; Y Shimizu; W Watanabe; H Oomichi
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 42 (5) 329P - 329P 0161-5505 2001/05
  • S Dei; K Machida; N Honda; M Hosono; T Takahashi; K Kashimada; Y Shimizu; H Osada; N Ohtawa; M Ohmichi; M Takahashi; A Tanaka; JA Thie
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 42 (5) 191P - 191P 0161-5505 2001/05
  • 遠藤 啓吾; 小泉 満; 菊地 透; 横山 邦彦; 木村 良子; 成田 雄一郎; 中沢 圭治; 木下 富士美; 小坂 昇; 細野 眞; 森 豊
    核医学 37 (5) 477 - 477 0022-7854 2000/09
  • MN Hosono; M Hosono; AK Mishra; A Faivre-Chauvet; E Gautherot; J Barbet; FF Knapp; JF Chatal
    ANNALS OF NUCLEAR MEDICINE JAPANESE SOCIETY NUCLEAR MEDICINE 14 (3) 173 - 179 0914-7187 2000/06 [Refereed]
     
    We have evaluated the potential of Re-188-labeled monoclonal antibodies (MAbs) modified with 2-iminothiolane (2IT) for targeting small-cell lung cancer (SCLC). Radiolabeled MAbs NK1NBL1 and C218 recognizing neural cell adhesion molecule were injected i.v. into athymic mice inoculated with human SCLC tumors, and the biodistribution was examined. NK1NBL1 localized in the tumors better than C218. Re-188-labeled MAbs cleared from the blood faster than I-125-labeled counterparts, resulting in higher tumor-to-blood ratios. In conclusion, the Re-188-labeled MAbs are attractive candidates for imaging and therapy of SCLC.
  • 楢林 勇; 今井 照彦; 佐々木 雅之; 西山 佳宏; 細野 眞; 吉田 祥二; 小森 剛; 戸川 貴史; 福本 光孝; 山路 滋
    核医学 37 (3) 251 - 253 0022-7854 2000/05
  • M Hosono; K Machida; N Honda; T Takahashi; A Kashimada; Y Shimizu; H Osada; S Dei; H Toyoda; M Ohmichi; K Ochiai; M Hondo
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 41 (5) 320P - 320P 0161-5505 2000/05
  • Y Shimizu; K Machida; N Honda; M Hosono; T Takahashi; H Osada; H Toyoda; M Ohmichi; T Kato; K Maruyama; S Tanaka; N Yoshimoto
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 41 (5) 162P - 162P 0161-5505 2000/05
  • Y Shimizu; K Machida; N Honda; M Hosono; T Takahashi; A Kashimada; H Osada; H Toyoda; W Watanabe; S Dei; M Ohmichi; N Ootawa
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 41 (5) 164P - 164P 0161-5505 2000/05
  • N Honda; K Machida; H Matsuda; M Ohshima; T Momose; T Matsumoto; M Hosono
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 41 (5) 107P - 107P 0161-5505 2000/05
  • S Dei; K Machida; N Honda; M Hosono; T Takahashi; A Kashimada; Y Shimizu; H Osada; H Toyoda; W Watanabe; M Ohmichi; N Ootawa
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 41 (5) 324P - 324P 0161-5505 2000/05
  • H Osada; K Machida; N Honda; M Hosono; T Takahashi; A Kashimada; Y Shimizu; W Watanabe; M Oumichi
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 41 (5) 323P - 323P 0161-5505 2000/05
  • HONDA Norinari; MACHIDA Kikuo; HOSONO Makoto
    日本醫學放射線學會雜誌 日本医学放射線学会,ニホン イガク ホウシャセン ガッカイ 60 (5) 237 - 242 0048-0428 2000/04
  • Honda Norinari; Machida Kikuo; Hosono Makoto
    日本医学放射線学会雑誌 日本医学放射線学会 60 (5) 237 - 242 0048-0428 2000/04
  • T Takahashi; K Machida; N Honda; T Takahashi; M Hosono; A Kashimada; Y Shimizu; H Osada; W Watanabe; M Omichi
    EUROPEAN JOURNAL OF CANCER PERGAMON-ELSEVIER SCIENCE LTD 35 S175 - S175 0959-8049 1999/09
  • M Hosono; MN Hosono; F Kraeber-Bodere; A Devys; P Thedrez; A Faivre-Chauvet; E Gautherot; J Barbet; JF Chatal
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 40 (7) 1216 - 1221 0161-5505 1999/07 [Refereed]
     
    The "affinity enhancement system," a two-step targeting technique using bispecific antibody and radiolabeled bivalent hapten, has been reported to be useful for carcinoembryonic antigen-expressing tumors. The purpose of this study was to evaluate the efficacy of this method for targeting human small cell lung cancer using an antineural cell adhesion molecule antibody. Methods: Antineural cell adhesion molecule/antihistamine bispecific antibody NK1NBL1-679 was prepared by coupling an equimolecular quantity of a Fab' fragment of NK1NBL1 to a Fab fragment of antihistamine 679. Athymic mice inoculated with NCI-H69 small cell lung cancer cells expressing neural cell adhesion molecule were administered bispecific antibody and then 48 h later I-125-labeled bivalent histamine hapten. I-125-labeled intact NK1NBL1 was injected into other groups of mice. Biodistributions were examined as a function of time. Results: In mice of the two-step targeting, tumor uptake was 2.5 +/- 0.2, 3.2 +/- 0.4, 6.4 +/- 2.0, 7.2 +/- 2.7, 6.1 +/- 2.1 and 2.2 +/- 0.4 %ID/g at 5, 30 min, 5, 24, 48 and 96 h, and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 1.4 +/- 1.1, 10.8 +/- 13.2 and 4.6 +/- 4.7, respectively, at 5 h, whereas I-125-labeled NK1NBL1 showed a tumor uptake of 5.7 +/- 0.4 %ID/g and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 0.3 +/- 0.1, 1.1 +/- 0.2 and 0.9 +/- 0.1, respectively, at 5 h. These results were confirmed by autoradiographic studies, which demonstrated clear tumor-to-normal tissue contrast. Dosimetry showed that the affinity enhancement system could enhance the therapeutic potential of the antineural cell adhesion molecule antibody NK1NBL1. Conclusion: This two-step targeting method seems promising for the diagnosis and therapy of small cell lung cancer.
  • 遠藤 啓吾; 日下部 きよ子; 細野 眞; 横山 邦彦; 木下 富士美; 菊地 透; 森 豊; 小坂 昇; 御前 隆; 中沢 圭治
    核医学 36 (3) 271 - 274 0022-7854 1999/04
  • 楢林 勇; 今井 照彦; 佐々木 雅之; 戸川 貴史; 細野 眞; 大塚 信昭; 末吉 公三; 西山 佳宏
    核医学 36 (3) 281 - 285 0022-7854 1999/04
  • M. Hosono
    Folia Pharmacologica Japonica Japanese Pharmacological Society 114 (2) 83 - 88 0015-5691 1999 
    Colforsin daropate hydrochloride (COL) is a water-soluble forskolin derivative for the treatment of acute heart failure. COL, like forskolin, stimulated adenylate cyclase (AC) directly and produced pharmacologic activities accompanied by the increase in cellular cAMP. COL was different from forskolin in watersolubility, duration of action, BBB permeability, oral activity and AC-subtype selectivity. COL was a inodilator with positive inotropic and vasodilator effects and was effective on a β-receptor desensitized-heart model in Which the effects of β-agonists and PDE inhibitors were attenuated. COL improved cardiac function in some heart failure models. In the clinical studies, COL improved hemodynamics, subjective and objective symptoms of heart failure patients, and was also effective in the catecholamine-resistant heart failure patients. COL is a first clinically available adenylate cyclase activator. Further information from the post-marketing-surveillance will provide information that will enable more adequate usage of this drug.
  • HOSONO Makoto
    核医学 35 (8) 681 - 687 0022-7854 1998/10
  • M Hosono; MN Hosono; F Kraeber-Bodere; A Devys; P Thedrez; M Fiche; E Gautherot; J Barbet; JF Chatal
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 39 (9) 1608 - 1613 0161-5505 1998/09 [Refereed]
     
    The purpose of this study was to evaluate biodistributions and absorbed doses of anti-carcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA)-indium (anti-DTPA-In) bispecific monoclonal antibody (BsMAb) F6-734 and I-125-labeled DTPA-indium dimer hapten (I-125-di-DTPA-In hapten) in athymic mice xenografted with human medullary thyroid cancer. Methods: Bispecific monoclonal antibodies F6-679 (anti-CEA/antihistamine) and G7A5-734 (antimelanoma/anti-di-DTPA-In) were used as irrelevant BsMAbs. Athymic mice inoculated with TT medullary thyroid cancer cells expressing CEA were administered BsMAbs F6-734, F6-679 or G7A5-734 and then, 48 hr later, I-125-di-DTPA-In hapten. Iodine-125-labeled F6 F(ab')(2) fragment was injected into other groups of mice. Biodistributions were examined at 30 min and 5, 24, 48 and 96 hr after injection of I-125-di-DTPA-In hapten or I-125-labeled F6 F(ab'),. Results: In mice injected with BsMAb F6-734 and I-125-di-DTPA-In hapten, tumor uptake was 9.1% +/- 2.1%, 8.7% +/- 3.5%, 8.0% +/- 2.3%, 5.1% +/- 0.9% and 3.5% +/- 1.5% of the injected dose/g at 30 min and 5, 24, 48 and 96 hr, and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 37.0 +/- 12.5, 32.3 +/- 10.9 and 10.4 +/- 2.7 at 24 hr. Iodine-125-F6 F(ab')(2) fragment showed a tumor uptake of 7.39% injected dose/g and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 1.8 +/- 0.6, 7.3 +/- 2.9 and 3.6 +/- 1.6 at 24 hr. In mice injected with F6-679 or G7A5-734, tumor uptake and tumor-to-normal tissue ratios were much lower than in the mice injected with F6-734. These results were confirmed by autoradiographic studies that demonstrated clear tumor-to-normal tissue contrast. Conclusion: This two-step targeting method seems very potent for the diagnosis and therapy of human medullary thyroid cancer and other CEA-producing tumors because it combines high tumor uptake and low normal tissue background.
  • Hosono M
    Kakuigaku 35 (7) 486 - 486 0022-7854 1998/08 [Refereed][Invited]
  • Hosono M
    Radioisotopes Japan Radioisotope Association 47 (6) 531 - 532 1884-4111 1998/06 [Refereed][Invited]
    ダウンロード
  • Makoto Hosono
    Kakuigaku 35 (8) 685 - 687 0022-7854 1998 
    Imaging and therapy using radiolabeled monoclonal antibodies have proved useful in many clinical studies. However, immunogenicity of mouse antibodies to human and insufficient tumor-to-normal tissue ratios remained to be solved. Chimerization and humanization by genetic engineering, and multistep targeting techniques have enabled lower immunogenicity and higher tumor-to-normal tissue contrast. Peptides like somatostatin-analogs have been reportedly useful in imaging tumors, which are either somatostatin receptor positive or negative. Elevated normal tissue accumulation of radiolabeled peptides is a drawback in aiming internal radiation therapy.
  • Masako N. Hosono; Makoto Hosono; Paul O. Zamora; Stefan Guhlke; Thomas Haberberger; Hans Bender; F.F. Russ Knapp; Hans J. Biersack
    Annals of Nuclear Medicine Springer Tokyo 12 (2) 83 - 88 0914-7187 1998 [Refereed]
     
    In order to evaluate the feasibility of 188Re-labeled antibodies for radioimmunotargeting, monoclonal antibody B72.3, recognizing TAG-72, expressed on the surface membranes of colorectal cancer cells, was directly labeled with 188Re, obtained from a 188W/188Re generator, using stannous tartrate and compared with 125I-labeled B72.3. As a control, a human IgG was also radiolabeled with 188Re and 125I. Prepared antibodies for 188Re labeling could be stored as kits. Biodistribution was determined in nude mice inoculated with human colorectal carcinoma LoVo. Labeling efficiency and immunoreactivity of 188Re-B72.3 were 80.3% and 64.7%, respectively. 188Re-B72.3 localized specifically in the LoVo tumors. Although the absolute tumor accumulation level of 188Re-B72.3 was lower than 125-B72.3, 188Re-B72.3 demonstrated higher tumor-to-blood contrast than the 125I-labeled counterpart, 2.04 ± 0.44 vs. 1.05 ± 0.28 at 96 hours, because of fast clearance from the blood. 188Re-B72.3 seemed efficient for the imaging and therapy of colorectal carcinoma.
  • H Kobayashi; C Shigeno; H Sakahara; T Yamamoto; M Hosono; R Fujimoto; J Konishi
    BRITISH JOURNAL OF RADIOLOGY BRITISH INST RADIOLOGY 70 (838) 1056 - 1059 0007-1285 1997/10 [Refereed]
     
    The use of three phase Tc-99(m) (V)DMSA scintigraphy is reported in a patient with Paget's disease of bone before and after intravenous pamidronate therapy. It was a useful modality for estimating the activity of Pagetoid lesions and the therapeutic effect of pamidronate, from a different aspect to bone scintigraphy. Three phase Tc-99(m) (V)DMSA scintigraphy evaluates both the blood flow and the metabolic activity of Pagetoid bone.
  • M Hosono; H Kobayashi; R Fujimoto; Y Kotoura; T Tsuboyama; Y Matsusue; T Nakamura; T Itoh; J Konishi
    SKELETAL RADIOLOGY SPRINGER VERLAG 26 (3) 150 - 154 0364-2348 1997/03 [Refereed]
     
    Objective. To-investigate the septum-like structures in predominantly lipomatous tumors, by correlating fat-suppressed MR images with histopathologic findings. Design and patients. The MR findings of three cases of well-differentiated liposarcoma (atypical lipoma), one case of lipoma-like component of dedifferentiated liposarcoma. and nine cases of lipoma were analyzed. T1-, T2-, and fat-suppressed T1- weighted images after Gd-DTPA administration were obtained. Surgical specimens from five patients (four with liposarcoma and one with lipoma) were also scanned with a MR unit, and compared with the pathologic findings. Results and conclusions. Enhancement features of lipoma and liposarcoma were well visualized on fat-suppressed T1-weighted images after Gd-DTPA administration. The septum-like structures of liposarcoma are thick and enhanced considerably, while septa of lipoma are thin and enhanced only slightly. Pathologically, the septum-like structures of Liposarcoma contained muscle fibers and the septa of lipoma represented fibrous capsule, Identification of well-enhanced septa in a predominantly lipomatous tumor helps to differentiate malignant tumors horn lipomas. As the septum-like structures of liposarcoma contain a skeletal muscle component the tumor might need more extensive surgical procedures including resection of adjacent muscles.
  • H Kobayashi; Y Kotoura; M Hosono; T Tsuboyama; H Sakahara; K Endo; J Konishi
    CLINICAL IMAGING ELSEVIER SCIENCE INC 21 (1) 35 - 39 0899-7071 1997/01 
    To determine whether extraabdominal desmoid can be correctly diagnosed using both magnetic resonance imaging (MRI) and scintigraphy with pentavalent technetium-99m dimercaptosuccinic acid and gallium-67 citrate, MRI (T1- and T2-weighted images) and scintigraphy were performed in 18 patients with 27 histologically proved extraabdominal desmoid tumors. The extraabdominal desmoid tumors were characterized by positive uptake of pentavalent technetium-99m dimercaptosuccinic acid and lack of uptake of gallium-67 citrate on scintigraphy. These tumors were isointense to skeletal muscle on T1-weighted MRIs and hyperintense on T2-weighted images. They also displayed septum-like internal inhomogeneity and surrounding hypointense capsular band. The combination of scintigraphy and MRI is of value in correctly diagnosing extraabdominal desmoid tumors except in the rare case of fibrotic very low-grade sarcoma. (C) Elsevier Science Inc., 1997.
  • M Hosono; MN Hosono; T Haberberger; PO Zamora; S Guhlke; H Bender; FFR Knapp; HJ Biersack
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 87 (9) 995 - 1000 0910-5050 1996/09 [Refereed]
     
    We examined the potential of radiolabeled somatostatin analogs, I-125-Tyr-3-octreotide (I-125-octreotide), In-111-DTPA(diethylenetriaminepentaacetatic acid)-D-Phe-1-octreotide (In-111-octreotide), and Re-188-octreotide for targeting small-cell lung cancer (SCLC) in a mouse model, Tyr-3-octreotide was labeled with I-125 by the chloramine T method, and In-111-octreotide was obtained as a kit, while Re-188 was eluted from a W-188/Re-188 generator, and octreotide was directly labeled with Re-188 by reducing disulfide bonds. The I-125-, In-111- and Re-188-octreotides were injected i.v. into athymic mice bearing NCI-H69 tumors, and the biodistributions were determined at 15 min, and 2, 4, 8, and 24 h. Tumor uptakes were 0.5 +/- 0.2, 0.3 +/- 0.1, 0.3 +/- 0.1 %ID/g, and tumor-to-blood ratios were 1.8, 11.9, 1.2 at 8 h for I-125-, In-111-, and Re-188-octreotides, respectively. Accumulations of In-111-octreotide in normal tissues were lower than those of I-125- and Re-188-octreotides. Re-188-octreotide can be used to localize SCLC lesions as efficiently as radioiodinated octreotide. However, In-111-octreotide was the most suitable agent to obtain high tumor-to-normal tissue contrast for localizing SCLC.
  • H Sakahara; M Hosono; H Kobayashi; ZS Yao; T Saga; S Yano; K Endo; T Mori; J Konishi
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 87 (6) 655 - 661 0910-5050 1996/06 [Refereed]
     
    The murine monoclonal antibody (mAb) 145-9 recognizes an epitope present on CA125 but different from the epitope defined by the mAb OC125. To evaluate the clinical usefulness of the 145-9 antibody, immunoscintigraphy was performed in ovarian cancer patients and the effect of circulating CA125 on tumor imaging was investigated. Two milligrams (74 MBq) of In-111-labeled 145-9 was injected intravenously into 11 patients with ovarian cancer. Pre-injection serum CA125 concentrations were between 166 U/ml and 7414 U/ml. Tumors were visualized in 10 of 11 patients. In two patients, lymph nodes that were not detected by other imaging modalities but were clinically suspected as metastases were visualized. There was no correlation between serum CA125 level and antibody uptake in the tumors. Immune complexes between the antibody and circulating antigen were observed in sera of all the patients, but the fraction of radioactivity in complex form did not correlate well with serum CA125 levels. The immune complexes survived in the circulation and the circulating radiolabel, including immune complexes, was still bound to solid-phase CA125. The plasma clearance rate and hepatic uptake of the antibody were not significantly affected by circulating CA125. In conclusion, the antibody 145-9 formed complexes with CA125 in vivo but this did not compromise the outcome of antibody imaging. The antibody 145-9 can be used in immunoscintigraphy of ovarian cancer irrespective of serum CA125 level.
  • H Kobayashi; Y Kotoura; M Hosono; T Tsuboyama; H Sakahara; J Konishi
    SKELETAL RADIOLOGY SPRINGER VERLAG 25 (4) 381 - 383 0364-2348 1996/05 
    Radiographic, computed tomographic and scintigraphic findings of a patient with separated, multilocular periosteal ganglion are reported. Multiple periosteal cystic masses with calcification in small parts of the cyst walls were demonstrated in the surface of the left tibia by plain radiograms and CT. The accumulations of technetium-99m hydroxymethylene diphosphonate and pentavalent technetium-99m dimercaptosuccinic acid were shown in the calcification in the periosteum and wall of the cyst. Needle puncture revealed that the masses were filled with jelly-like fluid. The masses were diagnosed as multiple ganglionic cysts at the periosteum of the left tibia.
  • 細野 眞
    Isotope news 502 (0) 2 - 5 0285-5518 1996/03
  • Shunichi Kametani; Shinichi Matsumoto; Takashi Takahira; Makoto Hosono; Yutaka Hashimoto; Hiroo Horinishi
    Journal of Pharmaceutical Sciences John Wiley and Sons Inc. 85 (4) 377 - 380 0022-3549 1996 [Refereed]
     
    A specific gas chromatography/mass spectroscopy method with a detection limit of 0.1 ng/mL was developed for the measurement of 6-(3- dimethylaminopropionyl)forskolin (1) in beagle plasma. Using this method, plasma concentrations of 1 in beagles given pharmacologically effective intravenous doses of 1-HCl were determined. The observed maximal plasma concentrations rapidly decreased with time, and half-lives of the α-phases were < 9 min. Pharmacological effects of 1 on the cardiovascular parameters were simultaneously evaluated in one of the studies. Decreases of the pharmacological effects were slower than decreases in plasma concentration of 1. In addition, 6-(3-methylaminopropionyl)forskolin (N-monodemethyl 1), an expected initial metabolite of 1, was prepared and found to be as pharmacologically active as 1 in beagles. These results and others strongly suggest that a metabolite(s) of 1 contributes to the pharmacological effects of 1 in beagles.
  • Osamu Ishizuka; Akira Fujita; Etsuko Kanbe; Mitsue Noguchi; Makoto Hosono; Katsuhiko Sakitama
    Folia Pharmacologica Japonica Japanese Pharmacological Society 108 (1) 23 - 30 0015-5691 1996 [Refereed]
     
    Effects of prolonged noradrenaline infusion on the density of cardiac β adrenoceptors, phosphodiesterase (PDE) and adenylate cyclase (AC) activities, and the ability of NKH477, 6-(3-dimethylaminopropionyl) forskolin hydrochloride, to increase tension development and heart rate were studied in rat cardiac preparations. Noradrenaline infusion (400 μg/kg/hr, s.c.) for 7 days significantly decreased cardiac β-adrenoceptor density (B(max)), whereas the binding affinity (Kd) of the ligand was unchanged. The basal cardiac PDE activity was increased in treated rats, whereas there was no difference in the basal cardiac AC activity between treated and untreated rats. Significant decreases in basal developed tension and heart rate were observed in the left and right atrial muscles from treated rats, respectively. The positive inotropic and chronotropic potencies of NKH477 were unaffected by noradrenaline infusion, whereas the positive inotropic potencies of isoproterenol and 3-isobutyl-1-methylxanthine were significantly reduced. Thus, NKH477 appears to be superior to β-adrenoceptor agonists or PDE inhibitors as a cardiotonic drug in the treatment of heart failure accompanied by β-adrenoceptor downregulation.
  • M HOSONO; A TAKAORIKONDO; ZS YAO; H KOBAYASHI; MN HOSONO; H SAKAHARA; K IMADA; M OKUMA; T UCHIYAMA; JJ KONISHI
    NUCLEAR MEDICINE AND BIOLOGY ELSEVIER SCIENCE INC 22 (7) 869 - 874 0969-8051 1995/10 [Refereed]
     
    Anti-Tac monoclonal antibody recognizes human interleukin-2 receptor, which is overexpressed in leukemic cells of most adult T-cell leukemia (ATL) patients. To examine the potency of anti-Tac for targeting of ATL, biodistributions of intravenously administered I-125- and In-111-labeled anti-Tac were examined in severe combined immunodeficiency (SCID) mice inoculated with ATL cells. Significant amounts of radiolabeled anti-Tac were found in the spleen and thymus. The trafficking of ATL cells in SCID mice was detected using In-111-oxine-labeled ATL cells. These results were coincident with the histologically confirmed infiltration of ATL cells. The radiolabeled anti-Tac seemed potent for targeting of ATL.
  • H Kobayashi; Y Kotoura; M Hosono; R Fujimoto; T Tsuboyama; H Itoh; J Konishi
    COMPUTERIZED MEDICAL IMAGING AND GRAPHICS PERGAMON-ELSEVIER SCIENCE LTD 19 (5) 419 - 422 0895-6111 1995/09 [Refereed]
     
    We report pre- and post-operative three-dimensional (3D)-spiral CT images in a patient with multiple exostoses, Images of 3D-CT, which were performed using the integrated 3D software of the CT system, showed the exact shapes and locations of the individual tumors around the knee joint in comparison with the surgical findings and resected specimen, 3D-spiral CT images of multiple exostoses would be useful for the planning of surgical procedure. (C) 1996 Elsevier Science Ltd.
  • H SAKAHARA; H ONODERA; M SHIRATO; ZS YAO; G OHSHIO; H KOBAYASHI; M HOSONO; S YANO; H NAKADA; M IMAMURA; YAMASHINA, I; J KONISHI
    CANCER IMMUNOLOGY IMMUNOTHERAPY SPRINGER VERLAG 41 (3) 157 - 161 0340-7004 1995/09 [Refereed]
     
    A murine monoclonal antibody MLS102 recognizes sialosyl-Tn antigen in mucin and immunohistochemically reacts with more than 80% of colorectal cancer tissues, The purpose of this study was to assess the usefulness of this monoclonal antibody for the immunoscintigraphy of colorectal cancer. Planar and SPECT images were obtained on day 2 or day 3 after injection of 2 mg and 74 MBq In-111-labeled MLS102 antibody into 17 patients with colorectal cancer. Nine of 11 primary tumors and 4 of 6 locally recurrent tumors were detected. Positive images were obtained in all tumors larger than 4.5 x 2.7 cm. Three tumors of less than 2.5 cm and 1 recurrent tumor, which was missed by other imaging modalities, were negative. There were no adverse reactions. Human anti-(mouse Ig) antibody developed in 4 patients. Although improvement of detectability for smaller tumors needs to be pursued, the antibody MLS102 is potentially promising for use in immunoscintigraphy of colorectal cancer.
  • 細野 眞
    核医学 32 (8) 738 - 738 0022-7854 1995/08
  • H KOBAYASHI; Y KOTOURA; T TSUBOYAMA; M HOSONO; H SAKAHARA; J KONISHI
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT-RAVEN PUBL 20 (7) 638 - 638 0363-9762 1995/07
  • M HOSONO; H KOBAYASHI; Y KOTOURA; T TSUBOYAMA; K TSUTSUI; J KONISHI
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LIPPINCOTT-RAVEN PUBL 19 (3) 455 - 459 0363-8715 1995/05 [Refereed]
     
    Objective: The purpose of this study is to investigate the CT and MR findings of muscular involvement by malignant lymphoma and identify the CT acid MR features that may assist in their diagnosis. Materials and Methods: Magnetic resonance imaging was performed on four patients (five lesions) with pathologically proven non-Hodgkin lymphoma using a 1.5 T unit (Cases 1, 2, and 4) and a 0.5 T scanner (Case 3). Computed tomography scans were carried out on three patients (Cases 1, 3, and 4). Results: The lesions that extended along muscle fascicles with preserved fat planes looking like swelling of the muscle were of slightly hyper- to isointensity relative to uninvolved muscles on T1-weighted images, of hyperintensity on T2-weighted images, and of low or isodensity on CT. Microscopically, lymphoma cells were seen clustering among normal and atrophic muscle fibers in a biopsy specimen of one patient. The lesions enhanced relatively homogeneously after Gd-DTPA injection. In three cases, vessels were coursing through the lesion on MRI and in two cases on enhanced CT. Conclusion: Magnetic resonance imaging proved useful to show the extension of involvement of muscular lymphoma compared with CT. The diagnosis of infiltration of muscle by lymphoma is entertained when a lesion of relatively homogeneous intensity and density extends along the muscle fascisles without obliteration of the fat planes and especially when vessels are identified within the lesion.
  • H KOBAYASHI; Y KOTOURA; M HOSONO; H SAKAHARA; M HOSONO; ZS YAO; T TSUBOYAMA; T YAMAMURO; K ENDO; J KONISHI
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT-RAVEN PUBL 20 (4) 361 - 364 0363-9762 1995/04 [Refereed]
     
    Technetium-99m (V) DMSA scintigraphy was performed in 17 patients with 37 chondrogenic tumors (13 osteochondromas, 14 enchondromas, and 10 chondrosarcomas) that had previously shown uptake of Tc-99m HMDP. Technetium-99m (V) DMSA showed high uptake by all chondrosarcomas, but low or no uptake always indicated benign chondrogenic tumors. Technetium-99m (V) DMSA scintigraphy may be superior to Tc-99m HMDP scintigraphy for distinguishing benign and malignant chondrogenic tumors, and could also be useful for diagnosing the malignant transformation of chondrogenic tumors.
  • H KOBAYASHI; Y KOTOURA; M HOSONO; T TSUBOYAMA; H SAKAHARA; J KONISHI
    COMPUTERIZED MEDICAL IMAGING AND GRAPHICS PERGAMON-ELSEVIER SCIENCE LTD 19 (2) 237 - 240 0895-6111 1995/03 
    The authors reported computed tomography (CT), magnetic resonance imaging (MRI) and scintigraphic findings of a patient with solitary muscular tuberculosis in the forearm. All these findings resembled those of other granulomatous inflammatory lesions in the soft tissue such as muscular sarcoidosis.
  • A TAKAORIKONDO; M HOSONO; K IMADA; ZS YAO; H SAKAHARA; H YAMABE; J KONISHI; M OKUMA; T UCHIYAMA
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 86 (3) 322 - 328 0910-5050 1995/03 [Refereed]
     
    To clarify the mechanism of in vivo proliferation of adult T cell leukemia (ATL) cells, we examined the organ distribution of ATL-43T cell line cells derived from original leukemic cells in severe combined immunodeficiency (SCID) mice using radiometric techniques. First, we injected In-111-oxine-labeled ATL-43T cells into SCID and CB17 mice. On day 6, significant accumulation of radioactivity was found in the spleen and thymus of SCID mice (33.3 +/- 9.4 and 10.0 +/- 3.6 % injected dose/g of tissue [%ID/g], respectively) in comparison with that in CB17 mice (19.1 +/- 2.5 and 3.7 +/- 0.9 %ID/g, respectively). Next, we injected radiolabeled anti-Tac monoclonal antibody (MoAb) recognizing human interleukin-2 receptor (IL-2R) alpha chain or isotype-matched control MoAb RPC5 in SCID mice bearing ATL-43T cells 4 weeks after cell inoculation. The amounts of radioactivity found in the spleen and thymus of SCID mice injected with I-125-labeled anti-Tac MoAb (22.5 +/- 6.9 and 22.8 +/- 9.6 %ID/g, respectively) were significantly higher than those in the corresponding organs of SCID mice injected with I-125-labeled RPC5 MoAb (12.0 +/- 5.1 and 7.5 +/- 4.6 %ID/g, respectively). Similar results were obtained with In-111-labeled anti-Tac MoAb. These results were consistent with the histological findings of SCID mice bearing ATL-43T cells, indicating that ATL-43T cells infiltrated preferentially into the lymphoid organs, such as the spleen and thymus, and proliferated there. Thus, the radiometric techniques employed in this study were very useful to evaluate the proliferation sites of ATL-43T cells in SCID mice. Furthermore, this murine model could give us an opportunity to test the feasibility of therapeutic application of radiolabeled anti-Tac MoAb.
  • H KOBAYASHI; H SAKAHARA; K ENDO; M HOSONO; ZS YAO; S TOYAMA; J KONISHI
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 86 (3) 310 - 314 0910-5050 1995/03 [Refereed]
     
    Injection of avidin can decrease the background radioactivity due to a radiolabeled biotinylated monoclonal antibody. We compared the chase effects of avidin, streptavidin, neutravidin, and avidin-conjugated ferritin on a radiolabeled antitumor monoclonal antibody in tumor-bearing nude mice, A radioiodine-labeled biotinylated monoclonal antibody (OST7) was administered to athymic mice bearing osteogenic sarcomas. After 24 h, an avidin, streptavidin, neutravidin or avidin-conjugated ferritin chaser was intravenously injected into the mice. At 2 h after the chase, the biodistribution of the radiolabeled monoclonal antibody was determined. Clearance from the blood was dose-dependently accelerated by avidin and its effect was 10-fold stronger than that of neutravidin or avidin-ferritin. Streptavidin did not promote clearance of the biotinylated antibody, Avidin was the most effective chasing agent for improving the biodistribution of the radiolabeled biotinylated monoclonal antibody among the four avidin derivatives tested.
  • Masashi Iida; Naomi Fujita; Makoto Hosono; Yoshikazu Sukenaga
    The Japanese Journal of Pharmacology 68 (3) 245 - 253 0021-5198 1995 [Refereed]
     
    The bronchodilator and cardiovascular effects of NKH477 (6-(3-dimethylaminopropionyl)forskolin hydrochloride) were evaluated. In anesthetized guinea pigs, i.v. bolus injections of NKH477 (1–100 µg/kg) inhibited the bronchoconstriction induced by inhaled leukotriene D4, increased the heart rate (HR) and decreased the diastolic arterial blood pressure (DBP) in a dose-dependent manner. The bronchodilator effect of NKH477 was 1500 times more potent than that of aminophylline and 17 times less potent than that of isoproterenol. The selectivity of NKH477 for bronchodilation vs an increase in HR was 15 times higher than that of isoproterenol and similar to that of aminophylline and vs a decrease in DBP, the selectivity was 4 times higher than that of aminophylline and similar to that of isoproterenol. I.v. infusion of NKH477 (0.1–3 µg/kg/min) for 2 hr dose-dependently inhibited the bronchoconstriction induced by i.v. histamine. Isoproterenol (0.1 µg/kg/min, i.v.) enhanced the bronchoconstriction after termination of the infusion, whereas NKH477 did not. In conscious guinea pigs, inhalation of NKH477 (0.1–5 mg/ml) concentrationdependently inhibited the bronchoconstriction induced by inhaled histamine, and a high concentration of NKH477 (35.4 mg/ml) increased the HR. The bronchodilator effect of inhaled NKH477 was 15 times less potent than that of isoproterenol. The selectivity of inhaled NKH477 was similar to that of isoproterenol. These results indicate that NKH477 may be useful as a bronchodilator. © 1995, The Japanese Pharmacological Society. All rights reserved.
  • Makoto Hosono; Naoaki Sone; Keigo Endo; Tsuneo Saga; Hisataka Kobayashi; Masako N. Hosono; Harumi Sakahara; Kojiro Yasunaga; Junji Konishi
    Nuclear Medicine and Biology 22 (1) 71 - 76 0969-8051 1995 [Refereed]
     
    To experimentally assess the kinetics of platelets in thrombocytopenia, we constructed a canine model using 111In-oxine labeled autologous platelets and an intact antiplatelet monoclonal antibody (MAb) NNKY2-11 (IgG2a). With the infusion of radiolabeled autologous platelets into dogs, the peripheral platelet count and blood radioactivity level were examined, and the radioactivity in the liver, spleen and heart was determined with scintigraphic analysis. Thereafter, i.v. injection of 100 μg/kg of NNKY2-11 had no effect on platelet counts or the biodistribution of radiolabeled platelets. However, 200 and 300 μg/kg of MAb reduced the platelets, and the radioactivity of the liver and spleen augmented clearly after injection of MAb. Platelet radioactivity in serum, which had decreased after MAb infusion, did not recover, even when peripheral platelet counts returned to the normal levels, indicating that these new platelets might be derived from the platelet-storage pool or new thrombocytogenesis. This model of antiplatelet MAb induced thrombocytopenia seems to be useful for analyzing the kinetics of platelets in thrombocytopenia. © 1995.
  • M HOSONO; N SONE; K ENDO; T SAGA; H KOBAYASHI; MN HOSONO; H SAKAHARA; K YASUNAGA; J KONISHI
    NUCLEAR MEDICINE AND BIOLOGY PERGAMON-ELSEVIER SCIENCE LTD 22 (1) 71 - 76 0883-2897 1995/01 [Refereed]
     
    To experimentally assess the kinetics of platelets in thrombocytopenia, we constructed a canine model using In-111-oxine labeled autologous platelets and an intact antiplatelet monoclonal antibody (MAb) NNKY2-11 (IgG2a). With the infusion of radiolabeled autologous platelets into dogs, the peripheral platelet count and blood radioactivity level were examined, and the radioactivity in the liver, spleen and heart was determined with scintigraphic analysis. Thereafter, i.v. injection of 100 mu g/kg of NNKY2-11 had no effect on platelet counts or the biodistribution of radiolabeled platelets. However, 200 and 300 mu g/kg of MAb reduced the platelets, and the radioactivity of the liver and spleen augmented clearly after injection of MAb. Platelet radioactivity in serum, which had decreased after MAb infusion, did not recover, even when peripheral platelet counts returned to the normal levels, indicating that these new platelets might be derived from the platelet-storage pool or new thrombocytogenesis. This model of antiplatelet MAb induced thrombocytopenia seems to be useful for analyzing the kinetics of platelets in thrombocytopenia.
  • H KOBAYASHI; Y KOTOURA; M HOSONO; H SAKAHARA; T YAMAMURO; K ENDO; J KONISHI
    BRITISH JOURNAL OF RADIOLOGY BRITISH INST RADIOLOGY 67 (802) 1030 - 1032 0007-1285 1994/10 [Refereed]
     
    The scintigraphic findings of a patient with pigmented villonodular synovitis are described and compared with the computed tomography and magnetic resonance imaging data. Intense uptake of pentavalent technetium-99m dimercaptosuccinic acid without gallium-67 citrate uptake indicates that pigmented villonodular synovitis has the features of a hyperplastic or neoplastic lesion rather than an inflammatory lesion from the point of view of nuclear medicine.
  • H KOBAYASHI; H SAKAHARA; M HOSONO; ZS YAO; S TOYAMA; K ENDO; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 35 (10) 1677 - 1684 0161-5505 1994/10 [Refereed]
     
    The techniques of radioimmunoimaging and radioimmunotherapy suffer from prolonged high background radioactivity because intravenously injected antibodies remain in the circulation and in the organs far longer than necessary for effective binding to the target. To decrease background and increase radionuclide excretion without decreasing the dose of radioactivity delivered to the target tumor, we used radiolabeled biotinylated antibodies followed by a ''chase'' avidin injection. Methods: A mouse monoclonal antibody, OST7 (IgG1), which reacts with human osteosarcoma, was biotinylated and labeled with I-125, I-131 or Tc-99m. Radiolabeled biotinylated OST7 (10 mu g) was administered intravenously into nude mice bearing human osteosarcomas and 30 mu g of avidin was injected intravenously 6 or 24 hr later. Results: Following avidin injection in mice pretreated with radiolabeled biotinylated antibodies, radioactivity was promptly cleared from the blood and deposited in the liver and spleen, after which radioiodine was rapidly detached from the antibody and excreted in the urine. The tumor-to-blood ratios at 6 and 24 hr after the injection of I-125-labeled biotinylated OST7 increased compared with the values before the avidin chase without any loss of tumor radioactivity. Furthermore, the tumor-to-background radioactivity ratio was improved and better images were obtained more rapidly after the injection of radiolabeled biotinylated antibodies than with conventional immunoscintigraphy. Conclusions: This method may find application in clinical radioimmunoimaging, especially using short half-life radionuclides such as Tc-99m and I-123.
  • H KOBAYASHI; C SHIGENO; H SAKAHARA; M HOSONO; M HOSONO; ZS YAO; K ENDO; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 35 (9) 1482 - 1484 0161-5505 1994/09 [Refereed]
     
    We report a case of histologically proven intraosseous hemangiomatosis in which marked accumulation of pentavalent technetium-99m-dimercaptosuccinic acid (Tc-99m(V)DMSA) and technetium-99m-hydroxymethylene diphosphonate (Tc-99m-HMDP) was observed in the osteolytic hemangiomatous lesions.
  • H KOBAYASHI; Y KOTOURA; H SAKAHARA; M HOSONO; M HOSONO; T TSABOYAMA; T YAMAMURO; K ENDO; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 35 (7) 1174 - 1178 0161-5505 1994/07 [Refereed]
     
    The diagnostic value of MRI and scintigraphy was studied in patients with Schwannomas of the upper or lower extremities. MRI (T1- and T2-weighted imaging), pentavalent Tc-99m-dimercaptosuccinic acid and Ga-67-citrate scintigraphy were performed in 11 patients with 12 histologically proven benign Schwannomas. All six tumors with a maximum diameter greater than or equal to 3 cm showed marked accumulation of pentavalent Tc-99m-dimercaptosuccinic acid, whereas they showed no uptake of Ga-67-citrate. MRI detected all of the tumors, and the lesions had a signal intensity equal to or slightly less than that of skeletal muscle on T1-weighted images and hyperintense to that of subcutaneous fat on T2-weighted images. MRI was superior to detect small Schwannomas of the extremities. A positive Tc-99m-dimercaptosuccinic acid scan and a negative Ga-67-citrate scan however is useful to distinguish sarcoma with myxoid change from Schwannoma.
  • Harumi Sakahara; Keigo Endo; Tsuneo Saga; Makoto Hosono; Hisataka Kobayashi; Junji Konishi
    Annals of Nuclear Medicine 8 (2) 133 - 137 0914-7187 1994/06 [Refereed]
     
    131I-metaiodobenzylguanidine (MIBG) therapy was given to five patients with malignant pheochromocytoma. The patients received 1-3 doses of 3.33-4.625 GBq (total dose: 3.7 to 10.73 GBq). Partial tumor regression was observed in two patients, the tumor was unchanged in two patients, and slow progression was noted in one patient. Marked improvement in clinical symptoms was achieved in four patients. The other patient had no symptoms before131I-MIBG treatment, but the serum epinephrine and dopamine decreased. There were no severe untoward responses in four patients. However, one patient developed transient but severe orthostatic hypotension, hypertension, and hyperglycemia from 1 weekto 1 month after131I-MIBG administration. Although complete remission was not obtained, all the patients achieved some benefit from131I-MIBG therapy. Thus,131I-MIBG appears to be useful for the palliation of malignant pheochromocytoma. © 1994 Springer-Verlag.
    ダウンロード
  • H KOBAYASHI; H SAKAHARA; M HOSONO; M SHIRATO; S KONDO; S MIYATAKE; H KIKUCHI; Y NAMBA; K ENDO; J KONISHI
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY SPRINGER VERLAG 120 (5) 259 - 262 0171-5216 1994/03 [Refereed]
     
    Radiolabeled GA-17, a murine monoclonal antibody that reacts specifically with glioma cells, bound to a small-cell lung cancer (SCLC) cell line NCI-H69 derived from neural cells, both in vitro and in vivo. The affinity constant of GA-17 F(ab')(2) fragment binding to NCI-H69 was 1.02x10(8)/M while that to the glioma cell line U87MG was 1.22x10(8)/M. Iodine-l25-labeled GA-17 F(ab')(2) fragments injected i.v. localized well in NCI-H69 cells xenografted in nude mice. The percentage of the injected dose per gram accumulated in the xenografted tumor was 6.87+/-1.34%g(-1) (mean+/-SD, n=5) 24 h after injection. On the other hand, control monoclonal F(ab')(2) fragments accumulated in the xenografted tumor at 0.75+/-0.30%g(-1). The tumor-to-blood ratio was 1.8 for NCI-H69, while that of control F(ab')(2) was 0.60. In conclusion, the radiolabeled GA-17 F(ab')(2) fragment is expected to be useful clinically to visualize the small-cell lung cancer and in radioimmunotherapy.
  • H SAKAHARA; T KOUSAKA; N HATTORI; K TOMIDA; ZS YAO; M HOSONO; H KOBAYASHI; M SHIRATO; K ENDO; J KONISHI
    GYNECOLOGIC ONCOLOGY ACADEMIC PRESS INC ELSEVIER SCIENCE 52 (3) 301 - 305 0090-8258 1994/03 [Refereed]
     
    The new immunoradiometric assay for CA125 (CA125II assay) uses the monoclonal antibody M11 as an immunoadsorbent. The epitope recognized by M11 is different from the OC125 epitope. Monoclonal antibodies 130-22 and 145-9 recognize an epitope designated as CA130 on the molecule expressing the OC125 epitope. Similarity of M11 epitope to the epitope of anti-CA130 antibodies and dissociation of antigen levels measured by the original CA125 assay and new CA125II assay were examined. Anti-CA130 antibodies partially competed with M11 for the M11 epitope. Among more than 20,000 serum samples we found 12 patients in whom the serum CA125 concentration measured by the CA125II assay was different from that measured by the original assay. In 11 out of 12 patients the CA125 concentration was moderately or extremely high by the original assay but very low by the CA125II assay. Eight of the 11 patients had benign disease, one had no apparent disease and two had cancer. The antigen level determined by CA130 assay was very low in all the 11 patients. In one patient the CA125II assay showed a higher antigen level than the original assay or CA130 assay. The heterogeneity of the epitope expression could cause the dissociation of CA125 levels measured by the different monoclonal antibodies. (C) 1994 Academic Press, Inc.
  • MN HOSONO; M HOSONO; K ENDO; R UEDA; Y ONOYAMA
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 35 (3) 504 - 509 0161-5505 1994/03 [Refereed]
     
    This study was performed to examine the effect of hyperthermia on the intratumor accumulation of a monoclonal antibody (Mab) in an animal model. Mab NE150 (IgG1) recognizes the neural cell adhesion molecule (NCAM) expressed by human small-cell lung cancer (SCLC) cells. Methods: Athymic mice inoculated with NCI-H69, an SCLC cell line, received an intravenous injection of I-125- and In-111-NE150 and the serial changes of the biodistribution were determined. Furthermore, athymic mice bearing NCI-H69 were either sham-treated or treated by a single hyperthermia at 42 degrees C or 43 degrees C for 1 hr, with the tumor-bearing leg in a water bath using pentobarbital anesthesia. Immediately after heating, the mice were given an intravenous injection of radiolabeled NE150, and the biodistribution was examined at 24 and 48 hr. Results: NE150 localized well in the transplanted tumor when compared with a control Mab. In mice treated at 43 degrees C, there was a 1.34- to 1.67-fold increase in the tumor uptake of I-125- and In-111-NE150 compared to sham-treated mice at both 24 and 48 hr. In addition, a 1.84- to 2.22-fold increase of the tumor-to-blood ratio was demonstrated, since radiolabeled NE150 cleared faster from the circulation in the mice given hyperthermia. A histological study demonstrated the infiltration of neutrophils in the perivascular spaces, indicating an increase of tumor vascular permeability, which might be one of the main reasons for the enhancement of Mab uptake. Conclusion: Hyperthermia seems to be a potential method of achieving an increased tumor accumulation of Mab in the radioimmunotargeting of SCLC.
  • M HOSONO; K ENDO; MN HOSONO; H KOBAYASHI; M SHIRATO; H SAKAHARA; R UEDA; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 35 (2) 296 - 300 0161-5505 1994/02 [Refereed]
     
    Human small-cell lung cancer (SCLC) is considered a feasible target for immunotherapy using a radiolabeled monoclonal antibody (Mab). A murine Mab, NE150 (IgG1), reacts with the neural cell adhesion molecule, which is identical to cluster 1 antigen of SCLC. Methods: To estimate their therapeutic effects, NE150 and an isotype-matched control Mab were labeled with I-131 and administered intravenously as a single dose into athymic mice inoculated with a NCI-H69 SCLC xenograft. The absorbed dose in organs was also examined based upon a long-term biodistribution study of I-131-NE150. Results: Tumors (initial volume 563.4 +/- 223.5 mm(3)) treated with 11.1 MBq (300 mu Ci) of I-131-NE150 diminished and became invisible at days 30-33, demonstrating a 60-day mean growth delay to reach a tripled initial volume compared with sham-treated tumors. Cumulative absorbed doses were estimated to be 2310, 410, 500, 330, and 790 cGy for the tumor, liver, kidney, spleen and lung, respectively. Conclusion: Iodine-131-NE150 had potent therapeutic effects against SCLC transplants in athymic mice, however, careful assessment of the side effects, improvement of radioiodination and chimerization of the Mab might be necessary to achieve efficient targeting in clinical therapeutic applications.
  • H KOBAYASHI; H SAKAHARA; M HOSONO; M SHIRATO; J KONISHI
    CLINICAL NUCLEAR MEDICINE LIPPINCOTT-RAVEN PUBL 19 (2) 136 - 137 0363-9762 1994/02 [Refereed]
     
    The authors report marked accumulation of pentavalent technetium-99m dimercaptosuccinic acid in metastatic tumors from a renal cell carcinoma in the brain and the scalp on brain SPECT images.
  • Yasushi Arano; Hiroshi Matsushima; Masaaki Tagawa; Tatsuo Inoue; Mitsuru Koizumi; Makoto Hosono; Harumi Sakahara; Keigo Endo; Junji Konishi; Akira Yokoyama
    Nuclear Medicine and Biology 21 (1) 63 - 69 0969-8051 1994 [Refereed]
     
    Target-to-non-target ratio of radioactivity can be enhanced by the injection of monoclonal antibodies (MoAbs) labeled with metallic radionuclides, if some modality to accelerate the urinary excretion of radioactivity accumulated in non-target tissues could be introduced. In this study, a radioimmunoconjugate chemically designed to release a hippurate-like radiometal chelate was synthesized and tested in vivo. A 67Ga chelate of succinyldeferoxamine (SDF) was conjugated with a MoAb against osteogenic sarcoma (OST7, IgG1) through an ester bond using a new metabolizable MESS linker, N-[[4-(maleimidoethoxy)succinyl]oxy]succinimide (67Ga-DFO-MESS-OST7). When injected into normal mice, 67Ga-DFO-MESS-OST7 exhibited faster clearance of radioactivity from circulation with less accumulation in the liver, kidney and spleen than those observed with 67Ga-DFO-EMCS-OST7, which was prepared under identical conditions to 67Ga-DFO-MESS-OST7 except for using a non-metabolizable linker holding no ester bond to release 67Ga-SDF. Size exclusion HPLC analysis of the liver homogenate obtained from mice 24 h after injection of 67Ga-DFO-MESS-OST7 indicated that all the radioactivity was eluted in the high molecular weight fraction with most of it being present as the 67Ga-DFO-MESS-OST7 fraction. Reverse-phase HPLC analysis of urine sample from the same mice showed a single radioactivity peak at the same retention time as that of 67Ga-SDF. In athymic mice bearing osteogenic sarcoma, 67Ga-DFO-MESS-OST7 exhibited higher tumor-to-blood and tumor-to-organ ratio of radioactivity when compared with 67Ga-DFO-EMCS-OST7. These results indicated that 67Ga-DFO-MESS-OST7 achieved enhanced target-to-non-target ratio of the radioactivity, due to preferential cleavage of the ester bond in non-target tissues, followed by rapid urinary excretion of the resulting chelate (probably as 67Ga-SDF). These results also suggest that the present design would become an applicable modality for enhancing the target-to-non-target ratio of radioactivity by MoAbs. © 1994.
  • Y ARANO; H MATSUSHIMA; M TAGAWA; T INOUE; M KOIZUMI; M HOSONO; H SAKAHARA; K ENDO; J KONISHI; A YOKOYAMA
    NUCLEAR MEDICINE AND BIOLOGY PERGAMON-ELSEVIER SCIENCE LTD 21 (1) 63 - 69 0883-2897 1994/01 
    Target-to-non-target ratio of radioactivity can be enhanced by the injection of monoclonal antibodies (MoAbs) labeled with metallic radionuclides, if some modality to accelerate the urinary excretion of radioactivity accumulated in non-target tissues could be introduced. In this study, a radioimmunoconjugate chemically designed to release a hippurate-like radiometal chelate was synthesized and tested in vivo. A Ga-67 chelate of succinyldeferoxamine (SDF) was conjugated with a MoAb against osteogenic sarcoma (OST7, IgG(1)) through an ester bond using a new metabolizable MESS linker, N-[[4-(maleimidoethoxy)succinyl]oxy]succinimide (Ga-67-DFO-MESS-OST7). When injected into normal mice, Ga-67-DFOMESS-OST7 exhibited faster clearance of radioactivity from circulation with less accumulation in the liver, kidney and spleen than those observed with Ga-67-DFO-EMCS-OST7, which was prepared under identical conditions to Ga-67-DFO-MESS-OST7 except for using a non-metabolizable linker holding no ester bond to release (GaSDF)-Ga-67. Size exclusion HPLC analysis of the liver homogenate obtained from mice 24 h after injection of Ga-67-DFO-MESS-OST7 indicated that all the radioactivity was eluted in the high molecular weight fraction with most of it being present as the Ga-67-DFO-MESS-OST7 fraction. Reverse-phase HPLC analysis of urine sample from the same mice showed a single radioactivity peak at the same retention time as that of Ga-67-SDF. In athymic mice bearing osteogenic sarcoma, Ga-67-DFOMESS-OST7 exhibited higher tumor-to-blood and tumor-to-organ ratio of radioactivity when compared with Ga-67-DFO-EMCS-OST7. These results indicated that Ga-67-DFO-MESS-OST7 achieved enhanced target-to-non-target ratio of the radioactivity, due to preferential cleavage of the ester bond in non-target tissues, followed by rapid urinary excretion of the resulting chelate (probably as Ga-67-SDF). These results also suggest that the present design would become an applicable modality for enhancing the target-to-nontarget ratio of radioactivity by MoAbs.
  • Initial studies on Tc-99m- and Re-188-somatostatin analogues: stannous-mediated direct-labeling and biodistribution in normal mice
    Haberberger T; Zamora P; Hosono M; Hosono MN; Bender H; Guhlke S; Knapp FFR; Biersask HJ
    Technetium and Rhenium chemistry and nuclear medicine 1994 [Refereed]
  • H KOBAYASHI; H SAKAHARA; M HOSONO; M SHIRATO; K ENDO; Y KOTOURA; T YAMAMURO; J KONISHI
    RADIOLOGY RADIOLOGICAL SOC NORTH AMER 190 (1) 277 - 280 0033-8419 1994/01 [Refereed]
     
    PURPOSE: to assess the potential of technetium-99m (V) dimercaptosuccinic acid (DMSA) scintigraphy for diagnosis of soft-tissue tumors. MATERIALS AND METHODS: Tc-99m (V) DMSA scintigraphy was performed in 76 patients with histologic proof of soft-tissue tumors. In 57 of these patients, gallium-67 citrate scintigraphy was performed within 2 weeks after Tc-99m (V) DMSA scin-tigraphy. RESULTS: Uptake of Tc-99m (V) DMSA was clearly detected in almost all sarcomas, metastatic carcinomas, highly recurrent benign tumors (ie, extraabdominal desmoids and teno-synovial giant cell tumors), superficial and deep hemangiomas, and granulomatous soft-tissue lesions but was not found in other benign solid tumors of soft tissue. Uptake of Ga-67 citrate was clearly detected in all inflammatory lesions and metastatic carcinomas, eight of 14 sarcomas (57%), and two of 10 highly recurrent benign tumors (20%) but was not found in hemangiomas or benign soft-tissue tumors. CONCLUSION: Low-grade malignant and highly recurrent benign lesions, which often recur after surgery, were detected more accurately with Tc-99m (V) DMSA scintigraphy than with Ga-67 citrate scintigraphy.
  • H SAKAHARA; T SAGA; K ENDO; T KOUSAKA; M HOSONO; H KOBAYASHI; M SHIRATO; J KONISHI
    BRITISH JOURNAL OF CANCER STOCKTON PRESS 68 (5) 920 - 925 0007-0920 1993/11 [Refereed]
     
    The concentration of carcinoembryonic antigen (CEA), CA130, CA125, SLX, CA19-9, SPan1, and tumour-associated glycoprotein 72 (TAG-72) in the culture supernatant of 15 cancer cell lines and in the sera of 58 cancer patients was measured, and the co-expression of these antigens was examined by double determinant immunoradiometric assays. The high correlation coefficient of the concentrations and significant binding in the double determinant assays indicated a close relationship between CA125 and CA130 and between CA19-9 and SPan1. There was variable binding of the I-125-labelled anti-SLX, anti-CA19-9, and anti-SPan1 antibodies to anti-CA130 beads that had been pre-incubated with the culture supernatants, suggesting the presence of the epitopes of SLX, CA19-9, and SPan1 on the molecule expressing CA130. Similarly, the epitopes of SLX, CA19-9, and SPan1 could be present on the molecule expressing CEA. I-125-labelled anti-CA19-9, anti-SLX, and anti-TAG-72 antibodies were bound in variable proportions to anti-CA130 beads or to anti-CEA beads that had been pre-incubated with patients' sera. However, CEA and CA130 were not expressed on the same molecule, either in the culture supernatant, or in patients' sera. In conclusion, the carbohydrate epitopes of CA19-9, SPan1, SLX, and TAG-72 could be present on the molecule recognised by the anti-CA130 or anti-CEA antibody; however, the epitopes of CA130 and CEA did not co-exist on the same molecule.
  • H KOBAYASHI; H SAKAHARA; M HOSONO; M SHIRATO; J KONISHI; JA TAKAHASHI; Y ODA; H KIKUCHI; K ENDO; Y KOZAI; M HATANAKA
    CANCER IMMUNOLOGY IMMUNOTHERAPY SPRINGER VERLAG 37 (5) 281 - 285 0340-7004 1993/10 [Refereed]
     
    A murine monoclonal antibody 3H3 recognizes the basic fibroblast growth factor (FGF) and inhibits the growth of human glioblastoma cells both in vitro and in vivo. We studied the potential of a scintigraphic technique using the 3H3 antibody to detect tumors that produce basic FGF. I-125- and In-111-labeled 3H3 bound to U87MG human glioblastoma cells in vitro. U87MG cells were inoculated subcutaneously into nude mice. After development of the tumor, radiolabeled 3H3 was injected into the subcutaneous space surrounding the tumor. A high level of radioactivity from 3H3 was retained at the tumor, whereas an irrelevant antibody cleared rapidly from the injected site. Radiolabeled 3H3 was not retained in tumors that did not produce basic FGF. Scintigraphic detection of tumors expressing basic FGF would be valuable for the therapeutic application of the antibody.
  • H KOBAYASHI; H SAKAHARA; M HOSONO; M SHIRATO; J KONISHI; Y KOTOURA; T YAMAMURO; K ENDO
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 34 (10) 1745 - 1747 0161-5505 1993/10 [Refereed]
     
    Technetium-99m(V) dimercaptosuccinic acid (DMSA) and Ga-67-citrate scintigraphy were performed in three patients with primary and recurrent tenosynovial giant-cell tumor (one localized type and two diffuse type). In all cases, Tc-99m(V)DMSA showed marked accumulation in all primary and recurrent tumors; however, Ga-67-citrate showed no accumulation in any of the tumors. Technetium-99m(V)-DMSA scintigraphy was useful in detecting tenosynovial giant-cell tumor and in diagnosing recurrence of this tumor.
  • Toshiharu Nakai; Harumi Sakahara; Keigo Endo; Makoto Shirato; Hisataka Kobayashi; Makoto Hosono; Tsuneo Saga; Masaru Sakamoto; Junji Konishi
    Annals of Nuclear Medicine 7 (3) 133 - 139 0914-7187 1993/09 [Refereed]
     
    The effect of drugs on the release of CA125 antigen and the binding of anti-CA125 mono-clonal antibody (MoAb) to malignant cells was evaluated in vitro. TMCC-1, uterine cervical adenocarcinoma cells, were exposed to dexamethasone (DEX), sodium n-butyrate (NaB), dibutyryl cyclic AMP (dbcAMP), retinoic acid (RA), calcitriol (VD3), and interferon-γ (IFN-γ). NaB, RA and VD3 increased CA125 release per cell and125I-labeled anti-CA125 MoAb binding to the cells. DEX also increased the125I-labeled anti-CA125 MoAb binding to the cells, and CA125 antigen release per cell was also slightly increased. IFN-γ suppressed both CA125 release and125I-labeled MoAb binding. A combination of DEX, VD3 and RA and increased the binding of MoAb to TMCC-1 cells, but the amount of bound MoAb was not significantly different from that obtained by single drug treatment. DbcAMP had no significant effect on enhancing MoAb binding. Drugs can increase the binding of anti-CA125 MoAb to malignant cells and they may be applied to increase the tumor uptake of radiolabeled MoAbs in vivo. © 1993 Springer-Verlag.
  • H KOBAYASHI; H SAKAHARA; T SAGA; M HOSONO; M SHIRATO; H KANDA; K ISHIBASHI; T WATANABE; K ENDO; ISHIWATA, I; J KONISHI
    CANCER IMMUNOLOGY IMMUNOTHERAPY SPRINGER VERLAG 37 (3) 143 - 149 0340-7004 1993/08 [Refereed]
     
    Murine monoclonal antibody 196-14 recognizes the ovarian-cancer-associated antigen CA125, but the epitope it recognizes is different from that of monoclonal antibody OC 125. We developed a human/mouse chimeric 196-14 using the variable regions of the murine 196-14 and human heavy-chain (gamma1) and light-chain (kappa) constant regions. Cell binding and competitive inhibition assays using chimeric 196-14 labeled with I-125, In-111 or Tc-99m demonstrated that the in vitro immunoreactivity of the chimeric antibody was identical to that of the parental murine monoclonal antibody. However, in mice bearing human ovarian cancer xenografts, the clearance from blood was faster and absolute levels of accumulation in the tumor were lower for the I-125-labeled or Tc-99m-labeled chimeric antibody than for the murine antibody labeled with the corresponding radionuclides. The tumor-to-blood radioactivity ratio was not significantly different between the chimeric antibody and the murine antibody, regardless of the radionuclide used for labeling. Chimeric antibody 196-14 labeled with I-131, In-111 or Tc-99m is promising for the radioimmunoimaging of ovarian cancer.
  • H SAKAHARA; T SAGA; K ENDO; N HATTORI; M HOSONO; H KOBAYASHI; M SHIRATO; T YAMAMURO; S TOYAMA; Y ARANO; A YOKOYAMA; J KONISHI
    NUCLEAR MEDICINE AND BIOLOGY PERGAMON-ELSEVIER SCIENCE LTD 20 (5) 617 - 623 0883-2897 1993/07 [Refereed]
     
    A murine monoclonal antibody that reacts with human osteogenic sarcoma (OST7) was reduced and directly labeled with Tc-99m without any loss of immunoreactivity. No fragmentation of the antibody was detected by high performance liquid chromatography after the labeling. However, SDS PAGE analysis of the labeled antibody demonstrated the presence of low molecular weight species. Although more than 95% of the radioactivity remained bound at the antibody after incubation with human serum for 24 h, Tc-99m-labeled OST7 was cleared faster from the circulation than I-125-labeled OST7 or In-111-labeled OST7 in mice. Urinary and fecal excretion of Tc-99m were higher than those of I-125. When the I-125-labeled antibody was dual-labeled with Tc-99m, the blood clearance of Tc-99m was faster than that of I-125, suggesting release of Tc-99m from the antibody in vivo. Tc-99m-labeled OST7, however, gave a higher tumor-to-blood ratio than I-125- or In-111-labeled OST7 in mice bearing human osteogenic sarcoma. The Tc-99m-labeled antibody prepared by the direct method was unstable in vivo, but retained a good tumor targeting ability.
  • H KOBAYASHI; H SAKAHARA; T ITOH; T KUDOH; T TAKAGI; K SHIBUYA; S NOMURA; M HOSONO; K ENDO; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE SOC NUCLEAR MEDICINE INC 34 (5) 815 - 817 0161-5505 1993/05 [Refereed]
     
    Technetium-99m(V)dimercaptosuccinic acid (DMSA) scintigraphy was performed in two patients with pathologically confirmed primary amyloidosis. Both patients had tumor-like deposits of AL-type amyloid in the abdomen. Marked uptake of the tracer by the amyloid deposits was noted. Technetium-99m-(V)DMSA scintigraphy appears to be useful in detecting the distribution of amyloid deposits and in determining the appropriate site for biopsy.
  • M HOSONO; T SAGA; H SAKAHARA; H KOBAYASHI; M SHIRATO; K ENDO; T YAMAMOTO; T AKIYAMA; K TOYOSHIMA; J KONISHI
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 84 (2) 147 - 152 0910-5050 1993/02 [Refereed]
     
    The human c-erbB-2 protooncogene product (erbB-2 protein) is a 185 kilodalton glycoprotein closely related to epidermal growth factor receptor protein. In this study, we measured the concentration of circulating erbB-2 protein in cancer patients by means of a new immunoradiometric assay (IRMA). Two monoclonal antibodies (MoAbs), SV2-61gamma and 6G10, recognize erbB-2 protein but bind to separate epitopes. SV2-61gamma was used as an immunoadsorbent and 6G10 as an I-125-labeled probe. A serum was considered positive for erbB-2 protein if the percent binding exceeded the mean of the normal group by more than 3 standard deviations. Eleven of 21 patients with advanced breast cancer and 1 of 15 with advanced gastric cancer were positive. Serum erbB-2 protein levels correlated well with the therapy and the status of the patients with breast cancer. On the contrary, all patients with advanced colon, ovarian, or pancreatic cancers, showed levels below the cut-off value. These results suggest that circulating erbB-2 protein can be measured using the newly constructed IRMA. Since c-erbB-2 protooncogene amplification and overexpression are accepted as a good marker of aggressiveness, relapsing potency, and poor prognosis, this IRMA should be a promising tool with which to help manage breast cancer patients.
  • H. Sakahara; T. Kousaka; N. Hattori; M. Hosono; H. Kobayashi; M. Shirato; Z. Yao; J. Konishi
    Kakuigaku 30 (12) 1475 - 1479 0022-7854 1993 [Refereed]
     
    We evaluated 'BALL ELSA CYFRA21-1' kit, an immunoradiometric assay kit for cytokeratin 19. Monoclonal antibodies KS19-1 and BM19-21 are used for immunoadsorbent and indicator, respectively. There was no problems in reproducibility, dilution test and recovery test. Minimum detectable concentration was 0.42 ng/ml. The antigen measured by this kit was immunologically cross-reactive with tissue polypeptide antigen (TPA) and CYFRA21-1 concentration was closely correlated with TPA concentration in patient's serum. One of twenty-six healthy subjects showed serum concentration over a cut-off value of 2.0 ng/ml. Serum CYFRA21-1 concentration elevated in 5 of 10 esophageal cancer patients, 5 of 10 gastric cancer patients, 7 of 10 colorectal cancer patients and 6 of 10 pancreatic cancer patients. Positive rate in patients with benign disease including hepatopathy was low. BALL ELSA CYFRA21-1 kit is reliable and CYFRA21-1 could be a useful tumor marker in gastrointestinal cancer.
  • Harumi Sakahara; Tsuneo Saga; Keigo Endo; Noriko Hattori; Makoto Hosono; Hisataka Kobayashi; Makoto Shirato; Takao Yamamuro; Sakuji Toyama; Yasuo Arano; Akira Yokoyama; Junji Konishi
    Nuclear Medicine and Biology 20 (5) 617 - 623 0969-8051 1993 [Refereed]
     
    A murine monoclonal antibody that reacts with human osteogenic sarcoma (OST7) was reduced and directly labeled with 99mTc without any loss of immunoreactivity. No fragmentation of the antibody was detected by high performance liquid chromatography after the labeling. However, SDS-PAGE analysis of the labeled antibody demonstrated the presence of low molecular weight species. Although more than 95% of the radioactivity remained bound at the antibody after incubation with human serum for 24 h, 99mTc-labeled OST7 was cleared faster from the circulation than 125I-labeled OST7 or 111In-labeled OST7 in mice. Urinary and fecal excretion of 99mTc were higher than those of 125I. When the 125I-labeled antibody was dual-labeled with 99mTc, the blood clearance of 99mTc was faster than that of 125I, suggesting release of 99mTc from the antibody in vivo. 99mTc-labeled OST7, however, gave a higher tumor-to-blood ratio than 125I- or 111In-labeled OST7 in mice bearing human osteogenic sarcoma. The 99mTc-labeled antibody prepared by the direct method was unstable in vivo, but retained a good tumor targeting ability. © 1993.
  • MN HOSONO; K ENDO; H SAKAHARA; Y WATANABE; T SAGA; T NAKAI; M HOSONO; T NAKAJIMA; Y ONOYAMA; J KONISHI
    CANCER WILEY-LISS 70 (12) 2851 - 2856 0008-543X 1992/12 [Refereed]
     
    Background. CA 125 is a representative ovarian cancer-associated antigen defined by monoclonal antibody OC125. Recently, monoclonal antibodies were produced (designated 130-22 and 145-9) that were reactive with CA 125 but bound to a separate epitope named CA 130. There was a close correlation between serum CA 125 and CA 130 values in most instances. However, among more than 8000 serum samples, 5 apparently normal women had high serum CA 125 values, despite having normal CA 130 values. In this study, the antigenic nature of these five women was investigated. Methods. Using gel chromatography, the molecular masses of CA 125 and CA 130 were estimated that were found in the five women with false-positive CA 125 values. The sera were examined using double-determinant assays combining iodine-125-labeled OC125 or iodine-125-labeled 130-22 with OC125-coated or 145-9-coated beads. Results. The molecular masses of both CA 125 and CA 130 were estimated as greater than 1000 kilodaltons (KD); the CA 130 mass from one of the five women with an abnormal CA 125 level was approximately 200 KD using gel chromatography. Using the double-determinant assays that combined iodine-125-labeled OC125 or iodine-125-labeled 130-22 with OC125-coated or 145-9-coated beads, high radioactivity was found only in the homologous assay using iodine-125-labeled OC125 with OC125-coated heads. These results suggest that the antigenic nature of CA 125 found in apparently healthy women differs from that found in patients with ovarian cancer and that CA 130 epitopes are not present. Conclusions. Measurement of serum CA 130 concentrations may be useful for excluding women with falsely elevated CA 125 values.
  • M HOSONO; K ENDO; H SAKAHARA; Y WATANABE; T SAGA; T NAKAI; C KAWAI; A MATSUMORI; T YAMADA; T WATANABE; J KONISHI
    BRITISH JOURNAL OF CANCER CHURCHILL LIVINGSTONE 65 (2) 197 - 200 0007-0920 1992/02 [Refereed]
     
    Human anti-murine antibody (HAMA) response is a serious problem in the repeated infusion of murine monoclonal antibodies (MoAbs). HAMA positive sera were obtained from seven patients with colorectal cancer, pancreas cancer, malignant melanoma or myocardial infarction who had previously received radiolabelled MoAbs. The nature of HAMA was analysed using size exclusion high performance liquid chromatography (HPLC) after incubating with radiolabelled MoAbs including IgG, Fab or human mouse chimeric Abs. Immune complexes composed of HAMA and MoAbs were formed. The percentage of radioactivity with a high molecular weight was related to HAMA levels determined by enzyme linked immunosorbent assay. Most radioactivity present in immune complex shifted to the antibody fraction after the addition of normal murine serum. All of seven sera were reactive with all four murine IgGs and this suggests that HAMA in these patients recognised the constant region of MoAbs. In one patient, HAMA was considered to recognise the variable region and to be anti-idiotypic. There was no significant binding with human/mouse chimeric Abs in any HAMA positive serum, although five out of seven patients were reactive with murine MoAb Fab, indicating that HAMA was composed of Abs responsive to the CH1 or CL region of murine IgG. These results suggest that (1) HAMA was composed of Ab responsive to Fe portion and or CH1 or CL region of murine IgG, and (2) human mouse chimeric Abs look promising in the repeated infusion of MoAb in HAMA positive patients.
  • Akira Fujita; Takashi Takahira; Makoto Hosono; Keita Nakamura
    The Japanese Journal of Pharmacology 58 (4) 375 - 381 0021-5198 1992 [Refereed]
     
    The efficacy of NKH477, a novel water-soluble forskolin derivative, in improving cardiac failure was assessed in dog heart-lung preparations. Cardiac functions depressed by pentobarbital, propranolol or verapamil so that cardiac output had been reduced by about 40-50% of the respective control were all improved by NKH477 (10-100 μg) in a dose-dependent manner. With 100 μg NKH477, almost complete restoration of cardiac performance was attained in the respective cardiac failures. In the combination of NKH477 with ouabain (30 μg), 30 μg of NKH477 completely restored the cardiac function depressed by pentobarbital, associated with a slight but not significant increase in heart rate. No arrhythmias were induced by any of the NKH477 doses used in the experiments. These results suggest that NKH477 should be subjected to clinical trials in the treatment of cardiac failure. © 1992, The Japanese Pharmacological Society. All rights reserved.
  • 伊島理枝子; 赤坂一之; 中井敏晴; 遠藤啓吾; 細野真; 佐賀恒夫; 阪原晴海; 小西淳二
    NMR討論会講演要旨集 30th 341 - 342 1991/10
  • T NAKAI; K ENDO; M HOSONO; T SAGA; Y WATANABE; H SAKAHARA; K IMAI; A YACHI; Y KIYOZUKA; ISHIWATA, I; J KONISHI
    INTERNATIONAL JOURNAL OF CANCER WILEY-LISS 48 (3) 463 - 467 0020-7136 1991/05 [Refereed]
     
    CA125 is a high-molecular weight glycoprotein expressed on most serous-type ovarian cancer and some lung adenocarcinoma tissues. The effects of various drugs on the release of CA125 antigen into culture medium and on monoclonal antibody (MAb) binding to cancer cells were studied using 8 human cancer cell lines, all of which expressed CA125 on their cell surfaces. The effect of dexamethasone was seen at as low a concentration as 10(-9) m dexamethasone, and the release of CA125 and the binding of radiolabelled anti-CA125 antibody were completely inhibited after exposure to 10(-7) m dexamethasone. The number of antibody binding sites markedly decreased. In contrast, sodium butyrate increased CA125 expression. These findings were clearly detected in only 3 cancer cell lines and a significant effect was not seen in the 5 other cancer cell lines. Interferon-gamma, examined in 3 cell lines, suppressed in a dose-dependent manner in 2 CA125 expression cell lines, but enhanced it in one line. No apparent effects were seen after exposure to tissue necrosis factor or interleukin-2. These results suggest that drugs may regulate the CA125 antigen expression in some, but not all, cancer cells and may affect the biodistribution of radiolabelled MAbs.
  • T SAGA; K ENDO; T AKIYAMA; H SAKAHARA; M KOIZUMI; Y WATANABE; T NAKAI; M HOSONO; T YAMAMOTO; K TOYOSHIMA; J KONISHI
    CANCER RESEARCH AMER ASSOC CANCER RESEARCH 51 (3) 990 - 994 0008-5472 1991/02 [Refereed]
     
    Class-switched monoclonal antibody SV2-61r recognizes the extracellular domain of c-erbB-2 protooncogene products separate from the epidermal growth factor receptor. We studied the potential of SV2-61r for evaluating the amplification of c-erbB-1 protooncogene on cancer cells, which has been reported to have prognostic value in adenocarcinoma patients. Radiolabeled SV2-61r specifically bound to various adenocarcinoma cells in addition to c-erbB-1-transfected NIH-3T3 cells (A4) with the affinity constant of 4.4 X 10(8) M-1. SV2-61r injected i.v. localized well to A4 cells xenografted in nude mice. Tumor uptake and localization index of radioiodinated SV2-61r, probably due to the internalization and dehalogenation of formed antibody-antigen complexes. Biodistribution and specificity of targeting were assessed by comparison among three cells, A4, lung cancer SBC-3 (c=erbB-2 weakly positive) and B-lymphoblastoid Manca cells (c-erbB-2 negative). Tumor:blood ratios, obtained 48 h after injection, were 5.63, 1.45, and 0.68, respectively, indicating the potential of In-111-labeled SV2-61r for evaluating the amplification of c-erbB-2 protooncogene on cancer cells. Because of its close relationship with carcinogenesis and the uniform expression, c-erbB-2 protooncogene products seem to be the optimal target of imaging and therapy of adenocarcinoma patients.
  • C. Kawai; K. Endo; A. Matsumori; T. Nishimura; M. Hosono
    Kakuigaku 28 (11) 1289 - 1300 0022-7854 1991 [Refereed]
     
    In the multicenter clinical study of 111In-Antimyosin Fab (74 MBq, 0.5 mg), human anti-mouse antibody (HAMA) titers have been evaluated in serum from 456 patients using the sensitive enzyme-linked immunosorbent assay. Presence of HAMA was confirmed by the neutralization test or using the size exclusion high performance liquid chromatography (HPLC) analysis in 11 of 393 patients (2.8%). HAMA was still detectable in 2 patients even 40 weeks after injection. None of 7 patients judged as positive for the intradermal test, a patient with vascular pain or 3 patients with fever or flare and itching with fever, developed detectable levels HAMA in their serum. These results suggest that patients may develop HAMA response after infusion of 111In-Antimyosin Fab, but pathogenic role of HAMA in these patients remains to be studied.
  • HOSONO MAKOTO; ENDO KEIGO; NAKAJIMA KOTOKO; NAKAI TOSHIHARU; SAGA TSUNEO; SAKAHARA HARUMI; KONISHI JUNJI; MANABE TADAO; TOBE RYUKICHI
    月刊医学と薬学 25 (1) 117 - 123 0389-3898 1991/01
  • T SAGA; ISHIWATA, I; K ENDO; H SAKAHARA; M KOIZUMI; Y WATANABE; T NAKAI; M HOSONO; H ISHIKAWA; M SAWADA; J KONISHI
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 81 (11) 1141 - 1148 0910-5050 1990/11 [Refereed]
  • 中西雅子; 遠藤啓吾; 佐賀恒夫; 小野山靖人; 細野真; 中井敏晴; 渡辺祐司; 阪原晴海; 小西淳二; 小林久隆; 藤井信吾; 森崇英
    医学と薬学 23 (6) 1287 - 1292 0389-3898 1990/06
  • NAKAI TOSHIHARU; ENDO KEIGO; NAKAJIMA KOTOKO; HATTORI NORIKO; HOSONO MAKOTO; SAGA TSUNEO; WATANABE YUJI; SAKAHARA HARUMI; TOBE RYUKICHI
    核医学 27 (5) 505 - 511 0022-7854 1990/05
  • Y WATANABE; K ENDO; T SAGA; M KOIZUMI; H SAKAHARA; T NAKAI; M HOSONO; ZS YAO; M KUROKI; Y MATSUOKA; J KONISHI
    JAPANESE JOURNAL OF CANCER RESEARCH JAPANESE CANCER ASSOCIATION 81 (3) 266 - 271 0910-5050 1990/03 [Refereed]
  • 渡辺祐司; 遠藤啓吾; 中島言子; 服部典子; 阪原晴海; 佐賀恒夫; 中井敏晴; 細野 真; 姚 正生; 馬場信夫; 大塩学而; 真鍋忠夫; 戸部隆吉
    核医学 26 (12) 1559 - 1565 0022-7854 1989/12
  • Y NAGATA; S KOHNO; T SAGA; K OKAJIMA; M HOSONO; M TAMAKI; T KANATA; A TAKABAYASHI; S MATSUDA
    COMPUTERIZED MEDICAL IMAGING AND GRAPHICS PERGAMON-ELSEVIER SCIENCE LTD 13 (5) 419 - 422 0895-6111 1989/09 [Refereed]
  • K OKAJIMA; S KOHNO; M TAMAKI; M HOSONO; M KAWAMOTO; Y NISHIYAMA; M SUGANO; T MIYAOKA
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY SPRINGER VERLAG 12 (3) 128 - 130 0174-1551 1989/05 [Refereed]
  • Nagata Yasushi; Nakano Yoshihisa; Takahashi Masaji; Abe Mitsuyuki; Saga Tsuneo; Okajima Kaoru; Hosono Makoto; Kohno Shigene
    日本医学放射線学会雑誌 日本医学放射線学会 48 (4) 417 - 422 0048-0428 1988/04
  • Keisuke Satoh; Kazuo Nunoki; Toshikazu Goto; Makoto Hosono; Hiroo Hashimoto; Yoshinori Sato; Norio Taira
    The Japanese Journal of Pharmacology 47 (2) 189 - 195 0021-5198 1988 [Refereed]
     
    The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. MCI-154 in doses of 10–100 μg improved the cardiac function curve and restored it to the control level at 100 μg. At this dose, MCI-154 neither produced an increase in heart rate beyond the control value nor induced arrhythmias. The effects of MCI-154 were not affected by atenolol, a cardioselective β1-blocker. These results indicate that MCI-154 would be of potential use in the treatment of heart failure. © 1988, The Japanese Pharmacological Society. All rights reserved.
  • Makoto Hosono; Norio Taira
    Journal of Cardiovascular Pharmacology 10 (6) 692 - 698 1533-4023 1987 [Refereed]
     
    MCI-154 is a potent nonglycoside and non-sympathomimetic cardiotonic agent with a pyridazinone structure. We assessed its cardiac and coronary vasodilator effects by use of isolated, blood-perfused papillary muscle, sinoatrial (SA) node, and atrioventricular (AV) node preparations of dogs. The drug (I-100 nmol) was injected intraarterially. MCI-154 increased the force of contraction of paced and unpaced papillary muscles but failed to affect the rate of automaticity of the latter. It increased sinus rate and shortened AV conduction time by accelerating AV nodal conduction, but in all doses examined it produced no arrhythmias. In all preparations, it increased blood flow. All the effects were long-lasting (1-2 h). MCI-154, however, was not homogeneously effective on these cardiovascular variables. The drug was nearly equieffective in producing a positive inotropic effect and coronary vasodilatation, but less effective in producing positive chronotropic and dromotropic effects. In having such a cardiovascular profile, MCI-154 most resembles milrinone among new cardiotonic agents, although unlike milrinone, its main mechanism of cardiotonic action is believed to be the sensitization of the contractile proteins to Ca2+. Whatever mechanisms are involved, the revealed cardiovascular profile of MCI-154 justifies its clinical trial in the treatment of heart failure. © 1987 Raven Press, Ltd., New York.
  • Makoto Hosono; Norio Taira
    Journal of Cardiovascular Pharmacology 9 (6) 633 - 640 1533-4023 1987 [Refereed]
     
    We compared the coronary vasodilator and cardiac effects of MCI-176, a novel quinazolinone calcium antagonist, in isolated, blood-perfused sinoatrial (SA) node, atrioventricular (AV) node, and papillary muscle preparations of dogs. The drug was administered intraarterially. In SA node preparations MCI-176 reduced sinus rate and produced atrial standstill in large doses. In AV node preparations MCI-176 prolonged AV conduction time and produced second-or third-degree AV block in large doses only when administered into the artery supplying the AV node, but failed to affect AV conduction when administered into the artery supplying the His-Purkinje-ventricular system. In paced papillary muscle preparations MCI-176 reduced the force of contraction. In spontaneously beating papillary muscles MCI-I76 failed to change the beating rate. MCI-176 increased blood flow in all preparations. The dose that doubled blood flow was slightly larger than the dose that produced a 15% increase in AV conduction time, but about one-third the dose that produced a 15% decrease in sinus rate. The dose estimated to reduce the force of contraction by half was more than 10 times the dose that doubled blood flow. The results indicate that MCI-176 can be classified as a nonvasoselective calcium antagonist but that it differs from others. © 1987 Raven Press, New York.
  • Norio Taira; Kenzo Takahashi; Makoto Hosono
    Journal of Cardiovascular Pharmacology 10 (3) 274 - 279 1533-4023 1987 [Refereed]
     
    The effect of DHP-218, a dihydropyridine phosphonate Ca2+ channel blocker, on atrioventricular (AV) nodal conductivity was compared with its vascular effect in dogs. In isolated, blood-perfused AV node preparations, a long-lasting increase in AV conduction time which culminated in second- or third-degree AV block at large doses occurred when DHP-218 was injected into the AV node artery, but not when injected into the artery that supplies the His-Purkinje-ventricular system. However, with DHP-218, a far longer-lasting increase in blood flow through both arteries occurred, and at smaller doses it occurred with little effect on AV conduction. In anesthetized, open-chest dogs of which heart rate was controlled at 150 beats/min, intravenous DHP-218 produced an initially rather quick and later very slowly developing and long-lasting fall in blood pressure. AV conduction time was prolonged only after the largest dose. The functional refractory period of the AV conduction system was rather shortened in all doses examined except for the largest dose. A marked increase in AV conduction time which culminated in third-degree AV block was seen in one of six dogs, only under conditions in which the heart was deprived of central neural control. These results indicate appreciable selectivity of DHP-218 for vasculature versus the AV node. © 1987 Raven Press. Ltd., New York.
  • K. Fujiwara; K. Endo; Y. Iwasaki; M. Hosono; J. Konishi; K. Torizuka; M. Seki
    Japanese Journal of Clinical Radiology 31 (9) 1045 - 1048 0009-9252 1986 [Refereed]
  • Hiroyuki Satoh; Makoto Hosono; Susumu Satoh
    Prostaglandins 27 (6) 807 - 820 0090-6980 1984 [Refereed]
     
    The effect of angiotensin II (Ang II) on prostaglandin (PG) production in dog renal and femoral vasculature was examined in vivo and in vitro. In pentobarbital anesthetized dogs, the reduction of blood flow induced by intraarterial infusion of Ang II was potentiated by pre-treatment with indomethacin (5 mg/kg) in the renal but not the femoral vasculature. Isolated renal and femoral arterial strips were incubated and the release of PGE2 and PGI2 (as 6-keto-PGF1α) into the medium was measured by radioimmunoassay. Basal PGE2 and PGI2 production by renal and femoral arterial strips was approximately the same. PGI2 production was predominant for both strips. Ang II stimulated PG production in renal but not femoral arteries. In the renal artery, Ang II-induced PG production was inhibited by indomethacin (10-6 M), mepacrine (10-4 M) and saralasin (10-6 M). These results suggest that Ang II stimulates PG production by the renal artery per se and the Ang II receptor is linked to phospholipase A2 in the renal but not the femoral artery. © 1984.

Books etc

  • (Translation) ICRP Publication 138
    Kai M; Niwa O; Ozasa K; Sakai K; Sato T; Yonekura Y; Honma T; Saito N (Supervisor)Nuclear Regulation Authority 2021/03
  • (Translation) ICRP Publication 121
    Kai M; Niwa O; Ozasa K; Sakai K; Sato T; Yonekura Y; Honma T; Saito N (Supervisor)Nuclear Regulation Authority 2021/01
  • Translation: Use of chest imaging in COVID-19, A rapid advice guide, WHO, 11June2020
    Hosono M; Honda N; Hatabu H (Supervisor)QST NIRS 2020/09
  • Hosono M; Mikami Y; Watanabe H; Takenaka M; Koba Y (Joint work)Survey and research on actual conditions of exposure and reduction of exposure in radiation work in the medical field 2020/03
  • Hosono M; Kanda R; Akahane K; Torisu K; Yamamoto K; Sakamoto H; Yamada T; Sakaguchi K; Tochio M; Kato M; Kurosawa T (Joint work)Survey and research on actual conditions of exposure and reduction of exposure in radiation work in the medical field（190701-02） 2020/03
  • Perspectives in Nuclear Medicine Technology (Clinical)
    HOSONO Makoto (ContributorWhat is Theranostics?)Yamashiro Printing Co. Ltd. 2020/03 630 536-538
  • Health and labor science research grant aid research fiscal year 2016-2018 Research on medical radiation protection corresponding to new treatment method general research report
    HOSONO Makoto; YAMAGUCHI Ichiro; TAKAHASHI Takeo; AKAHANE Masaaki (Joint work)2019/03
  • Health and Labor Science Research Grants Subsidy Research 2018 "Research on medical radiation protection corresponding to new treatment methods general research report
    HOSONO Makoto; YAMAGUCHI Ichiro; TAKAHASHI Takeo; AKAHANE Masaaki (Joint work)2019/03
  • Heterogeneity of intratumoral antibody distribution
    HANAOKA Kohei; HOSONO Makoto (Joint work)Springer International Publishing 2018/04 9783319782379 158 99-104
  • Features of ibritumomab as radionuclide therapy. Resistance to ibritumomab in lymphoma
    HOSONO Makoto (Joint workResistance to ibritumomab in lymphoma)Springer International Publishing 2018/04 9783319782386 158 59-66
  • 厚生労働科学研究費補助金研究平成29年度「新たな治療手法に対応する医療放射線防護に関する研究」（H28-医療-一般-014）総括研究報告書
    細野 眞; 山口一郎; 高橋健夫; 赤羽正章 (Joint work)2018/03 1-14
  • 「診療用放射線照射器具における放射線安全確保に関する検討」厚生労働科学研究費補助金研究平成29年度「新たな治療手法に対応する医療放射線防護に関する研究」（H28-医療-一般-014）分担研究報告書
    細野 眞; 池渕秀治; 上田いづみ; 坂口健太; 高橋健夫; 中村吉秀; 花岡宏平; 山田崇裕; 柳田幸子 (Joint work)2018/03 33-53
  • 「甲状腺癌の放射性ヨウ素（131I）内用療法：甲状腺全摘術後の残存甲状腺の破壊（アブレーション）（１）-131I 1,110MBq(30mCi)を超える線量による外来治療における安全管理に関する研究-」厚生労働科学研究費補助金研究平成29年度「新たな治療手法に対応する医療放射線防護に関する研究」（H28-医療-一般-014）分担研究報告書
    細野 眞; 絹谷清剛; 志賀 哲; 阿部光一郎; 池渕秀治; 金谷和子; 柴田敬悟; 中村吉秀; 東俊博; 柳田幸子 (Joint work)2018/03 26-32
  • 「臨床研究におけるMRI室での可搬型PET装置の適正使用に関する検討」厚生労働科学研究費補助金研究平成29年度「新たな治療手法に対応する医療放射線防護に関する研究」（H28-医療-一般-014）分担研究報告書
    細野 眞; 池渕秀治; 大野和子; 清水公治; 中村吉秀; 柳田幸子 (Joint work)2018/03 15-25
  • 厚生労働科学研究費補助金研究平成28年度細野班報告書「イットリウム-90標識抗P-カドヘリン抗体注射液の治験における適正使用に関する 検討（イットリウム-90標識抗P-カドヘリン抗体注射液を用いるRI内用療法の治験 適正使用マニュアル（案）を含む）」
    細野 眞 (Joint work分担研究報告書)2017/03
  • 厚生労働科学研究費補助金研究平成28年度細野班報告書「ヨウ素-131による治療患者に適用した人工透析の安全取扱いに関する検討 （血液浄化療法を必要とする慢性腎不全患者にヨウ素-131ヨウ化ナトリウムカプセル によるRI内用療法を適用する場合に発生する固体状の放射性の感染性汚染物の取扱い マニュアル（案）を含む）」
    細野 眞 (Joint work分担研究報告書)2017/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「放射性医薬品（放射性ルテチウム-177標識ソマトスタチン類似体（177Lu-DOTA-TATE） 注射液）を投与された患者の退出基準について」
    細野 眞 (Joint work分担研究報告書)2017/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「前立腺癌患者に対してヨウ素125密封小線源永久挿入療法の適用後に帰宅した場合の 治療患者以外の第三者に対する放射線安全確保に関する検討」
    細野 眞 (Joint work分担研究報告書)2017/03
  • 厚生労働科学研究費補助金研究平成28年度細野班報告書「新たな治療手法に対応する医療放射線防護に関する研究」
    細野 眞 (Joint work総括研究報告書)2017/03
  • 放射線医科学
    細野 眞 (ContributorPET 放射線による診断と治療の基礎 94-96頁 （189頁）)2016/10
  • 厚生労働科学研究費補助金研究平成26-27年度細野班報告書「医療における放射線防護と関連法令整備に関する研究」
    細野 眞 (Joint work総合研究報告書)2016/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「ヨウ素-131による治療患者に適用した人工透析の安全取扱いに関する検討」
    細野 眞 (Joint work分担研究報告書)2016/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「ルテチウム-177標識ソマトスタチンアナログ（Lu-177-DOTA-TATE）注射液の適正使用に関する検討」
    細野 眞 (Joint work分担研究報告書)2016/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「放射性医薬品（放射性塩化ラジウム（223RaCl2）注射液）を投与された患者の退出基準について」
    細野 眞 (Joint work分担研究報告書)2016/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「医療放射線防護の国際動向」
    細野 眞 (Joint work分担研究報告書)2016/03
  • 厚生労働科学研究費補助金研究平成27年度細野班報告書「医療における放射線防護と関連法令整備に関する研究」
    細野 眞 (Joint work総括研究報告書)2016/03
  • 厚生労働科学研究費補助金研究平成26年度細野班報告書「ヨウ素-131による治療患者に適用した人工透析の安全取扱いに関する検討」
    細野 眞 (Joint work分担研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成26年度細野班報告書「核医学施設における安全キャビネットと排気設備(排気系統)との連結に 関する検討」
    細野 眞 (Joint work分担研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成26年度細野班報告書「IAEA General Safety Requirements Part3の刊行に伴う医療用放射線の 防護に関する対応としての放射性核種の吸入摂取及び経口摂取における 実効線量係数の比較検討」
    細野 眞 (Joint work分担研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成26年度細野班報告書「前立腺癌患者に対してヨウ素125密封小線源永久挿入療法の適用後に 帰宅した場合の治療患者以外の第三者に対する放射線安全確保に関する 検討」
    細野 眞 (Joint work分担研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成26年度細野班報告書「ルテチウム-177-DOTA-TATE 注射液の適正使用に関する検討」
    細野 眞 (Joint work分担研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成25年度細野班報告書「がんの骨転移及び原発性骨腫瘍等の治療に用いられる放射性ラジウム-223 の有効性及び投与された患者の管理区域からの退出などの放射線防護対策 について」
    細野 眞 (Joint work分担研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成26年度細野班報告書「医療における放射線防護と関連法令整備に関する研究」
    細野 眞 (Joint work総括研究報告書)2015/03
  • 厚生労働科学研究費補助金研究平成24-25年度細野班報告書「医療放射線防護に関する研究」
    細野 眞 (Joint work総合研究報告書)2014/03
  • 厚生労働科学研究費補助金研究平成25年度細野班報告書「RI内用療法に関する施設状況調査について」
    細野 眞 (Joint work分担研究報告書)2014/03
  • 厚生労働科学研究費補助金研究平成25年度細野班報告書「核医学診療施設における濃度限度等の評価に関する検討について」
    細野 眞 (Joint work分担研究報告書)2014/03
  • 厚生労働科学研究費補助金研究平成25年度細野班報告書「前立腺癌患者に対してヨウ素125密封小線源永久挿入療法の適用後に帰宅 した場合の治療患者以外の第三者に対する放射線安全確保に関する検討 ―退出後の患者家族の被ばく線量に関する検討（実測による検討）―」
    細野 眞 (Joint work分担研究報告書)2014/03
  • 厚生労働科学研究費補助金研究平成25年度細野班報告書「医療放射線防護の国際動向」
    細野 眞 (Joint work分担研究報告書)2014/03
  • 厚生労働科学研究費補助金研究平成25年度細野班報告書「医療放射線防護に関する研究」
    細野 眞 (Joint work総括研究報告書)2014/03
  • 前立腺癌放射線治療のすべて
    細野 眞 (Contributor転移に対するアイソトープ治療-塩化ストロンチウム-89-(307-317頁、総374頁))2013/10
  • 厚生労働科学研究費補助金研究平成24年度細野班報告書「PET/MRI複合装置の使用に伴う医療安全の確保に関する検討」
    細野 眞 (Joint work分担研究報告書)2013/03
  • 厚生労働科学研究費補助金研究平成24年度細野班報告書「塩化ラジウム（Ra-223）注射液の使用に当たって実施する放射線管理のための遮へい 計算並びに空気中及び排気・排水中の放射能濃度の計算方法について」
    細野 眞 (Joint work分担研究報告書)2013/03
  • 厚生労働科学研究費補助金研究平成24年度細野班報告書「ヨウ素-125シードによる前立腺がん治療における放射線安全確保に関する検討」
    細野 眞 (Joint work分担研究報告書)2013/03
  • 厚生労働科学研究費補助金研究平成24年度細野班報告書「医療放射線防護の国際動向」
    細野 眞 (Joint work分担研究報告書)2013/03
  • 厚生労働科学研究費補助金研究平成24年度細野班報告書「医療放射線防護に関する研究」
    細野 眞 (Joint work総括研究報告書)2013/03
  • 臨床放射線腫瘍学
    細野 眞 (Contributor放射性同位元素内用療法 162-165頁 (522頁))南江堂 2012/12
  • Gamut of FDG-PET
    HOSONO Makoto (Joint workGamut of FDG-PET)JSNM 2012/10
  • Safety and Efficient Use of Radiation in Medicine
    HOSONO Makoto (Joint workComprehensive Report)2012/03
  • 厚生労働科学研究費補助金研究平成22-23年度細野班報告書「医療放射線の安全確保と有効利用に関する研究」総合研究報告書
    細野 眞 (Joint work総合研究報告書)2012/03
  • 厚生労働科学研究費補助金研究平成23年度細野班報告書「PET-CT、PET-MRI及びSPECT-CT検査における放射線の安全確保に関する検討」
    細野 眞 (Joint work分担研究報告書)2012/03
  • 厚生労働科学研究費補助金研究平成23年度細野班報告書「切除不能肝癌の治療に用いられるイットリウム-90樹脂微小球体の有効性と 投与された患者の管理区域からの退出などの放射線防護対策について」
    細野 眞 (Joint work分担研究報告書)2012/03
  • 厚生労働科学研究費補助金研究平成23年度細野班報告書「核医学治療（RI内用療法）における放射線安全の確保に関する検討」
    細野 眞 (Joint work分担研究報告書)2012/03
  • 厚生労働科学研究費補助金研究平成23年度細野班報告書「中長期的に展望する医療放射線の安全規制に関する課題」
    細野 眞 (Joint work分担研究報告書)2012/03
  • 厚生労働科学研究費補助金研究報告書平成22年度細野班報告書「医療放射線の安全確保と有効利用に関する研究」総括研究報告書
    (Joint work)2011/03
  • 厚生労働科学研究費補助金研究平成22年度細野班研究報告書「ホルモン療法抵抗性前立腺癌の治療に用いられる放射性ラジウム-223の有効性および 投与された患者の管理区域からの退出などの放射線防護対策について」
    細野 眞 (Joint work分担研究報告書)2011/03
  • 厚生労働科学研究費補助金研究平成22年度細野班研究報告書「核医学治療（RI 内用療法）における放射線安全の確保に関する検討
    米矢吉宏; 細野 眞 (Joint work分担研究報告書)2011/03
  • 厚生労働科学研究費補助金研究平成22年度細野班分担研究報告書「医療放射線の安全確保と有効利用に関する研究」
    細野 眞; 藤村洋子; 堀越亜希子 (Joint editor中長期的に展望する医療放射線の安全規制に関する課題)2011/03
  • 厚生労働科学研究費補助金研究報告書平成21年度細野班「医療放射線の安全確保に関する研究」総括研究報告書
    2010/03
  • 厚生労働科学研究費補助金研究平成21年度細野班研究報告書「Positron Emission Mammography（陽電子放出乳房撮影装置）の有用性と 使用場所の放射線防護に関する検討」
    井上登美夫; 細野 眞 (Joint work分担研究報告書)2010/03
  • 厚生労働科学研究費補助金研究平成21年度細野班研究報告書「医療機関において想定される「クリアランス制度」の導入に関する検討（試案）」
    日下部きよ子; 細野 眞 (Joint work分担研究報告書)2010/03
  • 厚生労働科学研究費補助金研究平成21年度細野班研究報告書「甲状腺癌の放射性ヨード（131I）内用療法：甲状腺全摘術後の残存甲状腺の破壊 －131I 1,110MBq（30ｍCi）投与・退出における安全管理に関する研究－」
    日下部きよ子; 細野 眞 (Joint work分担研究報告書)2010/03
  • 厚生労働科学研究費補助金研究平成21年度細野班研究報告書「中長期的に展望する医療放射線の安全規制に関する課題」
    細野 眞 (Joint work分担研究報告書)2010/03
  • 厚生労働科学研究費補助金研究平成21年度細野班研究報告書「エックス線診療線量の測定とその全国実施の手法に関する課題」
    宇佐美公男; 細野 眞 (Joint work分担研究報告書)2010/03
  • 厚生労働科学研究費補助金研究平成19-21年度細野班報告書「医療放射線の安全確保に関する研究」総合研究報告書
    細野 眞 (Joint work)2010/03
  • 第3版今日の消化器疾患治療指針
    細野 眞 (ContributorPET 150-153頁)2010/03
  • 厚生労働科学研究費補助金研究報告書平成20年度細野班「医療放射線の安全確保に関する研究」総括研究報告書
    2009/03
  • 厚生労働科学研究費補助金研究報告書平成19年度細野班「医療放射線の安全確保に関する研究」総括研究報告書
    (Joint work)2008/03
  • 核医学診断ガイドライン
    日本核医学会 2008
  • 厚生労働科学研究費補助金研究報告書平成18年度油野班「中長期的に展望する医療放射線の安全規制に関する研究」
    2007
  • 厚生労働科学研究費補助金研究報告書平成17年度油野班「中長期的に展望する医療放射線の安全規制に関する研究」
    2006
  • Comparison of functions of CT, MRI, and PET
    細野 眞 (Joint work)文光堂 2005/10 
    CT,MRI,PETの機能の相互比較を論じた
  • CT,MRI,PETの機能の相互比較 Medical Practice
    文光堂 2005
  • 改訂版医療放射線管理の実践マニュアル
    日本アイソトープ協会 2004
  • Aubert François; Laissy Jean-Pierre; 細野 眞; 細野 真理子 白水社 1998 4560057990

Conference Activities & Talks

  • Hosono M
    BEAR2024 Biological Effects&Application of Radiation  2024/03
  • Hosono M
    International Conference on Integrated Medical Imaging in Cardiovascular Diseases, IAEA.  2022/12  Vienna  IAEA
  • Hosono M
    26th International Association of Pancreatology  2022/07
  • Hosono M
    EANM Multidisciplinary Days  2022/06
  • Hosono M
    International Organization for Medical Physics -IUPESM World Congress 2022  2022/06  Singapore  IOMP
  • Hosono M
    22nd Spring Meeting of Japanese Society of Nuclear Medicine  2022/05
  • Hosono M
    19th PET&Nuclear Medicine Nursing Seminar  2022/04
  • Hosono M
    NET Academy in South Osaka 2nd  2022/02
  • Recent topics on radiation safety management in medicine  [Invited]
    Hosono M
    Sagamihara Functional Imaging seminar  2021/11  web
  • Prospects for nuclear medicine treatment-177Lu-Clinical aspects of DOTATATE-  [Invited]
    Hosono M
    50th Naniwa RI seminar  2021/11
  • Updates in Nuclear Oncology: Learn from PRRT  [Invited]
    Hosono M
    33rd 21 Century Conference  2021/11
  • Development of guidelines and facilities for promoting nuclear medicine therapy  [Invited]
    Hosono M
    JSNM-JASTRO Joint Symposium 34th Annual Meeting of JASTRO  2021/11  Web  日本放射線腫瘍学会
  • Hosono M
    61st Annual Meeting of JSNM  2021/11
  • Giussani A; Mattsson S Nosske D; Hosono M; Andersson M
    Future of Radiological Protection Digital Workshop ICRP  2021/10
  • Uehara T; Doi H; Ishikawa K; Tatsuno S; Wada Y; Oguma Y; Inada M; Nakamatsu K; Hosono M; Nishimura Y
    2021 ASTRO Annual Meeting  2021/10  Chicago&Web  ASTRO
  • How we should enhance the efficacy of targeted radionuclide tumor  [Invited]
    Hosono M
    2nd TRTdose  2021/10
  • Tatsuno S; Doi H; Okada W; noue E; Nakamura K; Sano K; Wada Y; Uehara T; Inada M; Nakamatsu K; Monzen K; Hosono M; Matsumoto K; Tanooka M; Tanaka M; Nishimura Y
    ESTRO 2021  2021/08  Madrid  ESTRO
  • Hosono M
    94th Hokuriku Nuclear Medicine Conference  2021/08
  • Hosono M
    58th Isotope radiation research presentation meeting, Japan Radioisotope Association  2021/07
  • Hosono M
    21st Spring Meeting of Japanese Society of Nuclear Medicine  2021/05
  • Diagnostic Reference Levels (DRLs) 2020  [Invited]
    Hosono M
    80th Meeting of Japan Radiological Society  2021/04
  • Practice of treating prostate cancer bone metastases with radium-223  [Invited]
    Hosono M
    2nd Radionuclide Therapy Seminar, Japanese Society of Radiation Oncology  2021/03
  • Exposure management after revision of the Medical Care Act  [Invited]
    Hosono M
    18th PET / Nuclear Medicine Nursing Study Group Seminar Japan Nuclear Medicine Society Nuclear Medicine Nursing Subcommittee  2021/02
  • Hosono M; Yamanishi H; Kanai K; Hanada K; Ito T
    5th International Symposium, Research Center for Radiation Disaster Medical Science.  2021/02  Web  Research Center for Radiation Disaster Medical Science
  • Hosono M; Mikami Y; Watanabe H; Takenaka M; Koba Y; Kanda R; Akahane K; Torisu K; Yamada T; Sakaguchi K; Sakamoto H; Yamamoto K
    Annual Meeting of Radiological Society of North America 2020  2020/11  Virtual  Radiological Society of North America
     
    Digital Poster. Annual Meeting of Radiological Society of North America 2020. Virtual.
  • Hosono M
    Mongolian National Workshop on Diagnostic Reference Levels sponsored by IAEA  2020/11
  • Hosono M
    Mongolian National Workshop on Diagnostic Reference Levels sponsored by IAEA  2020/11
  • Hosono M
    Mongolian National Workshop on Diagnostic Reference Levels sponsored by IAEA  2020/11
  • Hosono M; Mikami Y; Watanabe H; Takenaka M; Koba Y; Kanda R; Akahane K; Torisu K; Sakamoto H; Yamamoto K
    Annual Congress of European Association of Nuclear Medicine 2020  2020/10 
    OP-423 European Journal of Nuclear Medicine and Molecular Imaging 2020;47 (Suppl 1): S212. DOI: 10.1007/s00259-020-04988-4
  • High Exposure Patients in Nuclear Medicine Imaging  [Invited]
    Hosono M; Yoshida S; Sakaguchi K; Matano K; Yamada K; Nishimura Y; Kudo M
    Technical Meeting on the Justification and Optimization of Protection of Patients Requiring Multiple Imaging Procedures (19-23 October 2020), IAEA  2020/10  Vienna, Web  IAEA
  • Guidelines in Radionuclide Therapy  [Invited]
    Hosono M
    Spring Meeting of Japanese Society of Nuclear Medicine  2020/05
  • Perspectives of Nuclear Medicine Therapy  [Invited]
    Hosono M
    Spring Meeting of Japanese Society of Nuclear Medicine  2020/05
  • Present status and revision works of DRLs  [Invited]
    HOSONO Makoto
    55th Autumn Meeting of Japan Radiological Society  2019/10  Nagoya  TOYAMA Hiroshi
  • Recent updates on radionuclide therapy -focusing on Ra-223-  [Invited]
    HOSONO Makoto
    19th Kinki Radiology Forum  2019/10
  • Basics of radiation therapy  [Invited]
    HOSONO Makoto
    84th Annual Meeting of Eastern Section of Japanese Urological Association  2019/10  Daiba, Tokyo  ASANO Tomohiko
  • 十二指腸球のガストリノーマの診断にソマトスタチン受容体シンチグラフィが有用であった1例  [Not invited]
    田中 寛彬; 川端 和奈; 細野 眞; 金柿 光憲; 岡 祥次郎; 汪 洋; 田中 宏明; 松原 菜穂子; 木村 弘之; 白潟 義晴; 栗本 信
    核医学  2019/10  (一社)日本核医学会
  • Ra-223投与患者の呼気に排泄されるRn-219放射能量の定量  [Not invited]
    大江 一弘; 渡部 直史; 神谷 貴史; 吉村 崇; 細野 眞; 篠原 厚; 畑澤 順
    核医学  2019/10  (一社)日本核医学会
  • Outline of research on radiation protection in medicine for novel therapeutic procedures by grant of MHLW for fiscal years 2016-2018  [Not invited]
    HOSONO Makoto; TAKAHASHI Takeo; YAMAGUCH Ichiro; AKAHANE Masaaki; IKEBUCHI Hideharu; YANAGIDA Sachiko; NAKAMURA Yoshihide
    36th Meeting of Japanese Society of Hyperthermia  2019/09  Kawagoe, Saitama  TAKAHASHI Takeo
  • 新たな治療手法に対応する医療放射線防護に関する研究 2016-2018年度厚生労働科学研究の概要  [Not invited]
    細野 眞; 高橋 健夫; 山口 一郎; 赤羽 正章; 池渕 秀治; 柳田 幸子; 中村 吉秀
    Thermal Medicine  2019/09  (一社)日本ハイパーサーミア学会
  • Trends in safe utilization of medical radiation  [Invited]
    HOSONO Makoto
    37th Meeting of Southern Osaka Imaging Study Consortium  2019/08
  • Optimization of respiratory gated 18F-FDG PET/CT scan protocol for cardiac sarcoidosis  [Not invited]
    Hanaoka K; Watanabe S; Kaida H; Hosono M; Ishii K
    Annual Meeting of Society of Nuclear Medicine Molecular Imaging  2019/06  Anaheim  Society of Nuclear Medicine Molecular Imaging
  • Comparison among 18F-FDG uptake parameters for assessing the prognosis of esophageal squamous cell carcinoma  [Not invited]
    Kaida H; Shiraishi O; Iwama M; Kimura Y; Kitajima K; Hosono M; Yasuda T; Ishii K
    Annual Meeting of Society of Nuclear Medicine Molecular Imaging  2019/06  Anaheim  Society of Nuclear Medicine Molecular Imaging
  • Evaluation of respiratory motion-corrected PET/CT in oncological patients  [Not invited]
    Otani T; Hosono M; Nakamoto Y; Kidera K; Kitaguchi K; Watanabe M; Miyake K
    Annual Meeting of Society of Nuclear Medicine Molecular Imaging  2019/06  Anaheim  Society of Nuclear Medicine Molecular Imaging
  • Examination of actual radiation exposure dose of the patients who performed EUS-guided dranage (EUS-BD/EUS-PD/EUS-CD)  [Not invited]
    Takenaka M; Hayashi S; Nishida T; Hosono M; Yoshikawa T; Ishikawa Rei; Okamoto A; Yamazaki T; Nakai A; Omoto S; Minaga K; Kamata K; Yamao K; Kudo M
    DDW 2019  2019/05  San Diego  DDW 2019
  • Radiation protection standards in novel radionuclide therapy  [Invited]
    HOSONO Makoto
    The 13th Asia Oceania Congress of Nuclear Medicine and Biology  2019/05  Shanghai  Asia Oceania Federation of Nuclear Medicine and Biology
  • Guidelines in radionuclide therapy  [Not invited]
    HOSONO Makoto
    19th Spring Meeting of Japanese Society of Nuclear Medicine  2019/04
  • Perspectives on radionuclide therapy  [Invited]
    HOSONO Makoto
    19th Spring Meeting of Japanese Society of Nuclear Medicine  2019/04
  • ICRP perspectives for individualized radionuclide therapy  [Invited]
    HOSONO Makoto
    Theranostics World Congress 2019 (TWC2019)  2019/03
  • Radiation protection for patients and practitioner in fluoroscopy-guided procedures  [Invited]
    HOSONO Makoto
    9th Meeting of FIGHT-Japan  2019/02
  • Contribution to PET and RNT as Pharmacist  [Invited]
    ASAMI Keita; HOSONO Makoto
    Japanese Society of Hospital Pharmacists  2019/01
  • ICRP C3  [Invited]
    HOSONO Makoto
    Radiation Effect Association  2018/12
  • Management of radiation control in short-lived radionuclides including alpha emitters  [Invited]
    HOSONO Makoto
    Japanese Society of Radiation Safety Management  2018/12
  • Nuclear Medicine in Oncology  [Invited]
    HOSONO Makoto
    62nd Meeting of Fukuoka RI Conference  2018/10  Fukuoka  Fukuoka RI Conference
  • Domestic Situations of Nuclear Medicine Therapy and Future Prospects  [Invited]
    HOSONO Makoto
    56th Annual Meeting of Japanese Society of Clinical Oncology  2018/10  PACIFICO Yokohama  Japanese Society of Clinical Oncology
  • Radionuclide Therapy  [Invited]
    HOSONO Makoto
    31st Annual Meeting of Japanese Society of Radiation Oncology  2018/10  Kyoto  Japanese Society of Radiation Oncology
  • Interpretation and determination of images  [Invited]
    HOSONO Makoto
    36th Safety handling course of radioimmunotherapy using Yttrium-90 labeled anti-CD20 antibody  2018/09
  • Significance and application of diagnostic reference levels in ICRP recommendation (Explanation of Pub.135)  [Invited]
    HOSONO Makoto
    Course held by Radiation Effect Association (ICRP Seminar)  2018/09
  • Medical use and reasonable safety management of radionuclides (including alpha emitting radionuclides)  [Invited]
    HOSONO Makoto
    平成30年度秋期放射線安全管理研修会 放射線障害防止中央協議会  2018/09
  • Radiological Protection for Innovative Targeted Therapy  [Invited]
    HOSONO Makoto
    Annual Meeting of Society of Nuclear Medicine and Molecular Imaging 2018  2018/06  Philadelphia, Pennsylvania, USA  Society of Nuclear Medicine and Molecular Imaging
  • Effectiveness of targeted alpha therapy  [Invited]
    HOSONO Makoto
    14th Workshop on safety handling of Ra-223  2018/05
  • Guidelines in radionuclide therapy  [Invited]
    HOSONO Makoto
    !8th Spring Meeting of JSNM  2018/05
  • From Molecular Imaging to Molecular Radiotherapy  [Invited]
    HOSONO Makoto
    18th Spring Meeting of JSNM  2018/05
  • Perspectives of radionuclide therapy  [Invited]
    HOSONO Makoto
    18th Spring Meeting of JSNM  2018/05
  • HOSONO Makoto
    12th Congress of the World Federation of Nuclear Medicine and Biology  2018/04  Melbourne, Australia  12nd Congress of the World Federation of Nuclear Medicine and Biology
  • HOSONO Makoto
    International Workshop on the Biological Effects on Radiation 2018  2018/03  Osaka University Nakanoshima Center, Osaka
  • Development and clinical application of targeted alpha therapy  [Invited]
    HOSONO Makoto
    Seminar at ARRONAX  2018/01  Nantes-Saint Herblain, France  ARRONAX, Nantes University
  • HOSONO Makoto
    International Conference on Radiation Protection in Medicine: Achieving Change in Practice  2017/12  Vienna  IAEA
  • Efficacy of Targeted Alpha Therapy  [Invited]
    HOSONO Makoto
    第12回（2017年度第4回）塩化ラジウム（Ra-222）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2017/11  Tokyo  Japan Radioisotope Association
  • 後腹膜発生動静脈奇形の一例  [Not invited]
    土居秀平; 松木 充; 細野 眞
    第317回公益社団法人日本医学放射線学会関西地方会  2017/11
  • 皮質病変を認めた非アルコール性ウェルニッケ脳症の一例  [Not invited]
    鈴木絢子; 松木 充; 細野 眞
    第317回公益社団法人日本医学放射線学会関西地方会  2017/11
  • Targeted Alpha Therapy in Japan  [Invited]
    HOSONO Makoto
    Seminar at Salgrenska Hospital, University Göteborg  2017/11  Göteborg, Sweden  Salgrenska Hospital, University Göteborg
  • HOSONO Makoto
    Joint FMU-ICRP Workshop on Radiological Protection in Medicine  2017/10  Fukushima  Fukushima Medical University and ICRP
  • Ra-223の臨床応⽤について  [Invited]
    細野 眞
    第53回日本医学放射線学会秋季臨床大会  2017/09
  • 呼吸同期FDG PET/CTによる放射線治療計画について  [Not invited]
    花岡 宏平; 奥村 雅彦; 西村 泰昌; 門前 一; 渡邊 翔太; 柴田 侑亮; 細野 眞; 石井 一成; 村上 卓道
    核医学  2017/09  (一社)日本核医学会
  • 転移に対するTargeted Alpha Therapyの現状と将来展望  [Not invited]
    細野 眞
    PETサマーセミナー2017in奈良  2017/08
  • Prognostic impact of 18F-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients  [Not invited]
    HOSONO Makoto
    Kaida H, Azuma K, Kawahara A, Sadashima E, Hattori S, Akiba J, Rominger A, Takamori A, Fujimoto K, Hosono M, Ishii K, Murakami T, Ishibashi M  2017/06
  • Clinical evaluation and optimization of Q.Clear; a new PET reconstruction algorithm  [Not invited]
    Otani T; Hosono M; Kanagaki M; Fukumoto G; Onishi Y; Matsubara N; Kimura H
    Annual Meeting of Society of Nuclear Medicine and Molecular Imaging  2017/06
  • Methods of survey and decontamination of radium-223 dichloride for radionuclide therapy in clinical facilities  [Not invited]
    Hosono M; Hohara S; Inagaki M; Sakaguchi K; Yoshida S; Yamanishi H; Wakabayashi G; Matsuda T; Ito T
    10th International Symposium on Targeted Alpha Therapy  2017/05
  • α線内用療法の有効性（臨床応用に関する基礎的事項）  [Invited]
    HOSONO Makoto
    第10回（2017年度第2回）塩化ラジウム（Ra-223）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2017/05
  • ソマトスタチン受容体イメージングからTheranosticsへ  [Invited]
    細野 眞
    第25回徳島核医学研究会・第38回徳島県核医学技術勉強会  2017/05
  • Clinical evaluation and optimization of Q.Clear; a new PET reconstruction algorithm  [Not invited]
    Tomoaki Otani; Makoto Hosono; Mitsunori Kanagaki
    JOURNAL OF NUCLEAR MEDICINE  2017/05  SOC NUCLEAR MEDICINE INC
  • Prognostic impact of F-18-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients.  [Not invited]
    Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Jun Akiba; Axel Rominger; Shinzo Takamori; Kiminori Fujimoto; Makoto Hosono; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
    JOURNAL OF NUCLEAR MEDICINE  2017/05  SOC NUCLEAR MEDICINE INC
  • RI治療の概要 核医学基礎セミナー  [Not invited]
    細野 眞
    第17回日本核医学会春季大会  2017/04
  • RI内用療法におけるガイドライン 核医学指導者コース  [Invited]
    細野 眞
    第17回日本核医学会春季大会  2017/04
  • 核医学診療の医療安全と放射線防護 教育講演（必須講習）  [Invited]
    細野 眞
    第76回日本医学放射線学会総会  2017/04
  • アルファ線核種の臨床利用における法令と指針  [Invited]
    細野 眞
    第73回日本放射線技術学会総会学術大会  2017/04
  • α線内用療法の有効性（臨床応用に関する基礎的事項）  [Invited]
    細野 眞
    第9回（2017年度第1回）塩化ラジウム（Ra-223）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2017/04
  • 去勢抵抗性前立腺がんのα線治療の実際（切れ味）とα線治療の未来  [Invited]
    細野 眞
    第24回核医学技術セミナー  2017/03
  • 4D-CTを用いた呼吸同期撮像法の有用性  [Not invited]
    藤井 康司; 白髭 賢也; 竹中 達明; 細野 眞
    日本放射線技術学会総会学術大会予稿集  2017/03
  • アルファ線核種の臨床利用における法令と指針  [Not invited]
    細野 眞
    日本放射線技術学会総会学術大会予稿集  2017/03
  • PRRTの現状について  [Invited]
    細野 眞
    第4回腫瘍核医学診断治療セミナー  2017/02
  • FDG-PET/CTで集積を認めた異所性甲状腺癌の一例  [Not invited]
    甲斐田 勇人; 石井 一成; 細川 知紗; 仁 誠雲; 細野 眞; 村上 卓道; 花岡 宏平; 乾 浩己
    核医学  2017/02  (一社)日本核医学会
  • 小西達郎; 坂口健太; 細野眞
    核医学症例検討会症例集  2017/02
  • 尾谷知亮; 細野眞; 金柿光憲; 乘本周平; 木村弘之
    核医学症例検討会症例集  2017/02
  • 上顎洞術後変化としての眼窩下管拡大  [Not invited]
    福井 秀行; 柏木 伸夫; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 細川 知紗; 熊野 正士; 鶴崎 正勝; 松木 充; 今岡 いずみ; 石井 一成; 細野 眞; 村上 卓道
    Japanese Journal of Radiology  2017/02
  • PET/CTにおける新しい再構成法Q.Clearの検討  [Not invited]
    尾谷 知亮; 金柿 光憲; 乗本 周平; 木村 弘之; 細野 眞
    Japanese Journal of Radiology  2017/02
  • 前立腺小線源療法後1年以内死亡の3例  [Not invited]
    横川 正樹; 中松 清志; 稲田 正浩; 福田 浩平; 建部 仁志; 石川 一樹; 立花 和泉; 門前 一; 金森 修一; 西村 恭昌; 細野 眞
    Japanese Journal of Radiology  2017/02
  • 医療放射線防護における診断参考レベルの意義  [Invited]
    細野 眞
    日本放射線診療技師会平成28年度第3回被ばく線量適正化講習会  2016/12
  • α線内用療法の有効性（臨床応用に関する基礎的事項）  [Invited]
    細野 眞
    第7回塩化ラジウム（Ra-223）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2016/12
  • 認知症を持つ患者さんと核医学診療  [Invited]
    細野 眞
    核医学看護フォーラム 認知症と医療安全 第56回日本核医学会学術総会  2016/11
  • Theranostics: イメージングと治療の融合  [Invited]
    細野 眞
    合同シンポジウム1 健康長寿社会をめざして-核医学の挑戦- 第56回日本核医学会学術総会  2016/11
  • PET/CTの診断、定量と標準化、放射線安全と規制  [Invited]
    細野 眞
    第4回京滋PETトワイライトカンファレンス  2016/10
  • Survey on radionuclide therapy facilities in Japan with grants by Ministry of Health, Labour, and Welfare  [Not invited]
    Hosono M; Ikebuchi H; Nakamura Y; Nakamura N; Yanagida S; Kitaoka A
    Annual Congress of European Association of Nuclear Medicine  2016/10
  • Estimation of administered fluorodeoxyglucose activity in patients on the basis of dose equivalent rate on head by multiple regression analysis  [Not invited]
    Hosono M; Sakaguchi K; Imamura T; Takahara N; Hayashi M; Hosokawa C; Yamada M; Ishii K
    Annual Congress of European Association of Nuclear Medicine  2016/10
  • Survey and decontamination of radium-223 dichloride for alpha- particle radionuclide therapy in clinical facilities  [Not invited]
    Hosono M; Hohara S; Inagaki M; Yamanishi H; Wakabayashi G; Matsuda T; Sakaguchi K; Hanaoka K; Ito T
    Annual Congress of European Association of Nuclear Medicine  2016/10
  • 認知症患者における線条体アミロイド沈着の検討  [Not invited]
    細川 知紗; 石井 一成; Sauerbeck Julia; Sheiwein Franziska; 甲斐田 勇人; 兵頭 朋子; 山田 穣; 細野 眞; 花岡 宏平; 村上 卓道
    核医学  2016/10  (一社)日本核医学会
  • 前立腺 前立腺がん診療の新技術 骨転移のある日本人の症候性去勢抵抗性前立腺癌患者への塩化ラジウム-223の第II相試験  [Not invited]
    永森 聡; 上村 博司; 和久本 芳彰; 植村 天受; 木村 剛; 横溝 晃; 菊川 浩明; 絹谷 清剛; 細野 眞; 山口 郁; 筒井 弘一; 松永 瑛典; 松原 伸晃
    日本癌治療学会学術集会抄録集  2016/10
  • 診断参考レベル（DRLs）の国内導入  [Invited]
    細野 眞
    第33回南大阪画像診断研究会  2016/09
  • α線内用療法の有効性（臨床応用に関する基礎的事項）  [Invited]
    細野 眞
    2016年度第4回塩化ラジウム（Ra-223）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2016/09
  • ソマトスタチン受容体イメージングと治療への応用  [Invited]
    細野 眞
    第63回関東核医学画像処理研究会  2016/09
  • Pretherapeutic FDG heterogeneity in tumors can predict local control in oropharyngeal cancer patients undergoing intensity-modulated radiation therapy  [Not invited]
    Hanaoka K; Hosono M; Tatebe H; Ishikawa K; Monzen H; Ishii K; Nishimura Y
    Annual Meeting of Society of Nuclear Medicine Molecular Imaging  2016/06
  • Texture analysis for FMISO PET/CT in oncology patients receiving extra-beam radiation therapy  [Not invited]
    Hosono M; Tachibana I; Nishimura Y; Hanaoka K; Sakaguchi K; Ishikawa K; Nakamatsu K; Kanamori S
    Annual Meeting of Society of Nuclear Medicine and Molecular Imaging  2016/06
  • JSNM Education, Accreditation, and Multidisciplinary Team Practice  [Invited]
    HOSONO Makoto
    Annual Meeting of Society of Nuclear Medicine  2016/06
  • α線内用療法の有効性（臨床応用に関する基礎的事項）  [Invited]
    細野 眞
    2016年度第2回塩化ラジウム（Ra-223）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2016/05
  • α核種ターゲット治療の現状と将来展望  [Invited]
    細野 眞
    第53回腫瘍免役核医学研究会  2016/04
  • RI治療の概要 核医学基礎セミナー  [Invited]
    細野 眞
    第16回日本核医学会春季大会  2016/04
  • ガイドライン（検査、センチネル、オムツ、他）核医学指導者コース  [Invited]
    細野 眞
    第16回日本核医学会春季大会  2016/04
  • Dose evaluation and control for Nuclear Medicine 合同シンポジウム 医療被ばくの線量評価と管理  [Invited]
    細野 眞
    第75回日本医学放射線学会総会  2016/04
  • アルファ線放出核種の基礎と国内導入  [Invited]
    細野 眞
    第75回日本医学放射線学会総会  2016/04
  • Dose evaluation and control for Nuclear Medicine. Joint Symposium 2: Dose evaluation and control for medical radiation exposure  [Invited]
    HOSONO Makoto
    Japan Radiology Congress  2016/04
  • α線内用療法の有効性（臨床応用に関する基礎的事項）  [Invited]
    細野 眞
    2016年度第1回塩化ラジウム（Ra-223）注射液を用いたRI内用療法における適正使用に関する安全取扱講習会  2016/04
  • 細野 眞
    JART = 日本診療放射線技師会誌  2016/04  日本診療放射線技師会
  • Clinical evaluation and optimization of a new PET reconstruction algorithm Q.Clear in lung cancer  [Not invited]
    Otani T; Hosono M; Kanagaki M; Fukumoto G; Onishi Y; Matsubara N; Kimura H
    ECR 2017  2016/02
  • 11C-PiB PET陽性認知症の線条体集積の検討  [Not invited]
    細川 知紗; 石井 一成; Sauerbeck Julia; Scheiwein Franziska; 甲斐田 勇人; 山田 穣; 兵頭 朋子; 細野 眞; 花岡 宏平; 村上 卓道
    核医学  2016/02  (一社)日本核医学会
  • 花岡宏平; 細野眞
    核医学(Web)  2016
  • 細川知紗; 石井一成; SAUERBECK Julia; SHEIWEIN Franziska; 甲斐田勇人; 兵頭朋子; 山田穣; 細野眞; 花岡宏平; 村上卓道
    核医学(Web)  2016
  • 放射線に関わる法規制・対策  [Invited]
    細野 眞
    第2回核医学治療国際シンポジウム  2015/12
  • α核種による治療の現状と将来  [Invited]
    HOSONO Makoto
    第132回関西Cancer Therapistの会  2015/12
  • 診断参考レベルの国内導入  [Invited]
    細野 眞
    シンポジウム 診断参考レベル（DRL）を理解する 第31回日本診療放射線技師学術大会  2015/11
  • 塩化ラジウム-223による前立腺癌骨転移の治療  [Invited]
    細野 眞
    第18回癌と骨病変研究会  2015/11
  • 核医学看護の専門性確立に向けて  [Invited]
    細野 眞
    核医学看護フォーラム 第55回日本核医学会学術総会  2015/11
  • Tumor hypoxia detected by 18F-misonidazole (F-MISO) PET/CT as a prediction of initial tumor response of radiation therapy (RT)  [Not invited]
    Tachibana I; Hosono M; Inada M; Fukuda K; Tatebe H; Ishikawa K; Yokokawa M; Nakamatsu K; Kanamori S; Nishimura Y
    ASTRO 2015, 57th annual meeting  2015/10
  • Occupational radiation exposure of nursing staff in PET facility in association with performance status of patients  [Not invited]
    Hosono M; Takahara N; Yakushiji Y; Sakaguchi K; Yamada Y; Hosokawa C; Ishii K
    Annual Congress of European Association of Nuclear Medicine  2015/10
  • Therapy planning and dose prescription in radioiodine-131 therapy for hyperthyroidism using radioiodine-123 SPECT/CT imaging  [Not invited]
    Hanaoka K; Hosono M; Otsuka M; Asai Y; Okumura M; Ishii K; Murakami T
    Annual Congress of European Association of Nuclear Medicine  2015/10
  • Texture analysis for tumor hypoxia visualized by FMISO PET/CT during radiation therapy  [Not invited]
    Hosono M; Tachibana I; Nishimura Y; Hanaoka K; Kanamori S; Nakamatsu K; Ishikawa K; Sakaguchi K
    Annual Congress of European Association of Nuclear Medicine  2015/10
  • Assessment of heart injury induced by radiation therapy for esophageal cancer using FDG-PET/CT  [Not invited]
    Hanaoka k; Hosono M; Inada M; Sakaguchi K; Shimomura K; Tamura M; Matsumoto K; Monzen H; Nishimura Y
    Annual Congress of European Association of Nuclear Medicine  2015/10
  • 核医学における医療安全と放射線防護  [Invited]
    細野 眞
    第51回日本医学放射線学会秋季臨床大会  2015/10
  • こころと体の健康と放射線  [Invited]
    細野 眞
    福島県市町村教育委員会連絡協議会  2015/08
  • α線内用療法の現状と展望  [Invited]
    細野 眞
    第52回アイソトープ・放射線研究会  2015/07
  • 読影・判定について  [Invited]
    細野 眞
    第28回イットリウム-90標識抗CD20抗体を用いた放射免疫療法の安全取扱講習会  2015/07
  • Radiation exposure of nursing staff in PET practices in correlation to performance status of patients  [Not invited]
    Hosono M; Takahara N; Yakushiji Y; Sakaguchi K; Ishii K
    SNMMI 2015 Annual Meeting  2015/06
  • Updates and Prospects of Alpha-emitters in Targeted Radionuclide Therapy  [Invited]
    HOSONO Makoto
    15th International Conference of Radiation Research  2015/05
  • Predictive values of 111In-ibritumomab tiuxetan SPECT/CT and 18F-FDG PET/CT in radioimmunotherapy for B-cell non-Hodgkin's lymphoma  [Not invited]
    Hanaoka K; Hosono M; Ishii K; Sakaguchi K; Tatsumi Y; Nishimura Y
    15th International Conference of Radiation Research  2015/05
  • Tumor hypoxia imaging with 18F-misonidazole (F-MISO) positron emission tomography (PET) during radiation therapy (RT)  [Not invited]
    Tachibana I; Hosono M; Ishikawa K; Nakamatsu K; Matsuura T; Tatebe H; Inada M; Fukuda K; Kanamori S; Nishimura Y
    International Conference of Radiation Research  2015/05
  • ふくしま国際医療科学センターへの期待  [Invited]
    細野 眞
    核医学治療国際シンポジウム 核医学治療の現状と未来  2015/05
  • RI治療の概要 核医学基礎セミナー  [Invited]
    細野 眞
    第14回日本核医学会春季大会  2015/04
  • RI治療の概要 核医学基礎セミナー  [Invited]
    細野 眞
    第15回日本核医学会春季大会  2015/04
  • ガイドライン（検査、センチネル、オムツ、他）核医学指導者コース  [Invited]
    細野 眞
    第15回日本核医学会春季大会  2015/04
  • INADA Masahiro; FUKUDA Kohei; TATEBE Hitoshi; ISHIKAWA Kazuki; TACHIBANA Izumi; YOKOKAWA Masaki; NAKAMATSU Kiyoshi; KANAMORI Shuichi; NISHIMURA Yasumasa; HOSONO Makoto
    日本医学放射線学会総会抄録集  2015/02
  • 川俣町における報告 日常生活における個人線量の活用例 福島復興に向けた取り組みと放射線防護上の課題  [Invited]
    細野 眞
    保物セミナー2014  2014/12
  • Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition  [Not invited]
    Ishii K; Hosokawa C; Hyodo T; Wakabayashi Y; Yamada M; Kozuka T; Hosono M; Murakami T
    Annual Congress of European Association of Nuclear Medicine  2014/10
  • Texture analysis of intratumoral hypoxia on FMISO PET/CT in radiation therapy  [Not invited]
    Hosono M; Tachibana I; Nishimura Y; Hanaoka K; Kanamori S; Nakamatsu K; Ishikawa K
    Annual Congress of European Association of Nuclear Medicine  2014/10
  • Predictive value of heterogeneity of intratumoral In-111-Zevalin and FDG distributions for tumor response in Zevalin therapy  [Not invited]
    Hosono M; Hanaoka K; Ishii K; Sakaguchi K; Yamada M; Komeya Y; Tsuchiya N; Im SW; Tatsumi Y; Matsumura I
    Annual Congress of European Association of Nuclear Medicine  2014/10
  • Measurement and parameters of α-emitting radium-223 for radionuclide therapy in accordance with radiation protection standards  [Not invited]
    Hosono M; Hohara S; Yamanishi H; Inagaki M; Wakabayashi G; Matsuda T; Sakaguchi K; Hanaoka K; Itoh T
    Annual Congress of European Association of Nuclear Medicine  2014/10
  • Heterogeneity of intratumoral hypoxia on FMISO PET/CT in association with local control in radiation therapy  [Not invited]
    Hosono M; Tachibana I; Nishimura Y; Hanaoka K; Kanamori S; Nakamatsu K; Shibata T; Ishikawa K; Tamura M
    ASTRO 2014, 56th annual meeting  2014/09
  • 被ばくってそんなにこわいの？  [Invited]
    細野 眞
    PETサマーセミナー2014in小樽  2014/08
  • 知って貰いたい放射線の光と影  [Invited]
    細野 眞
    大研医器医療教育セミナー  2014/07
  • Comparison between SUV and BP images acquired using 11C-PIB PET: Questionable PIB accumulation in SUV images  [Not invited]
    Hosokawa C; Ishii K; Kimura Y; Sakaguchi K; Hosono M; Murakami T
    SNMMI 2014 Annual Meeting  2014/06
  • Heterogeneity of intratumoral In-111-Zevalin and FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell lymphoma  [Not invited]
    Hosono M; Hanaoka K; Ishii K; Sakaguchi K; Im SW; Tsuchiya N; Yoshihiro K; Tatsumi Y; Matsumura I
    SNMMI 2014 Annual Meeting  2014/06
  • Measurement and radiation control of α-emitting radium-223 in radionuclide therapy for prostate cancer with bone metastases  [Not invited]
    Hosono M; Hohara S; Yamanishi H; Inagaki M; Wakabayashi G; Sakaguchi K; Hanaoka K; Itoh T
    SNMMI 2014 Annual Meeting  2014/06
  • PETによるがん検診  [Not invited]
    細野 眞
    第15回がん診療アップデート  2014/05
  • ガイドライン（検査、センチネル、オムツ、他）核医学指導者コース  [Invited]
    細野 眞
    第14回日本核医学会春季大会  2014/04
  • 新BSSの概要と本邦の取り組み The outline of the new BSS - Are we prepared? –  [Not invited]
    細野 眞
    第70回日本放射線技術学会総会学術大会・第73回日本医学放射線学会総会  2014/04
  • RI内用療法の臨床における最近の動向  [Not invited]
    細野 眞
    放射線医学総合研究所 分子イメージングセンター講演会  2014/02
  • Present status and future of radionuclide therapy  [Invited]
    HOSONO Makoto
    Applied physics meeting  2013/12
  • Therapy planning and dose prescription in radioiodine therapy for hyperthyroidism using SPECT/CT  [Not invited]
    Hosono M; Hanaoka K; Ishii K; Im S; Sakaguchi K; Yagyu Y; Matsukubo Y; Ohno Y; Ikegami H
    Annual Congress of European Association of Nuclear Medicine  2013/10
  • Association among heterogeneity of intratumoral anti-CD20 antibody distribution, glucose metabolism and therapeutic response in radioimmunotherapy for B-cell lymphoma  [Not invited]
    Hosono M; Hanaoka K; Ishii K; Im S; Sakaguchi K; Yagyu Y; Komeya Y; Tsuchiya N; Tatsumi Y; Matsumura I
    Annual Congress of European Association of Nuclear Medicine  2013/10
  • Application of NM imaging to radiation therapy  [Invited]
    HOSONO Makoto
    Tokai nuclear medicine meeting  2013/09
  • Present status and future of radionuclide therapy  [Invited]
    HOSONO Makoto
    Imaging meeting of South Osaka  2013/08
  • 11C-PIB-PET SUV画像の視覚判定と定量評価  [Not invited]
    細川 知紗; 村上 卓道; 石井 一成; 木村 裕一; 兵頭 朋子; 細野 眞; 坂口 健太; 宇佐美 公男
    第46回日本核医学会近畿地方会  2013/07  大阪  第46回日本核医学会近畿地方会
  • PET ans Radiation Safety  [Invited]
    HOSONO Makoto
    PET and nuclear medicine nurse seminar  2013/06
  • Therapy planning and dose prescription in radioiodine therapy for hyperthyroidism using SPECT/CT  [Not invited]
    Therapy planning; dose prescription in; radioiodine therapy for hyperthyroidism using; SPECT/CT
    SNMMI 2013 Annual Meeting  2013/06
  • Heterogeneity of CD20 antigen expression and glucose metabolism in correlation with therapeutic response in radioimmunotherapy for B-cell lymphoma  [Not invited]
    Hosono M; Hanaoka K; Ishii K; Im SW; Sakaguchi K; Yagyu Y; Komeya Y; Tsuchiya N; Tatsumi Y; Matsumura I
    2013/06
  • Guidelines in nuclear medicine  [Invited]
    HOSONO Makoto
    JSNM Spring Meeting  2013/04
  • Review on radionuclide therapy  [Invited]
    HOSONO Makoto
    JSNM Spring Meeting  2013/04
  • Overview of Radiation Protection in Radionuclide Therapy  [Not invited]
    HOSONO Makoto
    international conference on radiation protection in medicine - setting the scene for the next decade  2012/12
  • Radiation Protection in PET/CT  [Invited]
    HOSONO Makoto
    international conference on radiation protection in medicine - setting the scene for the next decade  2012/12
  • 伊丹 祥隆; 清水 信貴; 林 泰司; 永井 康晴; 小林 泰之; 山本 豊; 南 高文; 辻 秀憲; 野澤 昌弘; 吉村 一宏; 石井 徳味; 植村 天受; 米矢 吉宏; 細野 眞; 沖 貴士; 吉岡 伸浩
    泌尿器外科  2012/11  医学図書出版(株)
     
    近畿大学附属病院における前立腺癌骨転移症例に対するSr-89治療の有効性と安全性について検討した。2008年1月から2011年10月までにSr-89を投与した患者は16例であり、評価可能な12例を対象とした。有効例は7例(58.3%)、不変例は4例(33.3%)、悪化例は1例(8.3%)であった。副作用として、Grade2の白血球減少が1例、ヘモグロビン減少が6例、血小板減少が2例認めたが、Grade3以上は認めなかった。有効例ではALP高値例が多く、Sr-89投与後に低下する傾向にあり、不変例・無効例のPSA値はSr-89投与後上昇する傾向にあった。(著者抄録)
  • 腫瘤形成した慢性顎下腺炎のFDG-PET/CT所見  [Not invited]
    村上 卓道; 細川 知紗; 柏木 伸夫; 松久保 祐子; 山田 穣; 任 誠雲; 兵頭 朋子; 高橋 洋人; 栁生 行伸; 岡田 真広; 小塚 健倫; 今岡 いずみ; 鶴﨑 正勝; 松木 充; 足利 竜一朗; 細野 眞; 石井 一成
    第302回日本医学放射線学会関西地方会  2012/11  大阪  第302回日本医学放射線学会関西地方会
  • Three dimensional planning of radioiodine therapy for hyperthyroidism by iodine-123 SPECT/CT  [Not invited]
    Hanaoka K; Hosono M; Kurokawa T; Sakaguchi K; Yoshida S; Inoue R; Ishii K; Murakami T
    Annual Congress of European Association of Nuclear Medicine  2012/10
  • Prediction of tumor response by Indium-111-Zevalin SPECT/CT and FDG-PET/CT in radioimmunotherapy for B-cell non-Hodgkin lymphoma  [Not invited]
    HOSONO Makoto
    Annual Congress of European Association of Nuclear Medicine  2012/10
  • Radiation safety in Nuclear Medicine  [Not invited]
    HOSONO Makoto
    11th Annual General Meeting of Asian Regional Cooperative Council for Nuclear Medicine  2012/10
  • 脳血管性認知症のcilostazol投与前後における脳血流変化の検討  [Not invited]
    花田 一志; 細野 眞; 辻井 農亜; 船津 浩二; 明石 浩幸; 原田 毅; 三川 和歌子; 池田 真優子; 白川 治; 村上 卓道
    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集  2012/10  日本臨床精神神経薬理学会・日本神経精神薬理学会
  • 認知症における脳FDG-PET早期撮像の可能性について  [Not invited]
    兵頭 朋子; 石井 一成; 坂口 健太; 花岡 宏平; 宇佐美 公男; 島元 健次; 山添 譲; 山田 穣; 松木 充; 細野 眞; 村上 卓道
    第52回日本核医学会学術総会  2012/10  札幌  第52回日本核医学会学術総会
  • Infrastructure for Radionuclide Therapy  [Invited]
    HOSONO Makoto
    52nd Annual Meeting of Japanese Society of Nuclear Medicine  2012/10
  • PET and Radiation RIsk Communication  [Invited]
    HOSONO Makoto
    PET Summer Seminar 2012 in Shinshu  2012/09
  • レビー小体型認知症の頭頂側頭連合野の代謝低下はアミロイド沈着によらない  [Not invited]
    石井 一成; 村上 卓道; 兵頭 朋子; 坂口 健太; 花岡 宏平; 宇佐美 公男; 島元 健次; 山添 譲; 山田 穣; 松木 充; 細野 眞
    第45回日本核医学会近畿地方会  2012/07  京都  第45回日本核医学会近畿地方会
  • Chronological Documents on the Fukushima Accident-Nuclear Emergency at the Fukushima Nuclear Reactor Accident in March 2011  [Invited]
    HOSONO Makoto
    Annual Meeting of Society of Nuclear Medicine  2012/06
  • Continuing Education for Certified Doctor "Guidelines"  [Invited]
    HOSONO Makoto
    12th Spring Congress of Japanese Society of Nuclear Medicine  2012/04
  • Seminar for Young Specialists "Radionuclide Therapy"  [Invited]
    HOSONO Makoto
    12th Spring Congress of Japanese Society of Nuclear Medicine  2012/04
  • Indium-111-Zevalin-SPECT/CT and FDG-PET/CT as quantitative evaluation in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma  [Not invited]
    花岡 宏平; 細野 眞; 山添 譲; 村上 卓道
    Annual Congress of the European Association of Nuclear Medicine  2011/10  Birmingham  Annual Congress of the European Association of Nuclear Medicine
  • Measurement of functional thyroid weight using I-123 SPECT/CT as planning for radioiodine therapy  [Not invited]
    Hanaoka K; Hosono M; Shimosegawa E; Hatazawa J
    EANM’11 annual congress of European Society of Nuclear Medicine  2011/10
  • A prospective Clinical Trial on Tumor Hypoxia Imaging with 18F-misonidazole (F-MISO) positron Emission Tomography (PET)  [Not invited]
    Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Tamura M; Koike R; Nishikawa T; Ishikawa K; Hosono M
    53rd annual meeting of ASTRO  2011/10
  • ストロンチウム-89を2回投与した骨転移症例の検討  [Not invited]
    米矢 吉宏; 細野 眞; 土屋 典生; 村上 卓道
    第51回日本核医学会学術総会  2011/10  茨城  第51回日本核医学会学術総会
  • Clinical impact of CT attenuation correction by SPECT/CT in brain perfusion images  [Not invited]
    Ishii K; Hanaoka K; Okada M; Kumano S; Komeya Y; Tsuchiya N; Hosono M; Murakami T
    SNM 2011 Annual Meeting  2011/06
  • I-131アブレーション  [Not invited]
    細野 眞
    第11回日本核医学会春季大会  2011/05
  • 基礎セミナー RI内用療法  [Invited]
    細野 眞
    第11回日本核医学会春季大会2011年  2011/05
  • 専門医教育セミナー ガイドライン  [Invited]
    細野 眞
    第11回日本核医学会春季大会2011年  2011/05
  • The iliac wing sign: The feasibility for diagnosis of bone and/or soft-tissue injury of the pelvis and hips  [Not invited]
    Kakigi T; Hosono M; Shimono T; Hiraoka T; Nishimura K
    ECR 2011  2011/03
  • FDG and F-MISO PET-CT in the treatment planning for radiation therapy.  [Not invited]
    西村 恭昌; 立花 和泉; 大久保 充; 細野 眞
    the First International Conference on Real-time Tumor-tracking Radiation Therapy with 4D Molecular  2011/02  Kyoto  the First International Conference on Real-time Tumor-tracking Radiation Therapy with 4D Molecular
     
    FDG と F-MISO を用いたPET-CT が治療計画に有用であることを報告した。
  • A Prospective Clinical Trial of Tumor Hypoxia Imaging with 18F-misonidazole (F-MISO) Positron Emission Tomography (PET)  [Not invited]
    立花 和泉; 西村 恭昌; 柴田 徹; 金森 修一; 中松 清志; 小池 竜太; 西川 龍之; 石川 一樹; 細野 眞
    American Society for Radiation Oncology 53rd Annual Meeting  2011  Miami Beach, Florida, USA  American Society for Radiation Oncology 53rd Annual Meeting
     
    Purpose:PET with 18F-misonidazole (F-MISO) is a non-invasive method of depicting tumor hypoxia. Result: Mean ± SD of SUVmax of the normal muscles was 1.26 ± 0.17. Based on these data, accumulation of F-MISO above a value of mean + 2SD (1.60 SUV) was regarded as indicating a hypoxic area. Except in one patient with postoperative recurrent uterine body cancer, the remaining five tumors showed a decrease in SUVmax or T/M ratio after approximately 20Gy of fractionated RT. Conclusions: Based on the SUVmax of the normal muscles, accumulation of F-MISO above 1.6 SUV was regarded as indicating a hypoxic area. Decrease in the SUVmax or T/M ratio, suggesting reoxygenation, was observed for most tumors after approximately 20Gy of fractionated RT. SUVmax of F-MISO before or during fractionated RT may predict the clinical outcomes of the tumors.
  • ＲＩ内用治療の現状と将来  [Not invited]
    平成22年度放射線安全管理研修会  2011
  • 機能画像に基づくがん治療-機能画像の臨床応用  [Not invited]
    第13回癌治療増感研究シンポジウム  2011
  • RI標識モノクローナル抗体療法におけるIn-Zevalin, FDGの腫瘍集積と奏功について  [Not invited]
    花岡宏平; 細野 眞; 村上 卓道
    第50回日本核医学会学術総会  2010/11  埼玉  第50回日本核医学会学術総会
  • F-18フルオロミソニダゾールによる腫瘍内低酸素領域の画像化  [Not invited]
    立花 和泉; 西村 恭昌; 柴田 徹; 金森 修一; 小池 竜太; 中松 清志; 石川 一樹; 西川 龍之; 細野 眞
    日本放射線腫瘍学会 第23回学術大会  2010/11  浦安  日本放射線腫瘍学会 第23回学術大会
     
    目的：F-MISOを利用し低酸素状態をPETによって画像化し、腫瘍内低酸素領域と再酸素化現象について検討する。 対象と方法：頭頸部癌、肺癌、食道癌、子宮体癌の合計6例を対象とした。腫瘍長径は28-68mmであった。検査はPET/CT装置を用い、全例治療前にFDG-PETを撮影した。F-MISOは体重1kg当たり約3.7MBq静脈投与し、約3時間後に撮影を行った。F-MISO-PETは、放射線治療前および約20Gy/10回の時期に原則2回行った。腫瘍周辺の正常筋肉へのF-MISOのSUVmaxの値は、95%信頼区間で1.15-1.49であった。これをもとに1.5 SUV以上のF-MISO腫瘍内集積を有意とした。さらに、腫瘍内のF-MISO SUVmaxを筋肉のSUVmaxで割った値(T/M 比)を求めた。 結果：放射線治療前のPETでは、6例全例で腫瘍内に1.5 SUV以上の集積を認めた。F-MISOの分布は、FDGの分布とは異なり腫瘍の一部に局在する傾向を認めた。2回撮影の行えた5例中4例では、照射に伴いT/M 比は低下した。 結語：F-MISO-PETで腫瘍内低酸素領域の画像化が可能である。分割照
  • 機能画像を用いた放射線治療計画の現状と展望  [Not invited]
    西村 恭昌; 立花 和泉; 細野 眞
    第50回日本核医学学術総会  2010/11  大宮  第50回日本核医学学術総会
     
    機能画像を用いた放射線治療計画の現状と展望について述べた。（シンポジスト）
  • Definition of target volumes by PET/CT for radiation therapy planning using moving phantom  [Not invited]
    Hanaoka K; Hosono M; Okubo M; Usami K; Okumura M; Sumita M; Nishimura Y; Murakami T
    EANM'10  2010/10
  • 大久保充; 中松清志; 柴田徹; 金森修一; 西川龍之; 小池竜太; 立花和泉; 奥村雅彦; 西村恭昌; 細野眞
    Japanese Journal of Radiology  2010/07
  • 基礎セミナー 医療放射線被ばくとその防護  [Not invited]
    第10回日本核医学会春季大会  2010
  • 専門医教育セミナー PET/CT  [Not invited]
    第10回日本核医学会春季大会  2010
  • RI内照射療法の併用療法と今後の展望  [Not invited]
    第50回日本核医学会学術総会シンポジウム  2010
  • 放射線治療計画におけるPETデータの活用  [Not invited]
    PETサマーセミナー2010in岡山シンポジウム  2010
  • recovery coefficient (RC) ?SUV補正を用いた食道癌のリンパ節転移の評価  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    第49回日本核医学会学術総会  2009/10  旭川市  第49回日本核医学会学術総会
  • Measurement of regional cerebral blood flow associated with cilostazol tehrapy in vascular dementia.  [Not invited]
    花田 一志; 細野 眞; 村上 卓道
    SNM2009 Annual Meeting  2009/06  Tront  ISM 2009 Annual Meeting
  • Assessment of lymph node metastasis in esophageal cancer with SUV correction based on count recovery on 18F-FDG PET/CT.  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    SNM2009 Annual Meeting  2009/06  Toronto  SNM2009 Annual Meeting
  • Assessment of lymph node metastasis esophageal cancer with SUV correction based on count recovery on 18F-FDG PET/CT
    Yoshihiro Komeya; Makoto Hosono; Norio Tsuchiya; Masahiro Okada; Yuki Kagawa; Kohei Hanaoka; Kimio Usami; Yuzuru Yamazoe; Takamichi Murakami; Tetsuo Itoh
    JOURNAL OF NUCLEAR MEDICINE  2009/05  SOC NUCLEAR MEDICINE INC
  • 経過中に間質肉腫への悪性転化が疑われた前立腺cystic epithelial-stromal tumorの一例  [Not invited]
    荒木 哲朗; 桑原 雅知; 今岡 いずみ; 下野 太郎; 柳生 行伸; 熊野 正士; 香川 祐毅; 清水 利栄; 葉 輝明; 任 誠雲; 坪山 尚寛; 小塚 健倫; 岡田 真広; 米矢 吉宏; 足利 竜一朗; 細野 眞; 村上 卓道; 清水 信貴; 植村 天受; 前西 修; 木村 雅友; 筑後 孝章
    Japanese Journal of Radiology  2009/04  (公社)日本医学放射線学会
  • Reconery Cofficient(RC)-SUV部分容積効果補正による肺癌リンパ節転移の評価  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    第68回日本医学放射線学会学術集会  2009/04  横浜  第68回日本医学放射線学会学術集会
  • 医療における放射線防護の国際動向  [Not invited]
    細野 眞; 米矢 吉宏; 村上 卓道
    第68回日本医学放射線学会学術集会  2009/04  横浜  第68回日本医学放射線学会学術集会
  • 彭 英峰; 安田 卓司; 中森 康浩; 岩間 密; 武本 智樹; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均; 岡田 真広; 細野 眞
    日本外科学会雑誌  2009/02
  • 基礎セミナー 医療放射線被ばくとその防護  [Not invited]
    第9回日本核医学会春季大会  2009
  • 専門医教育セミナー PET/CT  [Not invited]
    第9回日本核医学会春季大会  2009
  • Malignant Lymphoma Post Therapy:Usefulness and Pitfalls Using FDG-PET/CT Compared to CT, MRI, and Ga Sxintigraphy.  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道
    94rd Radiological Society of North America  2008/12  Chicago  94rd Radiological Society of North America
  • CT appearance of post OOKP procedure.  [Not invited]
    桑原 雅知; 下野 太郎; 勝部 敬; 藤谷 哲也; 松久保 祐子; 足利 竜一朗; 福田 昌彦; 濱田 傑; 細野 眞; 村上 卓道
    第44回日本医学放射線学会秋季臨床大会  2008/10  福島  第44回日本医学放射線学会秋季臨床大会
  • Adrenal masses: The additional value of FDG-PET/CT for cancer patients  [Not invited]
    Okada M; Hosono M; Shimono T; Kumano S; Usami K; Yamazoe Y; Komeya Y; Kagawa Y; Tsuchiya N; Murakami T
    55th annual meeting of Society of Nuclear Medicine  2008/06  New Orleans  55th annual meeting of Society of Nuclear Medicine
  • Utility of partial volume correction based on count recovery on FDG PET/CT in lymph node metastasis of lung cancer  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    55th annual meeting of Society of Nuclear Medicine  2008/06  New Orleans  55th annual meeting of Society of Nuclear Medicine
  • New insight into the pathogenesis of malignant lymphoma by integrated FDG-PET/CT  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道
    55th annual meeting of Society of Nuclear Medicine  2008/06  New Orleans  55th annual meeting of Society of Nuclear Medicine
  • Evaluation of lymph node metastases in esophageal cancer with SUV correction for partial volume effect on FDG PET/CT  [Not invited]
    香川祐毅; 細野 眞; 村上 卓道
    55th annual meeting of Society of Nuclear Medicine  2008/06  New Orleans  55th annual meeting of Society of Nuclear Medicine
  • MDCT,MRI画像診断によるHCCのRFA治療効果判定  [Not invited]
    岡田 真広; 熊野 正士; 桑原 雅知; 柳生 行伸; 勝部 敬; 荒木 哲朗; 香川 祐毅; 葉 輝明; 安藤 理奈; 松久保 祐子; 任 誠雲; 米矢 吉宏; 小塚 健倫; 土屋 典生; 下野 太郎; 今岡 いずみ; 足利 竜一朗; 細野 眞; 工藤 正俊; 村上 卓道
    第44回日本肝癌研究会  2008/05  大阪  第44回日本肝癌研究会
  • 原発性肺癌のリンパ節転移の評価におけるrecovery coefficient(RC)－SUV補正の有用性  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    第67回日本医学放射線学学術集会  2008/04  横浜  第67回日本医学放射線学学術集会
  • 食道癌リンパ節のPET/CTによる評価  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道
    第108回核医学症例検討会  2008/02  大阪  第108回核医学症例検討会
  • 悪性リンパ腫のPET-CT診断に関するReview  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道
    第27回日本画像医学会  2008/02  東京  第27回日本画像医学会
  • 基礎セミナー 医療放射線被ばくとその防護  [Not invited]
    第８回日本核医学会春季大会  2008
  • 専門医教育セミナー PET/CT  [Not invited]
    第８回日本核医学会春季大会  2008
  • Reduction in radiation exposure to patients and personnel in PET/CT examinations  [Not invited]
    55th annual meeting of Society of Nuclear Medicine  2008
  • 新しい放射線規制 医療現場の対応  [Not invited]
    保物セミナー2008 保健物理学会セッション  2008
  • Recovery Coefficoent(RC)に基づくSUV補正用いた肺癌リンパ節転移の評価  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    第47回日本核医学会学術総会  2007/11  仙台  第47回日本核医学会学術総会
  • Static and moving phantom studies for treatment planning in an integrated PET/CT system.  [Not invited]
    西村 恭昌; 大久保 充; 中松 清志; 奥村 雅彦; 柴田 徹; 金森 修一; 小池 竜太; 廣井 啓二; 西川 龍之; 細野 眞
    the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology  2007/10  Los Angels, CA, USA  the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology
     
    PET-CTシミュレーションのためのファントム実験の結果を報告した。
  • Effect of attenuation correction on wall motion quantification in Tl-201 ECG-gated myocardial SPECT. Assessment of lymph node metastasis in lung cancer with SUV correction based on count recovery in FDG PET/CT.  [Not invited]
    細野 眞; 米矢 吉宏; 村上 卓道
    54th Annual Meeting of Society of Nuclear Medicine.  2007/06  Washington DC.  54th Annual Meeting of Society of Nuclear Medicine.
  • Assessment of lymph node metastasis in lung cancer with SUV correction based on count recovery in FDG PET/CT.  [Not invited]
    米矢 吉宏; 細野 眞; 村上 卓道
    54th Annual Meeting of Society of Nuclear Medicine.  2007/06  Washington DC.  54th Annual Meeting of Society of Nuclear Medicine.
  • 悪性リンパ腫のPET-CT診断  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道; 竹内亮; 佐藤範英
    第66回日本医学放射線学会学術集会  2007/04  横浜  第66回日本医学放射線学会学術集会
  • 核医学におけるイメージングと治療の現在  [Not invited]
    日本放射線影響学会第50回大会シンポジウム  2007
  • 新しいRI内用療法を有効かつ安全に行うための要点  [Not invited]
    第47回日本核医学会学術総会シンポジウム  2007
  • Abdominal calcifications: Pictorial review of liver, spleen, gallbladder, kidney, peritoneum, and vascular structure lesions  [Not invited]
    Im S; Okada M; Yoh T; Tsuchiya N; Hosono M; Murakami T
    92nd Scientific Assembly and Annual Meeting RSNA  2006/11
  • MR imaging, CT, and PET in patients with cancer of peritoneum and abdominal wall  [Not invited]
    Komeya Y; Okada M; Hosono M; Takeuchi R; Matsumura K; Murakami T
    92nd Scientific Assembly and Annual Meeting RSNA  2006/11
  • Biliary obstruction: Value of imaging for choledocholithiasis, pancreas, and bile duct cancer  [Not invited]
    Okada M; Im S; Yagyu Y; Shimono T; Murakami T; Hosono M
    92nd Scientific Assembly and Annual Meeting RSNA  2006/11
  • Hepatocellular carcinoma, cholangiocarcinoma, and liver metastasis by multimodality imaging: MSCT, US, MRI, and PET  [Not invited]
    Okada M; Yagyu Y; Murakami T; Numata K; Takeuchi R; Hosono M
    92nd Scientific Assembly and Annual Meeting RSNA  2006/11
  • 卵巣腫瘤との鑑別が困難であった限局性腹膜偽粘液腫の一例  [Not invited]
    清水利栄; 今岡 いずみ; 下野 太郎; 桑原 雅知; 小塚 健倫; 葉輝明; 坪山 尚寛; 柳生行伸; 熊野 正士; 足利 竜一朗; 村上 卓道; 米矢 吉宏; 土屋 典生; 岡田 真広; 細野 眞
    日本医学放射線学会関西地方会  2006/11  日本医学放射線学会関西地方会
  • PET first : Malignant Lymphoma.  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道; 竹内亮; 佐藤範英
    92nd Radiological Society of North America.  2006/11  Chicago.  92nd Radiological Society of North America.
  • Pulmonary hyalinizing granulomaが強く疑われMalignant mesotheliomaを合併した一例：FDG－PET/CTによる良悪性の検討  [Not invited]
    岡田 真広; 細野 眞; 村上 卓道; 松村要
    第4２回日本医学放射線学会秋季臨床大会  2006/10  福岡  第4２回日本医学放射線学会秋季臨床大会
  • Early cancer diagnosis in healthy population, an epidemiological dilemma  [Not invited]
    Takeuchi R; Sengoku T; Okada M; Hosono M; Ohta H; Matsumura K
    Annual Congress of EANM 2006  2006/10
  • 泌尿器科領域におけるFDG-PETの有用性  [Not invited]
    田中 基幹; 清水 信貴; 森 康範; 南 高文; 林 泰司; 辻 秀憲; 松本 成史; 能勢 和宏; 野澤 昌弘; 石井 徳味; 細野 眞; 植村 天受
    日本癌治療学会誌  2006/09  (一社)日本癌治療学会
  • Comparison of adrenal cortical scintigraphy, CT and chemical-shift MRI for differential diagnosis of adrenal cortical functioning adenoma  [Not invited]
    Yoh T; Hosono M; Tsuchiya N; Komeya Y; Hanada K; Im SW; Ashikaga R; Shimono T; Yagyu Y; Hiroi K
    53rd annual meeting of Society of Nuclear Medicine  2006/06
  • Difference of brain surface images between with and without attenuation correction for application to 3D-SSP technique  [Not invited]
    Hanada K; Hosono M; Hitomi Y; Yagyu Y; Komeya Y; Funatsu K; Takahashi E; Kudo T; Hitomi K; Nishimura Y
    53rd annual meeting of Society of Nuclear Medicine  2006/06
  • Quantitative assessment of wall motion and thickening on TL-201 stress myocardial gated SPECT for detecting ischemia  [Not invited]
    Komeya Y; Hosono M; Yoh T; Tsuchiya N; Hanada K; Ashikaga R; Yagyu Y; Koike R; Hiroi K; Kudo K
    53rd annual meeting of Society of Nuclear Medicine  2006/06
  • Quantification of left ventricular systolic and diastolic function using TL-201 gated SPECT and derivative analysis for detecting ischemia  [Not invited]
    Komeya Y; Hosono M; Yoh T; Tsuchiya N; Hanada K; Im SW; Ashikaga R; Yagyu Y; Okada M; Shimono T
    53rd annual meeting of Society of Nuclear Medicine  2006/06
  • Statistical image analysis of regional cerebral blood flow in patients of mild cognitive impairment and relation of MMSE subgroups  [Not invited]
    Hanada K; Hosono M; Hitomi Y; Yagyu Y; Komeya Y; Kitahata D; Ohga Y; Kudo T; Hitomi K; Nishimura Y
    53rd annual meeting of Society of Nuclear Medicine  2006/06
  • 大動脈解離後に発症した下腸間膜動脈領域の虚血性腸炎  [Not invited]
    任 誠雲; 下野 太郎; 清水 利栄; 葉 輝明; 米矢 吉宏; 坪山 尚寛; 桑原 雅知; 土屋 典生; 岡田 真広; 小塚 健倫; 今岡 いずみ; 足利 竜一朗; 細野 眞; 井上 剛裕; 梅原 泰; 土手 健作; 村上 卓道
    第283回日本医学放射線学会関西地方会  2006/06  大阪  第283回日本医学放射線学会関西地方会
     
    症例は73歳男性で、主訴は下痢。大動脈解離(DebakeyI型)術後1週間より発症。CTで解離の及んでいた下腸間膜動脈の閉塞を認め、虚血性腸炎と考えた。解離術後に発生する腸管虚血は稀な合併症で、上腸間膜動脈閉塞が原因となることが多く、下腸間膜動脈が原因となることは極めて稀（本邦１９８５～０３年の間で３例）である。虚血性腸炎発症時期は術後数週からという報告が多い。本症例でも術後1週間から発症しており、虚血性腸炎は解離術後から発症までにはタイムラグがあることを知っておくことは重要である。
  • A case of granular cell carcinoma of the kidney  [Not invited]
    栁生 行伸; 下野 太郎; 岡田 真広; 任 誠雲; 葉 輝明; 米矢 吉宏; 堀川 重樹; 植村 天受; 筑後 孝章; 細野 眞; 村上 卓道
    第20回腹部放射線研究会  2006/05  東京  第20回腹部放射線研究会
     
    腹部CTにて左腎腫瘍を指摘されて当院泌尿器科受診。腹部CTでは均一で骨格筋と同程度のCT値であり、内部に小さな石灰化がみられた。脂肪成分は指摘できず。造影CT早期相では均一によく造影されて、後期相では周囲の腎よりも低吸収であったがtime density curve 上は漸増性を示していた。MRI T2強調画像では骨格筋と同程度の低信号であり、chemical shift imageでは微少脂肪成分は指摘できず、in phase, opposed phaseとも腫瘤は腎実質よりも高信号を示していた。Dynamic studyではCT同様均一に造影されている。T2強調画像で腫瘍そのものが低信号を示しており、被膜の同定は不可能であった。脂肪成分が少ない血管筋脂肪腫との鑑別に苦慮したが、clear cell carcinoma以外の悪性腫瘍の可能性も考え、左腎摘出術を施行。Gerota筋膜表面の血管は強く怒張し、易出血性であった。左腎上極の癒着も著しかった。割面は灰白色で均一であった。組織診断はgranurlar cell carcinomaであった。
  • Management of acute reactions to contrast media in kinki univ. medical hospital  [Not invited]
    土屋 典生; 下野 太郎; 細野 眞; 足利 竜一朗; 岡田 真広; 米矢 吉宏; 栁生 行伸; 任 誠雲; 柴田 徹; 西村 恭昌
    第６５回日本医学放射線学会総会  2006/04  横浜  第６５回日本医学放射線学会総会
     
    造影ＣＴにおけるショック、過敏症はアナフィラキシー様反応と認識され、治療、予防のためエピネフリン（商品名：ボスミン）投与が必須となっている。 副作用発現時のボスミン投与時期の明確な報告はなく、中等症以上の症例では症状発現後遅くとも１分以内の投与が推奨されている。また、気道確保等の救命措置が遅れがちなＣＴ室ではより早期段階での投与が望まれる。 以上の観点から、ボスミンの投与開始時点を検討した結果、副作用軽症例のうち、 発赤を伴った場合はアナフィラキシー様反応に特有（アナフィラキシー様症状時、８４％発現）と考え、これが認められた時点でエピネフリン筋注を開始する事とした。
  • Management of acute reactions to contrast media in kinki univ. medical hospital  [Not invited]
    土屋 典生; 下野 太郎; 細野 眞
    第６５回日本医学放射線学会総会  2006/04  横浜  第６５回日本医学放射線学会総会
     
    造影ＣＴにおけるショック、過敏症はアナフィラキシー様反応と認識され、治療、予防のためエピネフリン（商品名：ボスミン）投与が必須となっている。 副作用発現時のボスミン投与時期の明確な報告はなく、中等症以上の症例では症状発現後遅くとも１分以内の投与が推奨されている。また、気道確保等の救命措置が遅れがちなＣＴ室ではより早期段階での投与が望まれる。 以上の観点から、ボスミンの投与開始時点を検討した結果、副作用軽症例のうち、 発赤を伴った場合はアナフィラキシー様反応に特有（アナフィラキシー様症状時、８４％発現）と考え、これが認められた時点でエピネフリン筋注を開始する事とした。
  • Management of acute reactions to contrast media in kinki univ. medical hospital  [Not invited]
    土屋 典生; 下野 太郎; 足利 竜一朗; 岡田 真広; 米矢 吉宏; 任 誠雲; 細野 眞; 栁生 行伸; 西村 恭昌; 廣井 啓二
    第２８１回日本医学放射線学会関西地方会  2005/10  大阪  第２８１回日本医学放射線学会関西地方会
     
    造影ＣＴにおけるショック、過敏症はアナフィラキシー様反応と認識され、治療、予防のためエピネフリン（商品名：ボスミン）投与が必須となっている。 副作用発現時のボスミン投与時期の明確な報告はなく、中等症以上の症例では症状発現後遅くとも１分以内の投与が推奨されている。また、気道確保等の救命措置が遅れがちなＣＴ室ではより早期段階での投与が望まれる。 以上の観点から、ボスミンの投与開始時点を検討した結果、副作用軽症例のうち、 発赤を伴った場合はアナフィラキシー様反応に特有（アナフィラキシー様症状時、８４％発現）と考え、これが認められた時点でエピネフリン筋注を開始する事とした。
  • Correlation of regional cerebral blood flow and MMSE subgroups in patients of mild cognitive impairment  [Not invited]
    Hanada K; Hosono M; Hitomi Y; Yagyu Y; Kirime E; Komeya Y; Koike R; Kitahata D; Kudo T; Hitomi K; Nishimura Y
    52nd annual meeting of Society of Nuclear Medicine  2005/06  トロント  Society of Nuclear Medicine 52nd Annual Meeting
  • Wall motion and thickening measurement on Tl-201 stress myocardial gated SPECT for detecting ischemia  [Not invited]
    Komeya Y; Hosono M; Kudo T; Koike R; Hiroi K; Yagyu Y; Hanada K; Nishimura Y
    52nd annual meeting of Society of Nuclear Medicine  2005/06
  • Assessment of left ventricular systolic and diastolic function using Tl-201 gated SPECT for detectiong ischemia  [Not invited]
    Komeya Y; Hosono M; Kudo T; Koike R; Hiroi K; Yagyu Y; Nin Seiun; Hanada K; Nishimura Y
    52nd annual meeting of Society of Nuclear Medicine  2005/06
  • MMSE下位グループの得点と局所脳血流変化の相関性の検討  [Not invited]
    花田 一志; 人見 一彦; 人見 佳枝; 切目 栄司; 北畑 大輔; 細野 眞; 柳生 行伸; 小池 竜太; 西村 恭昌; 米矢 吉宏
    第6回関西アルツハイマー病治療SPECT研究会  2005/06  大阪  第6回関西アルツハイマー病治療SPECT研究会
  • 統合失調症における妄想の有無による脳血流パターンの差異  [Not invited]
    花田 一志; 人見 一彦; 切目 栄司; 柴 育太郎; 細野 眞; 柳生 行伸; 中松 清志; 小池 竜太; 米矢 吉宏; 西村 恭昌
    第64回日本医学放射線学会  2005/04  横浜  第64回日本医学放射線学会
  • Quantification of attenuation correction in Tl-201 myocardial SPECT  [Not invited]
    細野 眞; 米矢 吉宏; 任 誠雲; 廣井 啓二; 西村 恭昌; 工藤崇; 横山裕; 横塚弘一
    日本医学放射線学会  2005/04  横浜  日本医学放射線学会
  • 長谷川式簡易知能評価スケール下位項目得点と局所脳血流変化の相関性の検討  [Not invited]
    花田 一志; 人見 一彦; 細野 眞; 下野 太郎; 小池 竜太; 米矢 吉宏; 任 誠雲; 土屋 典生; 葉 輝明; 西村 恭昌; 工藤 崇
    第45回日本核医学会総会  2005  東京  第45回日本核医学会総会
  • Diagnostic effectiveness of Alzheiwer disease by 3D-SRT  [Not invited]
    花田一志; 人見 一彦; 人見一彦; 細野 眞; 下野 太郎; 中松 清志; 小池 竜太; 米矢吉宏; 任誠雲; 西村 恭昌; 工藤 崇
    第44回日本核医学会総会  2004/11  京都  第44回日本核医学会総会
     
    3D-SRT(3-demensional stereotaxic ROI template)はSPMの標準化機能を利用し、あらかじめ決められた関心領域の局所脳血流を解析するソフトである。3D-SRTを用いてAlzheimer病の診断の制度、有効性を判別分析を用いて検討した。今回の結果では的中率は100％、誤判別率は5.39％との結果になり、臨床において診断に有用なツールであると思われた。
  • タリウム-201心筋QGSにおける壁運動と壁厚の定量的評価  [Not invited]
    米矢 吉宏; 細野 眞; 任 誠雲; 栁生 行伸; 廣井 啓二; 中松 清志; 小池 竜太; 西村 恭昌; 花田 一志; 工藤 崇
    第33回断層映像研究会  2004/10  大阪  第33回断層映像研究会
     
    （目的）Tl-201心筋SPECTにおいて、QGS上の壁運動と壁厚の定量し、正常例における標準値を求めた。さらに、冠動脈造影にて冠動脈病変が確認された虚血性心疾患（IHD）患者のQGS壁運動と壁厚を求め、虚血心筋の診断における有用性について検討した。 （方法）対象は、心エコー、心電図、臨床経過によって、IHDを否定された10例を正常群（64±8歳）とした。IHD例は、冠動脈造影所見によってLAD群4例、RCA群8例、LCX群4例と群分けした。負荷・Tl-201投与直後（早期像）および3時間後（後期像）に、2検出器型ガンマカメラにより、180度収集、R-R間隔8分割により撮像した。 （結果）正常群の壁運動は、早期像と後期像の間で、心尖部、中隔、後下壁に有意差があった。正常群の壁厚は、早期像と後期像の間で、心尖部、中隔、後下壁、側壁に有意差があった。正常群とIHD群において、（後期像中隔壁運動を除く）いずれの領域にも壁運動と壁厚に有意差を認めた。また、正常群の標準値をもと
  • Tl-201心電図同期心筋SPECTの壁運動と壁厚の標準値に関する検討  [Not invited]
    米矢 吉宏; 細野 眞; 任 誠雲; 栁生 行伸; 小池 竜太; 廣井 啓二; 中松 清志; 西村 恭昌; 花田 一志; 工藤 崇
    第37回日本核医学会近畿地方会  2004/07  京都  第37回日本核医学会近畿地方会
     
    （目的）Tl-201心電図同期心筋SPECTにおいて、QGS上の壁運動と壁厚の定量し、正常例における標準値を求めた。さらに、冠動脈造影にて冠動脈病変が確認された虚血性心疾患（IHD）患者のQGS壁運動と壁厚を求め、虚血心筋の診断における有用性について検討した。（方法）対象は、Tl-201心筋SPECTを施行したが、心エコー、心電図、臨床経過によって、IHDを否定された10例を正常群（年齢64±8歳）とした。IHD例は、冠動脈造影所見によってLAD群4例、RCA群8例、LCX群4例と群分けした。負荷・Tl-201投与直後（早期像）および3時間後（後期像）に、2検出器型ガンマカメラにより、180度収集、R-R間隔8分割により撮像した。（結果）正常群の壁運動は、早期像と後期像の間で、心尖部（p=.0009）、中隔（p=.0018）、後下壁 （p=.0025）に有意差があった。正常群の壁厚は、早期像と後期像の間で、心尖部（p=.0001）、中隔（p=.0014）、後下壁（p=.0406）、側壁（p=.0356）に有意差があった。正常群とIHD群において、（
  • A trial to make a normal database of 99mTc-HMPAO SPECT in Kinki University Hospital  [Not invited]
    花田一志; 人見 一彦; 切目栄司; 大賀征夫; 田村善史; 人見一彦; 細野 眞; 足利 竜一朗; 栁生 行伸; 西村 恭昌
    第56回近畿大学医学会学術講演会  2004/07  大阪  第56回近畿大学医学会学術講演会
     
    脳血流SPECT検査において、統計学的画像解析はその詳細な血流低下領域を描出するために必要な手法となっている。3D-SSPは統計学的画像解析の一つであるが、解析の過程でNormal Databaseが必要になり、より詳細な検討のためには厳密には検査機器ごとのDatabaseを作成する必要がある。当院で使用している機器であるADAC社製FORTEにおいて99mTc-HMPAO SPECTのNorma Database作成を試みた。
  • Different regional cerebral blood flow patterns in chronic schizophrenia with and without delusion  [Not invited]
    花田 一志; 細野 眞; 栁生 行伸; 人見 佳枝; 中松 清志; 米矢 吉宏; 小池 竜太; 柴 育太郎; 人見 一彦; 西村 恭昌
    SNM  2004/06  SNM
  • Wall motion quantification on Tl-201 gated SPECT for detecting ischemia  [Not invited]
    細野 眞; 米矢 吉宏; 小池 竜太; 栁生 行伸; 中松 清志; 任 誠雲; 花田 一志; 西村 恭昌; Kudo T
    SNM  2004/06  SNM
  • Regional CBF change and detection of vasospasm in subarachnoid hemorrhage  [Not invited]
    細野 眞; Machida K; Matsui T Honda; N; Takahashi T; Osada H Ohtawa; N; Asano T
    SNM  2004/06  SNM
  • Disease severity and diagnostic performance of nuclear medicine physicians are not related in brain perfusion SPECT inpection for Alzheimer's disease  [Not invited]
    Honda N; 細野 眞; Machida K; Matsumoto T; Matsuda; H; Imabayashi E; Hashimoto J; Inoue; Y; Koizumi K Kosuda; S Momose T Mori; Y; Oshima M
    2004/06  SNM
  • Investigation of a diagnosis of Alzheimer disease by VOI classic  [Not invited]
    花田一志; 人見 一彦; 切目栄司; 辻井農亜; 人見一彦; 細野 眞; 栁生 行伸; 中松 清志; 小池 竜太; 米矢 吉宏; 西村 恭昌
    第５回関西アルツハイマー病治療SPECT研究会  2004/06  大阪  第５回関西アルツハイマー病治療SPECT研究会
     
    Alzheimer型痴呆の画像診断は、SPMや3D-SSPなどの統計学的画像解析により大きく変化し、早期の血流低下も診断可能となってきた。しかし、これらの方法では血流量の低下を視覚的に判断するもので、数値による比較は動脈血採血など煩雑な手技や、独自のデータベースの構築を必要とする場合が多く、実施が難しい面がある。VOI classicはTalairach atlasのグリッドを用いて脳の領域を設定し、その領域に含まれるピクセル数により領域毎の平均値を算出するソフトウェアである。各領域の血流量を比較的変化の少ない小脳と比較することにより、簡便にAlzheimer型痴呆の診断が可能であるかどうかをVOI Classicを用いて検討した。
  • タリウム心電図同期心筋SPECTの壁運動の標準値に関する検討  [Not invited]
    米矢 吉宏; 細野 眞; 栁生 行伸; 井上 正昭; 粟井 和夫; 中松 清志; 西村 恭昌; 小池 竜太; 工藤 崇
    第63回日本医学放射線学会総会  2004/04  横浜  第63回日本医学放射線学会総会
     
    （目的）テクネシウム製剤を用いたQGS負荷心筋シンチは、虚血心筋のviability評価の有用性が確立されている。今回、タリウム201を用いたQGS壁運動が虚血心筋の評価に有用であることを示すため、QGS壁運動を定量的、三次元的に評価し、虚血性心疾患群の冠動脈別比較、検討を行った。（方法）対象は当院でタリウム負荷心筋シンチを施行した患者で、心エコー、心電図、臨床経過で虚血性心疾患が否定された10例を正常群とした。虚血性心疾患例は、冠動脈造影検査で有意な狭窄を認めた患者をLAD群4例、LCX群8例、RCA群4例に分類した。負荷・タリウム投与直後（早期像）、および3時間後（後期像）とし撮像した。QGS（Quantitative Gated SPECT）プログラムのBull’s eye 表示画像から心尖部、前壁、中隔、後下壁、側壁の5区域を設定し、区域ごとの壁運動量の平均値をそれぞれの区域の壁運動量とした。（結果）正常群の壁運動は、早期像と後期像の間で、心尖部、中隔、後下壁に壁運動の有意差が
  • Utility of 3D-SRT in a diagnosis of Alzheimer disease  [Not invited]
    花田 一志; 人見 一彦; 切目栄司; 辻井農亜; 人見一彦; 細野 眞; 栁生 行伸; 中松 清志; 小池 竜太; 米矢 吉宏; 西村 恭昌
    第63回日本医学放射線学会  2004/04  東京  第63回日本医学放射線学会
     
    Alzheimer型痴呆の画像診断は統計学的画像解析により大きく変化し、早期の血流低下も診断が可能となってきた。3D-SRT(Three-demensional stereotaxic ROI template)は、SPMの標準化機能を利用し、あらかじめ決められた関心領域の局所脳血流を自動的に解析できるが、これらの関心領域についてAlzheimer群、正常群の2群間で比較を行った。
  • Alzheimer型痴呆の診断における3D-SRTの有用性  [Not invited]
    花田 一志; 細野 眞; 柳生 行伸; 中松 清志; 小池 竜太; 米矢 吉宏; 西村 恭昌; 切目 栄司; 辻井 農亜; 人見 一彦
    日本医学放射線学会雑誌  2004/02  (公社)日本医学放射線学会
  • Regional cerebral blood flow in assessment of major depression and Alzheimer's disease in early elderly.  [Not invited]
    花田 一志; 人見 一彦; 人見 佳枝; 切目 栄司; 柴 育太郎; 細野 眞; 柳生 行伸; 中松 清志; 小池 竜太; 西村 恭昌
    Society of Nuclear Medicine 51nd Annual Meeting  2004  フラディルフィア  Society of Nuclear Medicine 51nd Annual Meeting
  • Different regional cerebral blood flow patterns in chronic schizophrenia with and without delusion.  [Not invited]
    花田 一志; 人見 一彦; 人見 佳枝; 辻井 農亜; 田村 善史; 細野 眞; 柳生 行伸; 中松 清志; 小池 竜太; 西村 恭昌
    Society of Nuclear Medicine 51nd Annual Meeting  2004  フラディルフィア  Society of Nuclear Medicine 51nd Annual Meeting
  • Tl-201心筋血流QGS壁運動量と三次元壁運動画像の検討  [Not invited]
    米矢 吉宏; 細野 眞; 栁生 行伸; 井上 正昭; 粟井 和夫; 小池 竜太; 中松 清志; 西村 恭昌; 花田 一志; 工藤 崇
    第9回三次元CT・MRI研究会  2004/01  大阪  第9回三次元CT・MRI研究会
     
    目的：Tl-201心筋血流QGS上の壁運動の定量値について、正常例における標準値を求め、冠動脈造影にて冠動脈病変の確認された虚血性心疾患（IHD）患者と比較した。方法：対象は、Tl-201心筋SPECTを施行したが、心エコー、心電図、臨床経過によって、IHDを否定された10例を正常群（年齢64±8歳）と見なした。IHD例は、冠動脈造影所見によってLAD群4例、LCX群8例、RCA群4例と群分けした。負荷・Tl-201投与直後（早期像）および3時間後（後期像）に、2検出器型ガンマカメラにより、180度収集、R-R間隔8分割により撮像した。結果：正常群の壁運動（mm）は、心尖部、前壁、中隔、後下壁、側壁それぞれ、早期像にて、9.8±1.2、9.3±1.7、6.7±1.6、8.5±1.9、9.8±1.6、後期像にて8.2±1.8、8.4±1.3、4.9±1.9、6.8±1.5、9.7±2.1であった。早期像と後期像の間に、心尖部（p=.0009）、中隔（p=.0018）、後下壁（p=.0025）で壁運動の有意差があった。また、正常群、LAD群、LCX群、RCA群において、早期像、後期像とも、いずれの領
  • 幻覚妄想状態時の脳血流変化に対する検討  [Not invited]
    花田 一志; 細野 眞; 中松 清志; 小池 竜太; 米矢 吉宏; 杉本 美和; 東 睦広; 辻井 農亜
    核医学  2003/11  (一社)日本核医学会
  • Three-dimensional stereotacitc surface projection of brain perfusion SPET enhances diagnosis of Alzheimer’s disease  [Not invited]
    Honda N; 細野 眞; Machida K; Hosono; M; Matsumoto T; Matsuda; H; Momose; T; Oshima M Koizumi; K Hashimoto; Mori Y
    2003/08
  • 膝関節と足関節に発症した軟部血管腫の1例  [Not invited]
    米矢 吉宏; 下野 太郎; 井上 正昭; 細野 眞; 西村 恭昌
    第274回日本医学放射線学会関西地方会  2003/06  大阪  第274回日本医学放射線学会関西地方会
     
    症例は25歳、女性。主訴：右膝・右足関節の腫脹と違和感。膝関節と足関節に単純X-Pで軟部腫瘤と静脈石を認め、MRIでは、T1強調で低信号、T2強調で著明な高信号の腫瘤の内部に線状の低信号を認めた。T2＊強調ではヘモジデリンを示唆する低信号は認めず。画像上、静脈石が存在し、ヘモジデリンの沈着を認めないことから、膝関節と足関節の2関節に発症した滑膜血管腫との診断し、足関節の腫瘤摘出が施行された。滑膜血管腫は1関節に単独で発症するのが一般的であるが、2関節に発症したものは我々が検討した限りでは本例のみであった。同側の多関節に発症したことから、単なる滑膜血管腫というよりは、Klippel-Trenaunay-Weber症候群の不全型の可能性が考えられた。
  • Diagnostic performance of brain perfusion SPECT for Alzheimer's disease: comparison between visual interpretation and three-dimensional sterotactic surface display  [Not invited]
    Honda N; 細野 眞; Machida K; Matsumoto T; Matsuda H; Imabayashi E
    SNM  2003/06  New Orleans  SNM
  • Evaluation of regional CBF in subarachnoid hemorrhage using 99mTc-ECD  [Not invited]
    細野 眞; Machida K; Matsui T Honda; N; Takahashi T; Kashimda A Murata; O Osada H Ohtawa; N; Asano T
    SNM  2003/06  New Orleans  SNM
  • Isothiocyanato-dioxo-carboxymethyl-tetraazacyclotridecane as a new chelate to label antibody with technetium-99m  [Not invited]
    Mishra AK; 細野 眞; Chuttani K Mishra; P Sharma RK; Chatal JF
    SNM  2003/06  New Orleans  SNM
  • 201Tl SPECT and CT fusion in thoracic malignancy  [Not invited]
    Honda N; 細野 眞; Machida K; Kashimada A; Takahashi T; Osada H; Watanabe W Murata; O; Okada T
    SNM  2003/06  New Orleans  SNM
  • Global cerebral blood flow changes measured by brain perfusion SPECT immediately after whole brain irradiation  [Not invited]
    Ohtawa N; 細野 眞; Machida K Honda; Takahashi T; Kashimada; A Osada H; Watanabe W Murata; O; Okada T Nishimura; K Ohno; H; Yamano T
    ECNM  2003/06  Amsterdam  ECNM
  • Cerebral blood flow measurements by Tc-99m ECD and phase contrast MR  [Not invited]
    細野 眞; Machida K Honda; Takahashi T; Kashimada A; Murata O Osada; H Ohmichi M; Ohtawa N
    ECNM  2002/09  Vienna  ECNM
  • Brain perfusion SPET in Alzheimer’s disease has equivalent diagnostic power as MRI  [Not invited]
    Machida K; 細野 眞; Honda N; Matsuda; H; Matsumoto; T; Oshima M; Kashimada A; Takahashi T; Osada H
    ECNM  2002/09  Vienna  ECNM
  • Multiple marker image histogram analyses optimized for diagnostic performance: demonstration for SPECT lung V/Q  [Not invited]
    Thie JA; 細野 眞; Machida K Honda; N; Dei S
    SNM  2002/06  Los Angeles  SNM
  • Detection of esophageal cancer and prediction of response to chemoradiotherapy  [Not invited]
    Ohmichi M; 細野 眞; Machida K Honda; Takahashi T; Kashimada A Osada; K Ochiai K Ohtawa; N Hondo; M Usui; N; Okada T Nishimura; K Ohno H
    SNM  2002/06  Los Angeles  SNM
  • Quantitative measurement of regional pulmonary blood flow in normal volunteers  [Not invited]
    Usui Y; 細野 眞; Machida K Honda; N Osada; K; Takahashi T; Kashimada A; Watanabe W Murata; O Ohmichi M; Okada T; Takahashi M
    SNM  2002/06  Los Angeles  SNM
  • Quantitative measurement of regional pulmonary blood flow in normal volunteers.  [Not invited]
    Y Usui; K Machida; N Honda; M Hosono; H Osada; T Takahashi; A Kashimada; W Watanabe; O Murata; M Omichi; T Okada; M Takahashi
    JOURNAL OF NUCLEAR MEDICINE  2002/05  SOC NUCLEAR MEDICINE INC
  • 幻覚妄想状態時の脳血流変化に対する検討  [Not invited]
    花田 一志; 東 睦広; 細野 眞; 中松 清志; 小池 竜太; 米矢 吉宏; 柳生 行伸; 杉本 美和; 辻井 農亜
    第36回日本核医学会近畿地方会  2002  大阪  第36回日本核医学会近畿地方会
  • Comparison of cine phase contrast MR and 99mTc-ECD for quantification of cerebral blood flow  [Not invited]
    細野 眞; Machida K; Honda N; Takahashi T; Kashimada; A Osada H
    RSNA  2001/11  Chicago  RSNA
  • Regional cerebral blood flow quantification SPECT in aneurysmal subarachnoid hemorrhage  [Not invited]
    細野 眞; Machida K; Matsui T Honda; N; Takahashi T Asano
    RSNA  2001/11  Chicago  RSNA
  • Accuracy of left ventricular ejection fraction determined by pFAST, PC-based software different from Germano’s method, for quantitative EKG-gated myocardial perfusion SPECT (QGS)  [Not invited]
    Nishimura K; 細野 眞; Machida K Honda; N; Kashimada A; Takahashi T
    RSNA  2001/11  Chicago  RSNA
  • Diagnostic performance of nuclear medicine physicians interpreting brain perfusion SPECT in Alzheimer’s disease and other dementias  [Not invited]
    Honda N; 細野 眞; Machida K; Matsumoto T; Matsuda; H; Oshima M
    RSNA  2001/11  Chicago  RSNA
  • Regional CBF quantification in aneurysmal subarachnoid hemorrhage  [Not invited]
    Hosono M; Machida K; Matsui T; Honda N; Takahashi T; Kashimada A; Shimizu Y; Osada H; Dei S; Ohmichi M; Asano T
    ECNM  2001/08  Napoli  ECNM
  • Value of cerebral blood flow spet in dementia compared with magnetic resonance imaging  [Not invited]
    Machida K; Honda N; Hosono M; Shimizu Y; Kosuda S; Matsuda H; Ohshima M; Momose T; Koizumi K; Matsumoto H; Hashimoto J
    Congress 2001 of European Association of Nuclear Medicine  2001/08
  • Detection of changes in regional CBF in subarachnoid hemorrhage using 99mTc-ECD  [Not invited]
    Hosono M; Machida K; Matsui T; Honda N; Takahashi T; Kashimada K; Shimizu Y; Osada H; Dei S; Ohmichi M; Ootawa N; Okada T; Nishimura K; Asano, T
    48th annual meeting of Society of Nuclear Medicine  2001/06
  • Fractal analysis for ventilation/perfusion ratio map in differentiating lung diseases  [Not invited]
    Dei S; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Shimizu Y; Osada H; Ohmichi M; Ohtawa N; Takahashi M; Tanaka A; Thie JA
    48th annual meeting of Society of Nuclear Medicine  2001/06
  • Relationship between 99mTc-GSA scintigraphy and portal circulation in patients with hepatocellular carcinoma complicated by liver cirrhosis  [Not invited]
    Osada H; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Shimizu Y; Watanabe W; Ohmichi M
    48th annual meeting of Society of Nuclear Medicine  2001/06
  • Creation of quantitative regional pulmonary blood flow map by concurrent use of MR angiograpy and perfusion SPECT  [Not invited]
    Honda N; Machida K; Osada H; Hosono M; Takahashi T; Kamano T; Kashimada A; Shimizu Y; Watanabe W; Dei S; Oomichi M; Usui Y; Hondo M; Okada T; Nishimura K; Ootawa N; Tanaka A; Takahashi M
    48th annual meeting of Society of Nuclear Medicine  2001/06
  • Inexpensive tool for quantification of left ventricular ejection fraction from gated-myocardial perfusion SPET  [Not invited]
    Machida K; Honda N; Hosono M; Shimizu Y; Nishimura K
    Congress 2000 of European Association of Nuclear Medicine  2000/09
  • Changes of blood flow measured with Tc-99m ethyl cysteinate dimer in detection of vasospasm  [Not invited]
    Hosono M; Machida K; Matsui T; Honda N; Takahashi T; Kashimada A; Shimizu Y; Dei S; Ohmichi M; Asano T
    Congress 2000 of European Association of Nuclear Medicine  2000/09
  • Quantification of cerebral blood flow with 99mTc ethyl cysteinate dimer for detecting vasospasm in aneurysmal subarachnoid hemorrhage  [Not invited]
    Hosono M; Machida K; Matsui T; Honda N; Takahashi T; Kashimada A; Shimizu Y; Osada H; Dei S; Toyoda H; Ohmichi M; Asano T
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Interobsever variation in differential diagnosis of dementia by cerebral blood flow SPECT  [Not invited]
    Honda N; Machida K; Matsuda H; Ohshima M; Momose T; Matsumoto T; Hosono M
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Myocardial wall thickening idex on 99mTc tetrofosmin gated SPECT for quantitative evaluation of regional wall motion  [Not invited]
    himizu Y; Machida K; Honda N; Hosono M; Takahashi T; Osada H; Toyoda H; Ohmichi M; Kato T; Maruyama Y; Tanaka S; Yoshimoto N
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • 99mTc-Pyrophosphate SPECT is more sensitive for functional recovery after acute myocardial infarction than rest/redistribution 201Tl SPECT  [Not invited]
    Shimizu Y; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Osada H; Toyoda H; Watanabe W; Dei S; Ohmichi M; Ootawa N
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Quantitative gated SPECT with 99mTc tetrofosmin is more accurate than echocardiography in determining left ventricular ejection fraction  [Not invited]
    Nishimura K; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Shimizu Y; Osada H; Toyoda H; Watanabe W; Dei S; Ohmichi M
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Detection of intrapulmonary shunting in liver cirrhosis by quantitative 99mTc MAA scintigraphy  [Not invited]
    Hosono M; Machida K; Honda N; Takahashi T; Kashimada A; Shimizu Y; Osada H; Dei S; Toyoda H; Ohmichi M; Ochiai K; Hondo M
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Quantification of regional lung perfusion using 99mTc-MAA SPECT and cine phase contrast MR angiography  [Not invited]
    Osada H; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Shimizu Y; Watanabe W; Ohmichi M
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Ventilation/perfusion ratio maps with 99mTc-technegas and 99mTc-MAA in lung diseases  [Not invited]
    Dei S; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Shimizu Y; Osada H; Toyoda H; Watanabe W; Ohmichi M; Ootawa N
    47th annual meeting of Society of Nuclear Medicine  2000/06
  • Quantitative evaluation of regional wall motion by a wall thickening index of gated Tc-99m-tetrofosmin myocardial perfusion tomography  [Not invited]
    Shimizu Y; Machida K; Honda N; Hosono M; Takahashi T; Takahashi T; Kamano T; Kashimada A; Osada H; Watanabe W; Dei S; Oomichi M
    46th annual meeting of Society of Nuclear Medicine  1999/06
  • Quantification of regional pulmonary arterial blood flow using Tc-99m-MAA SPECT and cine phase contrast MR angiography  [Not invited]
    Osada H; Machida K; Honda N; Takahashi T; Hosono M; Takahashi T; Kashimada A; Shimizu Y
    46th annual meeting of Society of Nuclear Medicine  1999/06
  • Ventilation SPECI is superior to CT ventilation map by non-radioactive xenon inhalation  [Not invited]
    Honda N; Machida K; Hosono M; Takahashi T; Takahashi T; Kamano T; Kashimada K; Osada H; Shimizu Y; Watanabe W; Dei S; Oomichi M
    46th annual meeting of Society of Nuclear Medicine  1999/06
  • mCBF quantification and SPECT for detecting vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH) using Tc-99m ethyl cysteinate dimer (ECD)  [Not invited]
    Hosono M; Machida K; Honda N; Takahashi T; Takahashi T; Kashimada A; Osada H; Shimizu Y; Dei S; Toyoda T; Matsui T; Asano T
    46th annual meeting of Society of Nuclear Medicine  1999/06
  • Quantitative monitoring of cerebral blood flow (CBF) in patients with aneurysmal subarachnoid hemorrhage (SAH) with Tc-99m ethyl cysteinate dimer (ECD)  [Not invited]
    Hosono M; Machida K; Honda N; Takahashi T; Takahashi T; Matsui T
    84th scientific assembly and annual meeting of RSNA  1998/11
  • Localization of small-cell lung cancer xenograft by two-step method with bispecific antibody and bivalent hapten  [Not invited]
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Faivre-Chauvet A; Machida K; Gautherot E; Barbet J; Chatal JF
    Joint Congress of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology  1998/08
  • Detection of vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH) by non-invasive cerebral blood flow quantification  [Not invited]
    Hosono M; Machida K; Honda N; Takahashi T; Takahashi T; Dei S; Shimizu Y; Kamano T; Kashimada A; Osada H; Matsui T; Asano T
    Joint Congress of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology  1998/08
  • Assessment of regional wall motion by gated myocardial perfusion tomography with 99mTc-tetrofosmin  [Not invited]
    Machida K; Honda N; Takahashi T; Hosono M; Takahashi T; Kamano T; Kashimada A; Osada H; Shimizu Y; Iwase T; Toyoda H; Ogawa K; Watanabe W; Dei S; Ohmichi M; Ohiai K; Takishima T
    Joint Congress of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology  1998/08
  • Diagnostic abilities of high resolution CT, dynamic CT, and Tl-201 SPECT for evaluation of pulmonary masses  [Not invited]
    Kashimada A; Machida K; Honda N; Hosono M; Takahashi T; Takahashi T; Kamano T; Shimizu Y; Osada H; Iwase S; Toyoda H; Ogawa K; Watanabe W; Ohmichi M; Dei S; Ochiai T
    45th annual meeting of Society of Nuclear Medicine  1998/06
  • Utility of thallium-201 SPECT in determining site of image-guide biopsy for patients with thoracic tumor  [Not invited]
    Ogawa K; Machida K; Honda N; Takahashi T; Hosono M; Kamano T; Kashimada A; Shimizu Y; Osada H; Iwase S; Toyoda H; Watanabe W; Ohmichi M; Dei S; Ochiai T
    45th annual meeting of Society of Nuclear Medicine  1998/06
  • Flow patterns of ascending aorta in aortic regurgitation analysed by velocity-encoding MR imaging  [Not invited]
    Honda N; Machida K; Takahashi T; Kamano T; Hosono M; Kashimada A
    83rd scientific assembly and annual meeting of RSNA  1997/11
  • Spiral CT of stapes: spectrum of findings in normal and abnormal ears  [Not invited]
    Osada H; Machida K; Honda N; Takahashi T; Hosono M; Kamano T
    83rd scientific assembly and annual meeting of RSNA  1997/11
  • Transient hypersecretion of catecholamines associated with exacerbation of symptoms after I-131 MIBG therapy in patients  [Not invited]
    Sakahara H; Saga T; Yao Z; Nakamoto Y; Sato N; Hosono M; Endo K; Konishi J
    44th annual meeting of Society of Nuclear Medicine  1997/06
  • Simultaneous dual-isotope Tc-99m-tetrofosmin and Tl-201 SPECT in evaluation of primary lung cancer  [Not invited]
    Hosono M; Machida K; Honda N; Takahashi T; Kamano T; Kashimada A
    82nd scientific assembly and annual meeting of RSNA  1996/12
  • Portal flow measurement with velocity-encoding MR imaging in diffuse liver diseases  [Not invited]
    Honda N; Machida K; Osada H; Takahashi T; Hosono M; Kamano T
    82nd scientific assembly and annual meeting of RSNA  1996/12
  • Two-step targeting of medullary thyroid cancer by bivalent hapten and bispecific antibody in mice  [Not invited]
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thedrez P; Barbet J; Gautherot E; Machida K; Chatal JF
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Evaluation of three-head gamma camera SPECT images in 6 institutes  [Not invited]
    Hosono M; Machida K; Honda N; Matsumoto T; Togawa T; Yui N; Murata H; Maruno H; Hatano O; Uno K; Ohta M; Oyamada H; Kubo K; Ishii K; Nishimaki H; Horiike S; Matsunaga K; Mori Y; Iinuma T
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Targeting of small-cell lung cancer xenografts by Re-188-labeled monoclonal antibodies  [Not invited]
    Hosono MN; Hosono M; Mishra AK; Faivre-Chauvet A; Barbet J; Gautherot E; Knapp FF; Yamada R; Chatal JF
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Cinematic display of ECG-gated Tc-99m-tetrofosmin myocardial perfusion SPECT  [Not invited]
    Shimizu Y; Machida K; Honda N; Hosono M; Takahashi T; Kashimada A; Osada H; Iwase T; Toyoda H; Ogawa K; Watanabe W; Dei S
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Whole body scan by 3-head SPECT system: comparison of 3-projection Tc-99m-MDP bone scan with conventional 2-projection scan  [Not invited]
    Honda N; Machida K; Hosono M; Shimizu Y; Toyoda H; Sakurai K; Takahashi T; Kamano T; Kashimada A; Osada H; Iwase T; Watanabe W; Ogawa K; Dei S
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Evaluation of I-123 iomazenil SPECT for cerebrovascular disease:comparison with brain perfusion SPECT and brain MRI  [Not invited]
    Kashimada A; Machida K; Honda N; Hosono M; Takahashi T; Kamano T; Shimizu Y; Osada H; Iwase T; Toyoda H; Ogawa K; Watanabe W
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Preliminary study of measurement of regional pulmonary flow using MRI and Tc-99m-MAA lung perfusion scintigraphy  [Not invited]
    Osada H; Machida K; Honda N; Mamiya T; Takahashi T; Hosono M; Kamano T; Kashimada A; Shimizu Y; Iwase T; Toyoda H
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Value of Tl-201 and I-123-BMIPP dual energy cardiac SPECT in patients with chronic renal failure on hemodialysis  [Not invited]
    Toyoda H; Machida K; Honda N; Hosono M; Takahashi T; Kamano T; Shimizu Y; Osada H; Iwase T; Toyoda H; Ogawa K; Watanabe W; S Dei; Kasahara N
    The 6th Asia and Oceania Congress of Nuclear Medicine and Biology  1996/09
  • Radioimmunodetection of medullary thyroid cancer by bivalent hapten and bispecific antibody in mice  [Not invited]
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thedrez P; Barbet J; Gautherot E; Machida K; Chatal JF
    Congress 1996 of European Association of Nuclear Medicine  1996/09
  • Localization of small-cell lung cancer xenografts by Re-188-labeled monoclonal antibodies  [Not invited]
    Hosono MN; Hosono M; Mishra AK; Faivre-Chauvet A; Barbet J; Gautherot E; Knapp FF; Yamada R; Machida K; Chatal JF
    Congress 1996 of European Association of Nuclear Medicine  1996/09
  • BMIPP and MIBG SPET finding in myotonic dystrophy  [Not invited]
    Honda N; Machida K; Hosono M; Mamiya T; Takahashi T; Kamano T; Kashimada A; Osaka H; Shimizu Y; Iwase T; Yoyoda H; Kinoshita S
    Congress 1996 of European Association of Nuclear Medicine  1996/09
  • Preliminary study of measurement of focal pulmonary flow using MRI and 99mTc-MAA lung perfusion scintigraphy  [Not invited]
    Osada H; Machida K; Honda N; Mamiya T; Takahashi T; Hosono M; Kamano T; Kashimada A; Shimizu Y; Iwase T; Toyoda H
    43rd annual meeting of Society of Nuclear Medicine  1996/06
  • Targeting of small-cell lung cancer by octreotide labeled with I-125, In-111, and Re-188 in a mouse model  [Not invited]
    Hosono M; Hosono MN; Haberberger T; Zamora PO; Guhlke S; Bender H; Knapp FF Jr; Biersack HJ
    Congress 1995 of European Association of Nuclear Medicine  1995/08
  • Imaging of small-cell lung cancer xenografts with I-125, In-111 and Re-188 octreotides  [Not invited]
    Hosono M; Hosono MN; Haberberger T; Zamora PO; Guhlke S; Bender H; Knapp FF Jr; Biersack HJ
    42nd annual meeting of Society of Nuclear Medicine  1995/06
  • Immunoscintigraphy of ovarian cancer using a monoclonal antibody to CA125  [Not invited]
    akahara H; Hosono M; Kobayashi H; Yao Z; Saga T; Yano S; Endo K; Mori T; Konishi J
    42nd annual meeting of Society of Nuclear Medicine  1995/06
  • Scintigraphic detection of colorectal carcinoma xenografts with Re-188 labeled monoclonal antibody  [Not invited]
    Hosono M; Hosono MN; Bender H; Zamora PO; Guhlke S; Knapp FF Jr; Biersack HJ
    6th World Congress of the World Federation Nuclear Medicine and Biology  1994/10
  • Improved biodistribution of radiolabeled biotinylated monoclonal antibody followed by the injection of avidin as a "chase"  [Not invited]
    Kobayashi H; Sakahara H; Hosono M; Yao Z-S; Yamamuro T; Toyama S; Endo K; Konishi J
    6th World Congress of the World Federation Nuclear Medicine and Biology  1994/10
  • Localization of infiltration of human leukemia cells in SCID mice  [Not invited]
    osono M; Kondo A; Yao Z; Kobayashi H; Hosono MN; Sakahara H; Imada K; Okuma M; Uchiyama T; Konishi J
    ongress 1994 of European Association of Nuclear Medicine  1994/08
  • Radioimmunotargeting with Re-188 labeled monoclonal antibody in mice bearing colorectal carcinoma xenografts  [Not invited]
    Hosono MN; Hosono M; Zamora PO; Guhlke S; Bender H; Biersack HJ; Onoyama Y; Ochi H; Konishi J
    Congress 1994 of European Association of Nuclear Medicine, Düsseldorf  1994/08
  • Detection of proliferation sites of ATL cells in SCID mice  [Not invited]
    Hosono M; Kondo A; Yao Z; Kobayashi H; Hosono MN; Sakahara H; Imada K; Okuma M; Uchiyama T; Konishi J
    41st annual meeting of Society of Nuclear Medicine  1994/06
  • RADIOTHERAPY IN MICE WITH I-131-LABELED ANTI-SMALL CELL LUNG-CANCER MONOCLONAL-ANTIBODY  [Not invited]
    M HOSONO; MN HOSONO; H KOBAYASHI; M SHIRATO; H SAKAHARA; K ENDO; R UEDA; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE  1993/05  SOC NUCLEAR MEDICINE INC
  • EFFECT OF HYPERTHERMIA ON UPTAKE OF MONOCLONAL-ANTIBODY IN SMALL-CELL LUNG-CANCER XENOGRAFTS  [Not invited]
    MN HOSONO; M HOSONO; H KOBAYASHI; M SHIRATO; H SAKAHARA; T NAKAJIMA; K ENDO; R UEDA; J KONISHI; Y ONOYAMA
    JOURNAL OF NUCLEAR MEDICINE  1993/05  SOC NUCLEAR MEDICINE INC
  • CHEMICAL MODIFICATION OF AN ANTIBODY TO AFFORD DISCRIMINATED RELEASE OF HIPPURATE-LIKE CHELATE IN NONTARGET FOR TARGET-SELECTIVE RADIOACTIVITY DELIVERY  [Not invited]
    Y ARANO; T INOUE; T MUKAI; M HOSONO; H SAKAHARA; J KONISHI; A YOKOYAMA
    JOURNAL OF NUCLEAR MEDICINE  1993/05  SOC NUCLEAR MEDICINE INC
  • BIODISTRIBUTION OF IN-111 OXIDE LABELED PLATELET IN DOG INJECTED WITH ANTI-THROMBOCYTIC MONOCLONAL-ANTIBODY  [Not invited]
    M HOSONO; N SONE; H SAKAHARA; H KOBAYASHI; M SHIRATO; K ENDO; K YASUNAGA; J KONISHI
    JOURNAL OF NUCLEAR MEDICINE  1993/05  SOC NUCLEAR MEDICINE INC
  • STAGING OF BILE-DUCT CANCER - COMPARATIVE-STUDY OF US, CT, AND MR IMAGING  [Not invited]
    K ITOH; M HOSONO; Y NAKANO; J KONISHI
    RADIOLOGY  1992/11  RADIOLOGICAL SOC NORTH AMER

MISC

Awards & Honors

  • 2020/08 Kindai University Faculty of Medicine Best Teacher Award (FY2019)
     Medical Education 
    受賞者: HOSONO Makoto
  • 2020/04 Kindai University Faculty of Medicine Best Teacher Award (FY2018)
     Medical Education JPN others 
    受賞者: HOSONO Makoto
  • 2019/11 ICRP Award to authors: ICRP Publication 140
     Radiological protection in therapy with radiopharmaceuticals 
    受賞者: HOSONO Makoto
  • 2009/10 Japanese Society of Nuclear Medicine 48th Japanese Society of Nuclear Medicine Award
     JPN japan_society 
    受賞者: HOSONO Makoto
  • 2008/12 RSNA Certificate of Merit
     Malignant lymphoma post therapy: usefulness and pitfalls using FDG-PET/CT compared to CT, MRI, and Ga scintigraphy USA international_society 
    受賞者: OKADA M;HOSONO M;SATO N;IM S;MATSUMURA K;MURAKAMI T
  • 2007/11 RSNA Certificate of Merit
     Wide spectrum of malignant lymphoma: new insight into the pathogenesis of lymphoid malignancies in PET-CT and MRI USA international_society 
    受賞者: OKADA Masahiro;HOSONO Makoto;KOMEYA Yoshihiro;TSUCHIYA Norio;MURAKAMI Takamichi;MATSUMURA Kaname
  • 2006/12 RSNA Certificate of Merit
     MR imaging, CT, and PET in patients with cancer of peritoneum and abdominal wall USA international_society 
    受賞者: KOMEYA Yoshihiro;OKADA Masahiro;HOSONO Makoto;TAKEUCHI Ryo;MATSUMURA Kaname;MURAKAMI Takamichi
  • 1997/10 Atomic Energy Research Foundation in Medicine Award, Atomic Energy Research Foundation in Medicine
     publisher 
    受賞者: HOSONO Makoto

Research Grants & Projects

  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2021/04 -2025/03 
    Author : 甲斐田 勇人; 石井 一成; 安田 卓司; 伊藤 彰彦; 細野 眞; 服部 聡; 河原 明彦
     
    本研究の目的は、術前化学療法を受ける進行食道癌患者対象に治療開始前FMISO PET/CTで治療効果予測が可能か病理学的評価を踏まえて検討することである。さらにFMISO集積で腫瘍内低酸素やPD-L1やCD8T細胞が発現する腫瘍免疫環境を予測可能か前向き研究で検討する。 科研費交付決定後に近畿大学医学部倫理委員会に研究計画書を提出し、一括申請を行った。倫理委員会で研究実施実施計画が承認された後に食道癌の病理組織標本に免疫染色行うための抗体やFMISOの薬剤合成にかかる消耗品の購入、FMISO PET/CTの検査が円滑に進められるように研究体制を整えた。倫理委員会承認後本研究を開始し、共同研究を行う上部消化管外科と密接に連携して、研究に参加可能な対象者を集め始めた。初年度は研究体制整備が主だった実績となった。 今年度は10症例程度を目標に予定していたが、医学部倫理委員会に申請する研究計画書の作成やその審査にかなり時間を要し、計画に遅れが生じた。次年度からは研究に該当する食道癌患者の収集を第一に努め、収集症例数をあげることである。また、食道癌の術前化学療法後、手術を行った患者の病理染色標本の染色および患者の経過観察に関して円滑に進めていけるように関係各所（近畿大学上部消化管外科、近畿大学病理学講座、久留米大学病院病理部病理診断科、大阪大学大学院医学系研究科情報統合医学講座医学統計学）との連携を再確認して、随時研究の打ち合わせの実施を行う。
  • Ministry of Health, Labour and Welfare：Health and Labor Sciences Research Grant
    Date (from‐to) : 2022/04 -2025/03 
    Author : Hosono M; Yamaguchi I; Takahashi T; Akahane M; Okuyama C; Higashi T; Matsubara K
  • JSPS：Kakenhi
    Date (from‐to) : 2021/04 -2024/03 
    Author : Hosono M
  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2020/04 -2023/03 
    Author : 竹中 完; 細野 眞; 工藤 正俊
     
    本研究は各国の医療に用いられる放射線の使用基準に消化器領域の透視下医療処置の記載がほとんどされていないのは、信頼度の高い実際の被ばく量データが存在しないためであり、各透視下処置における、装置から出力される放射線量、患者・医療従事者の被ばく量を明らかにすることは、現在世に存在しない信頼度の高い情報を得られるのみではなく、「消化器領域のさまざまな透視下処置における被ばく量の基準値を定めDRL設定に繋げる」こと、消化器領域のみならず、透視下医療処置全般に関する被ばく量の基準作りにまで繋がることが可能になると考え立案した。唯一の被ばく国として放射線被ばくに関心の高い本邦において、世界に先駆けて、特に消化器領域の透視下医療処置に関する放射線被ばく量の基準を作成し、世界に発信することを目的に立案した。 「実臨床での透視下手技における患者と医療従事者の被ばく線量集計・解析」については当院における患者への透視下内視鏡手技における被ばく線量測定を行い、その数値は十分に防護対策をとらなければ基準値を容易に超える値であることが判明した。この内容は消化器病学会誌の速報に取り上げられ報告し、日本中の消化器内科医の被ばく防護意識改善に寄与したことが予想される。
  • Ministry of Health, Labour and Welfare：Workers' illnessclinical research project
    Date (from‐to) : 2019/06 -2022/03 
    Author : HOSONO Makoto
  • Ministry of Health, Labour and Welfare：Health and Labour Sciences Research Grants
    Date (from‐to) : 2019/04 -2022/03 
    Author : HOSONO Makoto
  • Ministry of Education, Culture, Sports, Science and Technology：Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2018/04 -2021/03 
    Author : HOSONO Makoto
  • Research on reasonable radiation management for short-lived alpha emitters
    Nuclear Regulatory Agency：Project for promotion of radiation safety regulations
    Date (from‐to) : 2017/04 -2019/03 
    Author : HOSONO Makoto
  • Ministry of Health, Labour and Welfare：Ministry of Health, Labour and Welfare: Health and Labour Sciences Research Grants
    Date (from‐to) : 2016/04 -2019/03 
    Author : HOSONO Makoto
  • Ministry of Education,Culuture,Sports,Science and Technology：Grant-in-Aid for Scientific Research
    Date (from‐to) : 2013/04 -2017/03 
    Author : HOSONO Makoto
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2014/04 -2016/03 
    Author : ENDO KEIGO; HOSONO MAKOTO
     
    Radium-223 has been approved to use clinically for the first time as alpha-emitting radiopharmaceuticals in Japan. Radium-223 is not appropriate for the labeling other tumor seeking substances. Astatin-211, another promising alpha-emitter, has similar characteristics with iodine. In the present study, we found an efficient production method, that is the use of mixture of ethanol and 0.1 NaOH, for the recovery of astatin-211. Half life of astatin-223 is 7 hours, supposed to be too short for whole IgG, and we confirmed rapid distribution and high tumor uptake of iodine-125 labeled Fab fragment as expected. For the comparison between alpha and beta emitting radiopharmaceuticals, yttrium-90, widely used beta-emitter,was labeled with anti-CD 20 antibody and animal study was performes. Tumor suppressive effect was performed by yttrium-90 labeled ones, and this tumor-antibody model will be used for the basic studies of astatin-211 labeled antibody.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2013/04 -2016/03 
    Author : NISHIMURA Yasumasa; TACHIBANA Izumi; ISHIKAWA Kazuki; HOSONO Makoto
     
    18F-fluoromisonizazole (F-MISO) PET/CT is a non-invasive method of depicting tumor hypoxia. A prospective clinical trial of F-MISO PET/CT for patients scheduled for radiotherapy (RT) was conducted. F-MISO above a value of 1.60 SUV was regarded as indicating a hypoxic area based on our previous study. Of the 22 tumors examinied, 18 tumors had hypoxic area before RT. For 17 patients, F-MISO PET/CT was performed twice before and during fractionated RT. Except for one nasopharyngeal cancer, 16 of the 17 tumors showed a decrease in hypoxic indicators, indicating reoxygenation. Local control rate of patients with SUVmax <2.0 was significantly better than that of patients with SUVmax =>2.0 (p=0.03). Also, overall survival rate of patients with SUVmax <2.0 was significantly better than that of patients with SUVmax =>2.0 (p=0.004). In conclusion, most human tumors contain hypoxic areas before treatment. F-MISO SUVmax =>2.0 before treatment may predict poor prognosis by RT.
  • 医療における放射線防護と関連法令整備に関する研究
    厚生労働省：厚生労働科学研究費補助金
    Date (from‐to) : 2014/04 -2016/03 
    Author : 細野 眞
  • 環境省：原子力災害影響調査等事業（放射線の健康影響に係る研究調査事業）
    Date (from‐to) : 2013/04 -2016/03 
    Author : 細野 眞
  • 骨転移の疼痛緩和における塩化ストロンチウム-89の有効性の検証と背景因子との関係を探索する多施設共同前向き観察研究
    共同研究
    Date (from‐to) : 2010 -2014 
    Author : 細野 眞
     
    PMS-89 Study Group責任研究者 UMIN000004028
  • 医療放射線の安全確保と有効利用に関する研究
    厚生労働省：厚生労働科学研究費補助金
    Date (from‐to) : 2010/04 -2013/03 
    Author : 細野 眞
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2010 -2012 
    Author : NISHIMURA Yasumasa; TACHIBANA Izumi; HOSONO Makoto
     
    To visualize intratumoral hypoxic areas and their reoxygenation before and during fractionated radiation therapy (RT), 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) were performed. Ten patients, consisting of four head and neck cancers, four gastrointestinal cancers, one lung cancer, and one uterine cancer, were included. F-MISO PET/CT was performed twice before RT and during fractionated RT of approximately 20 Gy/10 fractions for eight of the 10 patients. F-MISO maximum standardized uptake values (SUVmax) of normal muscles and tumors were measured. The tumor-to-muscle (T/M) ratios of F-MISO SUVmax were also calculated. Mean SUVmax ± standard deviation (SD) of normal muscles was 1.25 ± 0.17, and SUVmax above the mean + 2 SD (≧1.60 SUV) was regarded as a hypoxic area. Nine of the 10 tumors had an F-MISO SUVmax of equal to or more than 1.60. All eight tumors examined twice showed a decrease in SUVmax, T/M ratio, or percentage of hypoxic volume (F-MISO ≧1.60) at approximately 20 Gy, indicating reoxygenation. In conclusion, accumulation of F-MISO of ≧1.60 SUV was regarded as an intratumoral hypoxic area in our F-MISO PET/CT system. Most human tumors (90%) in this small series had hypoxic areas before RT, although hypoxic volume was minimal (0.0-0.3%) for four of the 10 tumors. In addition, reoxygenation was observed in most tumors at two weeks of the fractionated RT.
  • Ministry of Education, Culture, Sports, Science and Technology：Grants-in-Aid for Scientific Research(基盤研究(C))
    Date (from‐to) : 2009 -2012 
    Author : Makoto HOSONO
     
    In patients with CD20 positive B-cell non-Hodgkin lymphoma who underwent yttrium-90 labeled anti-CD20 ibritumomab tiuxetan therapy, glucose metabolism by FDG and hypoxia by FMISO were evaluated with PET/CT before and after therapy, and changes were analyzed over time. Antigen expression of CD20 was also evaluated by SPECT/CT using indium-111 labeled anti-CD20 antibody. Association of glucose metabolism, hypoxia, and CD20 expression with therapeutic response was analyzed.
  • 医療放射線の安全確保に関する研究
    厚生労働省：厚生労働科学研究費補助金
    Date (from‐to) : 2007/04 -2010/03 
    Author : 細野 眞
     
    主任研究者
  • 陽電子断層撮影薬剤の開発に関する研究
    国立機関以外の国庫補助による研究
    Date (from‐to) : 2006 -2010
  • 厚生労働省：厚生労働科学研究費補助金
    Date (from‐to) : 2004/04 -2007/03 
    Author : 細野 眞
  • 放射免疫療法の最適化に関する研究
    科学研究費補助金
    Date (from‐to) : 2003 -2006
  • Radioimmunotherapy
    Grant-in-Aid for Scientific Research
    Date (from‐to) : 2003 -2006
  • Ministry of Education, Culture, Sports, Science and Technology：Grants-in-Aid for Scientific Research(基盤研究(C))
    Date (from‐to) : 2003 -2006 
    Author : Makoto HOSONO; Takeo TAKAHASHI
     
    Molecular targeting concept and technology have recently been established and applied to disease entities, and have proved efficient and indispensable in some pathological status. As one of molecular targeting applications, radioimmunoscintigraphy and radioimmunotherapy which use radiolabeled monoclonal antibodies recognizing malignancy have successfully been undertaken in laboratory studies and clinical applications. The purpose of this study was to develop tumor imaging and therapy using molecular targeting techniques. To conduct radioimmunotherapy with radiolabeled anti-HER2 antibody in patients, we investigated conditions of radiolabeling techniques of potentially therapeutic radionuclides and tumor-directed antibodies. Chelating agents having macrocycle structures are suitable for radioimmunotherapy because of conjugation stability. Parameters of radiolabeling for chelates have been determined and optimized in animal models with human cancers. Distributions of malignant cells were studied in animal models using radiolabeling of cancer cells. A liver metastasis model was constructed by injecting radiolabeled cancer cells into the portal vein or spleen. Biodistribution of cancer cells was determined by tracer studies using radiolabeled antibodies. The obtained data were used for analyzing parameters in forthcoming radioimmunotherapy. Basic safety standards in radiological protection were considered for prospects of radionuclide therapy in clinical facilities. In conclusion, our study demonstrates significant findings of basic investigation as molecular imaging and therapy are increasingly applied to clinical practices.
  • Ministry of Education, Culture, Sports, Science and Technology：Grants-in-Aid for Scientific Research(基盤研究(C))
    Date (from‐to) : 1999 -2002 
    Author : Makoto HOSONO; Takeo TAKAHASHI
     
    The "affinity enhancement system", a two-step targeting technique using bispecific antibody and radiolabeled bivalent hapten, has been reported to be useful for the targeting of carcinoembryonic antigen-expressing tumors. The purpose of this study was to evaluate the efficacy of this method for targeting human small cell lung cancer using an antineural cell adhesion molecule antibody.Antineural cell adhesion molecule/antihistamine bispecific anti-body NKI NBLIJ79 was prepared by coupling an equimolecular quantity of a Fab' fragment of NK1NBL1 to a Fab fragment of antihistamine 679. Athymic mice inoculated with NC1-H69 small cell lung cancer cells expressing neural cell adhesion molecule were administered bispecific antibody and then 48 h later 1251-labeled bivalent histamine hapten. 1251-labeled in tact NKINBLI was injected into other groups of mice. Biodisributions were examined as a function of time.In mice of the two-step targeting, tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 1.4 ± 1.1, 10.8 ± 13.2 and 4.6 ± 4.7, respectively, at 5 h, whereas 1251-labeled NK1NBL1 showed tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 0.3 ± 0.1, 1.1 ± 0.2 and 0.9 ± 0.1, respectively, at 5 h. Dosimetry showed that tumor-to-liver and -to-bone marrow ratios of absorbed irradiation doses were 14.3 and 16.8 for the two-step method and 4.2 and 2.6 for the one-step method. This suggested that the affinity enhancement system could enhance the therapeutic potential of the antineural cell adhesion molecule antibody NK1NBL1.This two-step targeting method seems promising for the diagnosis and therapy of small cell lung cancer by giving enhanced tumor-to-normal tissue contrast.
  • Ministry of Education, Culture, Sports, Science and Technology：Grants-in-Aid for Scientific Research(基盤研究(C))
    Date (from‐to) : 1998 -2001 
    Author : Kikuo MACHIDA; 細野眞
     
    Brain perfusion SPECT (BP-SPECT) has characteristic patterns of abnormality enabling differential diagnosis of dementia. The purpose was to measure inter-obserYer variations in diagnosis of dementia using BP-SPECT. BP-SPECT images of 57 cases, 19 of Alzheimer s Disease (AD) eight of multi-infarct dementia (MID), three of Pick's disease, five of other dementias and 22 normal controls, were interpreted by ten nuclear medicine physicians of variable experience before and after the addition of MRl. The physicians independently rated diagnoses that were listed beforehand according to a 5-point s...
  • 文部科学省：科学研究費補助金(奨励研究(A))
    Date (from‐to) : 1997 -1998 
    Author : 細野 眞
     
    モノクローナル抗体を放射性同位元素(RI)で標識して悪性腫瘍のイメージングや内部放射線療法を行う試みが現在まで数多くなされているが、RI標識抗体が血中プールや正常組織に留まり病変と正常組織のRI集積比(腫瘍/正常組織比)が不十分である点が問題であった。解決策のひとつとしてpretargetingの方法が考案された。本研究において検討したのは腫瘍関連抗原とハプテンに特異性のあるBispecific Antibody(BsAb)とRI標識ハプテンを用いる方法である(2ステップ法)。癌胎児性抗原CEAを発現している腫瘍をヌードマウスに皮下移植し継代した。さらに1ステップ法として抗CEA抗体を直接I-125標識した。2ステップ法、1ステップ法それぞれのマウスを経時的に屠殺し放射能の体内分布を調べた。マウスにおける体内分布は2ステップ法では、1ステップ法と同等の腫瘍集積が認められた。2ステップ法の腫瘍/正常組織比は早期から高く、腫瘍血液比は5時間後に6、24時間後に37、48時間後に66、96時間後182と極めて高い値に達した。I-125のデータを基にしてI-131を用いた場合の吸収線量を求めると、腫瘍、肝、腎の吸収線量は2ステップ法で5.50、0.15、0.31、1ステップ法で6.80、0.39、0.69cGy/μCiと計算された。2ステップ法を用いて正常組織の被曝を抑えながら腫瘍に治療量の内部放射線照射を行えることを示しており、放射免疫療法への応用が期待される。
  • Ministry of Education, Culture, Sports, Science and Technology：Grants-in-Aid for Scientific Research(基盤研究(C))
    Date (from‐to) : 1996 -1997 
    Author : Kikuo MACHIDA; 細野眞
     
    Fifteen-four studies of ^<20l>T1 brain tumor SPECT were independently interpreted by 9 nuclear medicine physicians with and without reference magnetic resonance images in 2 separate sessions to define an effect of referring images, and inter-observer variations. The physicians were requested to detect foci of abnormal deposits, and to discriminate whether they were malignant or not according to 5-grade scaling of subjective diagnostic confidence. Receiver-operating characteristics (ROC) analysis was performed. Mean sensitivity for presence of lesions (SFP), and sensitivity and specifcity fo...
  • 文部科学省：科学研究費補助金(奨励研究(A))
    Date (from‐to) : 1996 -1996 
    Author : 細野 眞
     
    モノクローナル抗体を放射性同位元素(RI)で標識して悪性腫瘍のイメージングを行う試みが現在まで数多くなされているが、この際問題となるのがRI標識抗体が血中プールや正常組織に留まり病変と正常組織のRI集積比(腫瘍/正常組織比)が不十分である点であった。解決策のひとつとしてpretargetingの方法が考案された。このうち今回検討したのは癌胎児性抗原CEAとDTPAハプテンに特異性のあるBispecific Antibody(BsAb)とDTPAハプテンを用いる方法である。当初は大腸癌細胞株を用いることを計画しており、それについても実験を行ったが、ヒト甲状腺髄様癌細胞株TTがCEAを発現しているため、これを用いて実験系を作るためにヌードマウスに皮下移植し継代した。2ステップ法のBsAbとして抗CEA/抗DTPA抗体F-6-743を用いた。さらに1ステップ法として抗CEA抗体F6のF(ab')2を用いた。BsAbをヌードマウスの尾静脈から投与した。48時間後、I-125標識DTPAハプテンを投与し、経時的に屠殺し放射能の体内分布を調べた。またI-125標識F6 F(ab')2も体内分布を調べた。マウスにおける体内分布で2ステップ法では、I-125標識F6 F(ab')2を用いる方法と同等の腫瘍集積が見られた。腫瘍/正常組織比は早期から高く、腫瘍血液比は5時間後に6、24時間後に37、48時間後に66、96時間後182と極めて高い値に達した。今回の検討で2ステップ法にて高い腫瘍/正常組織比を得ることができた。観察された高い腫瘍/正常組織コントラストは、甲状腺髄様癌の診断に2ステップ抗体シンチグラフィが有効であることを強く示唆している。また正常組織の被曝を抑えながら腫瘍に治療量の内部放射線照射を行えることも示しており、放射性免疫治療が期待される。

Committee Membership

  • 2022/06 - Today   Japan Radioisotope Association   Executive Board member
  • 2022/04 - Today   Radiation Council, Nuclear Regulatory Agency, Japan   Member
  • 2021/06 - Today   Japan Humboldt Association   Board member   https://avh-jp.com
  • 2020/04 - Today   Japan Radioisotope Association   Chairman, Division of Medical and Pharmaceutical Sciences
  • 2019/12 - Today   Society for Dose Estimation in Targeted Radioisotope Therapy   VIce President
  • 2019/06 - Today   The Humboldt Association of Japan   Councilor
  • 2017/11 - Today   Japanese Society of Nuclear Medicine, Nuclear Medicine Nurse Group   Board Member   https://www.kakuigaku.com
  • 2017/10 - Today   The Humboldt Association of Japan   Kansai Chapter Board Member
  • 2017/07 - Today   ICRP   C3 member
  • 2017/04 - Today   Japan Network for Research and Information in Medical Exposure   Chair   http://www.radher.jp/J-RIME/profile.html
  • 2016/12 - Today   National Association on Promotion of Nuclear Medicine   Executive board member
  • 2016/07 - Today   Japan Neuroendocrine Tumor Society   Executive board member, Chair of Nuclear Medicine Committee
  • 2016/04 - Today   Japan Radioisotope Association   Chair of Radionuclide Therapy Committee
  • 2015/11 - Today   Japanese Society of Nuclear Medicine, PET Group   Vice President
  • 2011/10 - Today   Japanese Society of Nuclear Medicine   Chair of PET Committee
  • 2011/10 - Today   Japanese Society of Nuclear Medicine, Group of PET Nuclear Medicine   Executive board member
  • 2011/10 - Today   Japanese Society of Nuclear Medicine   Executive board member
  • 2007/04 - Today   Research Group of Japanese Ministry of Health   Principal Investigator
  • 2006/04 - Today   Japan Radiological Society   Deputy
  • 2006 - Today   Japanese Association of Radioisotope   Member of Medico-pharmaceutical Subcommittee
  • 2003 - Today   Japanese Society of Nuclear Medicine   Councilor
  • 2003 - Today   Japanese Association of Tomography   Councilor
  • 2001 - Today   Japanese Society of Medical Imaging   Councilor
  • 2018/12 -2020/03   Ministry of Health, Labour, and Welfare, Committee on the exposure limit of the lens of the eye   Committee member
  • 2014/08 -2017/12   Japan Network for Research and Information in Medical Exposure   Chair of DRLs WG
  • 2013 -2016   Research Group of Ministry of Environment   Principal Investigator
  • 2012 -2014   Japanese Association of Radioisotope   Member of Academic Committee
  • 2011 -2013   Japanese Society of Health Physics   Executive board member
  • 2010 -2012   Japanese Association of Radioisotope   Executive board member
  • 2010 -2011   Japanese Society of Radiation Effect   Committee member
  • 2010 -2011   Nuclear Safety Research Association   Committee member
  • 1999 -2011   Radiation Council, Government of Japan   Member of Basics Committee

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.